backgroundobject
primari
infect
human
adenovirus
hadv
commonli
occur
earli
childhood
lead
viral
persist
differ
tissu
reactiv
patient
impair
immun
surveil
associ
high
morbid
mortal
particularli
paediatr
haematopoiet
stem
cell
transplant
hsct
recipi
although
invas
hadv
infect
thought
mainli
aris
gastrointestin
gi
tract
rise
viru
level
serial
stool
specimen
shown
preced
dissemin
diseas
specif
site
hadv
persist
prolifer
well
characteris
designmethod
prospect
screen
biopsi
immunocompet
children
undergo
routin
gastrointestin
endoscopi
monitor
serial
stool
specimen
paediatr
hsct
recipi
presenc
hadv
realtim
pcr
screen
intracellular
locat
protein
express
hadv
determin
insitu
hybridis
immunohistochemistri
result
persist
variou
hadv
speci
gi
tract
identifi
children
screen
highest
preval
termin
ileum
hadv
persist
identifi
primarili
lymphoid
cell
lamina
propria
immunohistochemistri
indic
low
viru
product
contrast
transplant
recipi
hadv
infect
reveal
high
concentr
replic
hadv
intestin
epitheli
cell
frequenc
hadv
persist
gi
tract
preval
hadv
speci
immunocompet
children
similar
rate
reactiv
preval
hadv
speci
found
hsct
recipi
detect
intestin
hadv
shed
pretranspl
correl
high
risk
invas
infect
gastrointestin
malign
rare
reach
adulthood
genom
landscap
respons
current
therapi
bmmrd
cancer
unknown
designmethod
analyz
cancer
correspond
normal
tissu
bmmrd
patient
use
genom
exom
sequenc
snparray
addit
develop
novel
function
assay
detect
bmmrd
examin
sensit
bmmrd
cell
current
chemotherapi
result
bmmrd
cancer
harbor
massiv
number
substitut
mutat
greater
childhood
adult
cancer
analyz
hypermut
signatur
diagnost
cancer
aris
germlin
bmmrd
p
function
assay
confirm
eight
famili
patient
biallel
mutat
mmr
gene
test
neg
mismatch
repair
activ
convers
nine
famili
member
heterozyg
mutat
cancer
phenotyp
normal
mmr
function
hypermut
bmmrd
brain
cancer
acquir
earli
conserv
somat
mutat
dna
polymeras
sequenti
tumor
analysi
reveal
brain
tumour
acquir
mutat
less
month
malign
transform
importantli
recurr
glioblastoma
display
higher
mutat
load
ultrahypermut
primari
tumor
polymeras
mutat
bmmrd
cell
resist
current
chemotherapi
antimetabolit
temozolomid
conclus
earlyonset
bmmrd
cancer
uniqu
mechan
malign
progress
secondari
mutat
dna
polymeras
rapid
mutat
accumul
quickli
reach
threshold
although
bmmrd
cancer
resist
current
chemotherapi
high
mutat
load
threshold
bmmrd
cancer
may
achil
heel
exploit
diagnosi
therapeut
intervent
backgroundobject
margin
interact
gender
type
alkyl
agent
cyclophosphamid
ifosfamid
eventfre
surviv
observ
random
control
trial
rct
ewe
sarcoma
better
judg
reliabl
interact
efficaci
investig
interact
toxic
perform
metaanalysi
rct
assess
cyclophosphamid
vs
ifosfamid
designmethod
systemat
review
metaanalysi
individu
patient
data
type
cancer
perform
endpoint
progressionfre
surviv
pf
overal
surviv
os
maximum
grade
acut
toxic
hazardratio
hr
oddsratio
confid
interv
treatmentbygend
interact
assess
use
multivari
regress
model
stratifi
trial
gender
heterogen
interact
trial
evalu
use
interact
term
result
metaanalysi
includ
patient
three
rct
pediatr
young
adult
sarcoma
irsiv
median
followup
year
failur
death
margin
overal
differ
pf
observ
four
group
defin
treatment
arm
gender
multivari
analysi
tend
identifi
poorer
pf
male
treat
cyclophosphamid
vs
metaanalysi
could
confirm
hypothesi
treatmentbygend
interact
efficaci
toxic
outcom
loss
effect
hear
loss
social
attain
adult
survivor
childhood
cancer
well
elucid
designmethod
three
hundr
twenti
two
adult
survivor
pediatr
central
nervou
system
cn
mean
sd
age
year
time
sinc
year
noncn
solid
tumor
mean
sd
age
year
time
sinc
year
treat
potenti
ototox
cancer
therapi
complet
audiolog
evalu
questionnair
assess
percept
social
function
attain
ie
independ
live
marriag
employ
audiogram
assign
grade
base
chang
ototox
grade
scale
seriou
hear
loss
dichotom
ye
chang
grade
vs
analys
stratifi
tumor
type
ie
cn
vs
noncn
multivari
logist
regress
model
adjust
age
sex
iq
impair
cn
model
conduct
examin
associ
seriou
hear
loss
social
outcom
adjust
odd
ratio
confid
interv
ci
report
result
seriou
hear
loss
hear
level
requir
hear
aid
deaf
preval
cn
noncn
tumor
survivor
seriou
hear
loss
associ
increas
risk
perceiv
neg
impact
social
function
cn
ci
noncn
ci
tumor
survivor
among
noncn
tumor
survivor
seriou
hear
loss
associ
increas
risk
nonindepend
live
ci
unemploy
ci
histori
never
marri
ci
conclus
substant
proport
adult
survivor
childhood
cancer
treat
potenti
ototox
therapi
seriou
hear
loss
treatmentinduc
hear
loss
associ
reduc
social
attain
perceiv
actual
larg
studi
sampl
backgroundobject
grow
evid
platinumbas
chemotherapeut
agent
may
upregul
gene
involv
mitochondri
superoxid
detoxif
lead
cochlear
oxid
stress
ultim
ototox
base
hypothes
epigenet
mechan
lead
differenti
express
gene
may
play
role
treatmentrel
ototox
therefor
evalu
role
methyl
profil
within
six
mitochondri
superoxid
metabol
gene
ototox
suscept
among
childhood
survivor
medulloblastoma
designmethod
peripher
blood
sampl
collect
childhood
survivor
medulloblastoma
texa
children
cancer
center
mean
time
sinc
diagnosi
year
patient
requir
hear
aid
year
follow
primari
therapi
assign
diagnosi
ototox
dna
methyl
profil
obtain
use
illumina
beadchip
array
assess
probe
promoterassoci
cpg
site
within
follow
gene
gsr
ototoxicityassoci
differenti
methyl
probe
assess
use
linear
regress
adjust
age
gender
cranial
radiotherapi
amifostin
cisplatin
dose
cellular
composit
fals
discoveri
rate
fdr
use
account
multipl
comparison
result
among
probe
includ
final
analysi
two
associ
ototox
fdr
q
gsr
rel
ototox
case
mean
beta
methyl
valu
higher
control
patient
respect
conclus
dna
methyl
cpg
site
promot
region
associ
decreas
gene
express
result
consist
evid
upregul
gene
involv
mitochondri
superoxid
detoxif
associ
ototox
studi
provid
preliminari
evid
epigenet
mechan
may
play
role
treatmentrel
ototox
inform
may
potenti
inform
improv
risk
stratif
chemoprotect
strategi
hear
loss
among
undergo
therapi
childhood
medulloblastoma
children
nation
health
system
psychiatri
behavior
scienc
pediatr
washington
dc
usa
yale
cancer
center
new
usa
backgroundobject
mani
childhood
cancer
survivor
develop
neurocognit
impair
impact
educ
psychosoci
function
consensu
guidelin
recommend
assess
atrisk
patient
convent
assess
timeconsum
costli
requir
special
expertis
computer
neurocognit
batteri
potenti
altern
requir
studi
evalu
feasibl
valid
cogstat
r
computer
batteri
method
crosssect
studi
childhood
cancer
survivor
diagnos
year
year
sinc
diagnosi
complet
cogstat
r
plu
convent
neuropsycholog
measur
two
us
cancer
center
standard
connecticut
academ
achiev
test
score
obtain
school
measur
administr
feasibl
converg
valid
associ
convent
measur
concurr
valid
abil
differenti
group
known
cognit
riskfactor
predict
valid
associ
academ
achiev
result
particip
mean
age
rang
year
diagnosi
rang
year
evalu
male
previous
diagnos
leukemia
lymphoma
brain
tumor
tumor
particip
complet
rate
respect
spearman
correl
reveal
associ
cogstat
r
convent
measur
attent
p
execut
function
p
selfpar
report
execut
function
p
linear
regress
confirm
expect
associ
younger
age
diagnosi
wors
cogstat
r
perform
execut
function
r
p
process
speed
r
p
brain
tumor
diagnosi
r
p
wors
cogstat
r
perform
process
speed
r
p
attent
r
p
work
memori
r
p
ttest
reveal
differ
survivor
connecticutdefin
read
goal
cogstat
r
process
speed
p
work
memori
p
task
math
goal
cogstat
r
execut
function
task
p
conclus
result
suggest
cogstat
r
feasibl
valid
method
identifi
patient
risk
neurocognit
difficulti
potenti
use
clinic
research
assess
backgroundobject
accur
histopatholog
grade
challeng
ependym
tumor
result
poor
interobserv
reproduc
addit
suitabl
prognost
marker
reliabl
risk
stratif
lack
therefor
aim
establish
uniform
molecular
classif
ependym
tumor
adequ
reflect
full
biolog
clinic
histopatholog
heterogen
across
major
anatom
cn
compart
age
group
grade
designmethod
genomewid
dna
methyl
profil
ependym
tumor
gener
use
illumina
methyl
array
follow
unsupervis
hierarch
cluster
subgroup
identif
copynumb
aberr
gene
express
pattern
signal
pathway
well
clinic
data
analyz
valid
character
identifi
molecular
subgroup
result
nine
distinct
molecular
subgroup
ependym
tumor
across
age
group
three
anatom
compart
cn
spine
sp
posterior
fossa
pf
supratentori
st
identifi
found
molecular
subgroup
genet
epigenet
transcript
demograph
clinic
distinct
one
subgroup
within
compart
enrich
grade
subependymoma
spse
pfse
stse
previous
describ
molecular
subtyp
hindbrain
ependymoma
epn
group
b
could
confirm
pfepna
pfepnb
two
supratentori
subgroup
character
prototyp
fusion
gene
involv
rela
stepnrela
respect
molecular
subtyp
spinal
cord
show
good
concord
histopatholog
diagnos
myxopapillari
ependymoma
spmpe
und
grade
ii
ependymoma
spepn
analysi
clinic
demograph
data
reveal
vast
major
highrisk
patient
mostli
children
restrict
two
nine
molecular
subgroup
pfepna
stepnrela
describ
analys
perform
minut
amount
dna
extract
archiv
materi
therefor
ideal
suit
routin
clinic
applic
regard
clinic
associ
molecular
classif
propos
herein
outperform
current
histopatholog
classif
thu
might
serv
basi
next
classif
cn
tumor
medulloblastoma
use
induct
chemotherapi
hyperfraction
acceler
radiotherapi
hart
follow
either
mainten
chemotherapi
two
myelobl
cours
thiotepa
stem
cell
rescu
patient
persist
diseas
prior
hart
report
milan
group
favour
outcom
year
eventfre
overal
surviv
respect
approach
subsequ
adopt
uk
recommend
treatment
strategi
diseas
undertook
ukwid
servic
evalu
review
outcom
follow
introduct
strategi
standard
care
designmethod
neurooncologist
paediatr
oncolog
primari
treatment
centr
uk
contact
anonymis
questionnair
complet
treat
use
strategi
februari
may
neurotox
defin
grade
defin
common
terminolog
criteria
advers
event
ctcae
version
result
total
patient
treat
uk
centr
accord
strategi
overal
surviv
rate
three
patient
die
receiv
hart
patient
receiv
thiotepa
none
develop
sever
neurotox
receiv
thiotepa
receiv
two
cours
sever
neurotox
observ
respect
observ
neurotox
associ
use
thiotepa
hart
includ
global
chang
myeliti
pattern
favour
surviv
seen
origin
report
seri
replic
uk
multicentr
set
combin
highdos
thiotepa
follow
hart
highrisk
medulloblastoma
associ
unaccept
rate
sever
neurotox
suggest
neurotox
interact
treatment
modal
intern
trial
highrisk
medulloblastoma
urgent
requir
backgroundobject
robust
clinic
biolog
correl
outcom
childhood
intracrani
ependymoma
still
requir
previou
analysi
european
paediatr
trial
cohort
suggest
incomplet
surgic
resect
chromosom
gain
marker
recurr
young
patient
older
patient
siop
ependymoma
may
reflect
limit
case
undergo
biolog
scrutini
latter
group
therefor
biolog
reevalu
perform
expand
siop
cohort
designmethod
patient
origin
enrol
siop
ependymoma
clinic
trial
follow
central
patholog
review
exclud
tissu
microarray
gener
formalinfix
paraffinembed
materi
case
subject
fish
analysi
also
investig
statu
multiplex
ligationdepend
probe
amplif
mlpa
subcohort
result
correl
clinic
histolog
updat
surviv
data
mlpa
result
result
children
enrol
complet
surgic
resect
cr
achiev
initi
surgeri
children
ef
os
cr
case
se
se
yet
se
se
respect
incomplet
resect
ir
case
accompani
tissu
gener
result
ir
hr
ci
p
gain
hr
ci
p
independ
predictor
tumour
progress
inde
integr
two
marker
enabl
stratif
case
three
diseas
progress
risk
group
independ
marker
advers
os
anaplast
histolog
hr
ci
p
conclus
gain
independ
predictor
poor
outcom
combin
ir
identifi
high
risk
group
optim
methodolog
identifi
gain
fish
vs
mlpa
siop
ii
trial
present
evalu
associ
lifestyl
hormon
statu
risk
low
bone
miner
densiti
bmd
frailti
among
adult
survivor
childhood
acut
lymphoblast
leukemia
designmethod
particip
includ
survivor
median
age
rang
year
receiv
evalu
st
jude
children
research
hospit
particip
st
jude
lifetim
cohort
studi
bone
densiti
measur
use
quantit
comput
tomographi
vertebra
low
bmd
defin
ageand
sexstandard
zscore
prefrailti
frailti
defin
follow
condit
respect
low
muscl
mass
selfreport
exhaust
low
energi
expenditur
slow
walk
speed
weak
logist
regress
stratifi
sex
use
examin
associ
odd
ratio
confid
interv
ci
lifestyl
smoke
alcohol
consumpt
activ
level
hormon
statu
low
bmd
frailti
result
thirti
percent
survivor
met
criteria
low
bmd
frailti
prefrailti
adjust
bodi
mass
index
male
growth
hormon
defici
ghd
current
smoker
increas
odd
low
bmd
compar
without
ghd
nonsmok
among
femal
ghd
ci
moder
alcohol
consumpt
associ
low
bmd
adjust
current
age
odd
prefrailtyfrailti
increas
among
male
ghd
smoke
among
femal
riski
drinker
survivor
low
bmd
increas
odd
prefrailtyfrailti
compar
survivor
normal
bmd
p
conclus
survivor
receiv
counsel
regard
lifestyl
habit
undergo
screen
hormon
deficit
minim
risk
low
bmd
frailti
data
avail
role
genet
variat
studi
whether
genet
variat
influenc
impair
bmd
cc
designmethod
crosssect
singlecent
cohort
studi
includ
adult
cc
median
followup
time
cessat
treatment
year
rang
median
age
followup
year
rang
total
bodi
bmd
bmdtb
lumbar
spine
bmd
bmdl
measur
dualxray
absorptiometri
dxa
bmd
express
agematch
gendermatch
standard
deviat
score
sd
zscore
select
candid
singl
nucleotid
polymorph
snp
gene
base
result
previou
studi
healthi
popul
vdr
wl
mthfr
mtrr
multivari
analys
includ
apart
candid
snp
patient
treatment
characterist
univari
associ
bmd
valu
result
multivari
analys
reveal
lower
bmd
tbl
associ
lower
weight
followup
p
bmdtb
associ
previous
administ
radiotherapi
survivor
homozyg
minor
allel
gg
genotyp
estrogen
receptor
type
lower
bmdtb
vs
agaa
genotyp
howev
bmdl
differ
carrier
two
minor
allel
gg
lowdens
lipoprotein
receptor
reveal
lower
bmdtb
vs
lower
bmdl
vs
valu
tttg
genotyp
carrier
vdr
vitamin
receptor
haplotyp
lower
bmdl
noncarri
vs
bmdtb
alter
conclus
cc
carrier
candid
snp
vdr
gene
seem
vulner
impair
bone
mass
earli
adult
age
addit
patient
treatment
relat
factor
inform
genet
variat
may
help
identifi
survivor
risk
low
bone
densiti
childhood
cancer
treatment
n
ludwig
n
nourkamitutdibi
c
back
n
graf
keller
e
mees
saarland
univers
human
genet
homburg
germani
saarland
univers
pediatr
hematolog
oncolog
homburg
germani
saarland
univers
clinic
bioinformat
saarbruecken
germani
backgroundobject
wilm
tumor
wt
common
childhood
kidney
cancer
treatment
accord
siop
includ
preoper
chemotherapi
without
histolog
confirm
wt
biopsi
minimalinvas
diagnost
marker
confirm
wt
diagnosi
relaps
highli
warrant
designmethod
studi
compar
mirna
profil
peripher
blood
patient
wt
five
differ
time
point
diagnosi
preoper
chemotherapi
surgeri
end
therapi
recurr
profil
patient
malign
control
nonmalign
diseas
identifi
mirna
biomark
potenti
wt
measur
express
mirna
use
microarray
total
sampl
identifi
differenti
express
mirna
use
ttest
mirna
signatur
use
supportvectormachin
approach
result
longitudin
studi
detect
significantli
deregul
mirna
patient
wt
compar
control
mirna
upregul
mirna
downregul
found
highest
number
deregul
mirna
comparison
first
three
time
point
ie
diagnosi
preoper
chemotherapi
surgeri
control
ie
patient
nonmalign
diseas
patient
malign
furthermor
identifi
allow
differenti
patient
wt
nonmalign
control
classif
accuraci
time
point
diagnosi
surgeri
time
relaps
respect
conclus
identifi
mirna
profil
peripher
blood
patient
wt
therapi
significantli
differ
patient
malign
nonmalign
diseas
report
mirna
signatur
show
promis
minimalinvas
biomark
differenti
wt
patient
control
high
accuraci
differ
time
point
includ
initi
wt
diagnosi
wt
recurr
backgroundobject
clear
cell
sarcoma
kidney
ccsk
rare
childhood
renal
tumor
use
whole
genom
mrna
sequenc
show
recurr
genet
mutat
segment
gainsloss
could
identifi
ccsk
therefor
perform
genomewid
gene
expressionand
dna
methyl
analys
find
clue
point
pathogenesi
major
ccsk
designmethod
therapeut
applic
research
gener
effect
treatment
target
initi
ccsk
analyz
chang
genomewid
gene
express
dna
methyl
addit
previous
perform
snp
array
analysi
whole
genom
sequenc
mrna
sequenc
methyl
chang
verifi
valid
realtim
quantit
polymeras
chain
reaction
follow
bisulfit
convers
independ
set
ccsk
tumor
sampl
result
integr
analysi
gene
express
dna
methyl
identifi
promot
hypermethyl
low
express
ccsk
case
except
one
case
verifi
valid
methyl
statu
sequenc
follow
bisulfit
convers
perform
show
higher
methyl
level
ccsk
ccsk
sampl
discoveri
set
ccsk
sampl
independ
valid
set
compar
pediatr
renal
tumor
n
normal
kidney
sampl
n
express
tarid
long
noncod
rna
respons
demethyl
virtual
undetect
ccsk
immunohistochem
stain
function
studi
current
perform
rais
hypothesi
hypermethyl
tumor
suppressor
gene
transcript
factor
involv
mesoderm
develop
shown
hypermethyl
mani
adult
cancer
andor
decreas
tarid
express
lie
within
pathogen
pathway
ccsk
thu
children
particular
risk
treatmentrel
sequela
bv
may
therapeut
option
designmethod
analyz
human
gct
cell
line
quantit
rtpcr
immunohistochemistri
cytotox
bv
free
mmae
measur
cytometrybas
hoechst
assay
differenti
measur
viabl
cell
time
result
express
gct
cell
line
predomin
detect
embryon
carcinoma
ec
compart
treatment
led
timeand
bv
dosedepend
reduct
cell
viabil
compar
daili
control
ngml
bv
contrast
cell
unabl
intern
bv
respond
free
mmae
residu
cell
viabil
respect
note
cocultur
also
cell
exhibit
profound
cytotox
respons
bv
time
dosedepend
manner
treatment
ngml
ngml
ngml
bv
cell
still
aliv
viabil
cell
reduc
respect
indic
mmae
releas
cell
destroy
target
cell
popul
also
cocultur
bystand
fashion
compar
potenc
conclus
base
vitro
find
brentuximab
vedotin
may
constitut
novel
treatment
approach
warrant
futur
clinic
evalu
children
malign
gct
pure
also
mix
backgroundobject
neuroblastoma
aris
sympathet
nervou
system
one
aggress
solid
tumor
earli
childhood
amplif
mycn
oncogen
found
around
neuroblastoma
patient
associ
rapid
tumor
progress
poor
prognosi
new
treatment
option
urgent
need
group
patient
metabol
adapt
crucial
cancer
cell
surviv
tumor
progress
identifi
metabol
discrep
aggress
tumor
may
central
order
find
new
treatment
strategi
designmethod
treat
neuroblastoma
cell
small
cmyc
inhibitor
shmycnrna
analyz
apoptosi
cell
cycl
progress
differenti
also
perform
proteom
analys
use
result
data
function
studi
includ
seahors
experi
use
set
metabol
inhibitor
result
find
suggest
small
chemic
molecul
previous
identifi
cmyc
inhibitor
also
target
mycnmax
complex
result
apoptosi
neuron
differenti
mycnamplifi
neuroblastoma
cell
importantli
found
inhibit
mycn
result
chang
neuroblastoma
cell
metabol
includ
mitochondri
dysfunct
lead
accumul
intracellular
lipid
droplet
use
function
assay
found
mycn
contribut
metabol
plastic
neuroblastoma
cell
conclus
taken
togeth
result
highlight
mycn
regul
import
metabol
pathway
mycnamplifi
neuroblastoma
may
basi
develop
futur
therapi
patient
group
l
zhang
hospit
sick
children
toronto
canada
backgroundobject
previou
studi
shown
topoisomeras
inhibitor
topotecan
induc
oxid
stress
breast
cancer
cell
topotecan
treatment
may
yield
increas
hypoxia
tumor
potenti
antitumor
effect
evofosfamid
hypoxiaactiv
prodrug
bromoisophosphoramid
mustard
studi
assess
oxid
stress
pediatr
tumor
cell
topotecan
treatment
also
investig
antitumor
efficaci
combin
topotecan
evofosfamid
treatment
preclin
tumor
model
designmethod
panel
twelv
neuroblastoma
nbl
rhabdomyosarcoma
rm
osteosarcoma
ewe
sarcoma
cell
line
cultur
expos
topotecan
singl
agent
combin
evofosfamid
hour
cell
viabil
measur
use
alamarblu
assay
tumor
cell
oxid
stress
determin
diacet
dcfda
assay
topotecan
treatment
withwithout
presenc
evofosfamid
vivo
antitumor
activ
evalu
nodscid
mous
model
cleav
use
apoptot
marker
vivo
result
test
tumor
line
show
antiprolif
respons
topotecan
rang
ad
topotecan
evofosfamid
treatment
significantli
increas
cytotox
tumor
cell
p
data
indic
increas
oxid
statu
reveal
increas
reactiv
oxygen
speci
measur
dcfa
assay
tumor
cell
expos
topotecan
compar
control
cell
p
nbl
rm
xenograft
model
ad
topotecan
significantli
inhibit
tumor
growth
compar
singleag
evofosfamid
topotecan
treatment
p
complet
tumor
regress
observ
sknbe
xenograft
model
combin
treatment
sknbe
metastat
model
combin
treatment
group
also
show
improv
anim
surviv
singleag
treatment
p
increas
tumor
apoptosi
confirm
cleav
immunostain
combin
treatment
backgroundobject
sensit
combin
cerebrospin
fluid
csf
cytolog
neuroimag
studi
diagnos
leptomening
dissemin
cn
tumour
key
inform
drive
treatmenti
rel
low
chang
csf
proteom
shown
reflect
cn
patholog
process
seek
character
csf
proteom
pediatr
cn
tumour
identifi
csf
biomark
predict
tumour
procliv
leptomening
spread
patient
recurr
assist
diagnosi
designmethod
csf
sampl
collect
lumbar
punctur
medulloblastoma
highgrad
glioma
ependimoma
pnet
atyp
teratoid
rhabdoid
tumor
either
initi
diagnosi
tumour
recurr
control
extracn
non
hodgkin
lymphoma
process
coreshel
hydrogel
nanoparticl
analyz
reversephas
liquid
chromatographyelectrospray
tandem
mass
spectrometri
msm
sever
physiolog
technic
statist
challeng
consid
face
result
among
non
redund
protein
identifi
msm
analysi
present
csf
databas
http
wwwbiosinoorg
express
subject
discrimin
protein
univari
select
procedur
identifi
signific
protein
least
one
perform
comparison
case
versu
control
metastat
metastat
case
versu
control
respect
twentysix
protein
afterward
select
biolog
relev
fourteen
subject
quantit
express
analysi
independ
valid
cohort
case
control
use
western
blot
revers
phase
protein
array
rppa
enzymelink
immunosorb
assay
elisa
backgroundobject
half
children
diagnos
retinoblastoma
rb
carrier
constitut
alter
gene
prognosi
rb
excel
carrier
mutat
higher
risk
gener
popul
develop
malign
particularli
irradi
field
previous
treat
extern
beam
radiotherapi
ebrt
craniofaci
second
primari
tumor
spt
irradi
field
poor
prognosi
designmethod
retrospect
monocentr
studi
includ
patient
diagnos
hereditari
rb
treat
ebrt
institut
curi
clinic
therapeut
radiolog
histolog
data
record
radiolog
histolog
central
review
perform
craniofaci
spt
rate
estim
use
kaplanmei
method
result
median
followup
month
followup
patient
develop
craniofaci
spt
third
tumor
diagnos
patient
among
spt
malign
benign
histolog
frequent
subtyp
undifferenti
sarcoma
patient
osteosarcoma
patient
predilect
site
facial
bone
orbit
ethmoid
sinu
year
ebrt
spt
rate
equal
conclus
undifferenti
sarcoma
osteosarcoma
common
craniofaci
spt
irradi
hereditari
rb
develop
specif
locat
poor
prognosi
explain
current
protocol
avoid
use
ebrt
actual
indic
becom
exceptionaland
justifi
effort
earli
detect
tri
improv
outcom
backgroundobject
synovi
sarcoma
common
nonrhabdomyosarcoma
soft
tissu
sarcoma
children
adolesc
account
soft
tissu
sarcoma
outcom
patient
nonextrem
ss
gener
poor
patient
extrem
tumour
designmethod
record
patient
extrem
nonextrem
synovi
sarcoma
treat
februari
octob
analys
result
complet
surgic
resect
histolog
clear
margin
achiev
patient
extrem
tumour
initi
delay
surgeri
chemotherapi
patient
nonextrem
tumour
initi
excis
perform
five
delay
surgeri
four
patient
median
follow
durat
month
local
recurr
patient
extrem
tumour
distant
metastas
occur
five
patient
two
patient
nonextrem
tumour
local
recurr
one
distant
metastas
overal
surviv
event
free
surviv
respect
entir
cohort
overal
surviv
event
free
surviv
respect
extrem
tumour
nonextrem
tumour
conclus
local
recurr
commonest
failur
nonextrem
tumour
distant
relaps
failur
patient
extrem
tumour
although
trend
toward
better
surviv
patient
extrem
tumour
statist
signific
l
lifson
inkosi
albert
luthuli
central
hospit
dietet
durban
south
africa
backgroundobject
develop
countri
preval
malnutrit
admiss
amongst
paediatr
patient
cancer
high
high
rate
malnutrit
occur
due
factor
poverti
comorbid
late
present
advanc
diseas
process
weight
shown
inaccur
paramet
nutrit
assess
patient
solid
tumour
influenc
tumour
mass
studi
aim
assess
preval
malnutrit
amongst
patient
wilm
tumour
wt
level
nutrit
support
receiv
within
week
admiss
well
influenc
nutrit
statu
outcom
designmethod
seventi
six
children
diagnos
wt
admit
inkosi
albert
luthuli
central
hospit
studi
prospect
nutrit
assess
took
place
start
treatment
includ
weight
height
midarm
circumfer
mac
tricep
skinfold
thick
tst
outcom
determin
year
date
admiss
time
commenc
nutrit
resuscit
natur
thereof
record
result
stunt
wast
evid
patient
respect
includ
mac
tst
preval
malnutrit
shown
malnourish
children
significantli
larger
tumour
well
nourish
malnutrit
predictor
poor
outcom
predict
advanc
diseas
relapsefre
patient
nutrit
statu
relat
treatment
toxic
eighti
four
percent
patient
receiv
nutrit
resuscit
within
week
admiss
conclus
nutrit
assess
children
solid
tumour
includ
mac
tst
malnutrit
time
admiss
shown
relat
poorer
outcom
year
may
due
effect
earli
aggress
nutrit
resuscit
part
manag
multidisciplinari
team
although
number
small
backgroundobject
evalu
case
initi
treat
wt
fact
prove
anoth
histolog
order
reduc
mistaken
diagnosi
therebi
avoid
neuroblastoma
nonwilm
renal
tumor
receiv
unnecessari
preoper
chemotherapi
designmethod
retrospect
analysi
medic
record
imag
wt
neuroblastoma
nonwilm
renal
tumor
diagnos
children
admit
pediatr
oncolog
institutegraacc
unifesp
clinic
characterist
imag
exam
patient
attend
inclus
criteria
studi
review
result
patient
mistakenli
diagnos
treat
wt
neuroblastoma
anoth
renal
tumor
show
accuraci
diagnosi
perform
patient
male
less
three
year
old
among
studi
patient
present
unilater
renal
involv
present
bilater
renal
involv
none
metastasi
diagnosi
conclus
case
difficult
perform
differenti
diagnosi
wt
neuroblastoma
renal
tumor
base
clinic
imag
data
mistakenli
diagnos
case
demonstr
efficaci
diagnosi
perform
iopgraaccunifesp
certainli
futur
studi
patient
enabl
deeper
view
neuroblastoma
nonwilm
renal
tumor
treat
wt
frequenc
well
impact
surviv
backgroundobject
despit
lack
guidelin
within
current
treatment
protocol
minim
invas
nephrectomi
increasingli
use
techniqu
tumor
remov
nephroblastoma
sever
issu
consid
concern
approach
analyz
children
undergo
laparoscop
wt
resect
institut
technic
aspect
safe
procedur
adequ
lymph
node
sampl
highlight
designmethod
irb
approv
obtain
august
march
children
underw
transperiton
laparoscop
nephrectomi
wt
patient
data
tumor
characterist
surgic
oncolog
outcom
assess
ln
sampl
review
special
emphasi
result
mean
age
surgeri
month
rang
children
receiv
neoadjuv
actinomycindvincristin
tumor
show
respons
chemotherapi
mean
tumor
volum
ml
diagnosi
ml
surgeri
complet
tumor
resect
achiev
via
trocartechniqu
children
result
local
stage
case
tumor
ruptur
occur
resect
specimen
retriev
abdomen
via
pfannenstiel
incis
use
retriev
bag
adequ
lymph
node
sampl
perform
dissect
kidney
realiz
case
appli
surgic
step
similar
procedur
upper
urinari
tract
elev
stay
sutur
vascular
dissect
tumor
mobil
posit
trocar
other
mean
oper
time
minut
complic
children
aliv
without
evid
diseas
mean
follow
month
conclus
minim
invas
surgeri
safe
option
wt
resect
provid
patient
care
select
oper
surgeon
suffici
expertis
pediatr
oncolog
minim
invas
urolog
adequ
ln
sampl
possibl
via
minim
invas
approach
howev
laparoscop
techniqu
must
reason
compli
gener
guidelin
wt
surgeri
backgroundobject
preval
mildtomoder
renal
dysfunct
wilm
tumor
patient
surviv
beyond
agerel
physiolog
renal
function
declin
may
due
adjuv
therapi
rather
reduct
renal
parenchyma
aim
evalu
renal
function
adult
patient
underw
nephrectomi
childhood
receiv
receiv
postop
radiotherapi
designmethod
assess
estim
glomerular
filtrat
rate
egfr
blood
pressur
patient
older
year
underw
nephrectomi
childhood
medic
caus
group
wilm
tumor
patient
surviv
beyond
age
year
nephrectomi
postop
radiotherapi
group
b
primari
outcom
studi
evalu
renal
function
amongst
two
group
data
express
number
result
signific
differ
age
surgeri
diastol
blood
pressur
vs
mmhg
similar
followup
renal
dysfunct
document
patient
group
group
b
systol
hypertens
blood
pressur
mmhg
diastol
hypertens
blood
pressur
found
vs
vs
patient
respect
conclus
present
data
suggest
children
undergo
nephrectomi
oncolog
nononcolog
caus
requir
lifelong
nephrolog
surveil
renal
dysfunct
dosedepend
predictor
morbid
cardiac
event
overal
mortal
children
cancer
surgeri
cairo
egypt
helwan
univers
surgeri
cairo
egypt
pediatr
oncolog
cairo
egypt
pediatr
oncolog
cairo
egypt
backgroundobject
intestin
obstruct
one
main
postop
complic
wilm
tumor
author
postul
manipul
small
intestin
si
cut
anatom
periton
reflect
open
way
si
migrat
retroperiton
space
predispos
obstruct
modifi
approach
describ
techniqu
entail
conserv
approach
toward
si
manipul
cut
periton
reflectionsevalu
role
aforement
surgic
approach
regard
technic
util
incid
postop
intestin
obstruct
designmethod
retrospect
review
patient
wilm
tumor
underw
surgeri
januari
decemb
use
approach
data
collect
includ
demograph
data
tumor
characterist
size
stage
intraop
tumor
ruptur
post
oper
radiotherapi
postop
intestin
obstructionth
techniqu
use
transvers
incis
periton
caviti
cut
periton
reflect
short
ceacum
short
sigmoid
phrenocol
ligament
well
reserv
colon
reflect
si
pack
proceed
nephrectomi
lymph
node
sampl
result
studi
includ
patient
femal
mean
age
year
upfront
surgeri
done
patient
patient
receiv
preoper
chemotherapi
mean
tumor
largest
diamet
cm
local
stage
patient
ii
patient
iii
patient
forti
nine
patient
receiv
post
oper
flank
irradi
intraoprt
tumor
ruptur
occur
follow
period
month
year
one
patient
develop
postoperativ
inusssuscept
conclus
modifi
surgic
approach
allow
minim
manipul
si
prevent
migrat
retroperiton
space
contribut
decreas
incid
postop
intestin
obstruct
increas
risk
tumor
ruptur
backgroundobject
imag
defin
risk
factor
idrf
promulg
mean
predict
feasibl
safeti
complet
primari
tumor
resect
children
neuroblastoma
nb
unknown
whether
presenc
absenc
individu
idrf
differenti
effect
resectabilti
patient
outcom
multicent
databas
patient
highrisk
nb
interrog
answer
question
designmethod
patient
highrisk
neuroblastoma
age
year
elig
crosssect
imag
perform
least
twice
prior
resect
idrf
primari
tumor
measur
record
imag
studi
extent
resect
determin
imag
studi
andor
oper
report
result
patient
idrf
diagnosi
patient
idrf
present
presurgeri
although
signific
correl
overal
presenc
absenc
idrf
complet
resect
resect
significantli
like
absenc
two
overlap
subset
idrf
either
diagnosi
presurgeri
subset
nine
includ
invas
pancreaticoduoden
block
porta
hepati
encas
aorta
major
abdomin
branch
vena
cava
iliac
vessel
invas
renal
vascular
pedicl
addit
involv
diaphragm
signific
diagnosi
encas
origin
superior
mesenter
arteri
vs
branch
signific
presurgeri
signific
differ
eventfre
overal
surviv
patient
stratifi
presenc
vs
absenc
idrf
either
diagnosi
presurgeri
conclus
subset
idrf
present
either
diagnosi
induct
chemotherapi
significantli
influenc
probabl
complet
resect
children
highrisk
nb
signific
differ
eventfre
overal
surviv
patient
stratifi
presenc
vs
absenc
idrf
diagnosi
presurgeri
hay
jordan
xy
c
kingsley
c
lockworth
craig
backgroundobject
valid
paediatr
risk
malign
index
prmi
examin
impact
surgic
practic
manag
paediatr
adnex
mass
designmethod
retrospect
review
clinic
chart
electron
record
perform
girl
age
year
manag
adnex
mass
institut
januari
decemb
surgic
approach
adopt
patient
manag
introduct
prmi
compar
result
one
hundr
fifteen
patient
analys
manag
introduct
prmi
score
valu
predict
benign
histolog
diagnosi
children
adnex
mass
sensit
posit
predict
valu
two
group
respect
p
elev
serum
afp
cea
associ
nonbenign
patholog
respect
follow
introduct
patient
prmi
initi
laparoscop
surgic
approach
increas
ovarian
spare
surgeri
increas
patient
prmi
underw
surgic
stage
procedur
includ
omentectomi
contralater
ovari
inspect
biopsi
lymph
node
biopsi
decreas
prmi
valid
postimplement
cohort
sensit
predict
benign
patholog
paediatr
adnex
mass
sinc
introduct
centr
girl
predict
benign
patholog
receiv
initi
laparoscop
approach
ovarianspar
surgeri
spare
unnecessari
surgic
stage
procedur
backgroundobject
examin
relationship
complet
therapi
outcom
children
primari
metastat
liver
tumor
treat
singl
program
designmethod
record
children
primari
metastat
liver
tumor
treat
institut
review
complet
therapi
defin
evid
diseas
ned
chemotherapi
result
thirti
five
children
treat
hepatoblastoma
hb
hepatocellular
carcinoma
hcc
rhabdoid
tumor
embryon
sarcoma
metastat
wilm
tumor
metastat
adrenocort
carcinoma
acc
benign
lesion
eighteen
hb
underw
biopsi
neoadjuv
therapi
pretext
underw
primari
resect
two
die
without
resect
three
chang
sector
pre
posttext
therapi
seventeen
resect
achiev
ned
nonhb
patient
extens
hcc
metastat
rhabdoid
tumor
liver
die
without
resect
one
child
underw
two
resect
month
apart
ned
statu
achiev
resect
includ
convent
extrem
treat
total
hepatectomi
liver
transplant
referr
hospit
extrem
resect
includ
reconstruct
vena
cava
hepat
vein
bile
duct
mesohepatectomi
trisectorectomi
hypertherm
intraperiton
chemotherapi
periop
death
eight
patient
common
terminolog
criteria
advers
event
ctcae
grade
postop
complic
three
patient
die
recurr
rhabdoid
progress
hcc
acc
diseas
year
resect
late
death
hb
benign
diseas
twenti
seven
twenti
eight
children
complet
therapi
ned
aliv
median
year
rang
backgroundobject
assess
outcom
efficaci
thoracoscopi
children
mediastin
neurogen
tumour
designmethod
retrospect
review
centr
patient
underw
thoracoscopi
neurogen
mediastin
tumour
assess
preoper
data
oper
complic
outcom
result
express
median
rang
result
identifi
patient
age
year
year
median
diamet
diagnosi
inrg
stratif
n
ms
n
n
eighteen
patient
imag
defin
risk
factor
idrf
preoper
chemotherapi
allow
decreas
largest
diamet
patient
among
still
idrf
preoper
median
diamet
surgeri
thoracoscopi
perform
insuffl
patient
tumour
spillag
occur
patient
convers
thoracotomi
necessari
patient
vascular
encas
difficult
locat
dissect
median
oper
time
hour
fiftyseven
patient
chest
drain
day
patholog
neuroblastoma
intermix
ganglioneuroblastoma
ganglioneuroma
immedi
postop
advers
event
consist
horner
syndrom
pneumothorax
chylothorax
length
hospit
stay
day
median
followup
month
long
term
complic
consist
horner
syndrom
scoliosisback
pain
delay
chylothorax
forti
patient
residu
diseas
postop
imag
among
mestatat
recurr
month
local
local
plu
metastat
pure
metatsta
two
patient
die
month
surgeri
conclus
minim
invas
surgeri
safe
thorac
neurogen
tumour
without
vascular
idrf
howev
relaps
mainli
local
without
identifi
preoper
risk
factor
primari
site
abdomin
pelvic
thorac
twenti
patient
neurolog
symptom
present
paraplegia
limp
unstabl
gait
root
pain
neurogen
bladderbowel
histori
neurolog
symptom
week
week
patient
neurolog
symptom
receiv
chemotherapi
alon
underw
laminectomi
decompress
spinal
canal
neurolog
recoveri
seen
patient
partial
complet
recoveri
progress
diseas
discontinu
treatment
earli
cours
neurolog
recoveri
could
assess
among
patient
receiv
initi
chemotherapi
recov
neurolog
backgroundobject
print
model
base
preoper
computer
tomographi
ct
imag
facilit
visual
complex
structur
vessel
tumor
use
understand
anatomi
varieti
organ
preoper
report
experi
preoper
surgic
simul
use
print
model
base
preoper
ct
imag
pediatr
malign
designmethod
multidetector
ct
imag
transfer
workstat
volum
data
obtain
reconstruct
section
model
made
printer
use
acryl
ultraviolet
curabl
resin
varieti
organ
tumor
kidney
liver
spleen
vessel
outer
bodi
select
fabric
case
result
use
model
case
pediatr
malign
neuroblastoma
nb
case
soft
tissu
sarcoma
case
one
hepatoblastoma
case
one
mediastin
yolk
sac
tumor
case
case
local
recurr
wilm
tumor
clear
cell
sarcoma
kidney
tumor
vessel
seen
transluc
bodi
liver
evalu
patient
anatomi
especi
tumor
locat
angl
use
model
laparoscop
surgeri
model
made
possibl
insert
trocar
pneumoperitoneum
discuss
port
layout
oper
simul
laparoscop
view
rang
forcep
movement
use
model
laparoscop
view
model
almost
complet
match
real
laparoscop
view
surgeri
nine
case
perform
surgic
treatment
without
complic
surgic
simul
use
print
model
base
preoper
ct
imag
pediatr
malign
use
understand
patient
anatomi
plan
surgic
strategi
backgroundobject
collabor
cameroonian
south
african
nurs
variou
challeng
face
nurs
regard
paediatr
oncolog
special
africa
collabor
result
nurs
roundtabl
siop
africa
neither
countri
formal
paediatr
oncolog
nurs
train
higher
educ
countri
particip
twin
program
tri
bridg
gap
identifi
learn
need
nurs
care
children
cancer
countri
designmethod
explor
experi
nurs
care
children
cancer
banso
baptist
hospit
charlott
maxek
johannesburg
academ
hospit
compar
local
nurs
challeng
train
need
highlight
import
need
analysi
result
cameroon
need
special
paediatr
oncolog
nurs
train
palli
care
counsel
techniqu
advocaci
skill
rais
public
awar
sinc
gener
practic
nurs
found
knowledg
childhood
cancer
south
africa
gener
nurs
lack
interest
paediatr
oncolog
nurs
believ
children
die
work
field
need
train
support
children
complianc
treatment
advocaci
skill
awar
well
critic
need
paediatr
oncolog
nurs
certif
higher
educ
nurs
truli
partner
physician
success
twin
program
depend
direct
nurs
lowincom
countri
conclus
african
nurs
must
identifi
commun
learn
need
twin
partner
rather
remain
passiv
recipi
westernnorthern
teach
great
need
dissemin
inform
african
countri
well
highincom
countri
ownership
learn
process
african
nurs
make
twin
program
curriculum
develop
relev
benefici
parti
includ
children
famili
come
care
v
van
de
veld
f
mussch
c
dhoog
grypdonck
univers
hospit
ghent
ghent
belgium
univers
hospit
ghent
pediatr
depart
ghent
belgium
univers
ghent
nurs
scienc
midwiferi
ghent
belgium
backgroundobject
understand
parent
experi
posttranspl
period
child
get
insight
commit
describ
influenc
factor
need
parent
order
improv
overal
support
parent
posttranspl
hospit
visit
designmethod
descript
qualit
studi
conduct
semi
structur
interview
held
parent
two
year
period
least
one
parent
hsct
patient
particip
interview
transcrib
code
constant
comparison
use
analys
data
result
home
parent
face
total
respons
care
child
continu
monitor
impli
great
burden
requir
great
effort
integr
rule
receiv
profession
daili
routin
parent
confront
insecur
medic
evolut
also
qualtiti
life
child
factor
influenc
experi
greater
lesser
extent
diseas
progress
durat
post
transplant
period
relationship
partner
famili
situat
social
environ
person
factor
person
background
practic
financi
situat
parent
adjust
lifestyl
take
care
child
priorit
need
depend
influenc
factor
parent
differ
need
trust
relationship
need
profession
need
receiv
inform
requir
need
psychosoci
practic
support
well
make
decis
parentsappreci
help
educ
sibl
need
profession
life
time
conclus
parent
face
immens
complex
extens
commit
return
home
child
hsct
furthermor
experi
ahc
highlight
valu
includ
nurs
support
role
plan
extend
program
cancer
continu
emphas
import
role
nurs
backgroundobject
patient
nephroblastoma
excel
surviv
rate
high
incom
countri
south
africa
upper
middl
incom
countri
access
chemotherapi
agent
excel
radiat
paediatr
surgic
intens
care
servic
howev
mani
patient
paediatr
malign
present
late
poor
outcom
studi
aim
characteris
cohort
patient
nephroblastoma
johannesburg
order
determin
nurs
prioriti
designmethod
retrospect
review
conduct
patient
nephroblastoma
treat
charlott
maxek
johannesburg
academ
hospit
januari
decemb
descript
statist
method
employ
result
record
patient
elig
inclus
male
femal
ratio
mean
age
year
distribut
stage
stage
stage
ii
stage
iii
stage
iv
stage
v
patient
treat
accord
siop
nephroblastoma
protocol
use
vincristin
actinomycin
adriamycin
crude
five
year
surviv
rate
caus
death
includ
infect
diseas
postop
complic
eight
patient
relaps
one
success
salvag
surviv
rate
cohort
encourag
middl
incom
countri
like
reflect
tumour
biolog
rather
access
care
qualiti
care
lack
success
salvag
therapi
south
africa
dictat
first
line
therapi
aggress
nurs
staff
awar
high
rate
infect
make
everi
effort
prevent
infect
treat
proactiv
occur
outreach
effort
nurs
concentr
malign
nephroblastoma
underdiagnos
south
africa
good
prognosi
backgroundobject
purpos
low
resourc
countri
like
india
child
famili
often
stagger
hospit
hospit
citi
citi
hope
reach
appropri
childhood
cancer
treatment
centr
object
identifi
delay
recognis
cancer
symptom
diagnosi
lack
referr
pathway
larg
vacuum
inform
guidanc
designmethod
retrospect
studi
review
topic
perform
parent
newli
diagnos
pediatr
cancer
patient
age
recent
diagnos
hospit
mumbai
inform
obtain
patient
file
initi
outsid
consult
record
individu
parent
interview
result
patient
rural
area
parent
littl
educ
low
econom
statu
urban
area
well
educ
middl
econom
statu
parent
interview
experienc
follow
challeng
recogn
sign
cancer
treat
child
fever
local
child
remain
undiagnos
absenc
clear
referr
pathway
resourc
get
child
medic
facil
clinic
hospit
lack
resourc
medic
equip
meant
diagnosi
made
even
cancer
recogn
referr
made
larg
vacuum
inform
guidanc
parent
experienc
referr
reach
pediatr
oncolog
ward
conclus
one
huge
challeng
face
low
incom
countri
includ
india
time
diagnosi
referr
treatment
lack
awar
among
parent
health
profession
hamper
time
present
cancer
treatment
advers
affect
outcom
requir
greater
treatment
intens
support
care
cost
treatment
toxic
treatment
abandon
rate
poorer
outcom
nurs
must
assum
strong
role
improv
childhood
cancer
awar
advoc
streamlin
referr
process
hdu
appropri
level
critic
care
intric
nurs
care
provid
critic
ill
children
requir
close
monitor
supervis
profici
nurs
medic
staff
relev
special
train
designmethod
due
need
pediatr
oncolog
children
cancer
hospit
cch
hdu
facil
expand
bed
januari
cch
collabor
outsourc
icu
manag
patient
requir
advanc
airway
support
provid
qualiti
healthcar
patient
within
facil
reduc
cost
outsourc
icu
hdu
expandedto
build
capac
pediatr
oncolog
nurs
technician
work
hdu
extens
thorough
oneweek
critic
care
cours
design
head
nurs
nurs
educ
depart
includ
theori
clinic
train
staff
also
recertifi
core
oncolog
nurs
process
result
current
hdu
nurs
technician
cch
train
provid
qualiti
focus
critic
nurs
care
pediatr
oncolog
patient
impact
aggress
capacitybuild
activ
hdu
nurs
process
monitor
evalu
motiv
nurs
staff
hdu
supplement
allow
given
conclus
cch
extend
capac
provid
advanc
nurs
care
optim
resourc
provid
qualiti
nurs
care
increas
skill
knowledg
critic
care
nurs
care
pediatr
oncolog
patient
designmethod
need
assess
spanish
creat
expert
nurs
educ
clinician
relev
intern
experi
use
snowbal
methodolog
onlin
survey
initi
sent
stakehold
hospit
countri
assess
current
chemotherapi
educ
common
chemotherapi
support
resourc
two
bilingu
chilean
nurs
educ
take
english
cours
provid
feedback
cultur
adapt
final
spanish
content
determin
survey
result
expert
feedback
peerreview
cours
pilot
chile
offer
across
latin
america
result
preliminari
survey
result
nurs
repres
hospit
countri
onethird
report
chemotherapi
educationtrain
new
nurs
twothird
offer
orient
variabl
durat
week
content
mani
exist
orient
program
lack
aphon
cours
content
latin
american
nurs
also
identifi
import
biotherapi
cancer
genet
drug
halflif
late
effect
legal
ethic
issu
psychosoci
issu
navig
research
protocol
fiftyperc
lack
chemotherapi
continu
educ
program
major
nurs
prepar
chemotherapi
wish
particip
aphon
cours
conclus
base
preliminari
survey
result
signific
demand
standard
comprehens
transcultur
appropri
chemotherapi
cours
latin
american
nurs
aphon
spanish
chemotherapybiotherapi
cours
offer
essenti
nurs
educ
enhanc
safe
chemotherapi
practic
improv
treatmentrel
outcom
r
punjwani
j
challinor
khatoon
n
ansari
bana
children
cancer
hospit
karachi
pakistan
univers
california
associ
adjunct
professor
nurs
san
usa
children
cancer
hospit
infect
control
karachi
pakistan
indu
hospit
indu
hospit
research
center
karachi
pakistan
children
cancer
hospit
nurs
servic
karachi
pakistan
backgroundobject
global
meet
support
care
need
children
famili
remain
challeng
continuum
cancer
care
pediatr
oncolog
nurs
play
major
role
support
care
sever
studi
suggest
nurs
educ
contribut
improv
patient
outcom
includ
reduc
mortal
contrast
extens
support
care
educ
clinic
train
provid
nurs
highincom
countri
pediatr
oncolog
nurs
educ
larg
unavail
pakistan
studi
design
determin
pakistani
pediatr
oncolog
nurs
percept
role
support
care
identifi
challeng
explor
learn
need
designmethod
experienc
pediatr
oncolog
nurs
educ
interview
nine
nurs
childhood
cancer
center
karachi
pilot
plan
indepth
studi
center
treat
approx
childrenyear
care
nurs
nurs
question
understand
support
care
saw
abil
provid
care
phase
two
studi
includ
indepth
interview
nurs
pediatr
oncolog
unit
public
privat
sector
hospit
facetofac
via
telephon
islamabad
karachi
lahor
result
major
theme
emerg
pilot
studi
includ
knowledg
deficit
commun
challeng
provid
psychosoci
supportuncertainti
doctornurs
boundari
commun
child
famili
time
constraint
staff
shortag
challeng
hinder
nurs
psychosoci
support
versu
activitybas
clinic
care
nurs
also
stress
need
support
care
educ
decreas
knowledg
gap
build
confid
studi
provid
much
need
initi
assess
gap
pakistani
nurs
understand
role
support
care
highlight
area
need
explor
studi
find
phase
two
use
design
curriculum
address
support
care
nurs
educ
need
backgroundobject
burnout
syndrom
emot
exhaust
depersonalis
result
reduc
person
accomplish
busi
understaf
paediatr
oncolog
unit
johannesburg
high
rate
absente
staff
turnov
note
popul
highli
skill
nurs
staff
previous
assess
sign
burnout
primari
object
studi
assess
perman
nurs
staff
work
paediatr
haematolog
oncolog
unit
charlott
maxek
johannesburg
academ
hospit
determin
preval
sign
burnout
secondli
determin
intervent
requir
designmethod
questionnair
base
maslach
burnout
inventori
mbi
administ
perman
nurs
staff
inand
outpati
unit
singl
research
mbi
valid
measur
burnout
measur
emot
exhaust
depersonalis
person
achiev
high
score
first
two
section
low
score
last
section
may
indic
burnout
nurs
staff
complet
questionnair
result
score
interpret
result
respons
rate
eight
respond
fulfil
criteria
burnout
remaind
particip
show
vari
level
emot
exhaust
depersonalis
decreas
person
achiev
though
none
met
criteria
full
blown
burnout
indic
popul
risk
senior
staff
member
encourag
debrief
freedom
express
possibl
contribut
low
rate
burnout
although
burnt
nurs
may
leav
unit
result
studi
confirm
hypothesi
nurs
unit
demonstr
high
level
burnout
nevertheless
nurs
staff
suscept
recommend
nurs
paediatr
oncolog
unit
made
awar
possibl
burnout
mind
selfcar
access
avail
support
servic
joshi
tata
memori
hospit
nurs
administr
mumbai
india
backgroundobject
high
qualiti
nurs
central
care
children
cancer
howev
nurs
india
face
mani
challeng
provid
nurs
care
children
differ
challeng
face
designmethod
exploratori
survey
structur
interview
schedul
result
major
nurs
age
group
year
educ
nurs
degre
undergon
oncolog
train
attend
special
train
pediatr
nurs
nurs
patient
ratio
inadequ
absente
put
pressur
nurs
complet
task
nurs
tri
complet
job
trial
error
agre
lot
time
util
non
nurs
job
like
control
rel
comput
work
etcnurs
sometim
face
challeng
new
equip
agre
train
function
equip
agre
function
assign
especi
even
night
shortag
staff
sometim
counsel
support
superior
accept
sometim
face
difficulti
commun
superior
father
child
subordin
never
problem
commun
fear
unsaf
environ
occup
psycholog
also
express
fear
medico
legal
issu
team
member
confid
take
decis
emerg
emot
upset
deal
parent
termin
ill
shown
concern
famili
children
come
far
distanc
treatment
face
difficulti
food
residenti
arrangementsveri
nurs
said
involv
treatment
plan
counsel
parent
conclus
nurs
pediatr
oncolog
setup
india
face
lot
challeng
caus
stress
need
identifi
factor
prepar
face
challeng
posit
way
thu
provid
qualiti
care
children
cancer
bana
k
arifa
r
punjwani
children
cancer
hospit
nurs
servic
karachi
pakistan
children
cancer
hospit
infect
control
karachi
pakistan
children
cancer
hospit
nurs
educ
servic
karachi
pakistan
backgroundobject
blood
cultur
sampl
essenti
tool
patient
investig
treatment
plan
improp
techniqu
lead
fals
result
eventu
caus
unnecessari
patient
suffer
morbid
addit
healthcar
coststh
rate
blood
cultur
contamin
children
cancer
hospit
although
rate
decreas
benchmark
blood
cultur
contamin
healthcar
clinic
laboratori
standard
institut
designmethod
qualityimprov
strategi
design
reduc
blood
cultur
contamin
base
earlier
find
new
nurs
inducte
began
work
unit
blood
cultur
contamin
rate
increas
intervent
two
compon
plan
implement
intervent
reduc
blood
cultur
contamin
inpati
emerg
depart
monitor
evalu
effect
intervent
plan
done
plandostudyact
modelth
head
nurs
design
implement
intervent
session
extens
exercis
certifi
recertifi
nurs
staff
blood
cultur
sampl
innov
teach
techniqu
monitor
evalu
process
coordin
laboratori
depart
analyz
rate
contamin
identifi
nurs
staff
respons
contamin
reevalu
practic
take
appropri
action
result
sinc
januari
nurs
staff
includ
regist
nurs
technician
work
abovement
depart
recertifi
blood
cultur
sampl
target
eventu
train
nurs
staff
conclus
week
octob
midjanuari
contamin
cultur
wherea
recertif
nurs
staff
five
blood
cultur
contamin
report
februari
trend
expect
decreas
nurs
staff
train
innov
toronto
canada
princess
margaret
cancer
centr
radiat
oncolog
toronto
canada
st
micheal
hospit
intern
medicin
toronto
canada
backgroundobject
aim
develop
test
usabl
secur
crossset
crossinstitut
interprofession
onlin
clinic
care
collabor
system
loop
adolesc
young
adult
cancer
caregiv
variou
healthcar
profession
hcp
designmethod
qualit
approach
semistructur
audiotap
interview
observ
train
observ
undertaken
three
iter
cycl
conduct
data
satur
determin
usabl
loop
interfac
purpos
sampl
englishspeak
adolesc
young
adult
year
recruit
two
canadian
tertiari
care
center
individu
interview
addit
purpos
sampl
englishspeak
hcp
special
pediatr
oncolog
n
pediatr
complex
medic
care
n
recruit
respect
focu
group
descript
statist
simpl
content
analys
use
organ
data
categori
reflect
emerg
usabl
theme
result
particip
access
comput
internet
home
report
high
level
comfort
use
overal
particip
like
appear
loop
valu
purpos
felt
easi
use
navig
understand
identifi
usabl
issu
problemat
navig
need
interfacerel
chang
format
layout
aesthet
necessari
addit
function
address
issu
follow
design
solut
implement
messag
stream
chang
present
messag
user
eg
hcp
patient
enhanc
collabor
parti
new
messag
notif
made
obviou
search
function
capac
enhanc
new
issu
identifi
follow
third
cycl
test
conclus
usabl
test
crucial
first
step
refin
clinic
collabor
system
meet
variou
endus
need
futur
work
focu
examin
impact
loop
patient
health
servic
util
outcom
use
random
control
trial
mozzilli
instituto
beaba
sao
paulo
brazil
backgroundobject
technolog
evolut
equip
modern
internet
access
contribut
increas
inform
technolog
especi
oncolog
area
patient
famili
member
eager
informationhowev
exponenti
growth
amount
inform
guarante
qualiti
respons
highlight
inadequaci
inappropri
inform
caus
fear
insecur
even
lack
commit
treatmentthi
studi
aim
inform
current
situat
renown
pediatr
oncolog
hospit
websit
designmethod
ten
websit
analyz
norm
descript
modelth
descript
model
contempl
exist
specif
area
lexivisu
content
organ
search
advanc
search
yesno
norm
model
base
principl
heurist
propos
ergonom
area
humancomput
interact
inform
design
inform
structur
simplic
clariti
uniti
usabl
acess
appropriateparti
appropriateinappropri
result
twenti
percent
evalu
websit
inform
twentyf
percent
websit
inform
search
thirtyf
percent
websit
compli
usabl
principl
hundr
percent
compli
access
principl
none
analyz
site
compli
adequaci
norm
model
increas
search
inform
natur
trend
inform
technolog
advanc
wherea
cancer
patient
like
involv
treatment
chronic
diseas
group
center
studi
health
system
chang
need
improv
websit
pediatr
oncolog
hospitalsth
appropri
product
inform
facilit
learn
provid
greater
identif
understand
ensur
messag
qualiti
inform
technolog
resourc
main
goal
assist
understand
treatment
assum
human
effect
meet
need
provid
relief
improv
patient
famili
qualiti
life
backgroundobject
studi
util
usercent
design
approach
develop
test
usabl
accept
understand
easi
navig
prone
errormak
smartphonebas
realtim
cancer
pain
manag
app
pain
squad
adolesc
designmethod
three
iter
cycl
usabl
test
involv
user
observ
use
refin
pain
squad
app
sixteen
adolesc
year
cancer
pain
previou
week
recruit
pediatr
tertiari
care
center
brief
app
demonstr
provid
entir
usabl
test
session
audiorecord
particip
use
app
think
aloud
issu
encount
interfac
content
two
experienc
observ
record
difficulti
navig
error
particip
answer
openend
question
address
experi
recommend
app
improv
use
rapidanalysi
approach
observ
discuss
session
content
develop
consensu
emerg
theme
relat
app
usabl
refin
made
audiorecord
refer
necessari
result
overal
adolesc
like
pain
squad
aesthet
content
endors
clinic
util
made
error
cycl
usabl
issu
relat
streamlin
navig
recommend
fewer
tap
navig
improv
access
gamif
element
abil
review
complianceencourag
video
chang
made
address
recommend
cycl
issu
relat
need
clearli
distinguish
mean
pain
assess
question
present
inform
relat
dose
time
recommend
pain
advic
chang
made
new
issu
identifi
cycl
multifacet
usabl
approach
util
provid
insight
realtim
pain
manag
app
made
amen
adolesc
cancer
next
step
includ
feasibl
test
test
intervent
effect
pediatr
blood
cancer
doi
random
control
trial
expect
accept
usabl
app
improv
pain
outcom
adolesc
cancer
j
challinor
backgroundobject
estim
patient
need
radiat
therapi
rt
access
lowand
middleincom
countri
lmic
samiei
effort
intern
atom
energi
agenc
pact
agart
program
global
twin
address
critic
situat
despit
effort
explor
elimin
rt
clinic
trial
highincom
countri
remain
essenti
tool
cure
diseas
retinoblastoma
hodgkin
lymphoma
ewe
sarcoma
central
nervou
system
tumor
palliat
particularli
relev
lmic
children
present
latestag
diseas
designmethod
literatur
review
identifi
rt
current
avail
lmic
nurs
role
special
area
search
term
includ
combin
key
word
radiat
therapi
nurs
develop
countri
lowand
middleincom
countri
addit
articl
identifi
articl
refer
list
result
twentysix
relev
articl
identifi
current
histor
rt
technolog
applic
state
rt
lmic
support
rt
side
effect
survivorship
nurs
mention
articl
despit
signific
effort
lmic
improv
rt
includ
govern
equip
purchas
physician
technician
train
signific
lack
inform
nurs
role
train
conclus
pediatr
oncolog
nurs
lmic
provid
mani
specialist
servic
eg
nutrit
guidanc
psychosoci
support
due
sever
shortag
alli
profession
lmic
nurs
basic
knowledg
rt
capabl
associ
risk
govern
twin
partner
scale
rt
children
particular
vulner
rt
rt
suitabl
palliat
low
public
awar
childhood
cancer
extend
myth
fear
surround
rt
lmic
whether
lmic
unit
current
rt
prepar
nurs
futur
rt
lmic
ensur
children
famili
inform
support
achiev
optim
outcom
childhood
cancer
rt
backgroundobject
children
cancer
regularli
subject
procedur
distress
even
traumat
parent
parent
play
essenti
role
care
physic
emot
children
parent
behavior
influenc
child
procedur
experi
shortand
longterm
run
reliabl
valid
theorybas
code
scheme
could
provid
mean
categor
parent
behavior
inform
theorybas
nurs
intervent
aim
support
parent
care
child
pain
procedur
exist
schema
neither
theorybas
nonverb
behavior
ampli
repres
thu
purpos
studi
develop
parent
care
respons
score
system
pcaress
base
swanson
theori
care
test
preliminari
reliabl
valid
designmethod
six
video
clip
show
parent
behavior
daughter
underw
procedur
visit
emerg
room
extract
documentari
wait
room
video
clip
use
induct
gener
preliminari
observ
code
pcaress
parent
behavior
code
gener
everi
second
code
deduct
structur
domain
consist
five
care
process
swanson
care
theori
interrat
reliabl
criterion
valid
pcaress
test
children
cancer
treatmentrel
port
start
result
pcaress
develop
three
type
parent
behavior
repres
verbal
item
nonverb
item
emot
indic
item
behavior
compris
seven
domain
know
item
item
backgroundobject
cancer
children
may
profoundli
affect
parent
term
psycholog
stress
increas
care
burden
spite
emot
impact
occur
one
child
diagnos
cancer
famili
receiv
limit
inform
support
assist
mani
factor
may
interfer
abil
parent
cope
child
diagnosi
nurs
awar
parent
teach
need
concern
critic
moment
purpos
studi
identifi
educ
need
concern
parent
children
cancer
designmethod
total
fifteen
parent
recruit
parent
associ
children
cancer
studi
focu
group
discuss
held
clinic
day
group
compris
five
particip
discuss
record
later
transcrib
analyz
result
nurs
identifi
lack
comprehens
diseas
process
princip
challeng
even
though
parent
counsel
treatment
begin
also
parent
concern
high
cost
treatment
childhood
cancer
cover
nation
health
insur
scheme
distanc
parent
travel
treatment
centr
yet
anoth
concern
rais
parent
sinc
two
cancer
treatment
center
countryaccra
kumasi
cope
chang
bodi
imag
treatment
outcom
diagnosi
durat
treatment
emerg
key
element
requir
educ
support
parent
conclus
even
though
educ
need
parent
children
cancer
drastic
chang
overnight
nurs
improv
qualiti
life
parent
children
cancer
provid
addit
psychosoci
support
cancer
inform
daili
interact
parent
backgroundobject
radiotherapi
treatment
aim
cure
orand
reliev
symptom
children
cancer
daili
treatment
day
per
week
period
day
leav
child
alon
treatment
room
expos
radiat
challeng
experi
mani
parent
gain
understand
parent
live
experi
parent
ask
write
diari
child
radiotherapi
treatment
designmethod
descript
induct
design
hermeneut
phenomenolog
approach
chosen
analyz
diari
parent
ask
write
live
experi
thought
reflect
child
radiotherapi
treatment
could
involv
eg
impact
famili
child
sibl
other
daili
note
short
long
desir
result
parent
describ
radiotherapi
treatment
twinpan
balanc
constantli
balanc
forc
protect
child
increas
child
chanc
surviv
parent
fight
child
live
child
emot
agoni
time
face
meanwhil
parent
struggl
despair
feel
powerless
protect
child
experienc
sens
hope
gain
control
conclus
parent
daili
written
reflect
import
clinic
practic
give
import
knowledg
parent
need
support
focus
forc
protect
child
need
help
inform
find
routin
gain
control
situat
acknowledg
would
like
express
gratitud
parent
agre
share
live
experi
us
swedish
childhood
cancer
foundat
fund
backgroundobject
teenag
young
adult
medicin
emerg
distinct
special
acknowledg
core
task
requir
enabl
young
person
transit
success
adulthood
aim
provid
intern
consensu
compet
requir
healthcar
profession
provid
specialist
cancer
care
popul
designmethod
modifi
intern
edelphi
survey
conduct
round
expert
defin
profession
work
field
cancer
care
month
identifi
public
invit
via
profession
organis
closedend
question
likert
scale
respons
openend
respons
identifi
skill
knowledg
attitud
round
contain
item
consensu
round
addit
suggest
item
compet
consensu
defin
median
score
rang
descript
statist
use
result
total
regist
member
expert
panel
valid
respons
avail
round
round
particip
nurs
doctor
europ
north
america
item
round
reach
consensu
addit
item
identifi
round
signific
differ
doctor
nurs
alli
profession
felt
import
skill
area
knowledg
attitud
exampl
nurs
vs
doctor
other
agre
provid
holist
care
import
wherea
doctor
vs
nurs
other
agre
abl
consent
clinic
trial
import
conclus
consensu
reach
compet
requir
healthcar
profession
care
popul
notabl
differ
across
profession
group
variat
accord
profess
highlight
import
distinct
explor
pursuit
effect
multidisciplinari
team
work
backgroundobject
aim
studi
evalu
construct
valid
reliabl
multidimension
smartphonebas
electron
pain
diari
pain
squad
schoolag
children
adolesc
cancer
designmethod
momentari
pain
data
collect
twice
daili
morn
even
particip
year
variou
cancer
diagnos
recruit
canadian
pediatr
tertiari
care
center
use
pain
squad
smartphon
diari
pain
squad
diari
measur
assess
multidimension
construct
pain
sensori
affect
evalu
dimens
construct
valid
assess
use
pearson
correl
averag
weekli
pain
intens
bothersom
interfer
score
pain
squad
diari
score
recal
averag
weekli
pain
score
converg
valid
b
overal
diseasespecif
healthrel
qualiti
life
hrql
discrimin
valid
week
reliabl
intern
consist
assess
use
cronbach
alpha
correl
averag
weekli
pain
intens
bothersom
interfer
score
week
result
adolesc
report
moder
level
pain
intens
pain
bothersom
pain
interfer
hypothes
pain
squad
diari
display
correl
averag
weekli
pain
intens
pain
bothersom
pain
interfer
moder
magnitud
posit
direct
recal
pain
b
low
magnitud
neg
direct
overal
hrql
diseasespecif
hrql
regard
reliabl
tool
predict
correl
averag
weekli
pain
intens
bothersom
interfer
high
cronbach
week
conclus
find
provid
evid
construct
valid
reliabl
pain
squad
smartphonebas
diari
adolesc
cancer
use
realtim
data
captur
approach
consid
futur
studi
selfreport
pain
pediatr
cancer
c
bartholdson
af
sandeberg
k
k
blomgren
p
pergert
backgroundobject
overal
aim
studi
describ
percept
paediatr
hospit
ethic
climat
among
healthcar
profession
treat
care
children
cancer
designmethod
studyspecif
questionnair
includ
modifi
version
item
hospit
ethic
climat
scale
develop
olsson
use
collect
data
descript
statist
perform
analys
percept
physician
nurs
nursingassist
work
three
paediatr
unit
children
cancer
admit
particip
result
item
less
select
posit
altern
indic
percept
poor
ethic
climat
item
select
posit
altern
nurs
rate
ethic
climat
posit
lesser
extent
physician
item
one
third
particip
state
abl
practic
ethic
good
care
also
greater
extent
nurs
physician
trust
one
anoth
guardian
wish
respect
twothird
state
inabl
practic
ethic
good
care
also
lower
extent
state
access
necessari
tool
abl
solv
ethic
issuesproblem
conflict
concern
ethic
issuesproblem
openli
dealt
avoid
atmospher
encourag
question
learn
seek
creativ
respons
ethic
problemsissu
treatmentcar
conclus
posit
percept
possibl
practic
ethic
good
care
seem
relat
interprofession
trust
listen
guardianspar
negativeneutr
percept
appear
influenc
lack
ethic
support
well
experi
ethic
conflict
might
risk
develop
moral
stress
backgroundobject
dramat
increas
surviv
children
acut
lymphoblast
leukemia
past
fifti
year
one
notabl
success
pediatr
oncolog
overal
surviv
rate
higher
document
contemporari
data
signific
racial
ethnic
dispar
mortal
rate
children
persist
reason
fulli
understood
sever
larg
cohort
studi
illustr
dispar
propos
variat
surviv
rate
may
aris
complex
interact
econom
social
cultur
biolog
pharmacogenet
factor
pediatr
oncolog
nurs
well
posit
identifi
patient
risk
poor
outcom
propos
strategi
earli
intervent
object
summar
find
recent
cohort
studi
describ
surviv
dispar
race
children
discuss
analyz
factor
may
contribut
suboptim
outcom
children
propos
strategi
nurs
mitig
risk
factor
may
interfer
diseasefre
surviv
children
designmethod
current
literatur
dispar
cancer
outcom
highlight
possibl
underli
caus
ethnic
racial
differ
surviv
children
leukemia
review
possibl
reason
ethicraci
differ
outcom
relat
nurs
care
children
cancer
present
result
socioeconom
environment
factor
correl
race
ethnic
impact
factor
earli
diagnosi
access
qualiti
health
care
enrol
clinic
trial
treatment
complianc
nurs
present
along
entir
trajectori
care
uniqu
posit
recogn
patient
risk
poor
outcom
due
racial
ethnic
factor
conclus
educ
pediatr
oncolog
nurs
identifi
risk
factor
harbing
poor
outcom
may
help
mitig
racial
ethnic
gap
surviv
rate
promot
optim
care
children
background
exclus
criteria
nonresearch
articl
literatur
review
particip
year
old
data
extract
includ
studi
content
analys
done
synthes
result
review
result
sixteen
articl
met
inclus
criteria
studi
focus
aspect
qol
includ
physic
psychosoci
social
spiritu
function
children
die
cancer
howev
studi
emphas
physic
psychosoci
function
dimens
commonli
neg
correl
qol
domain
physic
function
specif
fatigu
pain
dyspnea
children
die
due
treatmentrel
symptom
experienc
disproportion
pain
vomit
sleepi
weight
loss
poor
appetit
physic
fatigu
children
die
progress
diseas
children
receiv
intens
therapi
stem
cell
transplant
suffer
receiv
less
intens
therapi
chemotherapi
surgeri
chemotherapi
radiat
chemotherapi
alon
backgroundobject
purpos
comprehens
nurs
program
implement
pediatr
oncolog
unit
central
america
improv
qualiti
nurs
care
twentyfour
new
nurs
posit
creat
decreas
nurs
patient
ratio
fulltim
nurs
educ
hire
provid
pediatr
oncolog
educ
addit
process
establish
improv
nurs
qualiti
standard
purpos
studi
assess
program
impact
treatment
abandon
children
cancer
treatment
abandon
critic
problem
develop
countri
lead
caus
death
children
cancer
designmethod
preprogram
cumul
incid
cin
treatment
abandon
compar
postprogram
cin
intervent
site
control
site
new
nurs
intervent
implement
studi
period
sampl
includ
patient
diagnos
cancer
studi
period
result
preprogram
cin
treatment
abandon
intervent
site
significantli
higher
p
postprogram
cin
postprogram
cin
treatment
abandon
intervent
site
significantli
lower
p
postprogram
cin
control
site
conclus
signific
improv
cin
treatment
abandon
within
intervent
site
compar
control
site
found
sever
factor
may
contribut
studi
find
well
educ
nurs
better
abl
provid
parent
insight
regard
need
continu
therapi
improv
nursepati
ratio
allow
time
nurs
provid
individu
parent
educ
develop
countri
abandon
seen
primari
domain
psychologist
social
worker
combin
effort
nurs
psychosoci
intervent
may
best
option
prevent
abandon
murphi
white
k
viani
mosbi
agricultur
human
ecolog
foodnutrit
dieteticsdidact
program
dietet
tennesse
usa
backgroundobject
nutrit
screen
simpl
altern
nutrit
assess
identifi
children
cancer
risk
malnutrit
new
nutrit
screen
tool
childhood
cancer
scan
develop
scan
aim
identifi
need
nutrit
intervent
identifi
patient
current
undernourish
high
risk
becom
malnourish
scan
consist
score
question
total
score
identifi
patient
risk
malnutrit
refer
dietician
clinician
studi
aim
assess
scan
children
adolesc
cancer
designmethod
scan
use
screen
children
cancer
femal
solid
tumor
year
age
subject
classifi
risk
malnutrit
risk
malnutrit
accord
scan
measur
height
weight
bodi
mass
index
bmi
mid
upper
arm
circumfer
tricep
skinfold
taken
subject
measur
compar
malnutrit
risk
group
surviv
year
post
screen
record
result
scan
classifi
subject
risk
malnutrit
subject
identifi
risk
malnutrit
significantli
lower
valu
weight
z
score
p
bmi
z
score
p
tricep
skinfold
p
subject
risk
malnutrit
significantli
children
solid
tumor
classifi
risk
malnutrit
number
patient
surviv
year
screen
significantli
differ
risk
group
conclus
scan
new
tool
avail
screen
children
cancer
risk
malnutrit
enabl
earli
identif
treatment
malnutrit
children
screen
risk
malnutrit
reduc
weight
bodi
size
like
diagnos
solid
tumor
studi
tool
questionnair
four
aspect
nurs
care
commun
physic
psycholog
socioeconom
assess
biograph
data
parent
result
overal
rate
scale
averag
likert
scale
poor
rate
mean
score
highest
score
infect
control
practic
commun
well
time
reinforc
given
lowest
score
given
explan
orient
phase
diagnosi
physiolog
diseas
treatment
prognosi
child
import
nurs
improv
stereotyp
view
expect
parent
enhanc
satisfactori
level
trend
seen
patient
admit
first
time
satisfi
admit
nurs
score
mean
score
refer
given
social
help
given
hospit
variou
ngo
backgroundobject
physic
activ
paramount
import
enhanc
qualiti
life
cancer
survivor
nevertheless
grow
concern
declin
level
physic
activ
childhood
cancer
survivor
object
studi
examin
effect
adventurebas
train
enhanc
physic
activ
level
selfefficaci
qualiti
life
childhood
cancer
survivor
designmethod
random
control
trial
twogroup
pretest
repeat
posttest
betweensubject
design
conduct
childhood
cancer
survivor
particip
experiment
group
join
integr
adventurebas
train
health
educ
program
control
group
particip
receiv
amount
time
attent
experiment
group
way
specif
effect
outcom
measur
particip
exercis
behavior
chang
level
physic
activ
selfefficaci
qualiti
life
assess
time
recruit
month
start
intervent
result
baselin
month
intervent
experiment
group
report
statist
signific
differ
stage
chang
physic
activ
higher
level
physic
activ
selfefficaci
qualiti
life
control
group
conclus
adventurebas
train
found
effect
enhanc
physic
activ
level
selfefficaci
qualiti
life
among
childhood
cancer
survivor
least
month
healthcar
profession
consid
adopt
train
promot
regular
physic
activ
among
childhood
cancer
survivor
oncolog
nurs
led
modif
modif
discuss
skill
research
instrument
design
final
version
translat
back
english
ensur
equival
aim
keep
swedish
version
close
origin
adjust
necessari
exampl
statement
increas
dose
sedativesopi
believ
could
hasten
child
death
caus
confus
nurs
increas
dose
without
prescript
moreov
associ
made
euthanasia
anoth
statement
includ
fear
lawsuit
within
nordic
context
unusu
fear
report
author
relev
conclus
cultur
adapt
time
consum
necessari
ensur
respondentfriendli
relev
instrument
process
requir
expertis
pediatr
oncolog
nurs
linguist
ethic
well
questionnair
design
backgroundobject
cancer
cancer
treatment
affect
children
appetit
disrupt
normal
eat
behavior
pressur
ensur
adequ
intak
stress
parent
child
caus
struggl
control
within
famili
date
appropri
intervent
support
famili
lack
therefor
studi
aim
develop
intervent
reduc
feed
stress
support
children
famili
get
healthier
eat
behavior
designmethod
scientist
design
work
togeth
call
participatori
designsci
project
base
qualit
interview
children
parent
expert
session
health
care
provid
design
student
gener
idea
intervent
prototyp
intervent
test
among
famili
improv
design
test
iter
way
develop
intervent
pirat
game
children
year
age
explor
storytel
game
children
famili
travel
around
world
guid
treasur
map
visit
differ
contin
world
particip
fulfil
excit
foodrel
task
ie
pirat
tri
steal
food
prevent
steal
make
fruitcactu
pirat
tri
steal
fruit
prick
fulfil
task
children
earn
special
reward
everi
contin
repres
main
group
food
ie
dairi
product
game
teach
unconsci
food
fun
stimul
posit
food
associ
addit
game
provid
practic
tip
parent
stimul
reward
healthi
eat
behavior
pilot
test
reveal
famili
enjoy
game
children
spontan
tri
new
food
parent
felt
renew
inspir
deal
child
eat
behavior
come
month
game
test
famili
conclus
preliminari
result
look
promis
pirat
game
might
effect
manner
reduc
feed
stress
develop
healthi
eat
behavior
among
children
cancer
backgroundobject
patient
navig
track
shown
improv
outcom
adult
cancer
hiv
tuberculosi
similar
approach
could
help
reduc
treatment
abandon
ensur
followup
childhood
cancer
develop
log
book
pilot
aim
test
use
log
book
secondari
aim
investig
impact
outcom
designmethod
patient
male
median
age
year
four
childhood
cancer
centr
new
delhi
india
contact
cankid
nation
support
advocaci
group
assist
recruit
specif
parent
support
group
member
psgm
establish
initi
contact
everi
child
shortli
diagnosi
maintain
contact
least
weekli
basi
week
recruit
psgm
kept
record
successfulunsuccess
contact
treatment
statu
algorithm
lead
necessari
action
frequent
contact
counsel
financi
assist
etc
result
fivepoint
likert
scale
psgm
strongli
agre
log
book
simpl
use
decreas
work
load
deliv
better
patient
assist
contact
attempt
phone
inperson
success
contact
made
first
attempt
attempt
remind
subsequ
attempt
instanc
dissatisfact
express
ongo
treatment
instanc
wrong
phone
number
end
week
patient
aliv
treatment
patient
die
offer
treatment
abandon
treatment
abandon
return
subsequ
continu
treatment
carer
refus
provid
inform
contact
know
statu
pilot
demonstr
patient
navig
track
feasibl
accept
potenti
use
log
book
reduc
abandon
rate
ensur
followup
would
investig
larger
prospect
multicentr
studi
india
themat
analysi
interview
conduct
inform
prioritis
design
intervent
acceler
support
transit
result
themat
analysi
identifi
prepar
discharg
b
learn
live
disabl
c
move
new
normal
foster
emot
support
e
access
educ
vocat
support
f
promot
awar
late
effect
highlight
need
inform
train
famili
signpost
access
local
support
servic
promot
cope
strategi
young
peopl
need
address
develop
awar
day
train
cours
famili
support
inform
directori
local
sport
activ
directori
refin
discharg
plan
recommend
earli
referr
local
servic
new
partnership
health
psycholog
educ
servic
strengthen
knowledg
share
enhanc
awar
patient
need
teacher
train
day
way
forward
cours
design
multi
profession
group
includ
nurs
alli
health
profession
clic
sargent
social
care
team
youth
worker
parent
patient
repres
voluntari
organis
help
young
peopl
learn
cope
strategi
set
goal
support
new
partnership
local
brain
injuri
organis
headway
enhanc
access
learn
support
conclus
collect
evid
parent
young
peopl
live
brain
tumour
provid
new
insight
led
develop
initi
provid
inform
target
support
assess
impact
intervent
focu
futur
research
action
includ
format
implement
region
council
coordin
network
hospit
treat
childhood
cancer
led
design
hub
hospit
region
design
central
institut
nomin
advisori
board
author
present
member
repres
parent
organ
present
also
report
action
affect
frontlin
childhood
cancer
treatment
expect
patientspar
further
level
medic
treatment
childhood
cancer
japan
medic
profession
well
patientspar
expect
integr
turn
point
advanc
clinic
research
childhood
cancer
japan
cuntu
backgroundobject
sibl
often
refer
silent
suffer
diagnosi
childhood
cancer
life
threaten
blood
disord
place
tremend
strain
entir
famili
system
includ
sibl
children
percept
see
parent
take
strain
want
burden
rather
keep
quiet
parent
turn
know
commun
difficult
inform
intent
protect
talk
sibl
either
turn
creat
mani
conflict
emot
sibl
one
hand
feel
concern
anxieti
sick
sibl
yet
also
experi
anger
resent
designmethod
choc
psychosoci
support
team
develop
workbook
sibl
children
treatment
workbook
take
aspect
journey
impact
sibl
ill
famili
system
explor
understand
diagnosi
treatment
implic
provid
safe
space
feel
use
oneonon
basi
well
group
programm
also
incorpor
camp
context
combin
group
fun
element
camp
work
workbook
workbook
also
develop
bereav
sibl
result
parent
express
gratitud
comment
chang
children
profession
humbl
see
transform
sibl
work
workbook
learn
alon
good
express
thought
feel
may
fun
without
feel
guilti
sick
brother
sister
benc
backgroundobject
ngo
world
keep
within
budget
essenti
often
necessari
seek
assist
nonprofession
task
use
volunt
howev
born
mind
prior
start
volunt
programm
necessari
infrastructur
exist
within
organis
order
support
success
manag
volunt
programm
designmethod
sever
key
element
address
develop
volunt
programm
motiv
peopl
volunt
identifi
recruit
volunt
especi
region
histor
commun
high
level
volunt
screen
select
train
importantli
retent
recognit
manag
empower
volunt
provid
regular
support
supervis
ongo
evalu
essenti
protect
beneficiari
volunt
result
wellmanag
volunt
programm
result
greater
retent
volunt
turn
provid
essenti
support
organis
patient
famili
import
recognis
manag
volunt
take
signific
resourc
essenti
ensur
net
gain
organis
conclus
volunt
mobilis
coordin
becom
essenti
part
ngo
strateg
plan
howev
poorli
design
manag
programm
counterproduct
detriment
organis
result
obviou
former
pediatr
childhood
cancer
patient
get
activ
set
survivor
networkgrouporgan
offer
activ
survivorspati
austrian
survivor
group
consist
region
group
one
umbrella
group
region
survivor
group
focu
offer
meet
regular
basi
survivor
especi
offer
adapt
individu
need
person
exchang
addit
year
big
summer
parti
survivor
austria
organ
contrari
fun
activ
workshop
survivor
offer
twice
year
year
group
member
organ
first
symposium
survivor
medic
late
effect
besid
offer
survivor
mentor
patientsfamili
offer
three
austrian
hospit
coordin
region
survivor
group
moreov
group
repres
contribut
project
longterm
care
medic
profession
psychologist
parent
organ
involv
last
least
individu
survivor
get
possibl
activ
particip
european
intern
meet
conclus
one
major
aim
recruit
survivor
encourag
get
activ
member
furthermor
addit
object
expand
offer
seminar
activ
survivor
austria
focu
special
need
childhood
cancer
survivor
data
incom
employ
employ
statu
employednot
employ
obtain
longitudin
integr
databas
health
insur
labour
market
studi
databas
integr
data
labour
market
educ
social
sector
updat
year
outcom
studi
cohort
compar
use
regress
model
close
match
refer
group
parent
sampl
gener
popul
result
initi
analys
confirm
equival
averag
start
valu
two
year
diagnosi
caseand
refer
parent
civil
statu
parent
age
number
children
live
home
counti
resid
dispos
incom
educ
level
parent
incom
employ
decreas
significantli
follow
child
cancer
diagnosi
p
associ
pronounc
mother
incom
reduct
incom
mother
child
cancer
continu
six
year
postdiagnosi
p
father
incom
compar
refer
father
three
year
postdiagnosi
mother
also
like
stop
work
follow
child
cancer
diagnosi
compar
refer
mother
importantli
associ
father
employ
statu
identifi
conclus
parent
incom
employ
employ
statu
advers
affect
child
cancer
sweden
howev
famili
socioeconom
consequ
childhood
cancer
still
equal
distribut
men
women
father
incom
catch
year
mother
tend
disadvantag
regard
profession
life
sever
year
child
cancer
diagnosi
backgroundobject
one
everi
sixti
hundr
forti
young
adult
estim
survivor
childhood
cancer
survivor
may
longterm
side
effect
reduc
qualiti
life
famili
system
becom
secondord
survivor
data
long
term
psychosoci
adjust
specif
popul
lack
studi
explor
simultan
patient
famili
member
uncommon
major
exist
research
use
impair
model
adjust
ie
absenc
diagnos
psycholog
disord
howev
current
psychooncolog
research
direct
attent
toward
multidimension
flourish
model
wellb
ie
growth
purpos
realiz
person
capac
life
satisfact
aim
explor
adjust
wellb
group
thirtytwo
young
adult
survivor
five
year
stop
therapi
childhood
leukemia
fortythre
sister
brother
designmethod
measur
administr
psycholog
wellb
scale
satisfact
life
scale
gener
selfefficaci
scale
result
ttest
analys
show
differ
measur
patient
sister
brother
twelv
percent
particip
psycholog
disord
symptom
howev
thirtynin
percent
gener
selfefficaci
twenti
percentil
fiftyf
percent
show
lowtomoder
level
selfaccept
approxim
forti
percent
exhibit
lowtomoder
level
autonomi
environment
masteri
purpos
life
posit
relationship
thirtynin
percent
highli
satisfi
life
result
twelv
fifteen
questionnair
return
complet
respond
femal
fortytwo
percent
year
experi
nurs
year
experi
oncolog
ward
ninetytwo
percent
admit
work
relat
emot
stress
mostli
due
palli
care
death
children
financi
difficulti
famili
stress
led
feel
helpless
poor
concentr
main
symptom
headach
palpit
reduc
stress
rest
talk
colleagu
nurs
motiv
work
see
children
improv
given
financi
incent
appreci
servic
sixtyseven
percent
felt
like
leav
ward
reason
includ
death
children
perceiv
risk
chemotherapi
nurs
recommend
reduc
emot
stress
includ
psycholog
counsel
increas
staff
number
institut
recreat
activ
conclus
emot
stress
highli
preval
amongst
nurs
work
paediatr
oncolog
ward
ghana
seriou
potenti
staff
attrit
strategi
address
includ
psycholog
counsel
session
increas
staff
number
reduc
work
load
khatoon
r
punjwani
bana
r
rafiq
children
cancer
hospit
infect
control
karachi
pakistan
children
cancer
hospit
nurs
educ
karachi
pakistan
children
cancer
hospit
nurs
servic
karachi
pakistan
backgroundobject
improv
hand
hygien
complianc
chang
behavior
difficult
task
hospit
hand
common
mode
transmiss
infect
amongst
patient
health
care
worker
accord
center
diseas
control
prevent
cdc
proper
hand
hygien
singl
effect
strategi
reduc
health
care
associ
infect
hai
object
bring
behavior
chang
hand
hygien
practic
among
health
care
worker
hcw
reason
infect
control
nurs
manag
icnm
design
implement
care
effici
cost
effect
intervent
pediatr
oncolog
center
designmethod
intervent
plan
icnm
three
compon
avail
resourc
teach
train
session
hcw
monitor
evalu
appli
intervent
optim
avail
resourc
realiz
financi
constraint
icnm
advis
place
wall
mount
hand
rub
intraven
iv
stand
provid
intraven
therapi
keep
elbow
distanc
indic
moreov
hand
wash
station
also
place
everi
unit
reinforc
hand
hygien
practic
hcw
particip
hand
hygien
teach
session
organ
icnm
audit
feedback
system
design
monitor
evalu
complianc
hand
hygien
result
behavior
chang
strategi
massiv
impact
hand
hygien
practic
increas
amongst
hcw
implement
strategi
though
strategi
great
impact
high
depend
unit
hdu
reserv
attach
hand
rub
iv
stand
critic
care
area
alreadi
iv
pole
occupi
equip
infus
syring
pump
altern
strategi
plan
overcom
issu
hdu
conclus
behavior
modif
need
constant
reinforc
frequent
ongo
monitor
evalu
requir
keep
strategi
sustain
subsequ
therapi
abandon
rang
mean
lowest
three
countri
free
drug
highest
subsidi
avail
philanthrop
help
reduc
abandon
somewhat
bangladesh
produc
cytotox
depend
import
three
countri
govern
directli
control
import
five
role
deleg
specif
pharmaci
adult
hospit
one
free
market
forc
operateal
report
inconsist
suppli
key
drug
mercaptopurin
methotrex
cytosin
asparaginas
vincristin
antibiot
morphin
qualiti
doubt
express
brand
gener
drug
princip
sourc
india
designmethod
donor
must
realis
paediatr
oncolog
unit
best
place
develop
longterm
sustain
project
goal
identifi
realist
indic
base
qualit
quantit
data
must
avoid
temptat
focu
sole
quantit
inform
encourag
local
team
collect
varieti
data
enabl
comprehens
pictur
overal
project
effect
built
process
paediatr
oncolog
unit
learn
true
import
measur
impact
whilst
donor
benefit
wealth
divers
data
account
transpar
fundament
overal
success
secur
maintain
fund
regular
reportingfeedback
templat
schedul
develop
collabor
process
parti
train
provid
necessari
result
realist
sustain
approach
impact
measur
strengthen
overal
e
process
increas
paediatr
oncolog
unit
chanc
secur
longterm
fund
support
support
develop
servic
unit
provid
ultim
result
better
outcom
patient
conclus
fairli
easi
secur
oneoff
intervent
longterm
support
requir
evidencebas
progress
report
sustain
built
longterm
invest
impact
measur
backgroundobject
assess
parent
children
comprehens
inform
given
seek
consent
child
particip
phase
iii
clinic
oncolog
trial
identifi
factor
signific
influenc
parent
decis
make
process
designmethod
one
hundr
nineteen
parent
approach
enrol
child
clinic
oncolog
studi
ask
complet
interview
understand
measur
score
includ
item
requir
obtain
valid
consent
accord
french
legisl
result
item
best
understood
parent
risk
procedur
potenti
benefit
children
right
withdraw
durat
particip
item
least
understood
possibl
altern
treatment
aim
studi
potenti
benefit
child
seventi
parent
report
decis
evid
thirti
two
parent
declar
made
decis
togeth
investig
thirti
three
parent
took
decis
forti
three
parent
felt
level
quantiti
inform
given
satisfactori
even
level
inform
qualiti
sixteen
children
understood
protocol
phase
iii
clinic
trial
understand
often
meant
children
famili
receiv
proper
treatment
therefor
may
unnecessari
fear
anxieti
confus
potenti
lead
abandon
treatment
designmethod
cankid
initi
pediatr
psychooncolog
program
serv
low
cost
model
cancer
institut
organ
oper
focu
provid
famili
center
care
view
cancer
diagnosi
impact
whole
famili
initi
outlin
set
protocol
child
friendli
ward
explanationclarif
diagnosi
diseas
orient
counsel
parent
child
bereav
support
inform
tool
patient
caregiv
capac
build
social
support
team
sensit
workshop
healthcar
provid
result
measur
result
includ
advanc
patient
famili
support
servic
via
aforement
protocol
sensit
increas
knowledg
concern
pediatr
psychooncolog
care
advocaci
enhanc
standard
pediatr
psychosoci
care
india
result
child
famili
show
higher
rate
complianc
treatment
long
term
psycholog
emot
wellb
cankid
pediatr
psychooncolog
model
provid
famili
center
care
approach
work
collabor
bridg
gap
psychosoci
approach
treatmentcentr
approach
unit
two
approach
child
famili
face
cancer
provid
comprehens
healthcar
experi
best
possibl
outcom
despit
repres
small
proport
total
number
children
treatment
famili
impact
way
medic
care
paediatr
cancer
provid
el
salvador
process
attempt
reduc
treatment
abandon
multidisciplinari
team
optim
resourc
provid
money
public
transport
meal
patient
parent
reorgan
task
respons
improv
close
followup
famili
focus
energi
refin
detect
risk
factor
famili
vulner
abandon
result
variou
initi
dedic
abandon
rate
decreas
approxim
risk
famili
becam
main
forc
push
multidisciplinari
team
reexamin
care
human
relationship
improv
qualiti
care
patient
conclus
sinc
imposs
identifi
absolut
certainti
advanc
parent
stop
bring
child
treatment
consequ
team
effort
tri
prevent
abandon
direct
benefit
patient
well
develop
profession
human
qualiti
multidisciplinari
team
n
rossel
backgroundobject
abandon
treatment
repres
substanti
obstacl
cure
children
cancer
lowincom
countri
lic
initi
research
focus
find
measur
factor
causeeffect
relationship
among
quantifi
variabl
socioeconom
issu
link
abandon
intervent
base
provis
materi
resourc
parent
posit
impact
reduc
problem
intervent
reduc
abandon
becom
effect
qualit
research
need
understand
solv
minor
case
continu
defi
health
team
effort
designmethod
base
analysi
multidisciplinari
team
intervent
data
collect
ethnograph
studi
abandon
treatment
el
salvador
research
clinic
practic
togeth
offer
valuabl
sourc
knowledg
improv
result
famili
experi
socioeconom
emot
stress
cultur
religi
belief
interplay
compon
doctorpar
encount
involv
abandon
treatment
equal
import
result
show
commit
multidisciplinari
team
work
individu
approach
famili
risk
abandon
probe
effect
data
studi
show
valu
qualit
research
medic
set
signific
psychosoci
team
oncolog
need
understand
abandon
put
psychosoci
team
forefront
challeng
promot
role
insid
medic
practic
personnel
occur
qualit
research
essenti
explain
mean
relationship
like
famili
dynam
live
circumst
emot
involv
experi
child
undergo
cancer
treatment
conclus
abandon
treatment
cruel
remind
health
team
recogn
impact
sociocultur
mean
treatment
cancer
outcom
highlight
need
approach
practic
inform
qualit
research
mobil
enhanc
psychosoci
team
backgroundobject
children
like
other
develop
resili
face
similar
level
trauma
exposur
compar
other
increasingli
clear
critic
role
predispos
genet
environment
influenc
differenti
mediat
psycholog
risk
resili
differ
tradit
concept
risk
protect
focu
individu
variat
respons
compar
experi
test
hypothesi
anxieti
depress
well
neural
repair
plastic
relat
polymorph
may
partli
account
differ
resili
observ
treatment
acut
lymphoblast
leukemia
designmethod
fortyf
patient
yr
old
diagnos
enrol
two
center
protocol
genotyp
bdnf
patient
famili
subject
short
screen
batteri
psychosoci
test
specif
assess
resili
treatment
resili
scale
compos
three
subscal
sens
masteri
ma
sens
related
rel
emot
reactiv
rea
result
patient
sl
allel
compromis
score
area
resili
patient
allel
presenc
allel
affect
emot
reactiv
rea
sens
masteri
ma
furthermor
age
import
factor
younger
children
display
reduc
trust
toler
versu
surround
contribut
importantli
overal
reduct
overal
resili
also
resili
reduc
one
year
therapi
vulner
significantli
enhanc
conclus
gene
regul
suscept
stress
bdnf
may
help
predict
suscept
toward
develop
resili
children
adolesc
treat
cancer
may
play
critic
role
predispos
factor
differenti
deal
effici
emot
risk
relat
cancer
treatment
backgroundobject
paediatr
brain
tumour
patient
pbtp
treat
medulloblastoma
increas
risk
neurocognit
deficit
compar
pbtp
radiat
dose
critic
factor
less
known
effect
social
behaviour
qualiti
life
qol
compar
tumour
type
investig
differenti
effect
pediatr
brain
tumour
typetreat
low
grade
glioma
lgg
medulloblastoma
medbl
brain
tumour
obt
includ
astrocytoma
pbtp
social
skill
qol
designmethod
eighti
pbtp
age
year
stabl
medic
condit
attend
school
particip
parent
selfreport
questionnair
use
assess
social
skill
social
skill
rate
system
ssr
qol
gener
pbtp
averag
year
postdiagnosi
one
way
anova
use
diagnosistreat
type
conduct
outcom
measur
alpha
level
bonferroni
correct
effect
size
report
result
social
skill
signific
differ
diagnosi
type
self
parentreport
total
social
skill
p
assert
score
p
selfreport
empathi
subscal
p
parentreport
selfcontrol
subscal
p
parent
report
poorest
selfcontrol
score
lgg
qol
parentreport
qol
indic
signific
effect
emot
p
social
domain
p
lgg
experienc
poorer
emot
qol
medbl
experienc
poorer
social
qol
selfreport
show
signific
effect
conclus
patient
treat
medbl
may
experi
social
skill
difficulti
pbtp
emot
qol
major
concern
lgg
patient
compar
pbtp
find
emphas
import
examin
detail
factor
diagnosistreat
might
critic
outcom
backgroundobject
qualit
studi
challeng
assumpt
made
adult
cultur
silenc
suppos
golden
childrenour
purpos
offer
cathart
space
young
cancer
patient
describ
experi
diagnosi
remiss
designmethod
collect
data
therapeut
group
children
hospit
pediatr
oncolog
unit
seneg
describ
treatment
process
hospit
repercuss
regular
live
instruct
write
letter
newli
diagnos
patient
prepar
upcom
cancer
experi
origin
idea
dr
wiener
collect
data
hospit
patient
age
result
patient
report
detail
descript
physic
explor
necessari
diagnosi
treatment
process
includ
frequent
blood
draw
chemotherapi
color
infus
surgeri
pain
aftermath
young
patient
also
address
bodili
chang
provok
chemotherapi
interact
appreci
staff
well
hospit
stay
daybyday
unexpectedli
paid
special
attent
temperatur
room
qualiti
food
distinct
qualiti
care
amongst
medic
practition
depend
time
day
newli
diagnos
pair
young
patient
focus
deepli
pain
procedur
emot
experi
away
home
depress
phase
treatment
stigmat
school
home
seneg
assum
children
fragil
inform
yet
surpris
mind
awar
cancer
experi
contrarili
popular
belief
assum
young
patient
ca
nt
talk
diseas
demonstr
children
eas
describ
patholog
detail
parent
focu
aspect
oblivi
adult
eye
backgroundobject
children
cancer
unitindu
hospit
provid
free
cost
servic
children
cancer
come
treatment
pakistan
afghanistan
sinc
pauciti
human
financi
resourc
visit
could
made
home
bereav
famili
offer
condol
support
therefor
protocol
devis
would
includ
offer
condol
call
via
telephon
bereav
famili
identifi
area
improv
end
life
care
servic
offer
designmethod
sixtyf
bereav
famili
approach
interview
spiritu
counselor
psychotherapist
train
person
center
care
telephon
result
qualit
analysi
carri
theme
preval
end
life
care
excruci
pain
children
cancer
face
parent
trauma
well
post
traumat
experi
parent
face
see
death
child
reli
divin
reason
end
suffer
death
subsequ
relief
also
factor
came
moreov
parent
want
way
eas
death
child
bereav
phase
factor
identifi
support
famili
felt
health
profession
children
cancer
unit
indu
hospit
better
cope
mechan
grief
lose
child
gratitud
sens
calm
get
condol
call
counselor
one
show
distress
given
grief
counsel
backgroundobject
treatment
abandon
import
hurdl
optimum
outcom
children
lowmiddl
incom
countri
malign
track
patient
abandon
therapi
recong
use
intervent
tool
herein
describ
experi
postabandon
track
effect
outcom
children
abandon
therapi
designmethod
patient
manag
author
institut
abandon
therapi
track
telephon
postal
commun
use
whenev
telephon
commun
fail
contact
famili
call
weekli
till
return
treatment
child
die
contact
parentsrespond
counsel
social
workerphysician
regard
import
resum
treatment
urg
return
immedi
result
patient
abandon
therapi
telephon
call
made
famili
could
contact
give
medianmean
rang
telephon
call
could
contact
telephonenumb
invalid
call
went
unattend
told
wrong
number
letter
sent
famili
evok
responsesin
total
famili
could
contact
upon
contact
patient
report
expir
patient
told
well
patient
return
repeat
counsel
assur
possibl
support
averag
call
made
famili
relaps
recurr
abandon
seen
patient
return
die
relaps
still
treatment
conclus
track
patient
postabandon
unsuccess
half
patient
outcom
abandon
remain
grim
despit
effort
postabandon
counsel
fail
ensur
complianc
major
contact
famili
futur
effort
need
focuss
preemptiv
strategi
backgroundobject
scoliosi
recogn
complic
children
receiv
radiotherapi
hemiabdomen
care
taken
radiat
oncologist
ensur
deliveri
homogen
radiat
width
vertebra
minim
complic
craniospin
irradi
csi
entir
width
vertebra
usual
given
homogen
dose
examin
incid
scoliosi
longterm
survivor
medulloblastoma
designmethod
sinc
children
surviv
least
year
photon
radiotherapi
medulloblastoma
one
institut
twentytwo
children
routin
spinal
xray
detect
scoliosi
subject
report
seventeen
male
twelv
year
age
csi
treat
use
photon
techniqu
craniospin
axi
gy
follow
imrt
boost
posterior
fossa
andor
tumor
bed
patient
also
receiv
chemotherapi
accord
one
multiinstitut
protocol
result
scoliosi
seen
patient
patient
follow
least
year
patient
routin
spine
xray
median
time
scoliosi
month
csi
rang
month
scoliosi
associ
gender
age
time
csi
csi
dose
length
followup
presenc
hemiparesi
degre
scoliosi
degre
patient
scoliosi
involv
thoracolumbar
region
thorac
spine
thoracolumbosacr
region
cervicothoracolumbar
region
none
patient
surgic
intervent
scoliosi
conclus
scoliosi
underreport
complic
csi
found
twothird
children
treat
medulloblastoma
despit
high
frequenc
minim
requir
intervent
howev
longer
followup
need
regard
signific
find
backgroundobject
aim
project
provid
comprehens
prepar
framework
incorpor
patient
involv
peer
support
practic
facil
work
miniatur
model
linac
linear
acceler
therapeut
play
increas
understand
familiar
radiotherapi
plan
procedur
prior
commenc
treatment
anxieti
level
lower
need
gener
anaesthet
may
decreas
demystifi
process
radiotherapi
also
increas
complianc
result
reduc
time
spent
treatment
room
designmethod
month
period
children
adolesc
age
year
film
interview
throughout
radiotherapi
procedur
film
organis
four
stage
introduct
radiotherapi
immobilis
ct
plan
treatment
download
onto
ipad
film
taken
patient
bedsid
clinic
consult
anoth
hospit
home
visit
child
famili
view
step
radiotherapi
process
via
prepar
film
practic
familiaris
individu
treatment
plan
miniatur
machin
commiss
within
depart
result
feedback
questionnair
adolesc
film
overwhelmingli
posit
patient
parent
report
increas
understand
radiotherapi
process
result
current
obtain
paediatr
version
use
ageappropri
questionnair
children
parentscar
opportun
view
children
similar
age
go
procedur
allow
peer
learn
support
practic
play
activ
miniatur
linac
help
normalis
experi
conclus
support
framework
ensur
paediatr
patient
come
radiotherapi
equal
access
tool
equip
appropri
effect
prepar
individu
child
treatment
regardless
languag
cultur
differ
backgroundobject
even
though
gener
anesthesia
ga
effect
proof
safeti
necessari
immobil
patient
radiotherapi
rt
session
stay
time
costli
method
know
littl
consequ
long
run
repeat
use
childhood
use
ritual
andor
hypnosi
encourag
multipl
field
medicin
enabl
distract
uncomfort
moment
treatment
seem
children
natur
propens
observ
studi
took
place
rt
children
cancer
depart
leon
berard
region
center
lyon
franc
aim
evalu
place
altern
ritual
andor
hypnosi
rt
designmethod
two
time
period
compar
second
one
introduc
accompani
method
hypnosi
systemat
children
year
benefit
rt
period
includ
pt
result
signific
differ
two
popul
age
sex
local
rt
significantli
hightechn
rt
second
period
vs
p
signific
reduct
use
ga
vs
p
global
techniqu
use
second
period
sophist
longer
session
optim
asset
limit
margin
ga
frequent
pt
like
undergo
rt
without
ga
oldest
patient
treat
abdomin
lesion
backgroundobject
estim
cancer
aris
accumul
mutat
tissu
stem
cell
effect
elimin
cancer
stem
cell
accomplish
use
varieti
particl
radiat
high
linear
energi
transfer
let
valu
caus
doublestrand
dna
break
hard
repair
lower
let
radiat
photon
electron
includ
betaemit
pharmaceut
alpha
particl
emitt
us
fda
ema
approv
prostat
cancer
improv
pain
bone
metastas
prolong
surviv
designmethod
success
reach
dose
expans
cohort
use
osteosarcoma
kbqkg
monthli
result
standard
dose
use
prostat
cancer
hematolog
toxic
minor
signific
grade
toxic
seen
preliminari
imag
data
osteoblast
tumor
shown
fluoridepetct
better
fdgpetct
mdp
bone
scan
evalu
respons
one
patient
brain
metastas
show
travers
blood
brain
barrier
new
technolog
provid
imag
guid
proton
beam
therapi
techniqu
rapidli
improv
also
cost
build
new
proton
center
enhanc
precis
capabl
estim
tenth
cost
decad
ago
improv
immobil
imageguid
proton
therapi
evolv
allow
deliveri
precis
particl
therapi
larger
fraction
hypofraction
proton
plan
current
develop
exampl
shown
sinc
relaps
site
nonosteoblast
metastas
continu
problem
mean
specif
target
proton
tumor
stem
cell
need
less
toxic
decreas
cost
potenti
increas
efficaci
particl
therapi
alpha
particl
andor
proton
becom
wide
use
children
adolesc
adult
malign
reli
radiat
durabl
local
control
eg
axial
osteosarcoma
ewe
sarcoma
bone
brain
metastas
mechanist
pevonedistat
led
dephosphoryl
via
upregul
perk
inhibitor
caus
proteotoxic
stress
failur
halt
protein
translat
pevonedistat
also
led
upregul
increas
protein
synthesi
augment
proteotoxic
stress
addit
studi
mechan
pevonedistatinduc
apoptosi
reveal
homeostasi
proand
antiapoptot
protein
rebalanc
favor
cell
death
decreas
prosurviv
activ
via
sequestr
noxa
bim
activ
pathway
follow
pevonedistatinduc
cell
death
also
note
possibl
compensatori
mechan
demonstr
vitro
synergi
pevonedistat
effect
antileukem
drug
show
nsg
mice
harbor
human
cell
treat
pevonedistat
plu
dexamethason
statist
signific
increas
surviv
compar
singl
agent
therapi
lend
support
clinic
investig
pevonedistat
part
multiag
approach
conclus
data
demonstr
nae
inhibitor
pevonedistat
alter
cell
translat
machineri
lead
vitro
vivo
er
stressuprmedi
cell
death
suggest
pevonedistat
may
prime
effect
cell
affect
apoptot
threshold
modul
prosurviv
activ
backgroundobject
acut
lymphoblast
leukaemia
common
childhood
malign
bangladesh
potenti
curabl
high
rate
treatment
refus
abandon
seen
princip
reason
cost
burden
famili
pay
drug
first
studi
perform
bangladesh
assess
cost
child
designmethod
crosssect
studi
cost
incur
famili
child
bsmmu
hospit
conduct
six
month
period
parent
request
keep
submit
receipt
cost
drug
transport
food
accommod
five
treatment
phase
initi
investig
remiss
induct
intensif
consolid
mainten
children
treat
modifi
uk
medic
research
council
protocol
backgroundobject
involv
central
nervou
system
cn
acut
lymphoblast
leukemia
associ
advers
prognosi
cn
direct
therapi
indispens
patient
indic
subclin
cn
manifest
mani
patient
therefor
aim
character
mechan
mediat
cn
leukemia
identifi
target
direct
treatment
designmethod
primari
bcell
precursor
cell
xenograft
nodscid
mice
onset
diseas
leukemia
cell
isol
bone
marrow
bm
cn
analyz
transcriptom
profil
cell
vegf
knockdown
overexpress
respons
vegf
antagon
antibodi
analyz
subset
patientderiv
xenograft
sampl
observ
leukemia
manifest
bm
spleen
peripher
blood
along
mening
infiltr
contrast
absent
cn
manifest
despit
high
infiltr
bm
spleen
blood
line
mening
enhanc
detect
magnet
reson
imag
express
profil
compar
cn
bmderiv
cell
identifi
vascular
endotheli
growth
factor
vegf
significantli
upregul
cnsall
cell
interestingli
increas
level
vegf
known
mediat
vascular
permeabl
transendotheli
migrat
report
cerebrospin
fluid
cnsposit
acut
leukemia
patient
vegf
overexpress
downregul
exposur
leukemia
cell
vegf
antivegf
antibodi
bevacizumab
affect
cellular
prolifer
surviv
brain
endotheli
cell
vegf
induc
signal
activ
mediat
endotheli
permeabl
interestingli
transwel
model
brain
endotheli
cell
vegfdepend
transendotheli
leukemia
cell
migrat
observ
moreov
vivo
model
cnsposit
antivegf
treatment
significantli
reduc
leukemia
load
cn
organ
compart
conclus
summari
identifi
vegf
mediat
cn
manifest
importantli
vivo
vegf
inhibit
significantli
decreas
involv
cn
indic
novel
therapeut
strategi
control
cn
leukemia
common
breakpoint
locat
within
mll
gene
intron
detect
case
less
frequent
breakpoint
intron
intron
other
found
estim
prognost
signific
mll
breakpoint
locat
case
homogen
treat
mllbabi
protocol
eventfre
surviv
significantli
lower
patient
breakpoint
intron
comparison
patient
breakpoint
local
intron
exon
vs
cumul
incid
relaps
remark
higher
first
group
patient
cardiactox
howev
none
toxic
death
occur
univari
analysi
age
ldh
sap
ul
thrombocytopenia
cardiotox
found
poor
prognost
variabl
howev
multivari
analysi
cardiotox
identifi
independ
variabl
df
os
ldh
sap
found
poor
prognost
marker
sap
ldh
albumin
found
predictor
gi
toxic
sap
alon
thrombocytopenia
conclus
nonhd
mtx
base
regimen
proven
effect
econom
easi
manag
even
nutrit
challeng
high
tumorburden
osteosarcoma
ldh
sap
albumin
identifi
nonconvent
potenti
prognost
marker
toxic
predict
baselin
cardiotoxicti
identifi
novel
marker
df
merit
explor
select
current
studi
patient
year
studi
entri
recruit
year
ago
aliv
free
diseas
year
inclus
patient
receiv
methotrexateetoposideifosfamid
chemotherapi
doxorubicinplatinum
postop
poor
histolog
respons
zainject
accord
randomis
height
normalis
age
gender
use
growth
curv
transform
zscore
repeat
zscore
time
model
use
mix
model
consid
time
treatment
followup
time
separ
covari
includ
treatment
za
versu
za
initi
zscore
age
pubert
statu
current
studi
focus
patient
mean
initi
zscore
significantli
higher
p
mean
followup
durat
year
mean
height
increas
cm
lower
expect
lead
mean
decreas
zscore
signific
differ
randomis
group
za
versu
za
multivari
model
zscore
significantli
decreas
time
even
end
treatment
although
slope
less
steep
treatment
slope
treatment
followup
interact
test
p
decreas
significantli
import
younger
patient
p
patient
high
zscore
studi
entri
observ
signific
impact
za
patient
growth
interact
treatment
time
conclus
patient
osteosarcoma
may
taller
healthi
peer
osteosarcoma
treatment
appear
impact
children
growth
regardless
zoledron
acid
result
base
skygband
analysi
genom
instabl
gi
score
estim
tumor
similar
human
osteosarcoma
wide
spectrum
gi
found
tumor
display
chang
other
display
chromosom
aberr
identifi
frequent
amplif
loss
skycgh
subsequ
array
cgh
fish
qrt
pcr
analysi
demonstr
coamplif
overexpress
transcript
amplicon
loss
decreas
express
homolog
human
chromosom
band
respect
shown
compel
homolog
genom
chang
identifi
mous
tumor
sever
human
cancer
studi
also
demonstr
coamplif
overexpress
myc
gene
regul
high
myc
protein
level
noncod
micro
rna
may
provid
consider
therapeut
target
mycdriven
osteosarcoma
addit
identifi
novel
tumor
suppressor
gene
proapopot
properti
function
signific
gene
need
ascertain
os
result
patient
complet
full
week
treatment
without
sign
activ
diseas
gbm
one
patient
die
due
pneumonia
without
clinic
tumor
progress
month
relaps
two
patient
aliv
progressionfre
followup
month
follow
seriou
advers
event
sae
observ
intracrani
hemorrhag
neurolog
deterior
seizur
pneumonia
edema
sever
obstip
pain
cellul
suspect
unexpect
seriou
advers
reaction
susar
occur
recruit
prematur
stop
due
alter
risk
assess
neg
clinic
data
employ
cilengitid
hgg
surviv
compar
histor
relaps
patient
databas
treat
individu
median
overal
surviv
hithggcilmetro
vs
year
signific
sinc
three
gbm
longterm
survivor
might
repres
true
respond
molecular
analys
done
therapeut
target
ie
integrin
express
gbm
without
differ
survivor
other
interestingli
cilmetro
respond
demonstr
unmethyl
mgmt
promot
statu
molecular
analys
includ
egfr
pdgfra
statu
atrx
mycnamplif
inconclus
conclus
hithggcilmetro
offer
feasibl
salvag
treatment
approach
toler
toxic
pediatr
patient
relaps
hgg
might
induc
increas
progressionfre
surviv
gbm
subgroup
potenti
unmeythyl
mgmt
promot
statu
backgroundobject
analyz
outcom
assess
prognost
impact
clinic
characterist
pediatr
patient
local
ependymoma
french
muticentr
cohort
designmethod
patient
newli
diagnos
intracrani
ependymoma
treat
adjuv
radiat
therapi
rt
french
major
radiat
oncolog
center
januari
decemb
clinic
data
retrospect
gather
webbas
nation
databas
januari
median
age
locat
posterior
fossa
supratentori
anaplast
featur
extent
resect
grosstot
median
deliv
dose
gy
sixtysix
patient
receiv
prert
chemotherapi
rt
conform
patient
intensitymodul
imrt
tomotherapi
protontherapi
median
follow
time
month
estim
cumul
incid
local
relaps
year
recurr
mainli
local
strictli
local
recurr
local
distant
strictli
distant
estim
overal
surviv
os
eventfre
surviv
ef
rate
respect
patient
receiv
dose
vs
dose
gy
p
threeyear
os
ef
respect
patient
older
year
initi
rt
children
less
year
threeyear
os
better
grosstot
resect
vs
larg
multicentr
french
cohort
children
local
intracrani
ependymoma
signific
better
surviv
dose
gy
age
younger
year
initi
rt
incomplet
surgeri
signific
prognost
factor
wors
outcom
backgroundobject
children
diagnos
diffus
intrins
pontin
glioma
dipg
succumb
within
twoyear
diagnosi
clinicaltri
last
four
decad
fail
demonstr
surviv
benefit
adjuv
chemotherapi
radiotherapi
effect
treatment
thu
far
limit
durat
aim
studi
determin
safeti
efficaci
reirradi
designmethod
sinc
septemb
patient
dipg
show
clinic
radiolog
progress
consid
reirradi
retrospect
review
demograph
clinic
radiat
data
patient
dipg
treat
canada
reirradi
result
sinc
septemb
patient
progress
dipg
receiv
reirradi
canada
median
age
diagnosi
year
rang
median
time
diagnosi
progress
month
rang
reirradi
total
dose
vari
institut
gy
patient
gy
patient
gy
patient
gy
daili
fraction
reradi
focal
except
two
patient
receiv
wholebrain
irradi
due
distantdissemin
relaps
one
patient
receiv
third
cours
focal
radiat
gy
month
reradi
reirradi
well
toler
children
dexamethason
avoid
feasibl
necessari
patient
four
patient
transient
tired
decreas
appetit
treatment
one
show
neurolog
improv
patient
show
fullrecoveri
median
followup
diagnosi
month
rang
seven
patient
die
median
time
reirradi
death
month
rang
compar
histor
cohort
patient
median
time
progress
death
day
non
reirradi
patient
vs
day
reirradi
one
p
limit
experi
reirradi
safe
feasibl
patient
progress
dipg
provid
neurolog
recoveri
prolong
life
span
f
ratio
patient
receiv
recommend
induct
chemotherapi
radiotherapi
patient
receiv
st
thiotepa
consolid
receiv
nd
dose
thiotepa
consolid
patient
die
end
studi
period
follow
rang
month
mean
progress
diseas
toxic
treatment
grade
neurotox
note
patient
develop
fairli
rapid
onset
global
neural
deterior
bulbar
dysfunct
patient
neurolog
intact
thiotepa
consolid
mri
brain
show
vari
degre
leucoencephalopathi
chang
patient
audit
show
sever
unexpect
neurotox
use
intens
chemotherapi
hart
high
dose
thiotepa
consolid
treatment
strategi
discontinu
uk
immedi
follow
audit
research
urgent
need
improv
outcom
enigmat
diseas
backgroundobject
aggress
chemoradi
treatment
introduc
improv
dismal
prognosi
high
risk
pnet
increas
concern
combin
therapi
may
result
neurotox
clinic
impact
find
remain
determin
aim
analysi
investig
relationship
brain
volum
loss
function
statu
children
treat
sequenti
chemotherapi
hyperfraction
acceler
radiotherapi
hart
highdos
thiotepa
autolog
stemcel
rescu
designmethod
retrospect
review
clinicoradiolog
data
children
primit
neuroectoderm
tumour
includ
supratentori
pnet
high
risk
medulloblastoma
pineoblastoma
treat
nation
referr
centr
accord
milan
cancer
centr
protocol
publish
gandola
et
al
j
clin
oncol
feb
serial
mri
scan
present
end
treatment
qualit
analys
two
board
certifi
neuroradiologist
assess
brain
volum
loss
signal
abnorm
quantit
brain
volum
analysi
undertaken
use
fsl
sienax
toolkit
function
statu
determin
use
lanski
perform
scale
result
thirteen
children
develop
generalis
brain
volum
loss
moder
sever
volum
loss
children
children
receiv
thiotepa
suffer
moder
sever
brain
volum
loss
mean
brain
volum
loss
subject
averag
year
present
two
children
develop
transvers
myeliti
patient
suffer
peripher
neuropathi
urinari
incontin
seizur
perform
statu
sever
restrict
children
lanski
score
mild
moder
impair
note
children
lanski
score
conclus
substanti
brain
volum
loss
evid
cohort
children
follow
treatment
children
sever
mild
moder
impair
clinic
perform
statu
presenc
imag
chang
associ
greater
perform
declin
end
therapi
backgroundobject
lymphoma
one
common
childhood
malign
incid
overal
subtyp
vari
significantli
worldwid
variabl
may
due
differ
genet
environment
factor
howev
work
need
elucid
pattern
childhood
lymphoma
develop
countri
therefor
analyz
childhood
lymphoma
incid
trend
thailand
compar
result
unit
state
us
data
evalu
follow
childhood
lymphoma
subtyp
hodgkin
lymphoma
hl
nonhodgkin
lymphoma
nhl
designmethod
use
populationbas
cancer
registri
data
five
provinc
thailand
data
us
obtain
surveil
epidemiolog
end
result
program
comput
agestandard
incid
rate
asir
use
standard
popul
evalu
tempor
chang
incid
year
diagnosi
use
joinpoint
regress
report
annual
percent
chang
apc
designmethod
follow
data
collect
retrospect
review
report
patient
diagnos
start
treatment
pediatr
oncolog
depart
south
egypt
cancer
institut
seci
age
sex
diagnosi
durat
travel
patient
home
seci
time
lag
first
symptom
till
first
visit
seci
first
visit
till
start
treatment
first
evalu
initi
cours
therapi
complianc
therapi
noncompli
therapi
defin
patient
miss
determin
appoint
therapi
week
refus
escap
therapi
result
includ
patient
noncompli
patient
miss
determin
appoint
therapi
refus
escap
therapi
signific
differ
noncompli
patient
vs
compliant
patient
follow
factor
travel
time
home
seci
vs
hour
first
symptom
till
first
present
vs
week
first
present
till
start
treatment
vs
day
respect
although
patient
complet
remiss
time
first
evalu
initi
therapi
patient
suffer
sever
complic
noncompli
therapi
differ
signific
addit
within
exclud
patient
escap
hospit
initi
suspicion
cancer
refus
chemotherapi
reach
final
diagnosi
cancer
escap
initi
surgeri
primari
step
therapi
conclus
treatment
refus
abandon
still
big
problem
face
cancer
manag
develop
countri
backgroundobject
time
diagnosi
td
lag
time
time
patient
first
symptom
recognit
diagnosi
cancer
delay
td
allow
tumor
progress
poor
outcom
childhood
cancer
mani
studi
although
remain
controversi
countri
high
rate
metastat
present
poor
surviv
describ
aim
studi
defin
clinic
sociodemograph
factor
associ
td
includ
parent
delay
pd
medic
delay
md
children
adolesc
diagnos
cancer
lima
peru
designmethod
total
patient
younger
year
age
diagnos
lymphoma
solid
tumor
januari
decemb
retrospect
evalu
clinic
demograph
variabl
type
diagnosi
clinic
stage
sex
age
parent
characterist
analyz
evalu
effect
td
pd
md
result
td
rang
week
month
median
week
median
pd
md
week
respect
among
type
diseas
found
signific
differ
td
longer
patient
hodgkin
diseas
osteosarcoma
shorter
patient
wilm
tumor
hepatoblastoma
greater
td
found
children
first
diagnos
gener
physician
surgeon
pediatrician
advanc
parent
age
low
level
educ
older
children
p
significantli
associ
delay
td
children
divorc
separ
coupl
longer
td
counterpart
metastat
diseas
clinic
stage
sex
affect
significantli
td
conclus
countri
median
td
compar
describ
develop
countri
index
suspicion
childhood
cancer
remain
low
necessari
establish
strategi
optim
earli
diagnosi
base
associ
factor
backgroundobject
survivor
brain
tumour
childhood
experi
advers
sequela
diseas
treatment
greater
preval
sever
encount
survivor
form
cancer
earli
life
reflect
burden
morbid
report
crosssect
survey
use
instrument
measur
healthrel
qualiti
life
hrql
howev
studi
chang
hrql
time
popul
object
studi
designmethod
patient
year
age
older
least
two
year
complet
therapi
abl
commun
english
elig
survey
gener
preferencebas
multiattribut
health
util
index
mark
studi
initi
year
later
hui
provid
util
score
singleattribut
domaindimens
morbid
multiattribut
hrql
hrql
score
scale
health
neg
score
repres
state
health
consid
wors
dead
respons
collect
patient
proxi
result
initi
cohort
patient
decreas
respect
though
one
death
occur
studi
period
overal
hrql
deriv
respons
patient
show
progress
clinic
import
size
declin
decad
median
hrql
score
respect
cognit
attrubut
compromis
often
pain
also
report
frequent
conclus
decreas
hrql
survivor
brain
tumour
childhood
multifacet
cognit
deficit
pain
promin
problem
pain
repres
unexpect
burden
morbid
studi
undertaken
explor
problem
pain
potenti
therapeut
intervent
backgroundobject
wilm
tumor
wt
common
renal
malignoma
childhood
consid
improv
outcom
better
understand
late
effect
wt
survivor
wt
need
aim
studi
evalu
renal
function
determin
preval
subclin
renal
impair
cohort
wt
use
clinic
sonograph
biomark
approach
designmethod
fourtynin
former
wt
enrol
prospect
singl
center
studi
glomerular
filtrat
rate
gfr
measur
creatinin
clearanc
estim
use
creatininebas
cystatincbas
approxim
addit
urinari
excret
total
protein
albumin
neutrophil
gelatinaseassoci
lipocalin
ngal
assess
clinic
examin
includ
kidney
sonomorpholog
blood
pressur
measur
result
examin
wt
mean
age
year
rang
year
mean
followup
year
treat
combin
surgeri
totalparti
nephrectomi
chemotherapi
receiv
adjuv
radiotherapi
creatinin
clearanc
age
norm
detect
wt
moreov
appli
ageadjust
cystatincbas
gfrestim
gfr
age
norm
identifi
wt
studi
patient
low
grf
glomerular
select
proteinuria
microor
macroalbuminuria
identifi
patholog
urinari
ngal
excret
marker
renal
tubulari
dysfunct
detect
ultrasound
reveal
compensatori
contralater
renal
hypertrophi
th
percentil
patient
fifteen
wt
present
hypertens
highnorm
blood
pressur
accord
definit
conclus
even
though
believ
wt
low
risk
end
stage
renal
diseas
studi
remark
part
former
wt
present
previous
unidentifi
subclin
sign
renal
function
impair
secondari
morbid
ceil
cumul
incid
wttherapi
time
studi
need
defin
optim
longterm
followup
wt
especi
regard
subclin
diseas
risk
stratif
backgroundobject
dna
methyl
crucial
role
cancer
biolog
perform
genomewid
analysi
dna
methyl
hepatoblastoma
hb
tissu
verifi
differenti
methyl
level
hb
normal
tissu
alphafetoprotein
afp
critic
role
hb
also
detect
afp
methyl
level
use
pyrosequenc
designmethod
normal
hb
liver
tissu
sampl
obtain
patient
hb
genomewid
analysi
dna
methyl
tissu
perform
use
infinium
humanmethyl
beadchip
result
confirm
quantit
rtpcr
qpcr
infinium
humanmethyl
beadchip
show
distinct
less
methyl
hb
tissu
nontumor
tissu
also
found
methyl
enrich
posit
near
transcript
start
site
afp
exhibit
lower
methyl
level
hb
tissu
nontumor
liver
tissu
lastli
found
signific
neg
correl
afp
mrna
express
dna
methyl
percentag
use
linear
pearson
r
correl
coeffici
conclus
result
demonstr
differenti
methyl
level
hb
normal
tissu
impli
aberr
methyl
afp
hb
could
reflect
hb
develop
expans
find
could
provid
use
insight
hb
biolog
backgroundobject
children
hepatocellular
carcinoma
phcc
overal
surviv
rate
poor
effect
cytostat
therapi
cisplatin
cddp
doxorubicin
limit
due
chemoresist
tumor
relaps
adult
hcc
sever
antitumor
properti
describ
vitro
model
use
curcumin
curcumin
one
best
investig
phytochem
complementari
oncolog
without
relev
side
effect
use
limit
low
bioavail
designmethod
orthotop
growth
pediatr
hepatocellular
carcinoma
cell
line
null
mice
induc
intrasplen
cell
inject
splenectomi
increas
serum
alpha
fetoprotein
afp
uml
mice
randomli
assign
one
four
group
control
treatment
curcumin
micellar
curcumin
mgkg
bodi
weight
week
cisplatin
cddp
mgkg
bodyweight
day
micellar
curcumin
cddp
combin
therapi
cddp
curcumin
micel
curcuminoid
level
serum
organ
lysat
well
afp
serum
level
investig
result
tumor
uptak
serum
curcumin
decreas
nmoll
two
hour
administr
nmoll
five
hour
curcumin
concentr
significantli
differ
organ
highest
concentr
observ
lung
nmolkg
lowest
brain
nmolkg
concentr
tumor
tissu
nmolkg
higher
liver
backgroundobject
besid
mutat
betacatenin
gene
epigenet
alter
heavili
discuss
play
major
role
develop
hepatoblastoma
hb
investig
whether
epigenet
silenc
nmyc
downstreamregul
gene
may
contribut
hb
develop
designmethod
methyl
statu
mrna
express
level
human
hb
normal
liver
tissu
sampl
evalu
pyrosequenc
realtim
pcr
respect
subsequ
analyz
whether
promot
methyl
express
clinic
relev
correl
molecular
find
clinic
data
obtain
german
liver
tumor
registri
result
downregul
common
event
hb
case
transcript
potenti
downregul
promot
hypermethyl
express
significantli
lower
patient
metastat
diseas
downregul
significantli
correl
poor
prognosi
conclus
find
suggest
express
may
import
factor
mainten
normal
condit
infantil
liver
tissu
epigenet
silenc
could
contribut
hb
format
downregul
might
use
marker
poor
prognosi
backgroundobject
congenit
hepatoblastoma
previous
thought
poor
prognosi
differ
characterist
compar
hepatoblastoma
children
beyond
neonat
period
howev
recent
report
demonstr
could
similar
prognosi
standard
therapeut
strategi
consist
hepatectomi
chemotherapi
designmethod
analyz
clinic
characterist
outcom
neonat
patient
hepatoblastoma
enrol
protocol
japanes
studi
group
pediatr
liver
tumor
studi
enrol
total
children
malign
liver
tumor
studi
primari
chemotherapi
consist
cisplatin
pirarubicin
cita
unresect
unrespons
diseas
combin
ifosphamid
pirarubicin
etoposid
carboplatin
itec
use
result
seven
develop
hepatoblastoma
neonat
period
male
femal
patient
born
normal
birth
weight
associ
congenit
abnorm
tumor
classifi
pretext
ii
iii
metastat
diseas
median
level
ngml
rang
ngml
two
three
patient
underw
primari
resect
receiv
adjuv
chemotherapi
four
patient
underw
partial
hepatectomi
neoadjuv
chemotherapi
follow
postop
chemotherapi
patient
receiv
chemotherapi
consist
cisplatin
pirarubicin
cita
dose
reduct
patient
receiv
salvag
regimen
itec
grade
neutropenia
document
three
patient
cardiac
dysfunct
eject
fraction
occur
one
patient
one
patient
underw
primari
resect
without
adjuv
chemotherapi
metastat
recurr
lung
five
month
diagnosi
die
brain
metastasi
patient
aliv
without
evid
diseas
median
followup
month
rang
month
conclus
congenit
hepatoblastoma
could
success
treat
surgic
resect
standard
cisplatinbas
chemotherapi
dose
reduct
pediatr
blood
cancer
doi
backgroundobject
lymphoblast
lymphoma
acut
lymphoblast
leukemia
neoplasm
immatur
b
tcell
precursor
consid
uniqu
biolog
entiti
world
health
organ
classif
hematolog
neoplasm
treatment
evolv
time
convent
highgrad
nhl
schedul
allderiv
protocol
aim
work
estim
ef
os
common
chemotherapi
toxic
patient
treat
children
cancer
hospit
egypt
year
period
designmethod
retrospect
review
patient
chart
diagnos
treat
period
juli
till
end
decemb
done
patient
treat
accord
st
jude
children
research
hospit
total
therapi
xv
protocol
standard
risk
arm
result
studi
includ
patient
tcell
patient
bcell
median
age
year
rang
year
major
male
stage
iii
common
present
complet
remiss
post
induct
chemotherapi
seen
patient
partial
remiss
progress
diseas
event
suffer
diseas
recurr
common
chemotherapi
toxic
cerebr
venou
thrombosi
follow
bone
infarct
avascular
necrosi
head
femur
diseas
recurr
local
system
patient
end
studi
patient
aliv
cr
dead
mean
durat
follow
month
rang
month
year
overal
surviv
event
free
surviv
conclus
diseas
progress
chemotherapi
relat
toxic
main
caus
death
pediatr
patient
cerebr
vascular
thrombosi
steroid
induc
musculosklet
complic
major
chemotherapeut
advers
event
backgroundobject
reduc
anthracyclinealkylatingag
nonbleomycin
petct
respons
base
protocol
evalu
reduc
longterm
toxic
hodgkin
lymphoma
hl
aim
analyz
shortterm
outcom
patient
hl
treat
base
strategi
offstudi
comparison
perform
institut
earlier
publish
studi
use
chemotherapi
abvd
abvdcoppmopp
alon
nonradiotherapi
nonpet
base
approach
older
strategi
mean
number
cycl
administ
earli
latestag
respect
designmethod
retrospect
studi
result
fortynin
patient
treat
mean
age
year
rang
number
patient
respect
petct
perform
diagnosi
follow
twofour
cours
copdac
administ
treatmentgroup
tg
respect
radiotherapi
indic
inadequ
petrespons
mean
durat
followup
month
rang
inadequ
petrespons
observ
patient
radiotherapi
administ
radiotherapi
replac
cours
copdac
patient
due
physician
prefer
remain
patient
radiotherapi
addit
chemotherapi
administ
due
misinterpret
petther
episod
febril
neutropenia
patient
die
two
patient
relaps
one
progress
diseas
anoth
secondaryaml
os
respect
compar
os
institut
previou
studi
respect
rel
lower
ef
probabl
contribut
part
misinterpret
pet
earli
period
studi
conclus
chemotherapi
oepacopdac
decis
radiotherapi
base
reevalu
petct
permit
reduct
therapi
excel
shortterm
outcom
effort
made
adopt
riskstratif
respons
base
therapi
develop
countri
well
result
two
male
mean
age
year
present
lymphadenopathi
one
scalp
lump
one
mass
left
hip
one
swell
left
face
stunt
wast
hfa
wfa
sd
laboratori
investig
mean
hb
wcc
l
plt
l
ul
mean
number
l
none
metastat
diseas
bone
marrow
csf
radiolog
bone
scan
reveal
extens
bulki
diseas
immunophenotyp
analysi
two
mmi
one
strongli
posit
neg
tdt
stage
risk
group
treat
nhlbfm
protocol
arv
four
patient
complet
therapi
success
conclus
pbl
rare
tumour
nhl
hivinfect
arv
group
patient
associ
high
morbid
mortal
due
diseas
progress
relaps
diseas
infecti
complic
poor
complianc
describ
group
arv
naiv
patient
advanc
diseas
good
outcom
number
limit
draw
conclus
may
repres
group
patient
could
dosereduc
treatment
minimis
chemotherapi
relat
toxic
chart
review
perform
patient
multisystemrisk
receiv
initi
treatment
week
follow
continu
treatment
complet
drug
includ
vinblastin
prednisolon
patient
multisystemlowrisk
receiv
similar
treatment
except
singlesystemmultifocalbonediseas
patient
treat
month
event
defin
relaps
progress
diseas
death
patient
receiv
liver
hematopoiet
transplant
due
limit
access
result
fortynin
patient
diagnos
group
respect
mean
age
month
rang
patient
younger
median
followup
durat
month
rang
five
patient
abandon
treatment
death
median
durat
day
rang
treatment
progress
diseas
febril
neutropenia
meningoenceph
patient
die
partial
respons
progress
diseas
follow
induct
p
diseas
relaps
patient
mean
durat
month
incid
relaps
similar
group
increas
death
patient
respiratori
involv
vs
scleros
cholang
independ
predictor
mortal
fiveyearef
group
respect
fiveyearo
group
respect
conclus
major
patient
present
multisystemrisk
diseas
partial
respons
progress
diseas
major
concern
patient
multisystemrisk
diseas
result
suboptim
fiveyearef
patient
multisystem
lowrisk
multifoc
bone
diseas
recurr
skin
bone
lesion
treatment
relaps
treat
vincristin
cytarabin
prednison
due
sever
advers
effect
chemotherapi
interrupt
month
old
boy
present
lch
skin
liver
small
bowel
also
treat
accord
lch
iii
protocol
refractori
diseas
receiv
salvag
therapi
prednisolon
cytarabin
cladribin
mainten
therapi
indomethacin
relaps
multipl
bone
lesion
increas
liver
failur
cirrhosi
third
line
convent
chemotherapi
unfeas
patient
start
metronom
biomodulatori
therapi
approach
analog
adult
melanoma
trial
consist
low
dose
trofosfamid
ppar
alphagamma
agonist
pioglitazon
inhibitor
etoricoxib
lowdos
dexamethason
result
patient
treat
combin
biomodulatori
therapi
compassion
use
approach
respond
treatment
determin
clinic
mri
scan
biopsi
still
stabl
remiss
one
two
year
respect
far
liver
cirrhosi
boy
came
halt
conclus
combin
antiinflammatori
angiostat
drug
welltoler
feasibl
treatment
option
children
refractori
system
lch
confirm
efficaci
evalu
prospect
patient
fail
stabli
respond
convent
therapi
designmethod
studi
includ
children
age
year
expos
unexpos
benzen
use
medic
chart
clinic
data
includ
white
blood
cell
wbc
count
platelet
count
hemoglobin
hematocrit
blood
urea
nitrogen
bun
creatinin
alkalin
phosphatas
alp
aspart
amino
transferas
ast
alanin
amino
transferas
alt
review
analyz
result
total
children
benzen
expos
unexpos
includ
hematolog
analysi
indic
wbc
x
per
count
significantli
decreas
benzen
expos
children
compar
unexpos
children
versu
similarli
mean
hemoglobin
gdl
level
decreas
significantli
benzen
expos
group
compar
unexpos
group
versu
convers
platelet
x
per
count
increas
significantli
benzen
expos
group
compar
unexpos
group
versu
similarli
benzen
expos
children
significantli
higher
level
alp
conclus
children
expos
benzen
signific
alter
hematolog
liver
function
indic
children
higher
risk
develop
soft
tissu
bone
marrow
relat
malign
disord
backgroundobject
adult
pediatr
acut
myeloid
leukemia
aml
character
divers
mutat
cytogenet
profil
poor
outcom
high
incid
relaps
well
rel
advanc
treatment
past
year
given
high
incid
fusion
mutat
affect
compon
epigenet
machineri
sought
character
featur
confer
better
wors
outcom
within
risk
group
among
pediatr
case
previous
shown
power
approach
two
larg
adult
cohort
designmethod
comprehens
assay
result
among
adult
stem
cancer
genom
atla
tcga
aml
project
ley
et
al
nejm
assay
target
pediatr
aml
project
compar
conduct
tcga
aml
cohort
allow
direct
transfer
dna
methyl
signatur
copi
number
variat
gene
express
marker
former
latter
vice
versa
without
modif
refit
appli
pediatr
case
dna
methyl
signatur
deriv
adult
nonfab
case
outperform
known
mutat
cytogenet
marker
well
standard
care
risk
score
pediatr
case
deriv
adult
risk
panel
significantli
profoundli
separ
higherrisk
subgroup
children
standardor
lowrisk
subgroup
previous
observ
adult
associ
time
relaps
stronger
pediatr
case
observ
adult
suggest
analysi
pediatr
case
may
uncov
predictor
also
appli
treatment
adult
case
suggest
approach
uncov
signific
clinic
relev
aspect
leukem
progress
overlook
studi
focus
sole
primarili
mutat
covari
may
provid
mean
better
stratifi
patient
age
group
effect
treatment
backgroundobject
neuroblastoma
common
extracrani
malign
childhood
myc
famili
protein
implic
etiolog
mani
cancer
regul
cell
growth
prolifer
mycn
amplifi
neuroblastoma
associ
poor
prognosi
member
mad
famili
inhibit
nmyc
activ
identifi
altern
splice
variant
differ
first
exon
exon
whose
function
unknown
hypothesi
differenti
impact
nmycdepend
neuroblastoma
cell
prolifer
designmethod
express
shep
neuroblastoma
cell
shep
cell
stabli
transfect
express
high
level
mycn
shepmycn
also
util
nativ
neuroblastoma
cell
line
induc
express
cell
prolifer
surviv
quantifi
apoptosi
measur
propidium
iodid
stain
immunohistochemistri
subcellular
local
protein
detect
immunofluoresc
result
overexpress
inhibit
nmyc
mediat
cell
prolifer
improv
chemosensit
absenc
nmyc
overexpress
independ
inhibit
cell
prolifer
induc
cell
apoptosi
convers
overexpress
lead
enhanc
prolifer
chemoresist
suggest
counterregulatori
final
examin
subcellular
locat
reveal
resid
nucleu
found
cytoplasm
differenti
local
appear
determin
presenc
exon
conclus
overexpress
neuroblastoma
cell
line
lead
inhibit
nmycmedi
cell
prolifer
appear
promot
cell
growth
express
enhanc
chemosensit
neuroblastoma
cell
opposit
effect
exon
may
play
import
role
differenti
function
better
understand
interact
affect
neuroblastoma
physiolog
may
aid
develop
effect
target
therapi
improv
outcom
children
neuroblastoma
backgroundobject
longterm
infus
lti
emerg
promis
treatment
concept
relapsedrefractori
neuroblastoma
patient
role
addit
stimul
immun
system
concomit
treatment
unclear
set
designmethod
pt
treat
cycl
lti
mgm
combin
ium
sc
pt
without
singl
center
program
surrog
paramet
activ
pain
toxic
determin
use
whole
blood
cytotox
test
wbt
analysi
intraven
iv
morphin
usag
result
specif
kill
neuroblastoma
cell
analyz
wbt
assay
found
patient
cycl
cytotox
activ
base
line
sampl
preced
subsequ
applic
increas
cycl
indic
persist
lytic
activ
entir
treatment
period
month
interestingli
differ
specif
cytotox
activ
neuroblastoma
target
cell
time
point
patient
treat
without
iv
morphin
usag
cycl
patient
treat
combin
reveal
cumul
dose
mgkgcycl
contrast
patient
treat
mgkgcycl
correspond
increas
associ
pain
toxic
addit
treatment
reduct
iv
morphin
usag
subsequ
treatment
cycl
observ
cohort
howev
patient
treat
without
addit
patient
requir
iv
morphin
cycl
greater
contrast
combin
group
conclus
neither
surrog
wbt
activ
paramet
higher
pain
toxic
profil
support
combin
treatment
pilot
studi
ongo
siopen
trial
eudract
random
lti
front
line
relapsedrefractori
patient
clarifi
optim
approach
backgroundobject
india
exact
epidemiolog
outcom
neuroblastoma
nb
known
due
lack
appropri
network
report
system
nation
neuroblastoma
network
nnn
form
bridg
gap
object
nnn
studi
epidemiolog
establish
diagnost
prepar
uniform
risk
group
stratif
creat
uniform
therapeut
protocol
improv
outcom
nb
designmethod
juli
nnn
form
amongst
member
indian
pediatr
hematolog
oncolog
group
start
fortnightli
onlin
meet
use
st
jude
hospit
websit
portal
particip
centr
report
data
everi
month
final
data
analysi
done
yearli
basi
result
month
nnn
held
onlin
physic
meet
attend
member
fourteen
case
base
discuss
held
cover
histopatholog
stage
role
nmyc
risk
stratif
treatment
centr
across
state
new
case
report
rang
sixteen
center
provid
detail
male
femal
ratio
sixteen
age
less
month
nmyc
could
done
case
amplifi
twenti
six
stage
diseas
bone
marrow
involv
seen
risk
stratif
present
could
done
children
high
risk
intermedi
low
risk
data
collect
analys
year
treatment
protocol
low
intermedi
risk
nb
final
high
risk
relaps
nb
prepar
conclus
nnn
success
link
centr
report
data
central
registri
nb
care
improv
across
centr
onlin
tumor
board
meet
major
case
high
risk
cooper
group
like
nnn
need
improv
outcom
backgroundobject
clinic
import
minim
diseas
detect
bone
marrow
bm
local
neuroblastoma
patient
diagnosi
remain
unclear
prospect
multicent
studi
bm
sampl
diagnosi
larg
cohort
studi
use
realtim
quantit
pcr
qpcr
designmethod
total
bm
sampl
local
patient
prospect
collect
dutch
german
center
qpcr
perform
use
five
neuroblastoma
specif
marker
th
ddc
associ
biolog
factor
prognost
impact
bm
posit
clinic
respons
assess
result
patient
neuroblastoma
mrna
detect
bm
posit
sampl
one
marker
found
posit
bm
posit
significantli
associ
mycn
amplif
delet
chromosom
total
patient
event
patient
progress
stage
bm
posit
associ
unfavor
outcom
howev
detect
one
marker
associ
unfavor
outcom
system
local
relaps
ef
vs
whole
cohort
observ
group
conclus
bm
posit
associ
unfavor
biolog
factor
might
repres
aggress
tumor
patient
qpcr
posit
bm
upstag
system
event
cohort
howev
patient
observ
group
one
marker
posit
care
followup
might
requir
target
next
gener
sequenc
analysi
use
pgm
tm
ion
torrent
system
platform
target
gene
panel
assay
ion
ampliseq
tm
cancer
hotspot
panel
dna
extract
formalinfix
paraffinembed
tissu
sampl
patient
tumor
peripher
blood
sampl
normal
control
need
molecular
techniqu
situ
hybrid
use
order
character
genet
alter
cover
target
gene
sequenc
panel
studi
date
pediatr
tumor
either
relaps
diagnosi
prognosi
dismal
eleven
patient
brain
tumor
made
sequenc
analysi
iontorr
system
patient
also
appli
molecular
studi
found
druggabl
gene
alter
four
patient
cn
tumor
two
braf
mutat
one
pdgfra
gene
amplif
one
mutat
treat
three
patient
target
therapi
dabrafenib
braf
mutat
dasatinib
amplif
pdgfra
vorinostat
retino
acid
mutat
pediatr
tumor
highlight
current
molecular
heterogen
cancer
prove
need
understand
molecular
biolog
order
identifi
druggabl
alter
improv
clinic
manag
patient
especi
affect
aggress
type
sequenc
whole
tumor
search
mutat
target
therapyth
massiv
sequenc
panel
initi
orient
adult
tumor
goal
redesign
studi
includ
relev
alter
pediatr
tumor
hypersensit
tumor
cell
camptothecin
effect
trabectedin
strong
synergist
effect
also
report
human
rhabdomyosarcoma
xenograft
twelv
patient
endstag
refractori
translocationposit
sarcoma
treat
trabectedin
follow
irinotecan
within
compassion
use
program
designmethod
twelv
patient
refractori
sarcoma
heavili
pretreat
chemotherapi
treat
trabectedin
follow
irinotecan
diagnosi
ewe
sarcoma
eight
soft
tissu
sarcoma
four
patient
februari
partial
remiss
accord
recist
criteria
achiev
one
patient
stabl
diseas
five
patient
progress
diseas
seen
six
patient
median
surviv
three
month
start
therapi
major
patient
signific
hematolog
toxic
grade
observ
revers
liver
toxic
diarrhea
also
occur
one
patient
suffer
dose
limit
diarrhea
sever
prolong
neutropenia
irinotecan
omit
subsequ
cours
conclus
experi
combin
trabectedin
follow
irinotecan
patient
advanc
sarcoma
show
promis
result
control
refractori
solid
tumor
hematolog
toxic
signific
revers
qualiti
life
therapi
maintain
observ
encourag
larger
clinic
trial
backgroundobject
optim
system
busulfan
exposur
area
concentrationtim
curv
auc
improv
outcom
hematopoiet
stem
cell
transplant
hsct
auc
convent
calcul
use
six
plasma
concentr
drawn
first
intraven
busulfan
dose
given
twohour
infus
everi
six
hour
aim
studi
develop
limit
sampl
strategi
lsss
use
three
fewer
busulfan
concentr
reliabl
calcul
children
undergo
hsct
designmethod
follow
administr
singl
dose
busulfan
test
dose
first
dose
busulfan
condit
regimen
blood
sampl
collect
patient
six
timepoint
hour
start
infus
busulfan
concentr
plasma
measur
use
high
perform
liquid
chromatographi
busulfan
calcul
accord
trapezoid
method
use
moment
program
employ
six
avail
data
point
lsss
use
one
two
three
plasma
busulfan
concentr
develop
multipl
linear
regress
result
pharmacokinet
sampl
total
auc
collect
patient
lsss
use
one
busulfan
plasma
concentr
six
hour
start
infus
two
three
plasma
busulfan
concentr
develop
multipl
linear
regress
show
excel
agreement
actual
predict
base
significantli
correl
statist
differ
actual
valu
follow
r
p
mean
bia
precis
contrast
predict
auc
deriv
sampl
singl
point
meet
criteria
singlepoint
sampl
strategi
predict
lss
use
six
data
point
demonstr
excel
agreement
backgroundobject
children
cancer
rare
increas
understand
underli
genet
featur
mani
tumour
type
increas
number
target
therapi
may
becom
avail
need
evalu
reliabl
also
remain
need
identifi
optim
convent
therapi
eg
chemotherapi
radiotherapi
surgeri
given
frequent
pauciti
reliabl
evid
designmethod
randomis
control
trial
rct
consist
two
arm
mani
singl
arm
studi
also
undertaken
run
trial
long
process
concept
public
includ
substanti
set
period
sever
treatment
interest
rather
select
one
possibl
wrong
one
evalu
standard
mam
design
permit
treatment
assess
insuffici
activ
treatment
term
intermedi
outcom
drop
phase
ii
recruit
continu
remain
arm
phase
iii
evalu
furthermor
novel
agent
regimen
interest
come
along
incorpor
trial
adapt
design
much
effici
process
set
separ
trial
test
new
agent
randomis
compar
avoid
bias
singlearm
phase
ii
trial
result
mam
trial
underway
plan
sever
tumour
type
includ
reecur
trial
relaps
ewe
sarcoma
compar
four
wide
use
chemotherapi
regimen
trial
relaps
rhabdomyosarcoma
evalu
sever
novel
agent
ad
convent
chemotherapi
backbon
trial
newli
diagnos
rhabdomyosarcoma
compar
three
novel
regimen
trial
low
grade
glioma
beacon
trial
neuroblastoma
adapt
becom
mam
design
ad
two
new
arm
initi
step
widespread
use
mam
design
enabl
quicker
identif
effect
therapi
lead
improv
outcom
children
cancer
result
patient
diagnos
median
followedup
month
median
extens
bone
lesion
three
patient
present
chylothorax
one
abdomin
lymphangioma
interferon
use
firstlin
two
patient
secondlin
two
patient
sirolimu
use
minim
respons
calcitonin
use
one
pamidron
zoledron
acid
use
two
patient
osteopenia
bone
lesion
respons
propranolol
first
patient
progress
bone
lesion
chylothorax
interferon
secondlin
treatment
start
bevacizumab
chylothorax
regress
due
patholog
fractur
bevacizumab
stop
month
sirolimu
treatment
stabl
diseas
restrict
lung
diseasesecond
patient
spleen
cyst
abdomin
macrocyst
lymphangioma
bone
lesion
month
interferon
treatment
new
bone
lesion
occur
sirolimu
given
remain
stabl
sirolimusthird
patient
chylothorax
bone
lesion
receiv
sirolimu
firstlin
treatment
within
month
chylothorax
increas
treatment
chang
interferon
still
receiv
interferon
stabl
diseaseth
last
patient
massiv
chylothorax
bone
lesion
chylothorax
didnot
respond
sirolimu
decreas
interferon
offtherapi
sever
restrict
lung
diseas
conclus
standard
treatment
recommend
gorhamstout
syndrom
interferon
seem
benefit
sirolimu
propranolol
show
posit
effect
bevacizumab
might
help
chylothorax
bone
lesion
might
worsen
biphophon
might
effect
bone
lesion
multicent
studi
prospect
trial
treatment
regimen
undertaken
lymph
node
oral
util
previous
describ
pediatr
ks
stage
classif
stage
lymphadenopath
subtyp
stage
woodi
edema
subtyp
stage
base
upon
widespread
involv
skin
skin
lesion
none
patient
present
viscer
diseas
overal
surviv
median
followup
month
rang
four
patient
die
median
time
death
month
rang
two
stage
patient
achiev
longterm
cr
howev
one
die
cr
anoth
caus
six
stage
patient
achiev
longterm
cr
die
progress
ks
month
multipl
relaps
aliv
stabl
diseas
amongst
stabl
diseas
experienc
relaps
requir
chemotherapi
stabil
two
stage
patient
die
month
ks
diagnosi
refractori
progress
diseas
conclus
case
seri
demonstr
high
rate
woodi
edema
subtyp
hivneg
children
ek
outcom
stratifi
accord
sever
clinic
present
howev
longterm
surviv
possibl
moderatelyintens
chemotherapi
regimen
sever
cytopenia
diagnosi
median
hemoglobin
rang
median
platelet
count
addit
patient
ks
skin
lesion
subcutan
nodul
one
facial
edema
lymph
node
biopsi
obtain
one
patient
reveal
ks
histolog
without
evid
multicentr
castleman
diseas
spindl
cell
infiltr
immunohistochem
stain
posit
lana
virolog
test
avail
one
patient
characterist
kic
reveal
viral
load
cell
level
pgml
level
pgml
failur
bv
appar
prednison
ad
treat
system
inflammatori
syndrom
cytopenia
dramat
improv
week
start
prednison
median
platelet
reach
rang
without
transfus
four
patient
achiev
longterm
complet
remiss
median
followup
month
rang
month
two
patient
die
earli
due
complic
opportunist
infect
conclus
case
seri
demonstr
distinct
sever
clinic
present
relat
kic
hiv
children
longterm
cure
achiev
ad
prednison
bv
plu
haart
result
nine
boy
three
girl
age
rang
month
median
age
month
time
diagnosi
rang
three
day
month
common
primari
site
head
neck
patient
trunk
patient
follow
extrem
scrotal
patient
preoper
evalu
includ
usg
six
ct
scan
seven
mri
four
patient
present
increas
volum
fourteen
resect
perform
tumor
size
rang
cm
lesion
complet
resect
histolog
confirm
one
local
pediatr
blood
cancer
doi
recurrencesurg
time
rang
one
four
hour
blood
loss
minim
averag
hospit
length
stay
daysther
surgic
complic
periop
mortal
follow
one
month
year
conclus
lb
rare
benign
tumor
embryon
fat
affect
children
three
year
age
mark
male
preponder
initi
diagnosi
seldomli
suspect
primari
care
physician
mri
studi
choic
extrem
paraspin
tumor
ct
scan
optim
head
neck
retroperiton
lesion
studi
differ
previou
report
sinc
found
larger
lesion
tumor
head
neck
interestingli
recurr
occur
one
girl
backgroundobject
despit
aid
epidem
ravag
south
african
popul
ebvassoci
smooth
muscl
tumour
remain
rare
tumour
associ
sever
immun
suppress
previous
diagnos
myofibroma
object
review
patient
biopsi
proven
diseas
designmethod
studi
initi
patholog
children
trace
biopsi
record
paediatr
oncolog
unit
patient
file
also
review
addit
case
six
case
found
total
data
extract
ethic
consent
retrospect
data
collect
obtain
result
strong
femal
predomin
note
age
rang
present
year
mean
year
month
symptom
featur
pain
predominantli
abdomin
back
patient
spinal
compress
paraspin
mass
gallbladd
involv
eye
mass
iri
prior
treatment
suspect
tb
contribut
delay
diagnosi
cd
count
vari
patient
viral
suppress
virolog
failur
tumour
site
singl
patient
spinal
eye
multipl
patient
spinal
adren
rib
unproven
basal
ganglia
lesiontherapi
includ
surgeri
radiat
chemotherapi
palliat
surviv
rang
month
month
one
patient
die
aid
relat
sepsi
one
lost
follow
aliv
deterior
weight
conclus
ebvassoci
tumour
may
prolong
surviv
aid
relat
comorbid
contribut
mortal
spinal
lesion
present
frequent
found
backgroundobject
mani
pediatr
patient
cancer
cure
diseas
yet
subset
patient
therapi
unsuccess
primari
goal
research
program
collect
tumor
germlin
specimen
patient
rare
recurr
refractori
cancer
perform
whole
genom
sequenc
wg
tumor
germlin
sampl
mrna
sequenc
tumor
sampl
sequenc
data
use
character
molecular
signatur
cancer
assess
diseas
may
circumv
therapi
identifi
way
cancer
may
treat
designmethod
sequenc
data
analyz
independ
bioinformat
pipelin
maxim
valid
result
genom
variat
identifi
wg
integr
gene
express
inform
mrna
sequenc
develop
molecular
profil
tumor
process
culmin
multidisciplinari
team
meet
result
interpret
clinic
action
plan
develop
result
end
potenti
particip
identifi
particip
andor
famili
provid
consent
suspect
recurr
refractori
diseas
suspect
new
diagnosi
wg
tumor
normal
genom
undertaken
patient
patient
sequenc
perform
case
patient
newli
diagnos
cancer
whole
genom
data
obtain
follow
brain
tumor
acut
leukemia
sarcoma
lymphoma
ganglioneuroblastoma
mix
germ
cell
tumor
carcinoma
remain
data
includ
obtain
one
hemophagocyt
lymphohistiocytosi
hlh
hepatoblastoma
melanoma
myelodysplast
syndrom
md
wilm
tumor
experi
demonstr
feasibl
effect
clinic
sequenc
pediatr
adolesc
oncolog
yield
result
inform
treatment
choic
well
refin
diagnos
review
medic
chart
perform
full
physic
exam
vital
sign
anthropometr
measur
bodi
composit
puber
develop
musculoskelet
deform
assess
renal
cardiac
function
result
initi
treatment
differ
two
group
gcbttw
indic
initi
surgeri
siop
preoper
chemotherapi
intraop
tumor
ruptur
abdomin
radiat
use
doxorubicin
common
group
seventynin
patient
underw
complet
evalu
group
group
differ
group
note
regard
weight
bmi
zscore
abdomin
fat
musculoskelet
deform
pubert
develop
cardiomyopathi
renal
dysfunct
group
patient
shorter
stand
height
sit
height
group
radiat
affect
growth
group
howev
effect
statist
wors
group
patient
alreadi
reach
final
height
hypertens
common
late
effect
follow
reduct
glomerular
filtrat
rate
musculoskelet
deform
cardiac
pubert
abnorm
conclus
least
one
late
effect
found
patient
present
one
complic
two
three
despit
high
cure
rate
longterm
followup
requir
survivor
wt
backgroundobject
recogn
lung
radiat
avoid
success
manag
metastat
wilm
tumor
wt
report
experi
treat
stage
iv
wt
institut
designmethod
conduct
retrospect
analysi
children
stage
iv
wt
present
juli
decemb
patient
characterist
treatment
modal
outcom
analyz
case
discuss
multidisciplinari
clinic
includ
pediatr
oncologist
radiologist
pediatr
surgeon
radiat
oncologist
accord
local
protocol
radiotherapi
rt
decid
base
radiolog
respons
initi
chemotherapi
result
identifi
patient
present
stage
iv
wt
median
age
diagnosi
fifteen
patient
local
stage
iii
diseas
stage
one
stage
ii
three
bilater
diseas
lung
metastasi
present
patient
three
metastasi
ovari
one
patient
lung
skin
second
lung
liver
third
four
patient
treat
accord
siop
protocol
rest
treat
accord
upfront
nephrectomi
done
three
patient
preoper
tumor
ruptur
detect
four
patient
receiv
whole
abdomen
rt
ten
patient
complet
respons
lung
metastasi
chemotherapi
nt
receiv
lung
rt
ten
partial
respons
given
whole
lung
rt
estim
os
respect
although
statist
signific
less
percentag
patient
irradi
among
diagnos
treat
siop
protocol
conclus
patient
metastat
wt
excel
outcom
despit
omit
radiotherapi
half
patient
use
radiotherapi
decreas
time
possibl
relat
team
experi
respons
assess
might
decreas
judici
use
metastectomi
accur
assess
respons
conclus
crr
shown
feasibl
use
complet
imag
set
receiv
influenc
clinic
decisionmak
process
next
step
implement
realtim
feedback
review
integr
report
combin
radiolog
oncolog
contextu
review
kenya
dismal
due
ontherapi
mortal
treatment
abandon
rate
parent
answer
multicent
survey
trace
call
confirm
financi
constraint
barrier
treatment
complet
therefor
aim
studi
impact
financi
support
treatment
abandon
surviv
rate
designmethod
prospect
cohort
studi
plan
patient
newli
diagnos
wt
collabor
kenyan
hospit
offer
us
dollar
toward
treatment
exchang
paraffin
block
tumor
time
resect
patient
visit
treatment
record
kenyan
wt
registri
patient
call
research
nurs
abandon
therapi
result
twentyfour
patient
enrol
studi
due
poor
document
exclud
analysi
ten
patient
abandon
treatment
cur
intent
nine
patient
die
ontherapi
patient
remain
aliv
adher
treatment
patient
abandon
treatment
abandon
prior
postop
chemotherapi
abandon
postop
chemotherapi
abandon
prior
radiat
therapi
fifti
percent
patient
abandon
care
confirm
aliv
give
known
surviv
rate
month
last
patient
consent
abandon
occur
slightli
later
previou
studi
actual
occur
higher
frequenc
intervent
therefor
fail
reduc
treatment
abandon
increas
surviv
conclus
surviv
remain
dismal
despit
provis
fund
hospit
administr
issu
releas
fund
problemat
one
site
trace
call
made
patient
site
reveal
continu
financi
barrier
parent
belief
children
healthi
longer
need
therapi
reason
abandon
financi
provis
without
improv
infrastructur
educ
insuffici
reduc
treatment
abandon
backgroundobject
wilm
tumor
wt
repres
approxim
six
seven
percent
pediatr
cancer
account
percent
tumor
kidney
pediatr
age
group
recent
center
explor
role
nephron
spare
procedur
children
unilater
wilm
tumor
concern
late
occurr
renal
dysfunct
unilater
nephrectomi
assess
long
term
renal
function
outcom
parenchymalspar
procedur
nonsyndrom
unilater
wilm
tumor
center
designmethod
retrospect
review
record
children
unilater
wilm
tumor
undergon
nephron
spare
surgeri
center
patient
longterm
renal
function
tumor
recurr
surviv
determin
review
patient
medic
record
result
total
eight
patient
underw
partial
nephrectomi
pn
remain
three
polar
tumor
underw
heminephrectomi
hn
follow
chemotherapi
smaller
tumor
volum
associ
preserv
renal
function
also
increas
egfr
followup
period
median
preoper
egfr
median
egfr
last
followup
conclus
properli
select
children
nonsyndrom
unilater
wilm
tumor
nephron
spare
surgeri
provid
excel
renal
function
preserv
major
caus
treatment
failur
lowincom
countri
poverti
direct
cost
treatment
associ
cost
famili
play
major
role
consensu
adapt
wilm
tumour
treatment
guidelin
implement
centr
subsaharan
africa
treatment
guidelin
includ
strategi
prevent
incomplet
treatment
perform
baselin
evalu
situat
start
project
help
decid
prioriti
improv
outcom
assess
improv
time
designmethod
retrospect
chart
review
perform
patient
admit
wilm
tumour
three
year
preced
collabor
project
percentag
patient
start
complet
treatment
document
interview
repres
particip
institut
cost
medic
treatment
health
insur
govern
extern
support
remain
treatment
cost
parent
avail
money
travel
hospit
accommod
food
stay
hospit
document
avail
adequ
counsel
result
averag
rate
incomplet
treatment
rang
centr
strategi
place
prevent
incomplet
treatment
lack
fund
complet
cover
cost
parent
remain
cost
treatment
parent
rang
around
us
malawi
us
ghana
centr
pay
travel
provid
food
hospit
stay
conclus
incomplet
treatment
common
caus
treatment
failur
prevent
aim
reduc
incomplet
treatment
less
strategi
includ
fund
medic
treatment
associ
cost
adequ
counsel
care
document
contact
detail
enabl
activ
follow
patel
hospit
eye
karachi
pakistan
backgroundobject
analyz
data
children
retinoblastoma
treat
initi
multidisciplinari
team
ophthalmologist
oncologist
radiotherapist
psychologist
social
worker
ocularist
compar
histor
control
designmethod
initi
multidisciplinari
team
outcom
retinoblastoma
institut
dismal
abandon
rate
poor
eye
salvag
lack
rehabilit
dismal
overal
surviv
includ
abandon
juli
collabor
began
pediatr
oncolog
ophthalmolog
depart
two
hospit
karachi
develop
multidisciplinari
retinoblastoma
team
retinoblastoma
treatment
guidelin
final
new
case
discuss
monthli
tumor
board
data
prospect
collect
implant
put
time
enucl
prosthesi
put
complet
treatment
document
stage
protocol
complianc
enucl
advers
histopatholog
factor
eye
salvag
abandon
placement
implant
prosthesi
screen
sibl
follow
visit
analyz
compar
histor
control
result
abandon
rate
reduc
parent
agre
upfront
enucl
document
stage
diseas
eye
improv
children
treat
accord
protocol
guidelin
histopatholog
report
per
guidelin
overal
surviv
includ
abandon
increas
histor
data
studi
previous
less
children
get
implant
prosthesi
screen
younger
sibl
almost
children
implant
time
enucl
eye
prosthesi
screen
sibl
offer
famili
conclus
initi
multidisciplinari
team
signific
improv
treatment
outcom
rehabilit
children
retinoblastoma
unlik
develop
world
cure
rate
outcom
lmic
suboptim
due
delay
diagnosi
advanc
diseas
addit
signific
factor
poor
outcom
therapi
abandon
report
upto
indian
subcontinentprimarili
due
sociocultur
nonaccept
enucl
henc
imper
strategi
globe
salvag
without
compromis
surviv
would
benefici
impact
overal
outcom
highli
curabl
diseas
evalu
role
soac
intraocular
retinoblastoma
context
designmethod
retrospect
analysi
children
group
retinoblastoma
underw
soac
children
underw
standard
baselin
diagnost
stage
evalu
children
extraocular
diseas
optic
nerv
involv
metastat
diseas
exclud
melphalan
carboplatin
drug
administ
age
depend
dose
result
total
session
soac
perform
eye
children
procedur
success
favour
respons
crpr
result
globe
salvag
seen
eye
give
globe
salvag
rate
median
follow
month
eye
ultim
need
enucl
one
eye
underw
ebrt
due
inadequ
respons
treatment
eye
salvag
previous
treat
eye
enucl
avoid
eye
salvag
rate
sporad
retinoblastoma
famili
retinoblastoma
treatment
abandon
rate
reduc
complic
minim
includ
lid
edema
opthalm
arteri
spasm
conjunctiv
chemosi
grade
iii
neutropenia
seen
procedur
perform
result
compar
western
publish
literatur
conclus
soac
feasibl
success
strategi
globe
salvag
lmic
power
tool
strategi
prevent
treatment
refus
abandon
median
age
sbrct
diagnosi
year
median
time
last
rb
treatment
sbrct
diagnosi
analysi
patholog
radiolog
featur
could
discrimin
true
secondari
srbct
late
rb
metastat
relaps
comparison
mutat
rb
match
sbrct
patient
show
normal
allel
constantli
lost
confirm
sbrct
develop
due
predisposit
context
ii
second
hit
sbrct
match
rb
differ
thu
prove
former
tumor
deriv
latter
similarli
avail
case
comparison
acgh
profil
rb
match
sbrct
strikingli
differ
result
argu
favor
sbrct
late
rb
metastas
rather
secondari
undescrib
tumor
link
rb
predisposit
syndrom
analys
transcriptom
profil
exom
sequenc
ongo
better
character
emerg
type
sbrct
backgroundobject
children
retinoblastoma
carri
high
risk
develop
second
primari
malign
alreadi
childhood
adolesc
studi
character
type
pediatr
second
primari
malign
retinoblastoma
treatment
investig
impact
differ
treatment
strategi
genet
predisposit
designmethod
nation
patient
treat
retinoblastoma
german
refer
center
current
age
year
invit
particip
studi
character
late
effect
result
data
pediatr
second
primari
malign
record
patient
ten
develop
malign
age
year
children
heterozyg
oncogen
variant
germlin
cumul
incid
develop
second
malign
age
year
result
elev
risk
sarcoma
sir
confid
interv
leukemia
sir
type
mutat
origin
show
signific
impact
previou
radiotherapi
increas
risk
three
children
chemotherapi
combin
radioand
chemotherapi
develop
acut
leukemia
treatment
modal
influenc
incid
latenc
type
malign
children
heterozyg
germlin
mutat
develop
second
primari
malign
without
previou
chemotherapi
extern
beam
radiotherapi
conclus
screen
second
primari
malign
critic
part
pediatr
oncolog
followup
patient
germlin
mutat
especi
patient
sporad
unilater
retinoblastoma
genet
inform
import
treatment
decis
allow
tailor
followup
schedulesth
deutsch
kinderkrebsstiftung
financ
studi
includ
respons
cht
assess
cycl
defin
good
tumor
reduct
poor
tumor
reduct
progress
immunohistochem
express
analyz
marker
assess
tissu
microarray
determin
neg
posit
base
semiquantit
criteria
result
respons
neoadjuv
cht
assess
patient
ten
achiev
good
respons
poor
respons
significantli
wors
patientssurvivin
express
patient
opn
cyclin
express
survivin
opn
significantli
frequent
poor
respond
good
respond
respect
correl
cyclin
borderlin
fn
signific
good
respond
express
maximum
two
marker
one
patient
express
marker
major
poor
respond
express
least
marker
none
marker
neg
demograph
result
show
male
femal
mean
age
year
lymph
node
common
site
involv
diagnosi
earli
case
easi
skin
lesion
found
amongst
children
sei
eye
involv
hiv
serolog
perform
case
parent
usual
refus
test
perform
test
children
hiv
posit
treatment
ks
includ
chemotherapi
base
cyclophosphamid
anthracyclin
prednison
chemotherapi
associ
haart
child
hiv
posit
prognosi
hiv
neg
children
treatment
better
hiv
posit
children
conclus
children
kaposi
sarcoma
cameroon
common
find
aid
epidem
backgroundobject
studi
clinicopatholog
characterist
outcom
rhabdomyosarcoma
tertiari
care
hospit
pakistan
designmethod
retrospect
chart
review
children
less
year
initi
diagnosi
rhabdomyosarcoma
till
treat
ir
protocol
receiv
altern
cours
cvd
cyclophosphamid
vincristin
doxorubicin
ie
ifosphamid
etoposid
local
control
surgeri
radiotherapi
base
protocol
guidelin
demographi
clinic
present
primari
site
histopatholog
stage
treatment
receiv
outcom
analyz
result
total
children
includ
male
femal
ration
median
age
year
rang
year
swell
pain
local
site
common
clinic
present
head
neck
common
primari
site
follow
extrem
genitourinari
orbit
abdomen
pelvi
major
children
present
advanc
stage
diseas
stage
iii
stage
iv
embryon
histolog
common
type
children
receiv
radiat
local
site
abandon
given
palli
treatment
compli
protocol
treatment
die
due
toxic
due
diseas
progress
relaps
overal
surviv
without
abandon
second
treatment
offer
differ
event
free
ef
overal
surviv
os
outcom
rhabdomyosarcoma
studi
suboptim
high
rate
abandon
toxic
death
advanc
diseas
present
major
advers
factor
pediatr
blood
cancer
doi
backgroundobject
present
experi
neoadjuv
altern
intraarteri
intraven
chemotherapi
treatment
advanc
malign
abdomin
pelvic
tumor
children
designmethod
twentytwo
patient
age
month
year
advanc
malign
abdomin
pelvic
tumor
includ
hepat
renal
tumor
receiv
neoadjuv
altern
intraarteri
infus
chemotherapi
system
chemotherapi
rhabdomyosarcoma
urinari
bladder
case
ovarian
yolk
sac
tumor
case
sacrococcyg
malign
germ
cell
tumor
case
vagin
rhabdomyosarcoma
case
vagin
endoderm
sinu
tumor
case
endoderm
sinu
tumor
omentum
case
pelvic
rhabdomyosarcoma
case
pancreatoblastoma
origin
mesenteri
case
abdomin
promot
prolifer
connect
tissu
tumor
caseth
select
arteri
intraarteri
infus
chemotherapi
bilater
iliac
arteri
pelvic
tumor
superior
mesenter
arteri
abdomin
tumor
drug
cisplatin
mgm
pirarubicin
mgm
vindesin
mgm
intraven
chemotherapi
use
vindesin
ifosfamid
etoposid
administ
week
arteri
chemotherapi
altern
arteri
intraven
chemotherapi
interv
repeat
cours
oper
oper
patient
underw
intraven
chemotherapi
radiotherapi
result
common
side
effect
altern
arteri
intraven
chemotherapi
grade
bone
marrow
suppress
druginduc
cardiotox
nephrotox
hepat
dysfunct
observ
patient
followedup
year
median
year
backgroundobject
outcom
paediatr
rhabdomyosarcoma
rm
sweden
high
nineti
last
decad
seen
decreas
trend
overal
surviv
os
aim
investig
incid
patient
diseas
characterist
treatment
outcom
whether
reason
possibl
declin
os
could
found
designmethod
two
hundr
ten
children
age
year
diagnos
rm
populationbas
swedish
childhood
cancer
registri
year
includ
studi
complementari
inform
collect
medic
chart
result
overal
annual
incid
per
million
os
period
respect
patient
localis
diseas
analys
separ
differ
outcom
period
os
outcom
os
significantli
wors
preval
metastat
diseas
unexpectedli
high
last
period
metastasi
rate
contrast
materi
total
result
suggest
higher
rate
metastat
diseas
may
explain
declin
trend
os
paediatr
rm
sweden
last
decad
reason
higher
rate
remain
unclear
could
due
coincid
backgroundobject
purpos
studi
examin
sibl
longterm
psycholog
health
relat
percept
commun
famili
friend
healthcar
profession
brother
sister
last
month
life
designmethod
questionnair
studi
conduct
nationwid
sweden
individu
lost
brother
sister
cancer
two
nine
year
earlier
sibl
contact
particip
hospit
anxieti
depress
scale
had
use
assess
psycholog
health
data
present
proport
rel
risk
rr
confid
interv
ci
result
sibl
satisfi
amount
talk
feel
other
brother
sister
last
month
life
like
report
anxieti
satisfi
true
unabl
talk
famili
bereav
avoid
healthcar
profession
fear
way
increas
sibl
risk
report
anxieti
followup
especi
avoid
hospit
set
differ
seen
ill
brother
sister
care
home
conclus
lack
commun
associ
higher
risk
anxieti
bereav
sibl
longterm
avoid
healthcar
profession
especi
brother
sister
care
hospit
backgroundobject
littl
uniform
fertil
preserv
care
children
diagnos
cancer
ensur
highqual
care
evidencebas
clinic
practic
guidelin
essenti
step
toward
guidelin
develop
aim
identifi
exist
guidelin
fertil
preserv
children
young
adult
diagnos
cancer
evalu
qualiti
explor
differ
recommend
designmethod
perform
systemat
search
pubm
guidelin
databas
websit
cancer
paediatr
fertil
organis
two
review
evalu
qualiti
identifi
guidelin
use
apprais
guidelin
research
evalu
instrument
agre
ii
high
qualiti
guidelin
evalu
area
concord
discord
among
recommend
identifi
guidelin
guidelin
focus
adult
children
adult
five
guidelin
apprais
older
version
identifi
guidelin
guidelin
underw
full
critic
apprais
averag
agreeii
domain
score
vari
applic
editori
independ
clariti
present
found
area
discord
regard
clinic
question
receiv
fertil
preserv
fertil
preserv
method
use
fertil
preserv
discuss
initi
involv
discuss
decis
fertil
preserv
ethic
aspect
conclus
find
show
variat
fertil
preserv
recommend
exist
affect
qualiti
care
clinic
practic
guidelin
includ
transpar
decis
process
fertil
preserv
start
cancer
treatment
help
health
care
provid
deliv
optimum
care
improv
qualiti
life
children
cancer
gramneg
pathogen
isol
blood
total
children
die
due
infecti
complic
median
time
diagnosi
aml
day
compar
multiinstitut
trial
amlbfm
lower
doseintens
bfmaml
incid
infecti
complic
significantli
higher
versu
infecti
episod
per
patient
wherea
infectionrel
mortal
significantli
decreas
versu
conclus
specif
antiinfect
recommend
treatment
protocol
implement
train
cours
educ
pediatr
hematologist
may
reason
reduc
infectionrel
mortal
children
aml
howev
studi
need
order
decreas
infectionrel
morbid
backgroundobject
infect
import
caus
morbid
mortal
children
treat
acut
myelogen
leukemia
aml
although
center
appli
nonpharmacolog
antiinfect
measur
littl
known
impact
infecti
outcom
designmethod
survey
site
determin
institut
standard
regard
recommend
restrict
social
contact
item
pet
item
food
item
children
treat
aml
accord
amlbfm
score
system
develop
restrict
score
item
alway
restrict
sometim
restrict
restrict
result
total
restrict
score
rang
univari
multipl
poisson
regress
use
estim
impact
restrict
incid
ratio
fever
bacteremia
pneumonia
diarrhea
intens
treatment
result
data
nonpharmacolog
antiinfect
measur
avail
institut
treat
children
aml
median
rang
overal
restrict
score
combin
item
social
contact
pet
food
small
signific
influenc
restrict
score
incid
fever
irr
incid
rate
ratio
nonpharmacolog
antiinfect
measur
impact
incid
infecti
complic
analyz
conclus
data
suggest
nonpharmacolog
antiinfect
measur
may
impact
incid
fever
bacteremia
howev
sinc
includ
potenti
confound
antibiot
prophylaxi
result
may
confound
support
care
practic
research
requir
identifi
independ
effect
nonpharmacolog
intervent
clinic
studi
demonstr
patient
low
risk
septic
complic
safe
treat
outpati
use
oral
antibiot
low
rate
treatment
failur
howev
review
rais
concern
reduct
therapi
particularli
outpati
treatment
may
accept
patient
parent
healthcar
profession
designmethod
metaethnographi
explor
qualit
studi
inform
theori
experi
earli
discharg
paediatr
febril
neutropenia
includ
report
studi
adult
febril
neutropenia
diseas
specif
data
b
paediatr
condit
provid
broader
social
context
systemat
literatur
search
preced
analysi
use
adapt
version
noblit
hare
phase
metaethnographi
result
nine
paper
includ
overarch
experi
patient
parent
healthcar
profession
decis
make
earli
discharg
complex
difficult
experi
influenc
variou
common
factor
includ
fear
time
resourc
within
decis
make
identifi
two
distinct
theme
first
famili
struggl
practic
aspect
associ
maintain
success
treatment
regimen
name
childcar
financ
attend
followup
second
parent
struggl
variou
social
emot
issu
rais
earli
discharg
includ
social
isol
relat
environment
issu
link
two
theme
particip
note
import
continu
care
need
inform
accept
earli
discharg
particip
describ
strategi
might
circumv
practic
challeng
face
allevi
feel
isol
experienc
conclus
decis
make
accept
earli
discharg
complex
featur
practic
social
emot
consider
along
desir
inform
continu
care
work
inform
design
support
care
servic
develop
futur
research
strategi
h
thakkar
lane
k
lakhoo
backgroundobject
surviv
childhood
cancer
substanti
increas
decad
experi
degre
malnutrit
relat
diseas
treatment
gastrostomi
feed
provid
mean
supplement
nutrit
support
neutropenia
increas
risk
gastrostomi
complic
sought
assess
incid
complic
nation
across
paediatr
surgic
oncolog
centr
designmethod
nation
paediatr
surgic
oncolog
centr
contact
particip
nation
committe
audit
proforma
design
data
collect
includ
patient
demograph
patient
diagnosi
treatment
protocol
date
gastrostomi
insertionschang
need
granulocyt
coloni
stimul
factor
gcsf
treatment
complic
patient
gastrostomi
site
januari
decemb
includ
studi
result
four
centr
respond
particip
studi
total
patient
studi
period
patient
diagnosi
either
central
nervou
system
primarili
medulloblastoma
solid
extracrani
malign
median
age
insert
gastrostomi
year
median
durat
last
chemotherapi
gastrostomi
insert
two
week
week
patient
given
gcsf
prior
gastrostomi
insert
line
reduc
count
patient
gastrostomi
remov
within
two
year
insert
median
durat
use
month
month
one
patient
gastrostomi
remov
recurr
infect
neutropen
overal
infect
rate
mainli
staphylococcu
aureu
caus
superfici
skin
infect
one
patient
develop
local
myositi
one
patient
suffer
block
gastrostomi
conclus
gastrostomi
feed
appear
safe
oncolog
patient
minim
complic
durat
use
often
short
provid
effect
mean
support
nutrit
catabol
state
backgroundobject
assess
bodi
composit
energi
requir
children
cancer
necessari
develop
individu
nutrit
support
regimen
recommend
aim
estim
bodi
composit
children
cancer
compar
measur
versu
predict
energi
requir
develop
new
predict
equat
use
pediatr
oncolog
designmethod
rest
energi
expenditur
ree
indirect
calorimetri
bodi
composit
bioimped
analysi
bia
access
three
group
children
age
year
group
patient
remiss
cancer
group
children
cancer
receiv
chemotherapi
earli
period
hematopoiet
stem
cell
transplant
group
hospit
children
nonmalign
diseas
gastrointestin
tract
elimin
influenc
age
gender
intergroup
comparison
bodi
composit
paramet
express
standard
valu
zscore
rel
refer
group
healthi
russian
children
n
result
group
character
excess
fat
content
intact
fatfre
mass
ffm
group
show
signific
ffm
deplet
pronounc
group
mask
increas
percentag
fat
group
use
convent
formula
harrisbenedict
other
underestim
ree
compar
indirect
calorimetri
new
formula
ree
provid
unbias
estim
group
propos
ree
kcalday
bcm
kg
height
cm
age
year
bcm
bodi
cell
mass
accord
bia
r
sd
kcalday
conclus
signific
differ
malnutrit
preval
bodi
composit
observ
studi
group
suggest
formula
ree
use
children
cancer
remiss
assess
effect
dietotherapi
nutrit
support
lack
inform
primari
metastat
pediatr
periton
tumor
impair
diagnosi
treatment
children
diseas
inexist
low
number
establish
wellcharacter
cell
line
repres
tumor
contribut
greatli
scenario
tumor
cell
lineag
studi
vitro
novel
target
inhibit
prolifer
metastasi
andor
surviv
determin
moreov
sensit
chemotherapeut
agent
also
analyz
vitro
improv
preclin
evalu
novel
treatment
protocol
object
establish
cell
line
pediatr
tumor
periton
dissemin
designmethod
primari
metastat
pediatr
periton
tumor
collect
immedi
surgeri
sampl
subject
mechan
separ
cell
andor
prepar
explant
vitro
cultur
enrich
medium
allow
isol
cell
line
sampl
result
cell
line
periton
desmoplas
tumor
periton
ovari
tumor
metastasi
establish
expand
preliminari
character
cell
lineag
show
high
tumorigen
potenti
immunosuppress
anim
grow
subcutan
intraperiton
inocul
marker
xenograft
tumor
evalu
immunohistochemistri
highli
express
human
vimentin
compar
origin
human
tumor
sensit
chemotherapeut
agent
also
evalu
cell
line
show
resist
commonli
use
chemotherapeut
drug
conclus
continu
effort
complet
character
cell
line
also
pursu
isol
repres
cell
line
periton
dissemin
pediatr
tumor
backgroundobject
immunoposit
ckit
observ
us
number
tissu
neuroblastoma
patient
studi
aim
evalu
preval
ckit
copi
number
variat
cnv
prognost
signific
neuroblastoma
designmethod
thirtyseven
histolog
confirm
neuroblastoma
nb
specimen
evalu
genom
dna
amplifi
realtim
pcr
rel
copi
number
ckit
gene
calcul
respect
three
housekeep
gene
succin
dehydrogenas
sdhc
nacetylglucosamin
kinas
nagk
rnase
p
patient
sampl
valu
least
respect
two
refer
gene
consid
amplifi
result
age
rang
month
mean
seven
patient
month
femal
male
locat
tumor
adren
nonadren
stage
nonstag
patient
case
receiv
neoadjuv
chemotherapi
nact
achiev
cr
pr
nr
pd
final
respons
assess
patient
cr
achiev
pr
nr
pd
patient
die
rest
surviv
till
end
studyrealtim
pcr
show
ckit
cnv
present
one
case
patient
month
old
male
adren
neuroblastoma
stage
undifferenti
histolog
high
mitosiskaryorrhexi
index
mki
make
unfavor
histolog
patient
die
soon
present
workup
without
receiv
treatment
conclus
ckit
gene
amplif
observ
one
case
suggest
ckit
amplif
rare
event
neuroblastoma
may
respons
observ
immunoposit
ckit
may
help
prognost
ewe
sarcoma
ew
malign
mesenchym
tumor
mmt
rhabdomyosarcoma
rm
synovi
sarcoma
ss
thirtyeight
thoracotomi
done
lung
metastas
alreadi
present
time
diagnosi
thoracotomi
done
lung
metastas
present
recurr
sixteen
patient
osa
hb
wt
bilater
metastas
underw
stage
metastasectomi
one
patient
bilater
rerecurr
follow
surgeri
one
side
whose
metastas
resolv
altern
chemotherapi
undergo
second
metastasectomi
three
patient
bilater
diseas
wait
contralater
surgeri
follow
unilater
metastasectomi
nine
repeat
thoracotomi
requir
patient
osa
wt
hb
fifteen
patient
underw
lobectomi
lobe
remov
patient
patient
wedg
resect
subpleur
resect
wedg
subpleur
resect
biopsi
perform
patient
unresect
tumor
two
neg
thoracotomi
ten
patent
die
patient
osa
wt
hb
mmt
mgct
rerecurr
lung
give
overal
surviv
ci
eventfre
surviv
conclus
pulmonari
metastasectomi
even
done
bilater
metachron
diseas
viabl
option
achiev
surviv
patient
lead
accept
eventfre
overal
surviv
rate
patient
otherwis
would
progress
die
begun
r
tarasevich
papkevich
backgroundobject
ultrasonographi
method
choic
primari
diagnosi
abdomin
solid
tumor
pediatr
patient
howev
signific
proport
advanc
form
cancer
among
children
admit
inpati
treatment
purpos
studi
compar
effect
ultrason
method
primari
diagnosi
pediatr
abdomin
malign
outpati
phase
special
clinic
designmethod
analyz
medic
record
patient
sex
age
day
year
median
year
success
admit
examin
andor
treatment
pediatr
oncolog
hospit
spectrum
diseas
consist
retroperiton
neoplasm
patient
tumor
tumorlik
process
liver
kidney
adren
evalu
diagnost
accuraci
ultrason
method
result
comprehens
analysi
data
presenc
solid
malign
child
use
estim
aggreg
classic
sign
ultrasound
detail
document
outpati
condit
onefifth
case
hospit
threequart
case
accuraci
method
evalu
diagnost
data
level
differenti
tumor
tumorslik
process
differenti
benign
malign
tumor
assumpt
nosolog
form
case
rang
outpati
condit
hospit
respect
regard
nosolog
form
lowest
effect
ultrasound
diagnosi
accord
criteria
set
retroperiton
tumor
effect
ultrasound
diagnosi
outpati
phase
lower
special
medic
facil
necessari
make
use
possibl
comprehens
assess
ultrasound
data
accord
diagnost
criteria
malign
success
ascertain
exist
tumor
till
assess
symptom
malign
growth
result
nonextrem
tumour
commonest
amongst
patient
analyz
patient
tumour
highrisk
featur
tumour
size
cm
high
grade
invas
neoadjuv
therapi
includ
chemotherapi
alon
patient
one
patient
receiv
radiotherapi
alon
along
chemotherapi
none
patient
complet
respons
major
respons
regress
record
minor
regress
case
stabl
progress
diseas
seen
eventfre
overal
surviv
respect
nine
relaps
three
local
site
abdomin
caviti
lung
respect
respons
neoadjuv
therapi
predict
outcom
conclus
initi
unresect
nrst
commonli
present
highrisk
featur
respond
poorli
neoadjuv
therapi
outcom
remain
dismal
compel
need
effect
therapi
patient
bhatnagar
backgroundobject
vascular
anomali
mani
time
pose
tremend
therapeut
challeng
due
type
site
rapid
growth
disfigur
complic
object
emphas
need
earli
intervent
patient
vascular
anomali
especi
head
neck
establish
efficaci
inject
bleomycin
scleros
vascular
anomali
designmethod
children
vascular
anomali
malform
vari
size
site
behaviour
select
inject
bleomycin
therapi
subject
sclerotherapi
regim
three
week
apart
dose
dilut
normal
salin
exceed
unitkg
per
session
januari
till
decemb
lesion
measur
photograph
serial
clinic
respons
complic
record
regress
lesion
term
excel
signific
poor
result
total
children
includ
studi
mean
age
month
rang
month
year
mean
number
inject
given
rang
mean
total
dose
administ
mg
rang
patient
achiev
respons
greater
reduct
size
complet
resolut
show
reduct
size
lesion
show
reduct
size
ulcer
occur
children
develop
patchi
hyperpigment
none
develop
pulmonari
fibrosi
conclus
vascular
lesion
tradit
left
alon
spontan
regress
occur
neither
certain
complet
occur
mani
year
treat
surgic
steroid
give
partial
respons
recurr
moreov
lesion
head
face
neck
caus
disfigur
often
rapidli
progress
anticanc
antiangiogen
agent
bleomycin
caus
perman
cure
larg
number
children
provid
excel
cosmet
result
resolv
minor
side
effect
drug
backgroundobject
sacrococcyg
tumour
germ
cell
tumour
within
divers
group
mass
may
occur
within
region
pericoccyg
area
time
surgic
resect
exact
diagnosi
alway
known
ukcclg
guidelin
resect
sacrococcg
teratoma
mandat
coccygectomi
either
primari
delay
due
risk
malign
recurr
designmethod
tertiari
paediatr
surgic
centr
retrospect
review
undertaken
lesion
resect
pericoccyg
region
determin
complianc
mandatori
coccygectomi
suspect
potenti
saccrococcyg
teratoma
case
identifi
patholog
report
snome
code
relev
topographi
morpholog
within
year
period
case
assess
tabul
precis
diagnosi
presenc
otherwis
coccygectomi
specimen
result
tumour
excis
coccygectomi
perform
case
case
evid
coccygectomi
one
presenc
absenc
coccyx
appar
word
report
germ
cell
tumour
resect
matur
teratoma
immatur
teratoma
remain
case
retrorect
cystic
hamartoma
fibrolipoma
lipoblastoma
germ
cell
tumour
mandatori
coccygectomi
perform
date
tumour
recurr
conclus
review
show
poor
complianc
ukcclg
guidelin
mandatori
coccygectomi
suspect
potenti
germ
cell
tumour
evid
base
guidelin
controversi
practic
worldwid
vari
implic
literatur
review
present
backgroundobject
whether
advers
effect
nephrectomi
unilater
renal
tumor
urt
childhood
outweigh
advers
effect
nephronspar
surgeri
nss
remain
controversi
aim
present
studi
evalu
advers
effect
nephrectomi
nss
cohort
children
urt
designmethod
conduct
retrospect
review
record
children
urt
underw
surgeri
institut
patient
older
six
month
age
neoadjuv
chemotherapi
delay
surgeri
nephrectomi
perform
children
partial
nephrectomi
children
tumor
enucl
children
renal
dysfunct
rd
defin
egfr
result
one
child
treat
multipl
wilm
tumor
enucl
underw
unnecessari
complet
nephrectomi
elsewher
anoth
child
stage
ii
diseas
partial
nephrectomi
develop
local
recurr
underw
complet
nephrectomi
pericav
lymphadenectomi
associ
radiotherapi
chemotherapi
stage
iii
diseas
instanc
kidney
remnant
tumorfre
three
children
underw
partial
nephrectomi
present
posit
margin
success
treat
chemotherapi
alon
stage
ii
diseas
mean
sd
age
year
nss
overal
eventfre
surviv
rate
one
patient
still
treatment
none
patient
treat
nss
present
renal
dysfunct
wherea
patient
stage
iiii
underw
nephrectomi
present
rd
conclus
experi
partial
nephrectomi
tumor
enucl
treatment
children
urt
appear
oncolog
safe
reason
therapi
price
shortterm
followup
patient
underw
nephrectomi
may
increas
risk
cardiovascular
diseas
overal
mortal
backgroundobject
sinc
nephrectomi
wilm
tumour
wt
compos
well
specifi
step
perform
similar
way
aim
studi
assess
import
durat
particular
step
designmethod
wt
patient
submit
postchemotherapi
nephrectomi
oper
team
within
last
year
nephron
spare
resect
patient
ivc
thrombu
exclud
case
analysi
conduct
pt
unilater
wt
surgic
step
analys
approach
abdomin
inspect
access
renal
pedicl
identif
ligat
renal
vessel
resect
tumour
lymph
node
sampl
closur
abdomen
result
approach
use
transver
transabdomin
last
minut
patient
ct
mri
prior
surgeri
abdomin
inspect
focus
search
periton
implant
last
minut
kocher
manoeuvr
right
side
laterocolon
left
side
access
renal
pedicul
last
minut
identif
ligat
renal
vessel
minut
resect
tumour
togeth
adipos
capsul
minut
lymph
node
sampl
minut
closur
abdomen
minut
durat
whole
procedur
last
minut
hr
minut
major
intra
oper
complic
tumour
ruptur
major
vascular
injuri
conclus
summari
postchemotherapi
nephrectomi
wt
well
organis
procedur
usual
last
less
hr
time
consum
appear
closur
abdomen
whole
oper
time
wherea
call
crucial
step
ligat
renal
vessel
dissect
mass
shorter
respect
seem
confirm
need
comfort
exposur
adequ
order
step
backgroundobject
pelvic
neuroblastoma
nb
includ
nb
aris
organ
zuckekandl
presacr
neuroblastoma
rare
tumor
case
report
report
experi
manag
two
case
presacr
nb
complet
resect
one
open
abdomin
sacralposterior
sagitt
tradit
advoc
best
treatment
presacr
retrorect
tumor
resect
tumor
often
entail
combin
abdominosacr
abdominoposterior
sagitt
approach
morbid
term
neurovascular
damag
share
innov
idea
laparoscopi
assist
posterior
sagitt
remov
presacr
neuroblastoma
designmethod
retrospect
studi
presacr
neuroblatoma
treat
depart
paediatr
surgeri
jipmer
februari
februari
analyz
term
clinicopatholog
profil
postop
outcom
term
hospit
stay
wound
infect
neurogen
bladder
result
total
case
presacr
mass
oper
period
one
presacr
teratoma
altman
type
iii
two
presacr
neuroblastoma
one
case
presacr
nb
oper
via
combin
abdominoposterior
sagitt
approach
one
oper
laparoscopi
assist
posterior
sagitt
approach
observ
case
laparoscopi
assist
posterior
sagitt
excis
presacr
mass
less
postop
pain
shorter
hospit
stay
neurogen
bladder
involv
postop
period
conclus
feel
laparoscop
mobil
pelvic
part
presacr
mass
follow
mobil
lower
part
via
posterior
sagitt
approach
excis
presacr
mass
definit
advantag
convent
abdominosacr
abdominoposterior
sagitt
approach
term
pain
relief
morbid
risk
neurovascular
damag
provid
better
magnifi
view
pelvi
presacr
area
backgroundobject
central
venou
punctur
selding
techniqu
often
use
obtain
short
longterm
cathet
although
safe
techniqu
complic
depth
needl
insert
standard
order
avoid
problem
develop
studi
determin
maximum
depth
insert
needl
intern
jugular
vein
cathet
insert
designmethod
anthropometr
data
pediatr
patient
submit
longterm
cathet
implant
collect
portabl
ultrasound
evalu
morphometr
paramet
intern
jugular
surgeri
needl
insert
depth
calcul
relationship
depth
weight
age
analyz
scatter
plot
linear
correl
coeffici
pearson
age
weight
categor
construct
graph
averag
depth
respect
confid
interv
comparison
age
group
depth
use
analysi
varianc
techniqu
anova
result
analyz
softwar
statistica
studi
includ
patient
depth
needl
insert
posit
correl
age
r
p
weight
r
p
mean
graph
show
depth
increas
age
weight
rise
result
confirm
anova
show
statist
signific
differ
p
subgroup
age
categori
multipl
regress
analysi
unsatisfactori
qualiti
adjust
observ
r
develop
mathemat
model
howev
linear
regress
could
guid
know
depth
insert
needl
secur
formula
calcul
insert
needl
weigh
kg
studi
show
posit
relationship
depth
needl
insert
age
weight
moreov
possibl
know
depth
insert
needl
jugular
vein
punctur
approxim
formula
weight
kg
result
boy
underw
right
hepatectomi
pretext
ii
fibrolamellar
hepatocellular
carcinoma
mobil
right
lobe
bilater
section
triangular
ligament
section
falciform
ligament
oper
standard
fashion
inflow
right
hepat
arteri
portal
vein
outflow
right
hepat
vein
ligat
prior
hepat
section
right
hepatectomi
develop
edema
lower
limb
inferior
abdomin
wall
increas
weight
kg
patient
diuresi
furosemid
doppler
ultrasonographi
find
vein
obstruct
abdomin
comput
tomographi
ct
reveal
remnant
liver
disloc
right
subphren
space
narrow
retrohepat
vena
cava
surgic
reposit
left
lobe
anatom
posit
venou
congest
disappear
progress
falciform
round
ligament
fix
anterior
abdomin
wall
keep
remnant
liver
anatom
posit
postop
cours
unev
posop
ct
show
improv
inferior
vena
cava
flow
conclus
fixat
remnant
liver
may
effect
prevent
hepat
venou
outflow
obstruct
right
hepatectomi
backgroundobject
invas
fungal
infect
becom
import
problem
patient
undergo
bone
marrow
transplant
pericardi
aspergillosi
uncommon
lethal
condit
designmethod
describ
patient
invas
aspergillosi
evalu
videoassist
pericardioscopi
intrapericardi
amphotericin
result
boy
diagnos
myelodysplast
syndrom
raeb
type
associ
left
leg
lymphedema
agenesi
lymphat
vessel
start
treatment
azacitidin
cycl
wait
unrel
donor
bone
marrow
transplant
underw
allogen
unrel
bone
marrow
transplant
myeloabl
condit
regimen
done
busulfan
cyclophosphamid
melphalan
thymoglobulin
graft
versu
host
diseas
prophylaxi
perform
cyclosporin
methotrex
present
graft
leukocyt
evolv
graft
dysfunct
hold
period
neutropenia
sinc
time
patient
develop
pulmonari
aspergillosi
treat
oral
voriconazol
stabil
clinic
sign
without
fall
level
galactomannan
requir
sever
chang
antifung
scheme
liposom
amphotericin
intraven
voriconazol
voriconazol
associ
micafungin
present
signific
pericardi
effus
echocardiographi
indirect
sign
cardiac
tamponad
underw
pericardiocentesi
exud
galactomannan
level
quit
high
videoassist
pericardioscopi
perform
procedur
allow
visibl
pericardi
sac
good
site
biopsi
intrapericardi
cathet
insert
receiv
intrapericardi
infus
amphotericin
b
day
keep
system
treatment
voriconazol
aspergillu
fumigatu
isol
pericardi
fluid
cultur
current
patient
receiv
system
treatment
voriconazol
even
posit
galactomannan
clinic
stabl
conclus
videoassist
pericardioscopi
minim
invas
techniqu
allow
prognosi
evalu
pericard
pericardi
biopsi
insert
pericardi
cathet
intrapericardi
amphotericin
option
pericardi
invas
aspergillosi
result
sixti
seven
patient
male
femal
age
rang
year
diagnosi
includ
fifti
three
remain
aliv
today
albeit
case
present
metastas
relaps
evolut
differ
histolog
type
frequent
embryon
rhabdomyosarcoma
alveolar
rhabdomyosarcoma
nonsurvivor
patient
die
mean
followup
rang
month
mean
followup
month
rang
month
tumor
locat
lower
limb
head
abdomen
liver
chest
upper
limb
other
ir
surgicopatholog
group
system
strongli
associ
surviv
case
aliv
ii
case
aliv
iii
case
aliv
iv
case
aliv
twenti
knownrisk
factor
present
among
patient
none
associ
ir
group
ir
group
associ
surviv
probabl
due
wide
histolog
varieti
tumor
multicent
supran
studi
necessari
draw
conclus
risk
factor
probabl
associ
prognosi
sharma
r
rahman
gupta
gupta
backgroundobject
neonat
tumour
infantil
tumour
vari
present
diagnosi
manag
challeng
tailor
casebas
describ
experi
challeng
tumour
designmethod
retrospect
review
case
challeng
malign
encount
neonat
infant
result
four
case
malign
present
infantil
age
group
period
nine
month
age
present
vari
week
gestat
month
age
three
femal
one
male
present
complaint
includ
respiratori
distress
poor
urinari
stream
haematuria
abdomin
lump
neck
mass
sacral
mass
patient
abdomin
lump
larg
heterogen
enhanc
mass
occupi
pelvic
caviti
presacr
region
displac
urinari
bladder
rectal
lumin
compromis
biopsi
suggest
embryon
rhabdomycosarcoma
given
half
dose
vincristin
adriamycin
cyclophosphamid
vac
chemotherapi
toler
chemotherapi
succumb
three
patient
oper
babi
respiratori
distress
thorac
mass
occupi
whole
hemithorax
start
vac
chemotherapi
probabl
diagnosi
neuroblastoma
howev
distress
worsen
babi
subject
emerg
thoracotomi
final
diagnosi
congenit
peribronchi
myofibroblast
tumour
month
old
child
neck
mass
initi
given
bleomycin
diagnosi
cystic
hygroma
outsid
refer
us
oper
suspicion
cervic
teratoma
final
diagnosi
infantil
fibrosarcoma
preterm
girl
sacral
mass
oper
week
age
diagnos
matur
sacrococcyg
teratoma
conclus
neonat
tumour
may
present
thorac
abdomin
sacrococcyg
neck
mass
surgic
excis
main
crux
manag
neonat
infantil
tumour
histopatholog
report
confirmatori
surgeri
neonat
toler
chemotherapi
well
reserv
select
nonoper
case
result
total
case
male
femal
age
rang
month
year
median
year
includ
case
hepatoblastoma
case
nephroblastoma
case
rhabdomyosarcoma
case
medulloblastoma
case
patient
underw
biopsi
primari
resect
chemotherapi
cours
treatment
pulmonari
metastasi
local
stabl
usual
becom
peripher
pulmonari
nodul
thoracoscop
lung
metastas
resect
malign
tumor
cell
detect
primari
patholog
case
activ
tumor
cell
discov
case
surgeri
chemotherapi
continu
accord
plan
patient
follow
month
year
conclus
children
stage
iv
malign
solid
tumor
still
treat
activ
resect
patholog
examin
help
evalu
prognosi
make
treatment
option
patient
whose
lung
metastas
stabl
chemotherapi
remov
primari
tumor
thoracoscopya
minim
invas
techniqu
provid
accept
option
parent
tumor
lysi
syndrom
traffic
accid
remain
patient
patient
diagnos
osteonecrosi
treatment
period
incid
significantli
higher
among
adolesc
femal
p
hip
frequent
involv
site
howev
patient
multipl
skelet
site
involv
conclus
compar
result
origin
protocol
incid
osteonecrosi
seem
much
higher
vs
group
nt
know
osteonecrosi
associ
genotyp
patient
argu
genet
suscept
howev
steroid
also
lasparaginas
known
risk
factor
age
gender
may
facilit
devast
complic
backgroundobject
loss
involv
chromosom
rare
cytogenet
abnorm
paediatr
patient
acut
lymphoblast
leukaemia
unclear
prognost
signific
treat
uk
protocol
designmethod
cytogenet
result
obtain
patient
year
age
confirm
diagnosi
treat
royal
marsden
england
januari
januari
bone
marrow
andor
blood
sampl
cytogenet
studi
process
gband
chromosom
analysi
follow
shortterm
cultur
use
standard
procedur
result
patient
chromosom
studi
success
patient
complet
partial
loss
chromosom
involv
median
age
diagnosi
year
rang
year
three
patient
isol
monosomi
one
patient
chromosom
eleven
patient
complex
karyotyp
includ
two
patient
philadelphia
chromosom
ph
addit
monosomi
two
patient
abnorm
result
patient
avail
data
diagnost
wbc
l
patient
includ
patient
ph
rapid
respons
induct
characteris
blast
day
patient
ph
proceed
transplant
first
remiss
patient
experienc
relaps
initi
refractori
diseas
patient
subsequ
die
one
refractori
diseas
one
secondari
myelodysplast
syndrom
post
transplant
one
transplantrel
hepat
failur
patient
remain
aliv
date
mainten
treatment
complet
treatment
remiss
patient
relaps
diseas
current
undergo
allogen
transplant
ph
relaps
patient
nilotinib
conclus
chromosom
abnorm
patient
seri
observ
frequent
patient
year
almost
half
patient
experienc
relaps
refractori
diseas
object
present
studi
identifi
way
elabor
independ
prognost
indic
patient
acut
lymphoblast
leukemia
basi
linear
spleen
size
designmethod
retrospect
studi
includ
children
sex
acut
lymphoblast
leukemia
age
year
median
year
underw
abdomin
ultrasound
receipt
protocol
treatment
evalu
signific
ultrasonograph
determin
length
spleen
predictor
outcom
diseas
order
mitig
influenc
growth
paramet
children
differ
age
data
evalu
base
normal
valu
length
spleen
nl
normal
length
spleen
spleen
lengthpati
height
calcul
cumul
incid
relaps
perform
method
compet
risk
data
censor
statist
differ
measur
frequenc
relaps
determin
use
gray
test
differ
compar
paramet
consid
statist
signific
p
result
level
surveil
year
cumul
incid
relaps
patient
depend
absolut
size
origin
length
spleen
group
less
equal
cm
patient
anoth
group
format
children
normal
spleen
length
less
equal
statist
significantli
differ
cumul
incid
relaps
backgroundobject
vincristin
import
chemotherapeut
agent
treatment
children
acut
lymphoblast
leukemia
one
side
effect
vincristin
sever
pain
neuropathi
difficult
treat
unit
neuropath
pain
often
treat
amitriptylin
far
hardli
anyth
describ
treatment
neuropath
pain
children
cancer
purpos
aim
cohort
studi
show
mani
children
develop
neuropathi
treatment
vincristin
mani
children
treat
amitriptylin
neuropath
pain
effect
treatment
designmethod
perform
retrospect
cohort
studi
use
questionnair
studi
popul
random
sampl
children
year
diagnos
treat
period
januari
novemb
academ
medic
centr
amsterdam
result
thirtyfour
patient
enrol
complet
questionnair
n
develop
symptomat
neuropathi
neuropath
pain
found
use
pain
medic
neuropath
pain
one
respond
use
amitriptylin
combin
acetaminophen
tramadol
mean
pain
score
measur
va
scale
scale
rang
without
medic
medic
gave
score
n
conclus
almost
children
develop
symptomat
neuropathi
treatment
vincristin
give
high
score
pain
vincristin
hurt
yet
big
profit
win
fight
neuropath
pain
total
bodi
irradi
prepar
regimen
significantli
associ
higher
risk
io
univari
analysi
conclus
io
frequent
complic
pediatr
longterm
survivor
posthsct
al
preval
seem
increas
time
studi
prolong
followup
cohort
warrant
confirm
determin
impact
io
longterm
morbid
mortal
popul
backgroundobject
major
sever
form
anemia
caus
new
complic
includ
malign
immun
imbal
respons
occurr
differ
malign
leukemia
lymphoma
condit
like
thalassemia
multipl
transfus
caus
excess
iron
accumul
result
gener
toxic
oxygen
free
radic
therefor
immun
system
modif
stimul
growth
infecti
organ
thu
assess
rate
malign
patient
major
designmethod
longterm
year
studi
carri
patient
major
well
healthi
individu
control
group
group
regularli
check
malign
standard
protocol
month
interv
suspect
case
malign
confirmatori
test
perform
result
mean
age
year
case
control
group
respect
seventeen
patient
male
patient
receiv
defroxamin
dfo
iron
chelat
therapi
mean
number
transfus
pack
cell
studi
time
mean
serum
ferritin
level
ngdl
time
studi
found
two
year
old
male
old
femal
thirti
case
patient
major
develop
acut
lymphoblast
leukemia
control
group
find
evid
malign
microscop
examin
patient
reveal
fab
classif
immunophenotyp
analysi
reveal
lymphoblast
follow
phenotyp
case
molecular
analysi
demonstr
homozyg
mutat
femal
patient
male
one
conclus
co
exist
thalassemia
leukemia
emphas
possibl
occurr
malign
thalassemia
major
patient
one
possibl
phenomena
carcinogen
toxic
effect
excess
iron
result
multipl
transfus
interim
mainten
imi
high
dose
mtx
imi
capizzi
mtx
delay
intensif
imii
mainten
manag
patient
includ
itmlcv
itha
itha
itmlcv
event
includ
mild
tiaweak
sever
tia
seizur
three
patient
second
event
post
itmlcv
eleven
patient
therapi
median
month
eleven
remain
therapi
complet
therapi
within
one
year
one
patient
cn
relaps
follow
itmlcv
backgroundobject
sudan
still
difficult
know
extent
cancer
profil
among
children
studi
conduct
find
pattern
childhood
cancer
tertiari
referr
center
sub
saharan
african
countri
designmethod
retrospect
descript
studi
data
retriev
medic
record
paediatr
patient
regist
nation
cancer
institut
sudan
period
januari
decemb
result
studi
period
total
children
year
age
regist
predomin
age
affect
observ
year
age
group
frequenc
cancer
found
higher
among
boy
male
femal
ratio
major
children
rural
area
leukemia
lymphoma
retinoblastoma
nephroblastoma
commonli
found
childhood
cancer
among
studi
popul
less
commonli
found
cancer
neuoroblastoma
central
nervou
system
tumour
soft
tissu
sarcoma
bone
tumour
nasopharyng
carcinoma
lymphoma
central
nervou
system
tumour
occur
higher
frequenc
boy
respect
compar
girl
respect
wherea
retinoblastoma
nephroblastoma
occur
less
frequent
boy
respect
girl
respect
conclus
studi
provid
knowledg
situat
childhood
cancer
sudan
show
leukaemia
lymphoma
repres
case
dedic
paediatr
cancer
registri
essenti
find
real
incid
type
surviv
childhood
malign
sudan
backgroundobject
vincristin
import
compon
treatment
protocol
acut
lymphoblast
leukemia
howev
vincristin
caus
neurotox
disabl
advers
effect
affect
qualiti
life
patient
neurotox
lead
dose
reduct
treatment
discontinu
impact
surviv
nowaday
one
challeng
medicin
predict
patient
go
respond
treatment
base
genet
characterist
order
adjust
treatment
beginningth
mechan
action
vincristin
base
bind
betatubulin
caus
inhibit
microtubul
assembl
cell
cycl
arrest
nervou
system
bind
vincristin
betatubulin
lead
sever
alter
axon
microtubul
result
axon
swell
nervou
fiber
damag
disturb
sensori
motor
function
characterist
neurotox
recent
genomewid
associ
studi
independ
cohort
childhood
patient
found
polymorph
promot
region
associ
increas
risk
vincristinerel
neurotox
gene
encod
centrosom
protein
essenti
microtubul
format
vincristin
exert
pharmacolog
effect
inhibit
microtubul
formationth
aim
studi
replic
polymorph
spanish
cohort
childhood
ball
patient
determin
polymorph
microtubulerel
gene
associ
vincristin
neurotox
designmethod
dna
blood
children
ball
complet
remiss
treat
lalshop
protocol
analyz
snp
gene
studi
result
found
sever
polymorph
gene
significantli
associ
vincristin
toxic
result
suggest
polymorph
microtubulerel
gene
may
affect
risk
vincristin
toxic
childhood
project
support
retic
basqu
govern
tall
lymphoblast
lymphoma
case
case
diagnos
basi
morpholog
cytogenet
avail
case
case
cn
diseas
time
diagnosi
patient
treat
accord
standard
arm
protocol
one
hundr
twenti
seven
case
categor
high
risk
treat
four
drug
regimen
b
induct
patient
standard
risk
treat
three
drug
regimen
major
problem
induct
infect
case
proxim
myopathi
case
drug
induc
hepatotox
case
neuropathi
case
eighteen
patient
die
induct
chemotherapi
due
infect
due
bleed
due
hepat
failur
one
due
anthracyclin
induc
cardiotox
conclus
infect
proxim
myopathi
major
concern
induct
chemotherapi
infect
alon
combin
factor
major
caus
death
induct
chemotherapi
backgroundobject
acut
lymphoblast
leukemia
common
childhood
cancer
pentoxifyllin
ptx
increas
chemotherapyinduc
apoptosi
pretreat
window
clinic
trial
develop
evalu
whether
ptx
increas
apoptosi
gene
express
profil
induct
steroid
window
phase
designmethod
thirtytwo
children
new
diagnosi
randomli
assign
receiv
prednison
prd
mgm
day
treatment
prephas
prd
group
receiv
prd
ptx
mgkgday
ptx
group
control
group
includ
children
normal
bone
marrow
bone
marrow
aspir
perform
diagnosi
group
end
prd
window
patient
prd
ptx
group
apoptosi
evalu
flow
cytometri
use
annexin
vflourescein
isothiocyan
propidium
iodid
stain
gene
express
profil
perform
microarray
sqpcr
result
apoptot
index
diagnosi
similar
group
treatment
apoptosi
significantli
higher
ptx
group
prednison
group
p
seriou
advers
effect
observ
ptx
express
wide
number
gene
regul
ptx
prd
group
ptx
group
gene
respect
p
prd
ptx
group
show
proapoptot
gene
express
profil
ptx
ad
prd
induc
express
proapoptot
gene
involv
death
induc
signal
complex
format
intrins
pathway
also
affect
regul
backgroundobject
immunophenotyp
great
import
diagnosi
classif
prognosi
acut
lymphoblast
leukemia
howev
resourc
constraint
complet
work
carri
mani
case
investig
immunophenotyp
subtyp
associ
cytogenet
clinic
featur
designmethod
total
children
studi
clinic
present
immunophenotyp
carri
children
flow
cytometri
use
panel
monoclon
antibodi
patient
also
subject
karyotyp
analysi
gband
techniqu
result
mean
age
patient
year
male
femal
ratio
patient
cell
count
l
half
count
l
patient
promin
musculoskelet
manifest
backgroundobject
object
studi
investig
frequenc
mortal
rate
invas
fungal
infect
assess
impact
infect
time
applic
chemotherapi
regimen
induct
consolid
therapi
pediatr
patient
acut
lymphoblast
leukemia
designmethod
retrospect
cohort
studi
analyz
patient
age
year
receiv
chemotherapi
remiss
induct
consolid
therapi
januari
decemb
patient
evalu
frequenc
invas
fungal
infect
either
probabl
proven
fungal
infect
also
date
chemotherapi
given
phase
chang
schedul
report
result
studi
period
patient
enrol
median
age
year
malefemal
ratio
pediatr
treatment
protocol
gener
contain
higher
cumul
dose
nonmyelosuppress
agent
includ
lasparaginas
hypercvad
asparaginasefre
chemotherapeut
regimen
wide
use
treat
aya
adult
hypercvad
regimen
consist
altern
cycl
fraction
cyclophosphamid
vincristin
doxorubicin
dexamethason
cyclea
highdos
methotrex
cytarabin
cycleb
treatment
aya
patient
hypercvad
common
us
noncompar
data
suggest
outcom
may
inferior
pediatricinspir
treatment
protocol
includ
lasparaginas
object
calcul
numberneededtotreat
nnt
prevent
relaps
death
pediatricinspir
treatment
versu
hypercvad
aya
patient
backgroundobject
purpos
minim
residu
diseas
mrd
monitor
becom
integr
part
manag
children
mrd
essenti
role
predict
relaps
overal
surviv
designmethod
method
retrospect
analysi
mrd
level
correl
diseas
outcom
children
acut
lymphoblast
leukemia
analys
children
receiv
treatment
jan
dec
children
treat
bfm
protocol
base
risk
stratif
mrd
level
done
flow
cytometri
method
induct
chemotherapi
end
reinduct
chemotherapi
result
mrd
induct
done
twenti
four
patient
thirti
three
end
reinduct
twenti
patient
mdr
twenti
patient
twenti
four
four
patient
nine
patient
mrd
level
couldnot
done
two
patient
die
induct
four
alreadi
receiv
treatment
local
centr
come
us
initi
flow
cytometri
avail
three
patient
cost
burden
caus
four
patient
high
mrd
level
induct
poor
prognosi
spite
treatment
intensif
two
earli
relaps
one
die
due
progress
diseas
one
late
relapseout
twenti
patient
mrd
induct
two
late
relaps
conclus
mrd
monitor
becom
standard
care
treatment
children
develop
countri
still
mani
center
reli
bone
marrow
morpholog
due
lack
facil
mrd
test
associ
cost
burden
patient
develop
conscious
intracrani
bleed
detect
patient
undergon
urgent
neurosurg
intervent
progress
lesion
shown
voriconazol
ad
treatment
lesion
cultur
demonstr
tricoderma
speci
characterist
resist
amphotericinb
sensit
voriconazolew
began
caspofungin
voriconazol
administ
togetherpati
continu
therapi
sever
neurolog
sequel
result
one
patient
perform
combin
therapi
die
due
progress
diseas
live
sever
neurolog
sequelour
one
case
respond
antifung
therapi
well
followedup
regularlytwo
patient
undergon
stereotax
biopsyth
earli
stage
surgic
intervent
could
perform
case
patient
undergon
surgeri
hydrocephali
intracrani
bleed
respect
intracranialfung
infect
show
highmort
patient
receiv
chemotherapi
aresom
studi
show
posit
effect
earli
surgic
intervent
prognosi
besid
antifung
therapyth
combin
antifung
therapi
still
controversi
backgroundobject
phosphor
basic
intracellular
anion
requir
mani
biolog
function
hypophosphatemia
inform
relat
sepsi
associ
sepsi
severityther
sever
studi
show
sever
hypophosphatemia
increas
mortal
septicemiather
studi
serum
level
phosphor
febril
neutropen
attack
fna
pediatr
cancer
patient
prospect
studi
aim
determin
whether
hypophosphatemia
associ
mortal
febril
neutropen
patient
malign
also
assess
relationship
serum
level
phosphor
characterist
attack
treatment
modif
case
febril
neutropenia
designmethod
studi
includ
febril
neutropen
children
malign
hospit
one
year
studi
group
consist
femal
male
median
age
year
number
febril
neutropenia
among
patientsth
case
burkitt
neuroblastoma
case
solid
tumorsth
patient
examin
perform
hematolog
biochem
analys
includ
phosphor
cultur
blood
urin
febril
attack
one
hundr
twenti
nine
fna
observ
patientsthey
divid
group
group
compris
attack
sever
hypophosphatemia
serum
inorgan
phosphat
pi
mgdl
group
compris
attack
without
sever
hypophosphatemia
pi
mgdl
attack
serum
level
phosphor
normal
level
attack
level
normal
rangether
signific
differ
durat
antibiot
microbiolog
document
number
attack
number
fever
unknown
origin
number
attack
treatment
modif
death
two
group
conclus
hypophosphatemia
occur
sepsi
associ
lifethreaten
conditionin
studi
show
lower
level
serum
phosphor
increas
mortal
length
stay
hospit
case
febril
neutropeniath
relationship
serum
level
phosphor
mortal
fea
need
confirm
studi
backgroundobject
although
modern
treatment
acut
leukemia
children
dramat
success
last
decad
result
could
reproduc
relaps
refractori
patient
standard
chemotherapi
clofarabin
could
use
patient
salvag
therapi
secondgener
purin
nucleosid
analogu
inhibit
dna
synthesi
repair
despit
efficaci
combin
dna
damag
agent
signific
toxic
designmethod
given
combin
chemotherapi
consist
clofarabin
relaps
aml
refractori
aml
leukemia
patient
time
aml
patient
receiv
clofarabin
combin
cytarabin
wherea
patient
clofarabin
along
cyclophosphamid
etoposid
one
resist
aml
one
resist
patient
receiv
clofarabin
therapi
relaps
stem
cell
transplant
sct
result
patient
experienc
hematolog
toxic
grade
iv
myelosupress
grade
iiiii
infecti
toxic
grade
iiiii
nausea
vomit
mucos
mucos
grade
iv
patient
cycl
hypokalemia
resist
therapi
observ
day
durat
none
patient
veno
occlus
diseas
one
patient
die
day
treatment
probabl
due
capillari
leak
syndrom
two
patient
die
day
clofarabin
therapi
sever
intracrani
fungu
infect
diseas
progress
remain
patient
immedi
undergon
sct
wherea
patient
receiv
clofarabin
sct
relaps
prepar
second
transplant
clofarabin
potent
effici
chemotherapeut
agent
relaps
refractori
leukem
children
howev
due
substanti
toxic
profil
could
use
salvag
therapi
bridg
sct
backgroundobject
brain
abscess
children
though
rare
remain
lifethreaten
complic
haematolog
malign
prognosi
dismal
littl
inform
appropri
manag
complic
review
literatur
manag
children
develop
multipl
fungal
brain
abscess
antileukem
therapi
tri
find
ideal
treatment
recommend
designmethod
six
year
old
girl
start
ukal
regimen
b
drug
induct
induct
develop
prolong
febril
neutropenia
later
episod
statu
epilepticu
investig
reveal
multipl
brain
abscess
bacteri
work
neg
includ
tuberculosi
among
fungal
work
csf
galactomannan
posit
high
titr
start
convent
amphotericin
mgkgday
voriconazol
mgkg
hrli
week
voriconazol
alon
continu
month
cours
treatment
repeat
titr
show
decreas
level
month
stabl
antileukaem
therapi
continu
current
remiss
receiv
mainten
chemotherapi
detail
literatur
review
show
one
studi
child
receiv
voriconazol
month
multipl
fungal
brain
abscess
result
case
first
document
surviv
case
indian
subcontin
right
antifung
treatment
need
continu
lesion
get
smaller
disappear
howev
child
becom
neutropen
treatment
need
address
aggress
conclud
patient
multipl
fungal
brain
abscess
salvag
develop
rigor
febril
neutropen
protocol
moment
consensu
durat
antifung
therapi
children
leukaemia
fungal
cn
infect
backgroundobject
muscl
weak
peripher
neuropathi
common
children
acut
lymphoblast
leukaemia
induct
therapi
mainli
due
steroid
vincristin
critic
ill
polyneuropathi
cipn
appear
common
complic
sever
sepsi
thought
repres
neurolog
manifest
system
inflammatori
respons
syndrom
sir
designmethod
month
old
boy
preb
whilst
regimen
induct
drug
present
us
day
induct
right
side
pneumonia
septic
shock
requir
multipl
fluid
bolus
mlkg
pack
red
cell
platelet
transfus
inotrop
support
hour
mechan
ventil
sedat
day
two
attempt
extub
day
ventil
unsuccess
due
poor
muscl
tone
power
gener
hypotonia
areflexia
muscl
power
upper
lower
limb
muscl
group
well
onset
hyptonia
happen
follow
septic
shock
possibl
cipn
consid
differenti
diagnosi
vincristin
induc
neuropathi
steroid
myopathi
guillain
barr
syndrom
gb
malnutrit
aggrav
patholog
thought
day
success
extub
non
invas
bipap
treat
antibiot
antifung
iv
igg
medic
result
mani
toddler
induct
period
stop
walk
due
muscl
weak
would
difficult
differenti
cipn
drug
induc
neuropathi
gb
follow
regular
physiotherapi
vitamin
nutrit
support
muscl
tone
power
improv
conclus
cipn
seen
children
admit
intens
care
unit
especi
septic
shock
follow
multidisciplinari
team
approach
would
abl
manag
children
treatment
tumour
lysi
syndrom
relat
hyperphosphatemia
role
sevelam
hydrochlorid
h
lashkari
backgroundobject
tumour
lysi
syndrom
tl
commonest
oncolog
emerg
seen
children
associ
high
level
uric
acid
phosphat
potassium
along
low
level
calcium
abnorm
renal
function
need
dialysi
casesth
standard
treatment
hyperleukocytosi
tl
major
centr
india
hyper
hydrat
alkalinis
urin
allopurinolin
case
haemodialysi
perform
improv
renal
function
control
high
uric
acid
phosphat
level
calcium
base
phosphat
binder
use
due
increas
chanc
develop
calcium
phosphat
crystal
sevelam
hydrochlorid
oral
phosphatebind
use
treatment
hyperphosphatemia
children
adult
haemodialysi
chronic
kidney
diseas
designmethod
herebi
report
two
case
tcell
present
high
white
cell
count
bulki
diseas
proceed
spontan
tumour
lysi
syndromeboth
case
receiv
rasburicas
sevelam
hydrochlorid
reduc
serum
uric
acid
phosphat
level
respect
result
case
serum
phosphat
level
high
mgdl
mgdl
enough
initi
haemodialysi
howev
perform
haemodialysi
newli
diagnos
tl
challeng
view
low
platelet
count
case
receiv
hyperhydr
urin
output
achiev
regular
diuret
howev
serum
creatinin
level
abnorm
mgdl
mgdl
initi
hr
follow
introduct
sevelam
hydrochlorid
success
avoid
hemodialysi
reduc
serum
phosphat
level
within
hr
conclus
develop
countri
like
india
children
diseas
present
late
diseas
progress
advanc
stage
high
tumour
load
sevelam
hydrochlorid
appear
effect
safe
treatment
hyperphosphatemia
associ
tumour
lysi
syndrom
backgroundobject
lasparaginas
lasp
standard
antileukaemia
agent
treatment
allergi
lasp
common
associ
antibodi
product
patient
allerg
nativ
e
coli
lasp
need
altern
lasp
prepar
outcom
patient
recruit
two
hong
kong
phosg
protocol
without
allergi
lasp
analys
backgroundobject
high
dose
corticosteroid
form
backbon
acut
lymphoblast
leukemia
induct
therapi
contribut
nonlif
threaten
side
effect
steroid
induc
hypertens
often
underreport
toxic
report
high
incid
hypertens
young
children
designmethod
induct
data
consecut
pediatr
patient
treat
per
protocol
januari
decemb
retriev
physician
note
blood
pressur
bp
record
medic
order
patient
receiv
prednisolon
day
day
hypertens
defin
bp
measur
percentil
age
sex
height
separ
occas
statist
analysi
done
use
spss
version
result
demograph
diseas
characterist
reveal
median
age
year
male
preponder
extramedullari
diseas
b
immunophenotyp
unfavour
molecular
genet
patient
bfm
standard
moder
high
risk
occur
case
respect
hypertens
observ
patient
requir
one
antihypertens
drug
patient
asymptomat
incid
vari
sex
male
femal
risk
group
incid
hypertens
children
year
year
respect
odd
ratio
hypertens
year
age
group
patient
requir
antihypertens
agent
belong
group
malnourish
bmi
percentil
patient
like
hypertens
compar
normal
nourish
bmi
percentil
patient
versu
odd
ratio
complet
remiss
rate
induct
mortal
conclus
hypertens
induct
common
children
age
year
underovernutrit
predispos
frequent
care
monitor
blood
pressur
recommend
condit
manag
medic
backgroundobject
acut
lymphoblast
leukemia
natur
leukemia
initi
cell
lic
remain
undefin
although
key
clinic
relev
sinc
lic
need
erad
order
cure
diseas
hierarch
concept
lic
abl
propag
leukemia
upon
transplant
onto
immunodefici
mice
challeng
data
show
licact
also
commit
cell
support
stochast
model
common
strategi
studi
base
defin
subpopul
distinct
surfac
marker
profil
order
altern
character
defin
lic
energi
metabol
cycl
phase
address
patient
deriv
xenograft
bcell
precursor
bcp
sampl
designmethod
cell
analyz
level
reactiv
oxygen
speci
ro
along
dna
rna
stain
allow
determin
cell
cycl
phase
repopul
activ
sort
cellular
subfract
investig
upon
transplant
onto
nodscid
mice
result
cell
cycl
fraction
show
licact
led
nodscidhual
engraft
howev
cell
earli
cell
cycl
phase
show
increas
repopul
activ
compar
cell
cycl
phase
interestingli
low
oxid
state
ro
low
identifi
cell
earli
cell
cycl
contrast
ro
high
cell
origin
later
cell
cycl
suggest
cell
oxid
state
indic
leukemia
initi
activ
function
address
hypothesi
sort
ro
high
ro
low
cell
transplant
interestingli
cell
low
oxid
state
ro
low
cell
show
higher
repopul
activ
short
leukemia
free
surviv
recipi
compar
ro
high
cell
lead
significantli
prolong
leukemia
engraft
conclus
data
indic
cell
show
lic
activ
cell
earli
cell
cycl
low
energi
metabol
repres
drive
leukemia
initi
cell
compart
thu
point
redox
modul
potenti
therapeut
target
basal
cell
carcinoma
within
median
followup
durat
year
cumul
incid
smn
ci
year
ci
year
respect
standard
incid
rate
ratio
sir
smn
sir
amlmd
brain
tumor
respect
univari
analysi
reveal
cranial
irradi
tendenc
associ
increas
risk
smn
howev
increas
risk
found
type
protocol
stem
cell
transplant
conclus
despit
exposur
intermedi
chemotherapi
cranial
irradi
includ
stem
cell
transplant
patient
cumul
incid
smn
unexpectedli
low
howev
sir
smn
childhood
significantli
higher
agematch
gener
popul
riskbas
followup
health
check
educ
survivor
collabor
survivor
physician
clinic
oncologist
encourag
prevent
earli
detect
smn
backgroundobject
mrd
well
establish
prognost
factor
manag
tcell
acut
lymphoblast
leukemia
tall
flow
cytometri
fc
easili
avail
wide
use
mrd
evalu
current
standard
fc
base
mrd
assay
assay
analyt
limit
lead
decreas
efficaci
aim
overcom
limit
improv
sensit
specif
studi
standard
fc
tall
mrd
assay
designmethod
studi
mrd
test
pediatr
tall
patient
januari
januari
differ
time
point
postinduct
day
postconsolid
day
three
mainten
sampl
tall
diagnos
per
criteria
use
comprehens
antibodi
panel
tencolor
tmrd
assay
standard
sampl
analyz
navio
flow
cytomet
beckman
coulter
use
kaluza
analysi
softwar
antibodi
tmrd
panel
includ
nuclear
stain
mrd
result
correl
high
risk
factor
fifti
tall
case
f
ratio
includ
earli
precursor
tall
etpal
studi
seventeen
postinduct
post
consolid
sampl
mrd
posit
mean
median
rang
two
etpal
posit
post
induct
neg
post
consolid
lowest
level
mrd
detect
assay
indic
high
sensit
fctmrd
equal
mrd
molecular
assay
conclus
tencolor
tall
mrd
assay
provid
high
level
sensit
help
better
monitor
respons
therapi
wechsler
wechsler
use
test
cognit
outcom
result
two
survivor
treat
chemotherapi
obtain
wisciii
total
intellig
quotient
iq
score
normal
rang
howev
score
significantli
level
match
control
norm
standard
wisciii
differ
patient
controlgroup
signific
p
level
measur
total
iq
verbal
iq
verbal
comprehens
index
freedom
distract
index
three
verbal
subtest
score
result
indic
impair
global
cognit
function
also
indic
verbal
function
process
speed
well
attent
complex
visualspati
problemsolv
may
affect
group
children
receiv
chemotherapi
taken
account
school
health
care
provid
therefor
essenti
implement
adequ
rehabilit
followup
program
children
remiss
result
survivor
treat
cto
obtain
significantli
lower
score
healthi
control
test
visualspati
construct
work
memori
memori
span
process
speed
tactil
stimuli
survivor
obtain
steeper
rise
learn
slope
lower
score
singletri
memori
problem
solv
task
catch
control
stimuli
repeat
result
indic
neuropsycholog
longterm
sequela
survivor
limit
specif
domain
especi
process
novelti
intervent
program
school
program
take
account
deficit
process
new
inform
focu
repetit
may
prevent
survivor
fall
behind
peer
backgroundobject
use
treatment
ukal
associ
hepatotox
small
subset
patient
treat
royal
marsden
hospit
report
long
term
followup
children
regard
hepat
statu
designmethod
case
sheet
followup
record
childrenwer
revisit
data
retriev
convent
descript
statist
use
analys
data
result
children
document
induc
hepatotox
databas
becam
symptomat
treatment
wherea
present
median
rang
month
end
therapi
former
group
present
featur
venoocclus
diseas
transamin
wherea
latter
group
low
count
hepatosplenomegali
isol
splenomegali
present
median
followup
month
children
persist
problem
isol
splenomegali
note
hepat
involv
evidenc
alter
hepat
echotextur
ultrasound
seen
patient
patient
underw
upper
gastrointestin
endoscopi
oesophag
varic
requir
band
liver
biopsi
perform
children
show
nodular
regen
hyperplasia
thrombocytopenia
present
children
associ
menorrhagia
pregnanc
loss
hepat
involv
major
patient
induc
hepatotox
cohort
progress
chronic
highlight
import
continu
longterm
hepatolog
haematolog
followup
patient
backgroundobject
folat
defici
common
children
resourc
limit
set
previous
observ
associ
folat
defici
increas
complic
mainten
chemotherapi
prompt
us
supplement
folic
acid
defici
children
mainten
effect
report
designmethod
children
current
undergo
mainten
chemotherapi
centr
enrol
provid
complet
least
one
cycl
day
folat
level
assess
prior
cycl
follow
unexplain
cytopenia
children
supplement
mg
folic
acid
daili
whenev
level
fell
clinicohaematolog
paramet
record
analys
result
sixtythre
children
includ
mean
followup
month
cycl
mainten
studi
folat
defici
note
begin
cycl
folic
acid
supplement
upfront
folat
defici
document
follow
screen
unexplain
cytopenia
anoth
cycl
cycl
screen
higher
incid
febril
neutropenia
vs
longer
durat
chemotherapi
interrupt
vs
day
p
note
children
latter
group
given
cycl
despit
supplement
children
detect
defici
supplement
routin
screen
ten
death
seen
mainten
occur
folat
defici
children
episod
unexplain
cytopenia
none
children
studi
relaps
diseas
till
last
followup
folat
defici
common
children
mainten
therapi
common
caus
unexplain
cytopenia
preemptiv
detect
folat
defici
frequent
period
screen
supplement
may
decreas
incid
complic
improv
outcom
mainten
therapi
children
particularli
resourc
limit
countri
chang
mirna
express
level
detect
use
empir
bayesian
approach
correct
fals
discoveri
rate
ten
mirna
differenti
express
chosen
valid
qrtpcr
use
taqman
probe
sampl
pediatr
nonneoplast
bone
marrow
bm
differ
express
group
analyz
mannwhitney
test
event
free
surviv
ef
overal
surviv
os
kaplanmei
plot
logrank
test
median
express
valu
use
cutoff
p
consid
signific
result
unsupervis
hierarch
cluster
evidenc
two
main
cluster
clearli
identifi
blineag
tall
valid
mirna
downexpress
overexpress
compar
nonneoplast
bm
compar
blineag
vs
tall
overexpress
observ
downexpress
overexpress
associ
death
blineag
higher
express
level
ball
also
associ
lower
ef
os
children
tall
overexpress
associ
higher
ef
present
result
suggest
role
mirna
leukemogenesi
potenti
prognost
childhood
backgroundobject
asparaginas
effect
drug
essenti
part
combin
treatment
children
acut
lymphoblast
leukaemia
surviv
rate
increas
significantli
sinc
introduc
treatment
protocol
failur
complet
treatment
asparaginas
lead
poorer
outcom
therefor
import
identifi
patient
clinic
subclin
allergi
uk
patient
receiv
dose
pegaspargas
dose
intramuscularli
im
depend
risk
stratifi
treatment
group
uk
protocol
ukal
interim
guidelin
ukal
advis
chang
dose
pegaspargas
dose
im
erwinia
asparaginas
case
system
allergi
prior
novemb
erwinia
asparaginas
avail
uk
patient
allerg
pegaspargas
discontinu
asparaginas
treatment
altogeth
designmethod
retrospect
identifi
evalu
patient
age
year
system
pegaspargas
allergi
treat
octob
march
royal
marsden
hospit
system
allergi
defin
grade
use
common
terminolog
criteria
advers
event
result
time
patient
receiv
treatment
per
ukal
interim
guidelin
trial
identifi
patient
pegaspargas
allergi
need
switch
erwinia
asparaginas
sever
reaction
vari
generalis
rash
fullblown
anaphylaxi
death
relat
allerg
reaction
conclus
incid
children
develop
pegaspargas
allergi
children
react
erwinia
asparaginas
switch
backgroundobject
common
chromosom
transloc
observ
childhood
acut
lymphoblast
leukemia
lead
gene
fusion
associ
favor
prognosi
follow
convent
therapeut
strategi
posit
leukemia
genom
breakpoint
flank
sequenc
transloc
chromosom
one
best
marker
minim
residu
diseas
mrd
monitor
quantit
realtim
polymeras
chain
reaction
qrtpcr
designmethod
studi
establish
nextgener
sequenc
ng
base
transloc
captur
sequenc
method
moreov
compar
patientspecif
breakpoint
flank
sequenc
pair
diagnost
relaps
sampl
result
found
patientspecif
breakpoint
case
childhood
sampl
besid
found
threeway
transloc
includ
patient
relaps
late
cessat
treatment
contrast
patient
without
threeway
transloc
still
remiss
p
threeway
transloc
may
reflect
degre
genet
instabl
gene
damag
moreov
compar
patientspecif
breakpoint
flank
sequenc
pair
diagnost
relaps
sampl
also
found
relaps
clone
mainli
deriv
primari
leukemia
clone
diagnosi
threeway
transloc
mayb
import
risk
factor
posit
leukemia
relaps
method
could
develop
becom
new
mrd
monitor
method
backgroundobject
proport
young
children
leukemia
without
blast
found
peripher
smear
review
unclear
result
autom
complet
blood
count
cbc
best
differenti
without
acut
leukemia
designmethod
record
clinic
present
result
cbc
peripher
smear
review
consecut
children
age
year
acut
leukemia
compar
cbc
result
consecut
outpati
age
result
patient
acut
leukemia
ci
blast
found
peripher
smear
review
without
blast
bone
marrow
examin
combin
present
symptom
find
autom
cbc
retrospect
found
combin
four
criteria
best
sensit
specif
differenti
patient
without
acut
leukemia
young
children
leukemia
without
leukemia
least
one
four
criteria
white
blood
cell
count
cellsl
absolut
neutrophil
count
cellsl
well
platelet
count
less
l
hemoglobin
valu
gml
children
identifi
least
one
four
criteria
clear
clinic
indic
bone
marrow
examin
conclus
signific
number
young
children
leukemia
blast
found
peripher
blood
smear
review
physician
reli
autom
cbc
test
result
present
symptom
determin
need
bone
marrow
examin
prospect
studi
larger
number
young
children
warrant
confirm
preliminari
find
suggest
autom
cbc
criteria
help
determin
need
bone
marrow
examin
x
zhao
backgroundobject
clinic
evid
indic
favor
glucocorticoid
gc
sensit
childhood
acut
lymphoblast
leukemia
tend
associ
high
period
acidschiff
pa
score
glycogen
stain
inhibit
glycolysi
activ
autophagi
designmethod
investig
whether
gcinduc
cytotox
influenc
autophagi
manifest
interrupt
glycogen
metabol
glycolysi
primari
cell
isol
patient
test
glucos
util
cultur
condit
without
rapamycin
pretreat
level
secret
vitro
well
plasma
origin
patient
examin
elisa
cellular
exist
distribut
glycogen
evalu
pa
score
crossexamin
transmiss
electron
microscopi
tem
result
rapamycin
treatment
abl
activ
autophagi
restrict
glucos
util
cultur
patient
differ
pa
score
howev
seem
lack
direct
correl
level
autophagi
activ
morpholog
chang
glycogen
interestingli
level
poor
gcrespons
group
low
autophagi
activ
higher
other
statist
signific
pediatr
blood
cancer
doi
siop
abstract
conclus
autophagi
increasingli
recogn
key
process
regul
glucos
metabol
approach
use
primari
cultur
probe
autophagi
activ
capac
could
attract
practic
method
clinic
outcom
evalu
despit
direct
associ
glycogen
autophagi
activ
cell
establish
studi
discoveri
indic
glucos
metabol
chang
impli
potenti
diagnost
valu
depend
secret
activ
autophagi
enabl
candid
marker
autophagi
tissu
type
applic
potenti
leukemia
remain
investig
sorafenib
administ
oral
start
dose
mgm
follow
possibl
escal
mgm
everi
hour
everolimu
oral
start
dose
mgm
follow
possibl
escal
mgm
day
consecut
cycl
diseas
progress
unaccept
toxic
effect
primari
endpoint
month
pf
result
common
toxic
skin
syndrom
oral
mucos
hematolog
toxic
grade
iii
three
patient
progress
free
month
maximum
pf
month
median
followup
month
rang
till
combin
sorafenib
everolimu
show
therapeut
effect
furtherlin
treatment
children
adolesc
refractori
osteosarcoma
backgroundobject
methotrex
mtx
one
frequent
chemotherapeut
drug
still
use
treatment
osteosarcoma
mtx
abl
inhibit
dihydrofol
reductas
also
interfer
enzym
methylenetetrahydrofol
reductas
methionin
synthas
methionin
sadenosyltransferas
therefor
probabl
mtx
involv
reduct
sadenosylmethionin
level
subsequ
lead
deplet
moreov
shown
mtx
act
inhibitor
histon
deacetylas
due
share
structur
similar
histon
deacetylas
inhibitor
designmethod
studi
use
mtt
assay
basic
assess
mtx
cytotox
gene
express
measur
use
qpcr
mtx
treatment
differ
dna
methyl
result
mtx
dna
demethyl
agent
treatment
studi
use
elisa
assay
histon
acetyl
level
detect
elisa
western
blot
result
mtx
treatment
influenc
express
gene
involv
drug
metabol
transport
sever
cell
line
mtx
abl
decreas
level
dna
mtx
almost
effect
concentr
cell
mtx
also
increas
level
acetyl
histon
assess
dnapk
rucaparib
inhibitor
singl
chemoor
radiosensitis
agent
ewe
sarcoma
cell
line
perform
growth
inhibit
clonogen
assay
evalu
cell
abil
repair
dna
doubl
strand
break
hrr
singl
agent
rucaparib
mgkg
ip
daili
evalu
vivo
orthotop
model
serial
bioluminesc
imag
result
caus
chemosensitis
etoposid
doxorubicin
radiosensitis
fold
increas
cytotox
chemosensitis
rucaparib
profound
temozolomid
fold
modest
camptothecin
ioniz
radiat
fold
depend
type
clonogen
assay
use
singl
agent
rucaparib
activ
differ
valu
rang
continu
versu
drug
exposur
respect
induct
dna
doubl
strand
break
cell
show
signific
increas
foci
format
indic
intact
hrr
vivo
test
rucaparib
nontox
fail
show
tumour
respons
surviv
advantag
conclus
ewe
sarcoma
cell
line
function
hrr
nevertheless
sensit
inhibit
despit
vitro
activ
monotherapi
parp
inhibitor
efficaci
vivo
given
chemoand
radiosensitis
effect
inhibitor
find
strongli
support
evalu
agent
combin
chemoor
radiotherapi
preclin
model
clinic
trial
past
year
seen
dramat
chang
field
pediatr
neurooncolog
larg
emerg
unbias
highthroughput
genomewid
analys
pediatr
brain
tumor
molecular
featur
uniqu
compar
adult
counterpart
one
exampl
pilocyt
astrocytoma
driven
mapk
activ
abnorm
often
braf
fusion
mutat
featur
may
serv
diagnost
prognost
marker
even
target
novel
therapi
aim
studi
genet
character
pediatr
brain
tumor
set
western
sweden
next
explor
function
relev
novel
mutat
identifi
designmethod
current
clone
novel
gene
mutat
transcript
transfect
neural
cell
line
skna
studi
cell
prolifer
clonal
expans
cell
adhes
migrat
invas
capabl
local
bind
partner
effect
mutat
protein
studi
livecel
imag
coimmunoprecipit
gene
express
analysi
studi
demonstr
transform
capabl
vitro
move
vivo
studi
use
xenograft
mous
model
rnasequenc
exomesequenc
identifi
novel
pointmut
gene
fusion
link
rabpathway
increas
evid
rab
regul
import
role
tumor
progress
first
time
rabassoci
mutat
link
pediatr
brain
tumor
conclus
conclus
increas
knowledg
downstream
effect
pathophysiolog
role
driver
mutat
facilit
develop
subgroup
tumorspecif
therapeut
braf
inhibit
agent
vermurafenib
enact
exampl
person
therapeut
potenti
cn
tumor
target
agent
provid
hope
treatment
advanc
incur
tumor
may
radic
improv
current
therapi
result
grade
area
emot
cognit
physic
social
use
pedsql
scale
gener
way
qol
survivor
good
emot
cognit
function
pedsql
affect
area
someth
import
patient
felt
anger
physic
area
also
affect
survivor
brain
tumor
suffer
numer
endocrin
metabol
consequ
major
develop
within
first
year
brain
tumor
therapi
conclus
activ
followup
aim
earli
diagnosi
therapi
essenti
improv
qualiti
life
patient
data
support
ongo
specif
interest
qol
longterm
cancer
survivor
suggest
need
studi
multidimension
function
popul
especi
brain
tumor
survivor
month
patient
obtain
therapi
line
protocol
hit
rez
tmz
surgeri
surgeryrt
rt
variou
nonprotocol
treatment
median
followup
pd
month
month
backgroundobject
cerebellar
astrocytoma
constitut
around
cn
neoplasm
childhood
surgeri
aim
complet
resect
princip
treatment
modal
although
need
durat
postsurg
mri
surveil
well
defin
respect
conduct
evalu
outcom
cerebellar
astrocytoma
region
paediatr
neurooncolog
centr
designmethod
tumour
databas
interrog
identifi
case
cerebellar
astrocytoma
variabl
includ
patient
age
gender
tumour
grade
complet
resect
durat
followup
remiss
statu
adjuv
therapi
result
patient
cerebellar
astrocytoma
review
pilocyt
astrocytoma
fibrillari
astrocytoma
ganglioglioma
unspecifi
lowgrad
tumour
thirti
seven
patient
underw
complet
resect
cr
none
relaps
patient
incomplet
resect
six
patient
progress
month
year
thu
chang
durat
mri
surveil
year
maximum
year
scan
month
post
surgeri
patient
undergon
cr
sinc
chang
practic
patient
grade
treat
data
decemb
allow
year
followup
eleven
tumour
complet
resect
near
total
resect
none
patient
relaps
median
followup
year
conclus
servic
evalu
none
patient
complet
resect
cerebellar
astrocytoma
relaps
support
chang
practic
shorten
durat
postop
surveil
result
time
cost
save
famili
health
servic
data
howev
rais
question
whether
surveil
imag
requir
complet
resect
pilocyt
cerebellar
astrocytoma
incomplet
resect
tumour
standard
postsurg
imag
schema
maintain
result
seventi
one
children
diagnos
treat
llg
twenti
p
perform
chemotherapi
patient
local
diseas
p
partial
resect
surgeri
perform
remain
surgeri
perform
chiasmat
cervic
cord
tumor
common
histolog
subtyp
pilomyxoid
astrocytoma
p
follow
pilocyt
astrocytoma
p
diffus
astrocytoma
p
frequent
locat
suprasellar
optic
pathaway
p
fifti
percent
p
perform
treatment
carboplatin
plu
vincristin
cog
p
perform
vinblastin
weekli
one
p
receiv
oral
temozolomid
three
p
made
secondlin
p
receiv
local
radiotherapi
progress
receiv
secondlin
treatment
fifteen
percent
grade
iii
hematolog
toxicityth
mean
followup
month
rang
die
progress
die
postop
complic
p
stabl
partial
remiss
date
yr
os
conclus
use
chemotherapi
children
unresect
lgg
progress
symptomat
appear
effect
achiev
stabl
diseas
minim
toxic
delay
use
local
radiotherapi
avoid
progress
backgroundobject
cmyc
protooncogen
play
major
role
regul
cell
growth
prolifer
differenti
apoptosi
addit
canon
cmyc
protein
human
cmyc
locu
also
encod
two
distinct
protein
design
mrtl
within
untransl
region
cmyc
mrna
aim
studi
examin
simultan
first
time
mrtl
cmyc
pediatr
brain
tumor
tissu
designmethod
mrtl
code
sequenc
pcr
amplifi
analyz
medullobastoma
malign
glioma
tissu
monoclon
mous
antimrtl
polyclon
rabbit
antisera
develop
western
analysi
done
whole
cell
lysat
immunofluoresc
stain
confoc
imag
perform
follow
methanol
fixat
result
sequenc
analys
confirm
known
polymorph
base
g
reveal
new
mutat
mrtl
sequenc
associ
nonsynonym
amino
acid
substitut
sequenc
reveal
variat
publish
sequenc
western
analys
visual
mrtl
cmyc
simultan
rel
intens
mrtl
posit
correl
stain
show
mrtl
dominantli
local
nuclear
envelop
along
promin
reticular
pattern
cytoplasm
consist
endoplasm
reticulum
er
observ
seri
bright
foci
locat
mainli
within
nucleu
partial
coloc
fibillarin
nucleolar
protein
also
stain
intranuclear
structur
recogn
fibrillarin
studi
show
evid
express
stabl
accumul
protein
mrtl
cmyc
encod
three
nonoverlap
read
frame
within
human
cmyc
locu
cmyc
mrna
seem
locat
specif
domain
nucleoli
well
intranuclear
structur
work
ongo
elucid
function
regulatori
relationship
molecul
ganglioglioma
sega
gemistocyt
astrocytoma
glioneuron
astrogli
ganglioneuroma
angiocentr
glioma
first
line
treatment
localis
lgg
follow
observ
biopsi
third
ventriculostomi
surgeri
chemotherapi
radiotherapi
progress
seen
patient
requir
treatment
death
eight
patient
metastaticmultifoc
diseas
patient
age
year
age
year
age
year
one
patient
diseas
restrict
cord
leptomening
spread
dissemin
diseas
histopatholog
includ
pilocyt
astrocytoma
pilomyxoid
astrocytoma
oligodendroglioma
diffus
astrocytoma
glioneuron
tumour
first
line
treatment
surgeri
chemotherapi
radiotherapi
five
patient
progress
need
treatment
one
death
infant
extens
pilomyxoid
astrocytoma
lgg
vari
histolog
localis
tumour
pilocyt
vs
patholog
children
lgg
cure
therefor
care
treatment
select
minimis
longterm
consequ
crucial
backgroundobject
medulloblastoma
common
posterior
fossa
tumor
childhood
outcom
depend
risk
stratif
base
age
diagnosi
extent
surgeri
spread
diseas
elig
radiotherapi
designmethod
retrospect
analysi
children
diagnos
medulloblastoma
treat
august
januari
centerchildren
treat
surgeri
concurr
chemotherapi
radiotherapi
follow
adjuv
chemotherapi
packer
regimen
high
dose
chemotherapi
stem
cell
rescu
data
analyz
use
spss
result
age
children
rang
year
median
year
children
male
femal
eight
averag
risk
high
risk
near
total
resect
done
patient
residu
diseas
post
resect
except
one
year
receiv
craniospin
radiotherapi
postsurgeri
weekli
vincristin
given
patient
two
patient
also
receiv
carboplatin
radiotherapi
fifteen
patient
averag
risk
high
risk
treat
packer
regimen
one
patient
receiv
babi
brain
protocol
four
patient
high
risk
diseas
treat
high
dose
chemotherapi
stem
cell
rescu
cycl
median
surviv
reach
median
follow
month
overal
surviv
os
averag
risk
high
risk
fifteen
twenti
one
aliv
till
januari
fourteen
diseas
free
one
relaps
aliv
five
six
die
due
diseas
progress
one
die
due
hlh
none
mortal
due
treatment
relat
sepsi
conclus
outcom
rare
diseas
reason
good
combin
modal
treatment
possibl
administ
high
dose
chemotherapi
stem
rescu
without
signific
side
effect
even
develop
countri
backgroundobject
human
cytomegaloviru
hcmv
ubiquit
herpesviru
infect
establish
latenc
major
human
popul
may
caus
fatal
infect
immunocompromis
patient
hcmv
detect
malign
glioblastoma
gbm
major
primari
meduloblastoma
mb
two
common
type
brain
tumor
epigenet
alter
believ
basic
factor
behind
malign
whole
genom
methyl
studi
gbm
tumor
suggest
gbm
recurr
link
epigenet
mechan
pathway
previou
studi
laboratori
shown
hcmv
infect
nontumor
cell
affect
host
cell
dna
methyl
machineri
dna
methyltransferas
dnmt
prevent
nuclear
local
may
strategi
hcmv
abrog
host
cell
defens
viral
replic
result
reloc
nucleu
cytoplasm
appear
associ
cell
express
hcmvlate
protein
could
restor
nucleu
antivir
ganciclovir
treatment
result
suggest
specif
viral
protein
interact
host
cell
protein
modul
host
cell
epigenet
respons
hypothes
hcmv
infect
may
lead
host
cell
epigenet
alter
surviv
cell
eventu
neoplast
event
epelman
v
odon
e
gorend
rss
medeiro
l
silva
backgroundobject
dipg
amongst
challeng
tumor
treat
childhood
drug
proven
effect
standard
care
remain
focal
radiotherapi
alon
howev
rapid
diseas
progress
usual
occur
median
overal
surviv
less
year
surviv
less
designmethod
patient
clinic
radiolog
confirm
central
review
newli
diagnos
dipg
elig
multicent
phase
ii
studi
antiepiderm
growth
factor
receptor
antibodi
nimotuzumab
administ
intraven
weekli
concomit
focal
radiotherapi
everi
week
tumor
progress
respons
evalu
base
clinic
radiolog
assess
primari
object
improv
surviv
histor
cohort
receiv
radiat
therapi
alon
result
twenti
one
patient
enter
studi
malefemal
median
age
year
rang
year
receiv
radiotherapi
treatment
well
toler
cycl
advers
effect
relat
drug
mild
major
advers
effect
associ
progress
diseas
diseas
free
surviv
month
overal
surviv
month
one
year
demonstr
better
result
compar
histor
trial
conclus
trial
demonstr
activ
nimotuzumab
dipg
well
toler
improv
overal
surviv
small
subset
patient
appear
benefit
antiegfr
antibodi
consid
futur
trial
synergist
drug
upfront
biopsi
bring
prospect
better
understand
dipg
biolog
select
better
treatment
treat
either
head
start
hsi
hsii
regimen
ten
children
underw
grosstot
neartot
subtot
resect
primari
tumor
three
children
metastas
diagnosi
result
fourteen
children
complet
cycl
induct
chemotherapi
one
die
candidemia
follow
hsi
cycl
two
develop
tumor
progress
hsii
induct
twelv
children
proceed
myeloabl
consolid
autolog
hematopoiet
cell
rescu
two
children
complet
induct
declin
therapi
children
ependymoma
subsequ
relaps
children
medulloblastoma
undergo
transplant
continu
aliv
without
recurr
year
transplant
overal
children
medulloblastoma
local
diseas
diagnosi
remain
aliv
irradiationfre
follow
strategi
conclus
experi
uppermiddleincom
asian
countri
demonstr
feasibl
chemotherapyonli
regimen
young
children
medulloblastoma
toler
efficaci
significantli
differ
encount
compar
experi
highincom
countri
expand
improv
infrastructur
support
care
manag
mani
childhood
cancer
especi
given
persist
substanti
lack
modern
radiotherapeut
equip
expertis
chemotherapyonli
strategi
evalu
prospect
wide
throughout
middleincom
develop
countri
year
metastas
complet
surgic
resect
radiotherapi
affect
result
treatment
best
surviv
rate
found
among
patient
got
region
mtx
backgroundobject
medulloblastoma
mb
one
common
pediatr
malign
brain
tumor
less
overal
surviv
rate
highrisk
group
aim
studi
assess
effect
singl
tandem
highdos
chemotherapi
hdct
autolog
hematopoiet
stemcel
transplant
autohsct
patient
group
designmethod
februari
februari
pediatr
patient
highrisk
relaps
mb
receiv
hdct
autohsct
induct
chemotherapi
radiotherapi
surgic
treatment
moment
hdct
patient
complet
remiss
cr
patient
partial
remiss
pr
patient
stabl
diseas
sd
patient
receiv
singl
tandem
autohsct
depend
age
bone
marrow
peripher
blood
stem
cell
use
stem
cell
sourc
median
followup
month
rang
median
time
engraft
day
rang
autohsct
six
patient
sd
moment
autohsct
die
diseas
progress
ten
patient
cr
pr
relaps
month
hdct
patient
current
cr
children
die
toxic
overal
surviv
os
diseas
free
surviv
df
df
significantli
better
among
highrisk
patient
st
cr
compar
patient
nd
follow
cr
accordingli
patient
cr
pr
moment
hdct
better
df
rate
patient
sd
respect
conclus
hdct
autohsct
pediatr
patient
highrisk
mb
may
feasibl
option
patient
cr
pr
induct
chemotherapi
ineffect
salvag
therapi
refractori
patient
backgroundobject
show
chang
treatment
base
molecular
studi
clinic
evolut
patient
cn
tumor
designmethod
caucasian
boy
diagnos
brain
stem
anaplas
ganglioglioma
present
clinic
summari
reveal
month
histori
gait
disturb
sever
cranial
nerv
paresia
dismetria
left
hemiparesia
tumor
unresect
biopsi
could
obtain
initi
treat
chemotherapi
vincristin
cisplatin
etoposid
cyclophosphamid
progress
cycl
treatment
start
irinotecan
bevacizumab
improv
next
month
cycl
irinotecan
stop
gastrointestin
toxic
bevacizumab
mantain
three
month
latter
tumor
progress
diagnos
molecular
studi
tumor
perform
diagnosi
show
mutat
braf
exon
c
treatment
dabrafenib
mgkgday
initi
rd
tumor
progress
week
later
clinic
improv
remark
confirm
cranial
nmr
week
six
month
later
treatment
stop
day
vp
shunt
infect
context
patient
neurolog
deterior
tumor
progress
nmr
dabrafenib
resum
cloroquin
ad
mgkgday
clinic
improv
confirm
cranial
nmr
child
attend
school
residu
left
hemiparesia
left
held
tilt
result
person
treatment
patient
improv
surviv
qualiti
life
conclus
molecular
analysi
patient
tumor
allow
us
identifi
druggabl
mutat
gave
us
chanc
administ
dabrafenib
sever
consid
standard
treatment
fail
patient
significantli
improv
sinc
start
dabrafenib
rol
ad
cloroquin
context
previous
report
order
induc
autophagi
show
canon
wnt
signal
pathway
regul
express
mgmt
childhood
neural
tumor
signific
correl
wnt
signal
mgmt
express
childhood
glioma
medulloblastoma
neuroblastoma
confirm
gene
express
analysi
immunofluoresc
demonstr
coloc
activ
mgmt
small
molecul
inhibit
key
molecul
within
canon
wnt
signal
cascad
knockdown
downregul
mgmt
express
restor
chemosensit
dna
alkyl
drug
mous
model
neural
tumor
conclus
find
potenti
therapeut
implic
treatment
chemoresist
cancer
especi
brain
tumor
use
temozolomid
frequent
includ
treatment
protocol
backgroundobject
survivor
pediatr
brain
tumor
suffer
reduc
qualiti
life
physic
health
psycholog
health
pauciti
research
examin
medic
factor
may
impact
physic
psycholog
health
outcom
aim
studi
identifi
impact
brain
tumor
type
primari
locat
treatment
modal
parentreport
child
pain
physic
function
emot
designmethod
particip
includ
mother
children
adolesc
age
year
femal
year
sinc
diagnosi
diagnos
brain
tumor
brain
tumor
type
includ
low
grade
gliomaastrocytoma
lga
pnet
ependymoma
craniopheringioma
germ
cell
primari
tumor
locat
includ
infratentori
supratentori
midlin
parent
complet
child
health
questionnair
child
behavior
checklist
multivari
regress
posthoc
ttest
util
result
control
age
diagnosi
tumor
type
associ
bodi
pain
f
p
physic
function
f
p
withdrawaldepress
symptom
f
p
specif
lga
associ
less
bodi
pain
better
physic
function
less
withdrawaldepress
compar
pnet
craniopheringioma
p
supratentori
tumor
locat
associ
less
withdrawaldepress
compar
infratentori
p
midlin
tumor
p
chemotherapi
radiat
associ
decreas
physic
function
p
increas
withdrawaldepress
symptom
p
radiat
also
associ
increas
bodi
pain
f
p
conclus
children
lga
supratenori
tumor
may
suffer
fewer
neg
physic
emot
outcom
children
brain
tumor
chemotherapi
radiat
appear
increas
risk
physic
emot
concern
identifi
risk
factor
may
help
guid
earli
monitor
intervent
backgroundobject
embryon
tumor
abund
neuropil
true
rosett
etantr
rare
childhood
embryon
brain
tumor
distinct
histopatholog
featur
standard
therapi
embryon
brain
tumor
ineffect
prognosi
dismal
designmethod
among
children
embryon
brain
tumor
treat
institut
three
patient
etantr
identifi
present
clinic
cours
analyz
molecular
characterist
includ
amplif
express
three
case
result
case
threemonthold
girl
present
increas
head
circumfer
mri
show
tumor
fourthventricl
subtot
resect
complet
resolut
tumor
imag
achiev
multiag
chemotherapi
focal
proton
therapi
tumor
recur
month
diagnosi
despit
subtot
resect
follow
highdos
chemotherapi
hematopoiet
stem
cell
rescu
tumor
progress
patient
die
year
diagnosi
case
oneyearold
girl
present
vomit
ct
show
tumor
right
cerebellar
hemispher
tumor
subtot
resect
tumor
recur
multiag
chemotherapi
craniospin
irradi
start
howev
tumor
progress
rapidli
patient
die
month
diagnosi
case
oneyearold
boy
present
left
lower
extrem
weak
gait
disturb
left
conjug
deviat
eye
imag
studi
show
tumor
invad
midbrain
pon
spinal
dissemin
tumor
biopsi
reveal
diagnosi
tumor
resist
multiag
chemotherapi
show
partial
respons
radiotherapi
howev
tumor
progress
two
month
radiotherapi
mri
find
etantr
iso
isohigh
neg
gadolinium
contrast
high
diffus
weight
imag
adc
valu
microscop
morpholog
typic
immunohistochem
stain
show
express
case
express
nuclei
case
amplif
confirm
fluoresc
situ
hybrid
case
backgroundobject
radiat
includ
recent
multimod
strategi
treat
atrt
concern
signific
neurocognit
deficit
young
children
led
pediatr
neurooncologist
avoid
use
systemat
adjuv
radiat
present
multi
institut
canadian
experi
radiat
spare
approach
designmethod
retrospect
review
patient
diagnos
canadian
center
calgari
vancouv
toronto
atrt
treat
high
dose
chemotherapi
hdc
intent
delay
avoid
radiat
result
femal
male
median
age
diagnosi
month
fourteen
patient
supratentori
tumor
metastat
diagnosi
fifteen
achiev
gross
total
resect
underw
second
look
surgeri
ten
patient
receiv
addit
tripl
chemotherapi
five
patient
test
evid
germlin
mutationcondit
regimen
consolid
consist
cycl
patient
cycl
carbothiotepa
cycl
patient
ten
patient
receiv
mainten
therapi
tamoxifen
ci
retino
acid
follow
high
dose
chemotherapyonli
patient
receiv
adjuv
radiat
radiat
consist
focal
radiat
craniospin
irradi
patient
median
age
time
radiat
month
eleven
patient
relaps
ten
patient
die
diseas
one
treatment
relat
toxic
median
time
month
patient
aliv
receiv
radiat
although
lack
clear
prognost
factor
identifi
patient
atrt
spare
upfront
radiat
experi
describ
promis
surviv
rate
patient
atrt
absenc
adjuv
radiat
upcom
molecular
classif
atrt
help
delin
indic
radiat
backgroundobject
purpos
prospect
studi
describ
qualityoflif
qol
children
lowgrad
glioma
lgg
treat
weekli
vinblastin
firstlin
chemotherapi
knowledg
first
studi
evalu
qol
treatment
children
lgg
designmethod
qol
assess
pedsql
tm
braintumormodul
version
obtain
baselin
week
end
week
vinblastin
therapi
children
year
elig
age
consist
patient
year
parent
request
fill
questionnair
item
explor
includ
cognit
problem
pain
hurt
movement
balanc
procedur
anxieti
nausea
worri
result
patient
elig
studi
questionnair
complet
sixtyseven
percent
least
one
complet
mean
chang
score
week
week
compar
baselin
qol
subscal
show
signific
chang
baselin
scale
lower
mean
score
cognit
problem
procedur
anxieti
accord
age
lower
score
seen
year
procedur
anxieti
year
cognit
problem
movement
balanc
procedur
anxieti
year
procedur
anxieti
teenag
procedur
anxieti
worri
conclus
qol
children
lgg
treat
vinblastin
firstlin
chemotherapi
alter
treatment
take
account
respons
rate
differ
chemotherapi
regimen
lgg
children
rel
similar
assess
qualiti
life
element
comparison
decid
chemotherapi
first
line
therapi
remain
vinblastin
lgg
patient
abl
maintain
qol
realm
vinblastin
may
good
choic
first
line
chemotherapi
popul
backgroundobject
prognosi
children
pediatr
high
grade
glioma
phgg
remain
poor
despit
aggress
multidisciplinari
therapeut
approach
current
standard
treatment
combin
surgeri
radiat
therapi
alkyl
agent
temozolomid
evofosfamid
evo
previous
known
hypoxiaactiv
prodrug
cytotox
bromoisophosphoramid
mustard
evo
shown
exhibit
preclin
activ
solid
tumor
present
first
data
evo
phgg
cell
line
designmethod
evo
evalu
wellcharacter
phgg
cell
line
cultiv
normox
hypox
condit
cytotox
evo
use
singl
drug
associ
doxorubicin
etoposid
evalu
vitro
use
mt
assay
synerg
analyz
chou
talalay
method
radiosensit
effect
investig
vitro
use
clonogen
assay
antitumor
activ
evo
assess
vivo
use
anim
model
result
growth
cell
line
inhibit
evo
singl
agent
expect
cytotox
evo
higher
hypox
condit
fold
higher
normox
vs
hypox
condit
previous
report
found
strong
synerg
evo
doxorubicin
also
demonstr
signific
synergist
effect
etoposid
drug
wide
use
pediatr
oncolog
everi
case
radiosensit
effect
vivo
evalu
current
ongo
conclus
hypoxia
wellknown
phenomenon
lead
glioma
cell
resist
cytotox
drug
report
first
preclin
data
novel
hypoxiaactiv
prodrug
evo
pediatr
high
grade
glioma
interestingli
evo
appear
effect
hypox
glioma
cell
synergist
effect
observ
doxorubicin
etoposid
interest
pediatr
oncolog
h
li
backgroundobject
medulloblastoma
mb
commonest
pediatr
brain
malignancyand
extrem
poor
prognosi
difficulti
remov
tumor
radic
lack
effect
adjuv
therapeut
approach
resveratrolr
natur
polyphenol
compound
exert
antimedulloblastoma
efficaci
signal
major
molecular
target
howev
mechan
underli
resveratrolsuppress
activ
remain
obscur
arhi
known
tumor
suppressor
gene
inhibitori
effect
activ
far
statu
arhi
express
medulloblastoma
yet
known
current
studi
aim
investig
arhi
express
pattern
relev
resveratrolcaus
inactiv
medulloblastoma
cell
designmethod
human
medulloblastoma
cell
line
cultur
dmem
cultur
medium
contain
fetal
bovin
serum
daoy
fetal
bovin
serum
contain
rpmi
medium
three
cell
line
treat
resveratrol
hour
sensit
treatment
determin
multipl
experiment
method
meanwhil
cell
without
resveratrol
treatment
collect
arhiand
immunocytochemicalicc
rtpcr
westernblot
analys
three
medulloblastoma
cell
line
far
check
sensit
resveratrol
term
suppress
growth
neuronallik
differenti
distinct
apoptosi
level
arhi
express
low
signal
activ
cell
line
resveratrol
treatment
arhi
upregul
accompani
decreas
frequenc
nuclear
transloc
situat
arhi
downregul
activ
three
medulloblastoma
cell
line
revers
resveratrol
suggest
opposit
correl
arhi
express
activ
medulloblastoma
potenti
involv
arhi
inactiv
resveratroltr
medulloblastoma
cell
acknowledg
support
grant
nation
natur
scienc
foundat
china
pcsirt
program
china
backgroundobject
diffus
invas
normal
brain
one
hallmark
featur
make
gbm
difficult
treat
due
lack
biolog
accur
invas
gbm
cell
patient
exist
studi
gbm
invas
conduct
surgic
sampl
primarili
tumor
core
tissu
although
cancer
stem
cell
shown
critic
tumor
initi
therapyresist
role
gbm
invas
well
understood
designmethod
identifi
cancer
stem
cell
subpopul
drive
gbm
invas
util
panel
pediatr
adult
patient
tumorderiv
orthotop
xenograft
pdox
mous
model
isol
match
pair
invas
gbm
cell
normal
mous
brain
tumor
core
gbm
cell
directli
compar
stem
cell
featur
invas
cell
exhibit
stronger
neurospher
form
effici
vitro
display
higher
tumorigen
capac
vivo
particularli
cellsmous
system
screen
put
cancer
stem
cell
marker
show
gbm
cell
invas
front
enrich
cell
fold
tumor
core
direct
implant
fac
purifi
per
mous
brain
nodscid
mice
confirm
tumor
form
capac
vivo
also
show
cell
express
high
level
selfrenew
gene
tend
stay
phase
addit
found
cell
frequent
dualposit
xenograft
tumor
patient
gbm
identifi
novel
gbm
stem
cell
marker
show
gbm
cell
particular
enrich
invas
front
gbm
find
suggest
new
antiinvas
therapi
develop
target
cell
addit
cell
li
backgroundobject
understand
imag
clinic
featur
intracrani
germinoma
order
improv
diagnosi
designmethod
fourtyon
case
intracrani
germinoma
review
one
convinc
patholog
one
case
typic
imag
find
clinic
coursethey
perform
ct
mri
oper
result
age
patient
rang
year
old
studi
common
locat
suprasellar
region
secondli
pineal
region
basal
ganglia
region
involv
two
region
ct
appear
germinoma
isoto
hyperdens
mass
uniform
enhanc
iv
infus
contraston
mri
mass
show
isointens
isoto
mild
hyperintens
isoto
hyperintens
dwi
suprasellar
region
patient
show
femal
predomin
present
mainli
diabet
insipidu
visual
disturb
none
tumour
calcifi
ct
scan
pineal
region
patient
show
male
predomin
present
hydrocephalu
ct
calcif
identifi
case
basal
ganglia
region
patient
show
male
predomin
present
hemiparesi
mental
statu
changeson
case
mass
seen
mri
manifest
pachi
abnorm
intens
ipilater
frontal
temper
lobe
atrophyaft
chemotherapi
radiotherapi
lesion
disappear
patient
recov
conclus
intracrani
germinoma
usual
occur
young
teenagerstumor
differ
locat
appear
differ
imag
find
differ
clinic
present
play
import
role
normal
cerebellum
develop
indic
alter
shh
signal
may
lead
dedifferenti
undifferenti
state
brain
cell
compon
medulloblastoma
format
resveratrolr
suppress
growth
promot
neuronallik
differenti
medulloblastoma
cell
via
certain
unknown
manner
aim
current
studi
statu
shh
singnal
compon
shh
nmyc
medulloblastoma
cell
potenti
influenc
resveratrol
shh
signal
promot
neuronalori
differenti
designmethod
two
human
medulloblastoma
cell
line
treat
resveratrol
status
shh
signal
cell
without
treatment
analyz
multipl
experiment
approach
select
inhibitor
sirna
interfer
shh
signal
employ
treat
cell
elucid
signific
shh
signal
medulloblastoma
cell
maintenancesurviv
resveratrol
antimedulloblastoma
effect
result
shh
nmyc
express
normal
cultur
cell
respect
downregul
cell
line
resveratrol
treatment
along
neuronallik
differenti
apoptosi
mb
cell
shh
select
inhibitor
gli
antagonist
effect
suppress
growth
without
induct
apoptosi
cell
time
doserel
fashion
downregul
express
sirna
interfer
inhibit
mb
cell
growth
result
demonstr
activ
shh
signal
neccessari
growth
medulloblastoma
cell
shh
activ
occur
downstream
smo
cell
line
inhibit
shh
signal
one
molecular
event
caus
resveratrol
medulloblastoma
cell
backgroundobject
determin
evid
avail
undertak
systemat
review
research
patient
benefit
rfpb
programm
effect
treatment
children
central
nervou
system
cn
tumour
map
evid
base
produc
designmethod
seven
electron
databas
search
intervent
studi
surgic
procedur
radiotherapi
rt
chemotherapi
ct
hormon
therapi
ht
immunotherapi
biolog
therapi
imag
novemb
across
spectrum
children
cn
tumour
studi
design
filter
appli
psychosoci
intervent
exclud
relev
studi
categoris
tumour
histolog
type
type
intervent
studi
design
basi
avail
abstract
result
total
uniqu
refer
identifi
includ
map
eleven
systemat
review
randomis
control
trial
rct
includ
patient
singl
arm
phase
ii
trial
identifi
singl
arm
phase
ii
trial
small
less
patient
includ
major
evid
base
limit
case
seri
studi
case
report
less
patient
chemotherapi
regimen
use
alon
combin
rt
frequent
assess
intervent
radiotherapi
rt
use
alon
also
assess
rct
singl
arm
phase
ii
trial
studi
surgeri
alon
ht
immunotherapi
biolog
agent
identifi
highest
proport
studi
conduct
either
patient
medulloblastoma
rct
singl
arm
phase
ii
trial
case
seri
patient
mix
tumour
histolog
rct
singl
arm
phase
ii
trial
case
seri
conclus
map
evid
base
children
cn
tumour
highlight
pauciti
well
conduct
rct
arena
patient
enter
uncontrol
studi
provid
lower
qualiti
evid
backgroundobject
medulloblastoma
mdb
common
malign
brain
tumor
children
prognost
system
base
clinic
paramet
histopatholog
variant
commonli
use
clinic
practic
four
differ
molecular
subgroup
recogn
differ
gene
express
genom
aberr
histolog
surviv
wnt
shh
group
specif
mutat
homonym
pathway
group
c
sever
genet
alter
associ
wors
outcom
molecular
classif
could
provid
consist
approach
therapeut
stratif
patient
purpos
studi
evalu
distribut
prognost
impact
four
molecular
subgroup
seri
mdb
metastat
onset
homogen
treat
singl
institut
designmethod
investig
protein
express
differ
subgroup
biomark
ihc
rtpcr
cdna
sequenc
fish
result
correl
patient
outcom
kaplanmei
statist
analysi
result
basi
molecular
subgroup
could
identifi
wnt
case
nuclear
transloc
posit
shh
case
tripl
posit
filamin
group
c
case
overexpress
group
case
neg
filamin
posit
neg
case
analyz
unclassifi
nc
heterogen
biomark
case
materi
enough
analyz
myc
amplif
frequent
compar
amplif
mycn
compar
literatur
wnt
nc
group
show
superior
statist
signific
os
pf
compar
shh
c
conclus
previous
shown
histolog
variant
maintain
prognost
valu
also
metastat
mdb
especi
refer
lca
histolog
subgroup
molecular
class
via
ihc
effici
allow
prognost
stratif
cohort
metastat
mdb
median
durat
first
symptom
appear
diagnosi
month
patient
focal
diseas
diffus
lesion
patient
present
long
tract
involv
cranial
nerv
involv
patient
treat
radiotherapi
patient
manag
support
care
median
radiotherapi
dose
gy
rang
gy
radiotherapi
schedul
convent
gyfract
period
week
patient
hypo
fraction
radiotherapi
gyfract
period
week
patient
result
radiolog
respons
seen
patient
partial
respons
stabl
diseas
patient
time
review
patient
die
tumor
progress
aliv
tumor
progress
aliv
continu
partial
respons
clinic
improv
year
overal
surviv
overal
median
surviv
month
rang
month
conclus
radiotherapi
appear
effect
treatment
modal
brainstem
glioma
pediatr
patient
poor
outcom
new
treatment
strategi
includ
safe
surgic
resect
altern
radiotherapi
schedul
chemotherapi
regimen
warrant
improv
outcom
group
patient
backgroundobject
gamma
knife
radiosurgeri
gk
provid
high
dose
radiat
focal
brain
lesion
singl
treatment
evalu
institut
experi
gk
pediatr
young
adult
patient
recurr
residu
brain
tumor
designmethod
patient
recurr
residu
brain
tumor
receiv
gk
treatment
primari
brain
tumor
includ
highgrad
neuroepitheli
anaplast
lowgrad
neuroepitheli
pilocyt
embryon
embryon
germ
cell
tumor
patient
prior
fraction
radiotherapi
rt
median
dose
gy
gy
per
fraction
toxic
score
use
ctcae
version
local
control
lc
distant
brain
control
overal
surviv
os
estim
use
kaplan
meier
method
result
median
age
time
gk
treatment
year
rang
median
followup
year
rang
year
median
gk
dose
gy
rang
gy
isodos
line
rang
treat
locat
includ
cerebellum
ventricular
system
cerebrum
brainstem
median
volum
treat
cm
rang
cm
oneand
lc
patient
respect
lc
similar
histolog
subtyp
patient
embryon
tumor
distant
brain
failur
histolog
median
os
gk
year
correl
os
respect
patient
highgrad
astrocytoma
wors
os
median
surviv
year
treatment
well
toler
radiat
necrosi
signific
late
toxic
associ
gk
use
result
suggest
gk
safe
effect
therapi
recurr
residu
brain
tumor
care
select
pediatr
patient
investig
efficaci
gk
pediatr
patient
warrant
pediatr
glioblastoma
multiform
mohammadianpanah
backgroundobject
glioblastoma
multiform
gbm
common
astrocytoma
adult
poor
prognosi
median
surviv
month
rare
children
report
experi
childhood
popul
year
younger
gbm
designmethod
twentythre
patient
gbm
treat
hospit
evalu
mean
age
year
major
male
receiv
radiotherapi
also
receiv
chemotherapi
mean
surviv
month
two
case
surviv
year
age
extent
surgic
resect
radiat
dose
perform
statu
significantli
relat
surviv
conclus
gbm
pediatr
patient
common
center
prognosi
unfavor
extent
surgic
resect
includ
gross
total
resect
lowgrad
highgrad
subtot
resect
lowgrad
highgrad
biopsi
lowgrad
highgrad
ten
patient
lowgrad
tumor
new
andor
worsen
postop
neurolog
deficit
patient
highgrad
histolog
receiv
chemotherapi
andor
radiat
therapi
patient
lowgrad
tumor
receiv
adjuv
radiat
chemotherapi
patient
highgrad
tumor
aliv
beyond
month
diagnosi
median
followup
patient
lowgrad
tumor
year
rang
year
three
year
progressionfre
surviv
pf
patient
death
unrel
tumor
lowgrad
histolog
significantli
associ
better
pf
overal
surviv
os
outcom
p
respect
hydrocephalu
present
unilater
versu
bithalam
involv
extent
resect
associ
pf
lowgrad
tumor
respect
conclus
major
thalam
tumor
lowgrad
histolog
though
recurr
observ
lowgrad
tumor
associ
good
os
risk
longterm
morbid
import
consider
manag
tumor
region
cancer
centr
thiruvanathapuram
india
region
cancer
centr
pediatr
oncolog
trivandrum
india
region
cancer
centr
pediatr
oncolog
thiruvanathapuram
india
region
cancer
centr
radiat
oncolog
thiruvanathapuram
india
backgroundobject
advanc
surgeri
integr
multimod
therapi
translat
improv
surviv
children
medulloblastoma
mb
recent
year
excel
result
reproduc
resourcelimit
countri
due
multipl
factor
sought
find
characterist
outcom
pediatr
medulloblastoma
treat
depart
designmethod
children
age
diagnos
medulloblastoma
treat
pediatr
oncolog
divis
rcc
trivandrum
period
identifi
patient
year
receiv
postop
craniospin
radiat
averagerisk
highrisk
concurr
vincristin
follow
cycl
chemotherapi
patient
receiv
cog
babi
brain
protocol
chemotherapi
delay
radiat
result
medulloblastoma
patient
brain
tumour
peak
age
group
male
predomin
observ
male
femal
ratio
averagerisk
highrisk
initi
metastat
diseas
found
adequ
surgeri
take
adjuv
treatment
combin
chemotherapi
radiotherapi
use
patient
chemotherapi
patient
complet
treatment
without
much
toxic
therapyrel
develop
recurr
diseas
progress
treatment
recur
treatment
complet
salvag
therapi
given
recurr
median
followup
month
patient
expir
losttofollowup
diseasefre
surviv
df
treat
cohort
df
significantli
low
children
highrisk
patient
signific
differ
outcom
patient
initi
metastat
statu
age
year
treatment
receiv
surgeryradiationchemotherapi
averagerisk
diseas
favour
prognost
factor
surviv
conclus
surviv
compar
publish
intern
data
achiev
averagerisk
pediatr
mb
patient
institut
current
multimod
therapytreat
refus
signific
minorityoutcom
poor
highrisk
patient
especi
younger
children
backgroundobject
intracrani
clear
cell
meningioma
ccm
repres
rare
potenti
aggress
subgroup
meningioma
observ
frequent
children
adolesc
despit
character
histolog
entiti
littl
evid
identifi
tumorigen
etiolog
recent
novel
mutat
encod
subunit
swisnf
chromatin
remodel
complex
identifi
cohort
spinal
ccm
date
intracrani
ccm
subject
analysi
designmethod
report
case
isol
intracrani
ccm
year
old
girl
gross
total
resect
achiev
follow
twostag
approach
evid
tumor
recurr
eight
month
follow
present
exon
sequenc
identifi
germlin
mutat
also
present
tumor
dna
result
extens
literatur
review
confirm
studi
first
seek
report
genet
anomali
childhood
intracrani
ccm
outsid
gene
locu
first
make
associ
germlin
mutat
childhood
intracrani
ccm
togeth
previou
descript
mutat
spinal
ccm
report
suggest
aberr
may
implic
establish
clear
cell
histolog
irrespect
meningioma
locat
would
advoc
feasibl
genet
sequenc
perform
futur
new
case
childhood
neuraxi
ccm
includ
interrog
gene
backgroundobject
despit
improv
pediatr
brain
tumor
outcom
survivor
childhood
brain
tumor
burden
multipl
comorbid
report
rel
surviv
ratio
excess
mortal
rate
children
astrocyt
tumor
past
four
decad
designmethod
surviv
analysi
conduct
use
flexibl
parametr
model
estim
rel
surviv
excess
mortal
rate
nonwhit
white
children
year
old
use
surveil
epidemiolog
end
result
seer
databas
incorpor
age
group
year
diagnosi
model
estim
indic
period
use
mortalitytoincid
ratio
mir
measur
mortal
ratio
studi
period
mir
defin
crude
number
death
divid
crude
number
cancer
incid
case
result
mean
age
diagnosi
year
femal
caucasian
particip
major
group
mir
highli
signific
race
nonwhit
children
compar
white
children
pvalu
progress
declin
rel
surviv
ratio
note
time
nonwhit
children
lower
surviv
rate
white
children
trend
persist
durat
studi
fifti
percent
nonwhit
survivor
deceas
year
post
diagnosi
compar
year
white
survivor
conclus
survivor
childhood
astrocyt
brain
tumor
progress
lower
surviv
rate
get
older
higher
nonwhit
compar
white
children
futur
research
effort
need
focu
understand
factor
mediat
effect
tumor
treatment
surviv
patient
ethnic
variat
drive
surviv
trend
backgroundobject
neoplast
mening
common
problem
malign
brain
tumor
especi
recurr
metastat
diseas
occur
even
often
worsen
significantli
prognosi
limit
attribut
system
chemotherapi
cn
one
known
problem
therapi
malign
brain
tumor
contrast
intrathec
administr
anticanc
drug
human
shown
high
concentr
cerebrospin
fluid
csf
leptomening
use
low
drug
dose
etoposid
demonstr
experiment
clinic
data
signific
cytotox
activ
penetr
etoposid
system
administr
csf
extrem
poor
exceed
cytotox
level
depend
cell
line
exposur
time
previou
studi
intraventricular
etoposid
administr
patient
leptomening
dissemin
brain
tumor
group
demonstr
etoposid
concentr
csf
hour
hour
hour
intraventricular
administr
designmethod
studi
present
pharmacokinet
data
phase
ii
trial
intraventricular
administr
etoposid
accord
determin
schedul
mg
etoposid
consecut
day
week
etoposid
measur
use
valid
rphplc
pk
calcul
perform
topfit
pharmacokinet
etoposid
well
describ
two
compart
disposit
model
cmax
calcul
csf
auc
etoposid
csf
st
dose
calcul
h
clearanc
calcul
mlmin
calcul
ratio
etoposid
measur
csf
plasma
concentr
mean
ratio
higher
concentr
maximum
ratio
higher
concentr
csf
minimum
detect
conclus
pharmacokinet
data
studi
confirm
result
feasibl
studi
without
signific
cumul
etoposid
repetit
administr
within
five
week
backgroundobject
despit
trimod
standardofcar
therapi
prognosi
patient
diagnos
highgrad
glioma
hgg
remain
dismal
dendrit
cell
dc
base
immunotherapi
yield
promis
result
object
respons
report
hgg
patient
efficaci
dc
vaccin
howev
abat
profound
hgginduc
immunosuppress
lack
attent
toward
immunogen
tumor
lysat
literatur
analysi
dc
vaccin
clinic
trial
hgg
show
two
frequent
use
method
prepar
tumor
lysat
freezethaw
ft
induc
necrosi
ftnecrosi
follow
highdos
xray
irradi
avail
clinic
evid
clear
methodolog
superior
immunogen
potenti
designmethod
made
use
glioma
murin
model
directli
compar
immunogen
ftnecrot
irradi
ftnecrot
tumor
lysat
result
puls
dc
irradi
ftnecrot
compar
ftnecrot
tumor
lysat
prolong
overal
surviv
increas
tumor
reject
gliomachalleng
mice
associ
increas
braininfiltr
cell
increas
cell
treg
ratio
parallel
reduc
accumul
regulatori
cell
treg
tumorassoci
macrophag
tam
myeloidderiv
suppressor
cell
mdsc
puls
dc
irradi
ftnecrot
tumor
lysat
influenc
phenotyp
function
matur
dc
analysi
show
overal
content
carbonyl
protein
surrog
immunogen
oxidationassoci
molecular
pattern
oamp
ftnecrot
lysat
increas
irradi
treatment
moreov
found
strike
correl
amount
protein
carbonyl
tumor
lysat
dc
vaccinemedi
tumor
reject
capac
latter
partial
significantli
abrog
addit
bona
fide
antioxid
conclus
togeth
data
strongli
advoc
use
protein
oxidationinduc
modal
like
irradi
increas
immunogen
tumor
lysat
use
puls
dc
vaccin
van
zyl
v
netshituni
kanyamuhunga
r
uy
p
hessel
kruger
backgroundobject
determin
diseas
free
surviv
df
children
treat
brain
tumor
sinc
till
secondari
object
determin
df
children
treat
prior
thereaft
singl
institut
designmethod
patient
year
age
diagnos
tygerberg
hospit
includ
divid
group
group
diagnos
group
onward
data
analysi
includ
demograph
data
age
diagnosi
sex
tumor
type
stage
treatment
receiv
final
outcom
month
result
children
includ
studi
mean
age
year
rang
year
group
patient
group
patient
overal
male
femal
ratio
respect
group
astrocytoma
respect
group
common
brain
tumor
follow
medulloblastoma
respect
group
df
improv
time
group
group
overal
patient
medulloblastoma
achiev
df
group
versu
group
overal
astrocytoma
group
versu
group
treatment
prior
includ
combin
surgeryradiotherapi
surgeri
alon
combin
surgeryradiotherapychemotherapi
radiotherapi
alon
treatment
similar
group
surgeri
alon
radiotherapi
alon
combin
surgeryradiotherapychemotherapi
treatment
except
patient
receiv
combin
surgeryradiotherapi
conclus
medulloblastoma
best
overal
df
follow
astrocytoma
improv
surviv
mainli
note
group
probabl
due
standard
treatment
protocol
use
onward
designmethod
partnership
public
health
sector
hospit
choc
appoint
first
social
worker
year
partnership
grown
encompass
five
social
worker
two
social
auxiliari
worker
employ
five
state
fund
academ
link
hospit
throughout
south
africa
placement
choc
employ
social
worker
made
signific
differ
children
famili
also
medic
nurs
team
differ
encompass
counsel
educ
parent
time
diagnosi
end
treatment
creat
awar
educ
parent
childhood
cancer
palliativeend
life
care
ensur
qualiti
life
digniti
die
process
bereav
support
support
medic
nurs
staff
allevi
pressur
alreadi
burden
workload
educ
medic
nurs
staff
psychosoci
emot
need
patient
famili
medic
head
paediatr
oncolog
unit
express
gratitud
choc
acknowledg
signific
impact
social
worker
made
live
patient
famili
one
doctor
quot
say
understand
paediatr
oncolog
unit
function
without
design
choc
social
worker
n
gravett
backgroundobject
concept
use
bead
reward
children
courag
undergo
treatment
utilis
sever
hospit
around
world
present
choc
idea
implement
frere
hospit
eastern
cape
africa
use
bead
variou
way
repres
cultur
pattern
colour
denot
differ
tribe
major
children
hospitalis
eastern
cape
come
rural
area
bead
part
everyday
live
designmethod
bead
programm
adapt
use
frere
hospit
decid
child
reward
courag
braveri
undergo
variou
treatment
procedur
beadseedbutton
repres
procedur
pain
procedur
greater
reward
reflect
beauti
bead
children
get
choos
appropri
bead
attach
string
known
memori
bead
result
children
enjoy
spend
time
choos
bead
add
string
much
pride
allow
child
choos
bead
easi
way
doctor
staff
choc
acknowledg
child
courag
braveri
heritag
memori
bead
creat
person
memori
child
famili
journey
travel
conclus
children
enjoy
spend
time
choos
bead
add
string
much
pride
allow
child
choos
bead
easi
way
doctor
staff
choc
acknowledg
child
courag
braveri
heritag
memori
bead
creat
person
memori
child
famili
journey
travel
cancer
treatment
lead
chronic
late
occur
problem
mani
year
therapi
commun
former
patient
relev
challeng
medic
psychosoci
followup
childhood
cancer
survivor
lead
first
symposium
austria
symposium
schedul
one
day
survivor
got
inform
paediatr
oncologist
lay
languag
possibl
ask
directli
conclus
import
give
inform
survivor
help
take
respons
health
often
lost
followup
know
go
problem
question
pediatr
oncologist
gener
practition
medic
specialist
futur
tool
develop
austria
focu
improv
qualiti
life
childhood
cancer
survivor
backgroundobject
emerg
voic
system
chang
canada
caregiv
need
scientif
approach
influenc
polici
decis
canadian
cancer
action
network
adopt
public
particip
spectrum
develop
evidencebas
recommend
system
chang
engag
caregiv
scientif
expert
ngo
name
conven
consult
session
famili
caregiv
childhood
cancer
understand
issu
impact
caregiv
children
address
financi
burdengap
healthcar
system
conduct
scan
research
public
resourc
inform
nation
dialogu
stakehold
developvalid
recommend
chang
collabor
stakehold
move
dialogu
action
designmethod
two
parallel
process
use
develop
recommend
edelphi
process
inform
collabor
caregiv
nation
action
plan
edelphi
particip
recruit
member
nation
steer
committe
key
stakehold
simultan
region
think
tank
held
across
canada
seek
multijurisdict
input
draft
recommend
relat
caregiv
children
think
tank
particip
recruit
ngo
support
group
children
hospit
result
systemat
process
result
practic
feasibl
recommend
address
high
financi
burden
famili
due
canada
geograph
dispers
fragment
support
system
particip
valid
need
uniqu
onlin
portal
canada
provid
time
inform
concern
financi
support
complet
abil
person
base
individu
famili
need
govern
program
tax
deduct
drug
coverag
align
polici
goal
famili
realiti
remain
gap
includ
strategi
allevi
immedi
financi
burden
canadian
famili
conclus
remain
need
direct
financi
support
famili
canada
support
implement
collabor
model
stakehold
caregiv
engag
collabor
framework
multisectoralmultijurisdict
engag
support
effort
ensur
issu
impact
caregiv
children
remain
key
share
prioriti
shower
play
room
live
room
kitchen
dine
room
garden
main
floor
occupi
foundat
meet
room
offic
presid
secretari
treasur
comput
space
kid
archiv
room
also
space
share
listen
help
meet
member
foundat
volunt
psychologist
advis
encourag
new
famili
arriv
director
hous
explain
rule
show
room
give
need
help
hous
keeper
secur
guard
driver
adult
pay
symbol
amount
mdh
usd
result
besid
hous
accommod
avenir
provid
famili
food
cloth
toy
transport
prosthesi
commun
mean
drug
entertain
long
treatment
requir
number
famili
kid
stay
hous
avenir
averag
day
stay
time
year
depend
type
diseas
treatment
averag
rate
occup
conclus
sinc
year
hous
contribut
soften
improv
social
medic
psycholog
condit
treatment
somehow
make
diseas
constraint
accept
conclus
ugam
support
group
help
member
significantli
bring
posit
chang
perspect
ident
survivor
therefor
survivor
support
group
play
import
role
psychosoci
rehabilit
young
adult
survivor
backgroundobject
children
cancer
rare
diseas
know
boundari
race
gender
class
nation
develop
countri
approxim
children
diagnos
cancer
age
year
histor
rate
mani
develop
nation
approxim
number
although
mani
children
undiagnos
area
often
scarc
resourc
treatment
survivorship
issu
minim
address
due
extrem
stretch
resourc
designmethod
author
use
archiv
nation
cancer
institut
publish
medic
psycho
social
student
work
studi
focu
upon
compar
avail
characterist
survivorship
monitor
care
unit
state
india
exampl
result
one
major
challeng
face
famili
childhood
cancer
patient
financi
common
develop
nation
one
parent
take
extend
leav
lose
employ
demand
travel
time
clinic
visit
hospit
stay
child
cost
travel
meal
park
often
lodg
also
usual
cost
two
issu
address
studi
center
lack
financ
unavail
transport
clinic
hospit
visit
access
survivor
appli
develop
develop
nation
travel
rural
area
exist
gener
lack
health
center
problem
develop
nation
conclus
author
conclud
examin
effort
advocaci
group
global
address
uniqu
challeng
face
childhood
cancer
survivor
backgroundobject
genet
predisposit
increasingli
accept
caus
childhood
cancer
howev
littl
known
percept
attitud
pediatr
oncologist
arab
countri
toward
disclosur
genet
predisposit
cancer
gpc
genet
test
gt
designmethod
design
questionnair
question
evalu
demograph
knowledg
practic
toward
gpc
email
list
oncologist
email
acknowledg
one
two
local
oncologist
exclus
includ
repli
arab
pediatr
oncologist
practic
arab
countri
aim
unifi
cultur
background
work
circumst
complet
respons
eastern
countri
median
particip
age
year
rang
year
equal
male
femal
ratio
thirti
one
report
year
oncolog
experi
oncolog
train
europ
north
america
gt
genet
counselor
like
avail
countri
major
oncologist
believ
confirm
genet
caus
chang
patient
oncologist
think
commun
accept
gt
believ
cancer
stigmat
idea
gpc
cultur
psycholog
unbear
despit
oncologist
feel
ethic
oblig
tell
parent
gpc
suspect
order
encourag
gt
cancer
screen
fact
half
oncologist
refer
patient
gt
almost
oncologist
offer
specif
gt
avail
patient
interestingli
demograph
factor
seem
influenc
oncologist
percept
attitud
p
conclus
major
arab
pediatr
oncologist
awar
gpc
would
encourag
discuss
famili
encount
realiz
logist
difficulti
cultur
social
challeng
disclosur
present
oncologist
need
util
genet
counselor
rais
public
government
awar
help
overcom
challeng
countri
high
consanguin
accord
surviv
rate
differenti
group
diseas
surviv
rate
includ
renal
tumour
lymphoma
hepat
tumour
group
surviv
rate
includ
acut
leukemia
retinoblastoma
soft
tissu
sarcoma
epitheli
tumour
group
surviv
rate
includ
neuroblastoma
cn
tumour
malign
bone
tumour
conclus
surviv
rate
studi
cohort
improv
previous
report
nation
group
except
malign
bone
tumour
patient
ewe
sarcoma
relaps
expect
patient
metastat
diseas
surviv
histolog
classif
cn
tumour
better
defin
patient
group
similar
outcom
intern
cooper
essenti
improv
outcom
bad
prognosi
diseas
mean
number
sign
symptom
correctli
recal
particip
mean
number
sign
correctli
recognis
respond
could
correctli
identifi
sign
correl
score
particip
gender
age
prior
contact
person
cancer
test
score
combin
use
equal
ratio
signific
correl
found
previou
clinic
experi
higher
score
p
pearson
chi
squar
test
conclus
medic
student
demonstr
mark
inconsist
recal
recognit
earli
warn
sign
childhood
cancer
howev
major
student
could
recognis
enough
symptom
meet
univers
pass
standard
despit
accept
recognit
sign
childhood
cancer
final
year
medic
student
age
standardis
ratio
children
cancer
south
africa
unaccept
low
indic
long
term
recal
medic
practition
poor
recommend
increas
exposur
medic
school
paediatr
oncolog
improv
awar
programm
increas
earli
referr
result
pediatr
patient
transplant
fiftythre
male
averag
age
year
rang
twentytwo
patient
aml
hematolog
disord
includ
immunodefici
solid
tumor
myelodysplast
syndrom
lymphoma
cml
fourteen
patient
receiv
autolog
transplant
full
match
relat
donor
mrd
use
wherea
full
partial
match
unrel
donor
mud
use
cord
blood
unit
haploindent
condit
regimen
includ
myeloand
nonmyelobalt
total
bodi
irradi
use
patient
graft
achiev
day
rang
grade
acut
gvhd
occur
patient
wherea
chronic
gvhd
seen
overal
surviv
rate
follow
time
conclus
hsct
feasibl
midincom
countri
like
neutrophil
platelet
engraft
time
longer
compar
hsct
center
might
explain
due
high
number
cord
blood
unit
transplant
well
use
bone
marrow
instead
peripher
blood
transplant
relat
mortal
decreas
year
due
princip
multidisciplinari
team
expertis
conclus
larg
proport
children
treat
cancer
requir
oncogenet
consult
howev
minor
patient
visibl
criteria
clinician
benefit
systemat
data
collect
file
seem
use
improv
identif
patient
risk
propos
one
exampl
data
collect
form
backgroundobject
chelyabinsk
region
child
popul
resid
mainli
major
industri
citi
therefor
expos
varieti
anthropogen
natur
advers
factor
activ
develop
region
pediatr
cancer
call
extra
attent
patient
follow
epidemiolog
indic
monitor
necessari
adequ
care
plan
therapi
result
improv
region
childhood
cancer
registri
set
address
challeng
designmethod
institut
registri
develop
provid
retrospect
pediatr
cancer
data
collect
period
sinc
prospect
data
collect
initi
start
case
childhood
cancer
patient
year
less
prospect
regist
result
januari
total
pediatr
cancer
patient
case
regist
median
patient
age
year
patient
younger
year
malefemal
ratio
common
pediatr
cancer
type
leukemia
central
nervou
system
tumor
account
pediatr
cancer
case
lymphoma
case
agestandart
rate
asr
world
standard
period
per
child
popul
examin
geograph
distribut
childhood
cancer
demonstr
one
high
risk
cluster
statist
signific
increas
incid
two
adjac
citi
asr
miass
citi
per
zlatoust
citi
per
conclus
result
region
incid
agesex
distribut
cancer
morbid
structur
correspond
previou
publish
data
cancer
incid
increas
describ
studi
requir
epidemiolog
research
greater
observ
span
retrospect
analysi
found
shorter
diagnosi
may
possibl
earlier
patient
overal
potenti
vital
risk
due
possibl
delay
diagnosi
estim
function
risk
conclus
overal
time
diagnosi
quit
fast
even
first
sign
pediatr
cancer
polymorph
seem
associ
social
also
age
econom
statu
slightest
measur
saw
sixtythre
new
children
cancer
two
year
number
almost
doubl
compar
previou
year
increas
number
seen
nonemirati
group
children
leukemia
compos
thirti
two
cancer
follow
renal
tumor
lymphoma
fortun
treatment
relat
death
chemotherapi
twenti
three
children
travel
abroad
either
therapi
avail
unit
arab
emir
back
home
person
choic
conclus
although
spectrum
cancer
seen
childhood
dubai
compar
rest
world
figur
rise
dramat
either
due
awar
net
immigr
need
priorit
alloc
resourc
pediatr
oncolog
servic
cope
increas
number
greatest
averag
annual
decreas
period
observ
leukaemia
lymphoma
signific
decreas
mortal
found
malign
bone
tumor
renal
tumor
cn
neoplasm
exept
soft
tissu
sarcoma
averag
annual
increas
rate
cancer
mortal
gener
decreas
russia
still
high
level
common
childhood
cancer
type
saxena
k
sodhi
n
khandelw
backgroundobject
major
new
pediatr
cancer
diagnos
made
resourc
poor
countri
surviv
rate
rang
compar
highresourc
countri
studi
provid
snapshot
pediatr
oncolog
burden
bugando
medic
centr
bmc
tertiari
referr
center
lake
zone
tanzania
one
two
cancer
treatment
center
tanzania
result
provid
pilot
data
highlight
area
need
direct
futur
intervent
improv
pediatr
oncolog
outcom
designmethod
studi
design
retrospect
review
record
hospit
admiss
clinic
visit
oncolog
ward
bmc
januari
fifti
chart
randomli
select
preliminari
analys
avail
review
result
patient
femal
averag
age
year
old
common
record
diagnos
retinoblastoma
burkitt
lymphoma
follow
wilm
tumor
lymphoma
n
acut
lymphoblast
leukemia
n
diagnos
clinic
avail
histopatholog
confirm
patient
receiv
least
one
chemotherapi
treatment
howev
complet
prescrib
cours
therapi
due
progress
diseas
therapi
toxic
medic
unavail
abandon
care
treatment
outcom
includ
overal
surviv
document
respons
treatment
lost
follow
die
record
death
occur
treatment
result
diseas
progress
took
place
follow
treatment
abandon
conclus
abandon
therapi
death
progress
diseas
two
common
outcom
studi
futur
intervent
improv
outcom
target
method
reduc
factor
contribut
treatment
abandon
includ
access
medic
transport
reduc
cost
therapi
educ
intervent
femal
also
adolesc
vs
age
group
abandon
oneyear
fiveyear
follow
also
great
variabl
regard
gender
state
type
tumor
extens
variabl
found
disaggreg
group
tumor
type
age
sex
geograph
locat
conclus
high
incid
childhood
cancer
mexico
extens
variabl
seen
among
differ
group
regard
age
gender
tumor
type
geographi
surviv
mortal
understand
differ
paramount
optim
care
deliveri
improv
outcom
backgroundobject
mention
recent
articl
signific
increas
incid
cancer
subsaharan
africa
ssa
howev
poor
access
pediatr
hematologyoncolog
pho
care
consequ
great
need
exist
build
capac
local
healthcar
infrastructur
workforc
meet
evolv
need
sinc
texa
children
global
hope
aim
increas
overal
surviv
qualiti
life
children
cancer
blood
disord
build
sustain
health
profession
capac
pho
care
designmethod
program
recogn
import
partner
local
stakehold
conduct
thorough
assess
current
capac
better
inform
jointli
develop
vision
strategi
achiev
aim
develop
systemat
methodolog
detail
electron
databas
conduct
site
assess
perform
strateg
plan
assess
approach
success
util
intern
domest
site
determin
uniqu
need
pho
program
environ
process
identifi
assess
countri
level
institut
specif
clinic
educ
research
administr
oper
resourc
identifi
gap
need
improv
propos
solut
advanc
pho
care
level
excel
partner
jointli
agre
attain
detail
implement
plan
develop
program
improv
includ
timelin
budget
result
methodolog
util
ssa
countri
outcom
includ
complet
countrywid
assess
sustain
intervent
plan
built
agreement
lmic
govern
conclus
partnership
essenti
make
signific
progress
advanc
pho
servic
lmic
recommend
util
help
tool
systemat
methodolog
approach
assess
plan
facilit
effect
effici
programmat
plan
outcom
extragonad
gct
mainli
observ
earli
childhood
sacrococcyg
local
common
gonad
gct
contrast
observ
late
childhood
ovari
frequent
site
origin
matur
teratoma
frequent
observ
histolog
classif
usual
local
ovari
alfafetoprotein
elev
elev
betahuman
chorion
gonadotropin
one
third
gct
malign
treat
chemotherapi
almost
case
surgeri
intracraniel
gct
irradi
relaps
rate
mortal
rate
children
advers
event
otoand
nephrotox
relat
chemotherapi
conclus
denmark
pediatr
gct
rare
mainli
benign
matur
teratoma
frequent
identifi
peak
extragonad
gct
earli
childhood
peak
gonad
gct
late
childhood
malign
gct
morbid
low
chemotherapi
administ
incid
gct
denmark
seem
similar
studi
result
fortynin
patient
gct
includ
analysi
gct
constitut
patient
median
age
diagnosi
f
ratio
primari
tumor
gonad
extragonad
intracrani
patient
histopatholog
reveal
matur
teratoma
immatur
teratoma
germinoma
embryon
carcinoma
yolk
sac
tumor
mix
germ
cell
tumor
disgerminoma
endoderm
sinu
tumor
sexcord
stromal
tumor
stage
distribut
gonad
gct
stagei
stageii
stageiii
stageiv
extragonad
gct
stagei
stageii
stageiii
stageiv
averag
four
cours
cisplatinum
base
chemotherapi
given
radiotherapi
perform
patient
gonad
gct
primari
surgeri
delay
surgeri
perform
two
case
respect
twentyon
patient
receiv
ct
two
patient
receiv
radiotherapi
three
die
progress
ekstragonad
gct
primari
surgeri
perform
complet
macroscop
biopsi
two
patient
sacrococcyg
gct
one
metastat
diseas
four
receiv
chemotherapi
two
die
progress
cr
achiev
primari
surgeri
one
retroperiton
gct
two
metastat
patient
anterior
intraabdomin
treat
incomplet
surgic
resect
chemotherapi
radiotherapi
cr
achiev
one
median
followuptim
result
nineteen
case
lch
diagnos
mean
age
present
month
male
femal
ratio
case
confirm
biopsi
stain
ten
present
multisystem
diseas
singl
system
diseas
risk
organ
involv
seen
case
liver
spleen
bone
marrow
eight
case
singl
system
involv
bone
case
multifoc
diseas
singl
lesion
axial
appendicular
skelet
involv
seen
lung
involv
seen
isol
mediastin
mass
nail
involv
seen
one
case
multipl
hypoecho
lesion
liver
mimick
abscess
lung
lesion
mimick
tuberculosi
seen
radiolog
find
assist
diagnosi
casestherapi
given
per
lchiii
protocol
eight
case
requir
two
induct
cycl
two
children
requir
salvag
chemotherapi
curettag
done
singl
site
bone
lesion
four
case
one
child
requir
spine
stabil
fourteen
children
complet
treatment
follow
median
month
rang
month
progress
scleros
cholang
requir
liver
biopsi
seen
two
children
one
opt
liver
transplant
one
child
develop
staphylococcu
aureu
mening
continu
treatment
abandon
treatment
high
index
suspicion
familiar
clinic
radiolog
find
lch
ensur
prompt
diagnosi
therapi
good
treatment
outcom
possibl
develop
world
also
reactiv
seen
patient
multisystem
involv
risk
organ
involv
seen
children
diseas
reactiv
onset
symptomatolog
less
two
year
age
sequala
includ
short
statur
diabet
insipidu
chronic
liver
lung
diseas
scleros
cholang
boni
defect
ear
dischargehear
defect
proptosi
pulmonari
arteri
hypertens
nail
chang
also
seen
conclus
lch
often
miss
diagnosi
vari
clinic
present
treatment
outcom
reactiv
diseas
occur
seen
often
children
diseas
onset
less
year
age
sequala
commonpet
ct
emerg
use
modal
assess
treatment
respons
newli
diagnos
refractori
case
lch
backgroundobject
hyperferritinemia
identifi
import
biomark
genet
primari
form
hemophagocyt
lymphohistiocytosi
hlh
diseas
associ
excess
inflamm
character
defect
lymphocyt
cytotox
function
hlh
may
also
develop
secondari
acquir
form
sever
ill
patient
potenti
treatabl
hyperinflammatori
condit
children
extent
hyperferritinemia
help
identifi
distinguish
hlh
condit
furthermor
increas
level
ferritin
correl
increas
risk
intens
care
unit
icu
admiss
death
analyz
ferritin
level
patient
admit
icu
order
correl
hyperferritinemia
clinic
laboratori
paramet
group
sever
ill
patient
designmethod
thirtytwo
adult
patient
ferritin
level
prospect
studi
icu
regard
clinic
laboratori
featur
admiss
includ
solubl
detail
lymphocyt
cytotox
analys
genet
studi
result
hyperferritinemia
elev
marker
inflamm
posit
associ
patient
septicemia
state
known
excess
inflamm
hyperferritinemia
also
associ
elev
crp
ferritin
level
invers
correl
platelet
count
total
cohort
patient
septicemia
notabl
thrombocytopenia
sign
sever
ill
affect
outcom
mortal
icu
patient
similarli
elev
invers
correl
hypoalbuminemia
interestingli
hyperferritinemia
also
associ
decreas
cytotox
function
notabl
four
patient
abnorm
low
cytotox
function
three
circul
nk
cell
one
heterozyg
variant
hlhcaus
gene
studi
suggest
correl
hyperferritinemia
laboratori
valu
indic
inflamm
poor
outcom
sever
ill
patient
intens
care
unit
frequenc
subject
cardiac
event
among
subject
underw
hsct
addit
event
detect
hsct
subject
underw
hsct
autolog
hsct
allogen
case
perform
median
age
year
rang
mf
ratio
diseas
distribut
follow
hodgkin
lymphoma
hl
nodular
sclerosi
ns
variant
pnet
cell
lymphoblast
lymphoma
primari
local
diseas
cervic
lymph
node
subject
pelvic
mass
subject
pelvic
bone
subject
subject
stage
iv
diseasepericardi
effus
subject
sinu
bradycardia
ventricular
tachycardia
patient
detect
mortal
rate
pericardi
effus
poor
risk
factor
myocard
pericard
heart
failur
owe
cumul
dose
anthracyclin
cyclophosphamid
cmv
infect
infect
mediastin
irradi
cryopreserv
stem
cell
product
dmso
main
reason
studi
conclus
cardiac
complic
hsct
import
side
effect
earli
intervent
prevent
death
relat
complic
followedup
close
complic
scr
use
chromium
ethylenediaminetetraacet
credta
measur
glomerular
filtrat
rate
gfr
marker
tubular
injuri
howev
less
well
defin
designmethod
twostep
systemat
review
undertaken
determin
marker
describ
studi
relat
children
cancer
specif
receiv
cisplatin
ifosfamid
embas
medlin
cinahl
search
search
term
independ
match
thesauru
databas
initi
search
conduct
gener
list
marker
renal
tubular
injuri
identifi
explor
either
vitro
vivo
biolog
clinic
studi
biochem
genet
peptid
microrna
marker
includ
second
literatur
search
conduct
identifi
articl
relat
renal
injuri
paediatr
patient
receiv
cisplatin
ifosfamid
two
search
crossreferenc
result
total
marker
tubular
injuri
identifi
defin
search
term
crossreferenc
defin
popul
includ
fraction
excret
phosphat
cystatin
c
varianc
amino
acid
metabolit
profil
clinic
util
potenti
biomark
current
limit
consider
small
sampl
size
studi
conduct
requir
specialist
modal
eg
nuclear
magnet
reson
spectroscopi
complex
analysi
eg
urin
amino
acid
profil
cost
assay
eg
elisa
work
need
identifi
new
biomark
tubular
kidney
injuri
aris
nephrotox
chemotherapi
studi
larger
cohort
patient
valid
util
sensit
specif
aim
character
frequenc
reproduct
sexual
health
discuss
occur
populationbas
cohort
young
cancer
patient
identifi
clinic
factor
associ
discuss
designmethod
patient
age
year
diagnos
solid
tumor
evalu
region
cancer
center
british
columbia
canada
aliv
year
origin
diagnosi
includ
demograph
tumor
treatment
characterist
inform
patientphysician
convers
regard
reproduct
sexual
health
analyz
use
regress
model
explor
relationship
clinic
factor
whether
discuss
occur
result
identifi
patient
median
age
year
iqr
men
ecog
report
relationship
tumor
site
includ
breast
testicular
gynecolog
colorect
signific
proport
patient
receiv
chemotherapi
radiat
pose
potenti
risk
infertil
sexual
dysfunct
howev
individu
discuss
reproduct
sexual
health
respect
within
first
month
diagnosi
month
addit
patient
discuss
concern
physician
age
gender
ecog
relationship
statu
type
chemotherapi
radiat
correl
whether
discuss
occur
p
regress
model
tumor
site
associ
differ
reproduct
sexual
health
discuss
individu
gynecolog
cancer
like
engag
convers
conclus
among
young
survivor
cancer
fertil
particularli
sexual
function
inadequ
address
near
time
initi
cancer
diagnosi
howev
chemotherapyinduc
neurotox
caus
longlast
function
deficit
survivor
besid
primari
cure
earli
identif
subsequ
care
individu
must
therefor
focu
research
child
oncolog
individu
polymorph
caus
lower
activ
methyltetrahydrofol
reductas
mthfr
enzym
higher
risk
methotrexateinduc
neurotox
sinc
enzym
play
key
role
folat
metabol
previous
report
increas
level
biomark
neurotox
cerebrospin
fluid
csf
patient
inform
process
difficulti
survivor
treatment
aim
link
mthfr
genotyp
biomark
treatment
longterm
neurocognit
function
survivor
nhl
designmethod
csftau
phosphotau
consecut
measur
treatment
respect
patient
nhl
median
time
sinc
treatment
year
outcom
neurocognit
test
questionnair
compar
sexand
agematch
control
genotyp
posit
mthfrgene
analyz
survivor
result
survivor
perform
significantli
slower
compar
control
task
assess
memori
focus
attent
cognit
flexibl
inhibit
observ
reflect
higher
score
selfreport
cognit
dysfunct
cc
genotyp
display
highest
level
biomark
combin
age
five
diagnosi
biomark
help
us
detect
patient
sever
neurocognit
problem
knowledg
first
studi
link
genet
suscept
biomark
final
neurocognit
outcom
develop
tool
identifi
earli
chemotherapi
children
risk
sever
late
neurocognit
difficulti
patient
support
earli
stage
appropri
learn
plan
result
studi
also
appli
assess
neurotox
futur
treatment
protocol
cross
section
studi
aim
determin
preval
extent
factor
associ
residu
effect
cancer
therapi
renal
system
designmethod
descript
cross
section
studi
perform
assess
children
age
year
complet
treatment
singl
institut
follow
paediatr
oncolog
unit
hospit
physic
examin
blood
pressur
screen
urin
dipstick
perform
patient
singl
research
blood
result
sampl
routin
drawn
part
current
standard
follow
protocol
unit
full
blood
count
calcium
magnesium
phosphat
urea
electrolyt
creatinin
analys
patient
abnorm
result
refer
paediatr
renal
clinic
evalu
result
median
followup
post
treatment
year
variou
manifest
renal
dysfunct
includ
decreas
glomerular
filtrat
rate
gfr
hypomagnesaemia
hypophosphataemia
proteinuria
haematuria
hypertens
total
survivor
least
one
manifest
renal
dysfunct
complet
treatment
none
clinic
signific
preval
manifest
renal
dysfunct
detect
decreas
gfr
hypomagnesaemia
hypophosphataemia
present
survivor
respect
patient
preexist
renal
dysfunct
three
time
like
renal
dysfunct
posttreat
ifosfamid
carboplatinum
nephrectomi
significantli
associ
reduct
gfr
p
conclus
although
rate
renal
dysfunct
rel
high
clinic
signific
patient
preexist
renal
dysfunct
assess
nephrologist
prior
initi
cancer
therapi
nephroprotect
measur
employ
stringent
children
cancer
result
ten
paper
meet
inclus
criteria
signific
relationship
found
cognit
neuroimag
measur
studi
signific
correl
found
hippocamp
size
visual
memori
hippocamp
structur
integr
iq
amygdala
size
verbal
memori
sustain
attent
structur
integr
frontal
lobe
process
speed
signific
relationship
found
abnorm
white
matter
connect
iq
respons
inhibit
greater
activ
dorsolater
prefront
cortex
work
memori
imag
find
includ
gross
volum
structur
integr
function
activ
conclus
despit
heterogen
studi
methodolog
current
literatur
suggest
brain
region
limbic
system
respons
new
learn
may
particularli
sensit
chemotherapi
treatment
well
white
matter
tract
deliv
inform
cortic
region
find
signific
implic
intervent
treatment
plan
futur
treatment
protocol
particular
inclus
sensit
imag
techniqu
explor
imag
biomark
may
predict
function
risk
use
neuroprotect
agent
andor
decreas
use
neurotox
agent
vulner
subgroup
need
explor
backgroundobject
adolesc
childhood
cancer
treatment
peer
come
contact
unhealthi
lifestyl
includ
smoke
drink
alcohol
use
cannabi
lack
exercis
unhealthi
nutrit
due
possibl
late
effect
treatment
might
vulner
consequ
unhealthi
lifestyl
peer
without
cancer
treatment
histori
purpos
studi
explor
lifestyl
adolesc
childhood
cancer
treatment
compar
lifestyl
adolesc
without
histori
cancer
treatment
designmethod
includ
adolesc
age
year
within
five
year
period
cancer
treatment
studi
data
collect
use
written
standard
questionnair
obes
physic
activ
smoke
drink
alcohol
cannabi
use
result
compar
nation
figur
gener
popul
age
group
result
adolesc
childhood
cancer
treatment
report
spend
significantli
less
time
physic
activ
per
week
cycl
leisur
time
p
sport
p
compar
refer
data
three
time
often
underweight
vs
respect
adolesc
childhood
cancer
treatment
state
know
significantli
less
cannabi
user
refer
group
p
percentag
adolesc
report
smoke
past
significantli
higher
compar
refer
group
p
group
similar
regard
alcohol
use
conclus
adolesc
childhood
cancer
treatment
gener
show
compar
lifestyl
peer
gener
popul
howev
lower
physic
activ
rate
healthi
adolesc
given
fact
adolesc
treat
childhood
cancer
probabl
vulner
consequ
unhealthi
lifestyl
monitor
advis
regard
lifestyl
essenti
year
postdiagnosi
complet
neurocognit
test
year
postdiagnosi
serum
collect
day
test
assay
marker
inflamm
tumor
necrosi
factoralpha
creactiv
protein
crp
oxid
stress
oxid
lowdens
lipoprotein
oxldl
myeloperoxidas
malondialdehyd
pharmacolog
physiolog
treatmentrel
factor
collect
therapi
includ
serum
concentr
highdos
iv
methotrex
hdmtx
plasma
homocystein
follow
hdmtx
dexamethason
quantifi
area
curv
auc
serum
cortisol
measur
follow
oral
dexamethason
spearman
correl
mannwhitney
u
test
use
assess
associ
among
treatmentrel
factor
inflammatori
oxid
stress
biomark
neurocognit
function
result
survivor
demonstr
excess
impair
defin
ageadjust
score
th
percentil
two
measur
execut
function
cognit
flexibl
verbal
fluenci
homocystein
auc
posit
correl
crp
r
p
oxldl
r
p
r
p
elev
crp
found
survivor
impair
cognit
flexibl
median
iqr
ngml
vs
p
verbal
fluenci
vs
p
compar
survivor
without
impair
mtx
auc
neg
correl
r
p
myeloperoxidas
r
p
associ
identifi
biomark
dexamethason
auc
cortisol
level
conclus
find
suggest
homocystein
level
follow
hdmtx
may
relat
chronic
inflamm
associ
execut
dysfunct
longterm
survivor
childhood
futur
research
assess
whether
effect
treatment
factor
neurocognit
function
mediat
chronic
system
inflamm
analyz
relationship
vdr
gene
polymorph
osteoporosi
osteosarcoma
survivor
designmethod
forti
osteosarcoma
patient
treat
ankara
oncolog
train
research
hospit
includ
studi
bone
miner
densiti
bmd
proxim
femur
nonoper
side
measur
dual
energi
xray
absorptiometri
dexa
patient
defin
osteoporot
osteopen
bmd
zscore
less
respect
singl
nucleotid
chang
polymorph
foki
bsmi
apai
taqi
region
vdr
gene
examin
snapshot
minisequenc
techniqu
relationship
vdr
genotyp
bmd
evalu
result
boy
girl
mean
age
year
patient
tumor
locat
femur
patient
receiv
protocol
methotrexatecisplatiniumdoxorubicin
extrem
spare
surgeri
perform
patient
amput
median
month
end
treatment
mean
bmd
score
reduct
bmd
present
patient
osteoporot
osteopen
frequenc
osteoporosi
higher
patient
fok
polymorph
allel
patient
wild
foki
genotyp
vs
fiftyf
percent
patient
heterozyg
homozyg
apai
polymorph
allel
osteopen
osteopenia
observ
patient
wild
type
apai
relationship
bmd
score
vdr
gene
polymorph
conclus
vitamin
receptor
import
role
regul
bone
metabol
associ
variat
vdr
gene
decreas
bmd
report
show
fok
apa
region
polymorph
vdr
gene
relat
osteoporosi
osteosarcoma
survivor
particip
believ
regular
exercis
help
long
term
effect
therapi
inclin
exercis
home
particip
would
recommend
fitbit
survivor
suggest
patient
receiv
therapi
suggest
therapi
overal
cardiorespiratori
fit
measur
maximum
test
increas
mlkgmin
mlkgmin
total
weekli
moder
vigor
physic
activ
increas
minut
minut
chang
statist
signific
respect
conclus
pilot
studi
motiv
activ
devic
demonstr
feasibl
measur
retent
recept
belief
util
improv
cardiorespiratori
fit
weekli
physic
activ
though
result
statist
signific
small
sampl
frequent
smn
encount
acut
myeloid
leukaemia
myelodysplast
syndrom
overal
cumul
incid
ci
median
interv
period
diagnosi
primari
secondari
malign
year
rang
year
overal
surviv
rate
smn
lower
primari
malign
conclus
reduc
exposur
radiotherapi
may
contribut
smaller
proport
secondari
solid
tumour
compar
western
cohort
signific
risk
smn
found
especi
survivor
childhood
osteosarcoma
like
therapyrel
suggest
need
review
current
treatment
protocol
relat
potenti
pharmacogenet
genet
predisposit
backgroundobject
inequ
patientreport
outcom
survivor
childhood
cancer
support
care
need
often
investig
well
understood
aim
studi
identifi
inequ
childhood
cancer
survivor
base
individuallevel
data
investig
inequ
late
effect
among
adult
childhood
cancer
survivor
designmethod
data
extract
nation
cancer
registri
ireland
peopl
age
diagnos
invas
cancer
exclud
nonmelanoma
skin
cancer
data
link
famili
socioeconom
statu
se
use
inform
parent
occup
child
birth
data
analys
estim
discrep
mortal
base
se
addit
data
collect
survivor
current
year
age
anticip
data
collect
support
care
need
healthrel
qualiti
life
function
statu
cancer
symptom
depress
anxieti
stress
scale
survey
data
link
registri
data
provid
rich
inform
social
inequ
childhood
cancer
survivor
result
childhood
cancer
survivor
ireland
femal
male
older
cancer
among
childhood
cancer
survivor
age
lymphoid
leukaemia
follow
hodgkin
diseas
brain
tumour
data
type
cancer
discrep
survivorship
inequ
late
effect
also
present
studi
collect
data
directli
larg
number
childhood
cancer
survivor
ireland
find
studi
highlight
inequ
late
effect
provid
critic
inform
health
need
inequ
among
longterm
childhood
cancer
survivor
center
depart
pediatr
nijmegen
netherland
pediatr
cardiolog
unit
tel
aviv
israel
radboud
univers
medic
center
depart
cardiolog
nijmegen
netherland
radboud
univers
medic
center
children
heart
center
nijmegen
netherland
backgroundobject
noninvas
screen
play
import
role
earli
detect
subclin
heart
failur
anthracyclin
treatment
childhood
cancer
aim
describ
ecg
abnorm
group
asymptomat
longterm
survivor
childhood
cancer
determin
agreement
ecg
echocardiographi
abnorm
followup
designmethod
ecg
echocardiographi
routin
perform
survivor
visit
center
period
year
inclus
criteria
past
exposur
anthracyclin
echocardiographi
ecg
followup
exclus
criteria
clinic
heart
failur
congenit
heart
diseas
use
cardiac
medic
level
agreement
ecg
echocardiographi
calcul
cohen
kappa
result
seventyfour
survivor
exclud
mean
followup
period
year
rang
year
mean
age
year
rang
year
ecg
abnorm
patient
common
abnorm
conduct
disord
high
left
ventricl
voltag
prolong
qtc
millisecond
found
survivor
cumul
anthracyclin
dose
mgm
echocardiographi
abnorm
patient
mostli
mild
valvular
abnorm
normal
fs
ef
level
agreement
ecg
echocardiographi
abnorm
low
group
normal
ecg
echocardiographi
compar
group
abnorm
detect
one
method
lvidsbsa
lower
end
systol
wall
stress
higher
group
one
abnorm
compar
group
without
abnorm
versu
number
abnorm
relat
anthracyclin
dosag
conclus
ecg
echocardiographi
abnorm
quit
common
survivor
childhood
cancer
level
agreement
correct
chanc
low
indic
import
test
longterm
followup
asymptomat
survivor
treat
anthracyclin
patient
receiv
whole
brain
irradi
wbi
part
treatment
protocolw
consid
patient
high
risk
patient
age
yearstot
leukocyt
count
earli
respond
inductionextramedallari
present
diseasesth
patient
divid
group
group
receiv
whole
brain
irradi
part
treatment
prococolgroup
b
receiv
whole
brain
irradi
part
treatment
protocol
result
differ
cn
relaps
two
group
group
showeda
signific
abnorm
hypothalam
pituitari
axi
eg
decreas
growth
hormon
p
decreas
thyroid
hormon
p
conclus
prophylact
whole
brain
irradi
given
high
risk
recommend
dose
due
lower
long
term
endocrin
abnorm
differ
cn
relaps
backgroundobject
physic
activ
posit
affect
cognit
function
human
neurogenesi
anim
model
hypothes
activ
video
game
avg
could
improv
cognit
function
ii
improv
execut
activ
daili
live
iii
improv
physic
function
survivor
childhood
brain
tumor
designmethod
children
year
old
complet
treatment
includ
radiotherapi
brain
tumor
year
earlier
random
either
intervent
waitinglist
week
group
crossedov
motioncontrol
video
consol
nintendo
wii
use
intervent
period
minimum
minutesday
daysweek
weekli
internet
base
coach
session
held
cognit
test
motor
test
well
test
execut
daili
activ
adl
use
assess
motor
process
skill
amp
done
period
blind
examin
test
score
intervent
compar
parallel
group
comparison
perform
sensit
analysi
result
children
mean
age
year
enrol
studi
six
boy
seven
girl
complet
program
signific
improv
seen
intervent
period
compar
baselin
bodi
coordin
p
motor
p
process
part
amp
parallel
group
analysi
improv
process
part
amp
remain
statist
signific
p
chang
amp
motor
p
bodi
coordin
p
statist
signific
chang
cognit
outcom
seen
although
trend
improv
sustain
attent
p
select
attent
p
conclus
avg
use
enjoy
homebas
intervent
survivor
childhood
brain
tumor
improv
bodi
coordin
well
motor
process
skill
adl
week
avg
period
backgroundobject
refin
diagnost
advanc
therapeut
support
care
overal
surviv
childhood
malign
increas
howev
cost
increas
morbid
form
variou
longlat
effect
cancer
treatment
comprehens
studi
assess
whole
spectrum
late
effect
impact
social
health
profession
life
survivor
still
lack
develop
economi
report
data
cohort
childhood
cancer
survivor
follow
pediatr
cancer
survivor
clinic
designmethod
retrospect
evalu
case
record
done
detail
primari
diagnosi
treatment
receiv
note
detail
remissionrelaps
growth
myocardi
function
obtain
pulmonari
function
assess
thyroid
profil
hear
vision
assess
done
indic
iq
assess
psycho
social
assess
also
done
transfus
relat
hazard
assess
detail
second
malign
neoplasm
note
grade
disabl
record
detail
social
adjust
home
school
societi
record
result
commonest
cancer
includ
hodgkin
lymphoma
acut
lymphoblast
leukemia
retinoblastoma
eleven
patient
relaps
two
second
malign
record
patient
minim
disabl
growth
impair
moder
disabl
major
due
hbsag
posit
grade
mental
retard
one
die
liver
diseas
grade
intellig
affect
behavior
abnorm
identifi
patient
height
less
rd
centil
hypothyroid
seen
azoospermia
seen
one
three
patient
found
asymptomat
mild
myocardi
dysfunct
conclus
long
term
morbid
childhood
cancer
survivor
emerg
concern
challeng
improv
surviv
reduc
sever
late
effect
studi
show
late
effect
concern
awar
toward
exist
late
effect
cancer
therapi
requir
among
parent
patient
health
profession
backgroundobject
obes
becom
increasingli
preval
condit
children
impact
million
children
age
five
today
pediatr
popul
great
risk
obes
survivor
pediatr
brain
tumour
due
posttreat
endocrin
abnorm
obstruct
sleep
apnea
osa
common
comorbid
obes
littl
known
osa
survivor
pediatr
brain
tumour
aim
studi
assess
risk
osa
evalu
sleeprel
breath
disord
srbd
symptom
survivor
pediatr
brain
tumour
case
compar
noncanc
control
use
chervin
pediatr
sleep
questionnair
psq
designmethod
one
hundr
particip
case
control
recruit
canadian
studi
determin
endometabol
health
children
candecid
tertiari
care
centr
hamilton
ontario
canada
recruit
base
follow
inclus
criteria
year
older
male
femal
histori
surviv
brain
tumour
histori
brain
tumour
previou
use
immunosuppress
therapi
steroid
week
without
activ
infect
particip
assign
srbd
score
use
chervin
psq
score
criteria
result
twentyseven
percent
case
control
identifi
overweight
obes
case
mean
srbd
score
compar
mean
srbd
score
control
linear
regress
correl
increas
bmicentil
increas
srbd
score
howev
result
statist
insignific
conclus
numer
case
report
identifi
srbd
survivor
pediatr
brain
tumour
crosssect
casecontrol
studi
complet
osa
intervent
use
treatment
obes
gener
popul
may
possibl
obes
intervent
survivor
pediatr
brain
tumour
research
need
determin
risk
osa
patient
surviv
pediatr
brain
tumour
backgroundobject
children
surviv
brain
tumor
prone
neurocognit
difficulti
frequent
absenc
school
often
compromis
educ
trajectori
close
monitor
school
staff
crucial
time
intervent
case
problem
unfortun
teacher
counselor
awar
inform
vulner
moreov
children
frequent
refer
profession
obviou
deficit
emerg
contemporari
research
aftercar
educ
trajectori
includ
parent
school
perspect
scarc
recommend
follow
aim
school
staff
caregiv
parent
need
want
identifi
key
event
aftercar
trajectori
explor
experi
need
expect
children
parent
addit
focu
commun
main
care
provid
famili
school
environ
designmethod
longitudin
qualit
studi
carri
among
group
children
parent
caregiv
key
figur
school
conduct
semistructur
interview
focu
group
two
year
children
includ
final
treatment
return
regular
elementari
school
start
studi
data
analyz
accord
case
studi
design
phenomenolog
perspect
result
preliminari
find
reveal
psychosoci
difficulti
neurocognit
sequela
impact
child
wellb
overal
develop
monitor
systemat
way
delay
implement
appropri
guidanc
support
parent
highli
concern
socioemot
function
child
confront
poor
academ
result
commun
key
figur
alway
suffici
effect
expect
respons
work
method
seem
differ
conclus
draw
result
hope
improv
wellb
children
surviv
brain
tumor
famili
develop
recommend
school
staff
care
provid
involv
backgroundobject
hepatoblastoma
hb
rare
malign
solid
tumor
commonli
liver
malign
tumor
childrenstudi
clinic
therapi
prognosi
children
hepatoblastoma
comprehens
treatment
analysi
morbid
charact
isk
factor
designmethod
studi
total
hepatoblastoma
subject
collect
septemb
june
clinic
record
followup
inform
subject
also
obtain
conduct
kaplanmei
surviv
analysi
logrank
test
result
case
median
age
subject
year
accord
clinic
stage
standard
ccgpog
case
ii
stage
accord
case
iii
stage
accord
case
iv
stage
accord
patholog
type
case
epitheli
accord
case
mix
accord
case
case
complet
remiss
cr
case
partli
remiss
pr
case
dead
comprehens
treatment
follow
januari
averag
follow
time
month
total
surviv
rate
ef
case
follow
time
month
case
averag
surviv
time
month
credibl
interv
month
analysi
kaplanmerin
eventfre
surviv
ef
ii
stage
ef
iii
stage
ef
iv
stage
ef
iv
stage
metastasi
ef
afp
less
conclus
distant
organ
metastasi
hepat
portal
vein
central
venou
invas
still
import
prognost
factor
note
well
younger
children
earli
diseas
afp
obviou
increas
case
earli
diseas
reduc
relaps
rate
backgroundobject
curcumin
yellow
dye
deriv
root
turmer
promis
agent
complementari
oncolog
former
low
oral
bioavail
curcumin
overcom
micellar
formul
high
concentr
curcumin
eg
experiment
pediatr
hepatocellular
carcinoma
vivo
recent
studi
analyz
photoact
properti
curcumin
hepatoma
cell
line
vitro
designmethod
hepatoblastoma
cell
line
hepatocellular
carcinoma
cell
line
treat
curcumin
increas
concentr
cultur
either
kept
dark
expos
blue
light
nm
analysi
cell
viabil
perform
mtttest
cellular
oxid
stress
analyz
measur
product
reactiv
oxygen
speci
ro
reduct
cancer
stem
cell
popul
csc
cisplatin
curcumin
alon
curcumin
pdt
investig
fac
analys
result
cell
line
significantli
lower
blue
light
exposur
curcumin
alon
p
twoway
anova
blue
light
exposur
result
signific
ro
product
cell
line
curcumin
alon
reduc
posit
csc
effect
cisplatin
alon
curcumin
pdt
conclus
consid
strong
potenti
reduc
viabil
proport
cancer
stem
cell
hepatoma
cell
line
curcumin
may
develop
potenti
photodynam
agent
well
chemotherapeut
agent
pediatr
solid
liver
tumor
result
total
patient
treat
period
major
male
patient
less
year
present
patient
receiv
chemotherapi
accord
siopel
three
patient
metastat
diseas
present
die
chemotherapi
two
lost
follow
presum
dead
patient
underw
surgeri
overal
surviv
mean
follow
month
observ
mortal
one
develop
lung
metastasi
two
incomplet
resect
develop
local
recurr
one
die
due
adjuv
chemotherapi
relat
issu
patient
aliv
complet
surgic
resect
one
patient
signific
diseas
involv
couinaud
segment
underw
associ
portal
vein
ligat
liver
partit
stage
hepatectomi
alpp
patient
complet
resect
tumour
suffer
liver
insuffici
conclus
long
term
overal
surviv
determin
complet
surgic
resect
result
group
patient
hb
complet
resect
possibl
patient
primari
liver
transplant
olt
indic
patient
aliv
follow
month
patient
relaps
complet
resect
primari
olt
patient
die
due
progress
treatment
patient
die
due
relaps
primari
resect
group
patient
hcc
complet
resect
possibl
case
patient
aliv
complet
remiss
follow
month
pt
relaps
complet
resect
curent
aliv
progress
diseas
pt
die
non
resect
tumour
conclus
case
complet
resect
outcom
better
patient
chanc
cure
past
two
decad
brought
signific
improv
manag
outcom
children
diagnos
liver
tumor
improv
result
multidisciplinari
approach
intern
trial
factor
observ
case
hcc
afp
level
rang
hb
hcc
case
complet
first
remiss
one
patient
hcc
reactiv
diseas
second
total
resect
tumour
receiv
nexavar
achiev
second
remiss
conclus
increas
risk
hepatoblastoma
among
children
low
birth
weight
predispos
factor
found
children
hcc
although
hcc
usual
diagnos
age
year
old
case
diagnos
earlier
childhood
surgic
resect
siopel
protocol
give
excel
outcom
even
stage
iv
without
radiotherapi
transplant
liver
perform
among
orthotop
transplant
later
section
liver
live
rel
donor
mother
execut
five
patient
stage
surgic
treatment
one
patient
hepatectomi
total
pancreatectomi
gastroduodenectomi
splenectomi
extend
lymphadenectomi
esophagojejunostomi
mesocav
shunt
orthotop
transplant
left
later
section
liver
live
rel
donor
mother
cava
portal
transposit
transplant
concern
recurr
hepatoblastoma
leftsid
expand
hepatectomi
execut
one
patient
averag
age
children
livingrel
transplant
liver
carri
made
year
chemotherapi
accord
clinic
protocol
siopel
carri
patient
group
high
risk
averag
time
execut
oper
made
hour
postop
period
biloma
resect
surfac
graft
develop
patient
remov
way
ultrasoundcontrol
punctur
complet
remiss
diseas
record
patient
livingrel
transplant
liver
execut
fiveyear
surviv
rate
patient
hepatoblastoma
transplant
liver
execut
make
fiveyear
surviv
graft
made
conclus
execut
livingrel
transplant
liver
children
hepatoblastoma
liver
difficult
stage
multimod
therapi
demand
consider
materi
technic
support
allow
achiev
good
remot
result
statist
authent
medicin
final
draft
review
intern
expert
resourcerich
resourcelimit
set
primari
aim
develop
protocol
prospect
collect
data
stage
riskstratif
manag
outcom
form
standardis
therapeut
strategi
regard
chemotherapi
radiat
lateeffect
monitor
result
prospect
observ
protocol
develop
evalu
abvd
chemotherapi
use
riskstratifi
fashion
earli
stage
patient
receiv
abvd
cycl
advanc
stage
patient
cycl
guidelin
consolid
radiat
therapi
involvedfield
radiotherapi
reserv
bulki
diseas
slownonrespond
followup
given
till
date
centr
join
protocol
newli
structur
indian
pediatr
oncolog
group
approach
regist
umbrella
studi
ethic
approv
ongo
individu
centr
recruit
expect
start
spring
conclus
prospect
observ
abvdbas
protocol
manag
hodgkin
lymphoma
indian
children
success
develop
found
accept
first
step
improv
standard
care
manag
diseas
india
thu
improv
outcom
stimul
research
burkitt
lymphoma
nzmaori
samoan
tongan
asian
conclus
hodgkin
lymphoma
patient
treat
khcc
excel
outcom
regardless
risk
group
omiss
radiotherapi
safe
lr
ir
patient
rer
treatment
intensif
hr
patient
feasibl
result
excel
cure
rate
toxic
data
suggest
mean
heart
dose
less
gy
gy
suffici
caus
acceler
atherosclerosi
valvular
diseas
respect
dose
cardiac
substructur
like
influenc
toxic
rt
plan
evalu
heart
singl
structur
ecggat
ct
angiographi
ecta
could
allow
accur
rt
dose
calcul
possibl
dose
reduct
critic
heart
structur
designmethod
provid
inform
consent
patient
receiv
rt
mediastin
hl
underw
ecta
breathhold
addit
convent
breathhold
imag
ecta
use
identifi
cardiac
vessel
valv
account
posit
diastol
systol
phase
target
organatrisk
oar
structur
includ
heart
contour
convent
imag
two
volumetr
intensitymodul
arc
rt
plan
gener
patient
convent
rt
crt
plan
gener
optim
target
oar
dosimetri
without
heart
substructur
constraint
coronaryspar
rt
csrt
plan
optim
target
coverag
normal
coronari
valv
structur
constraint
includ
oar
estim
maximum
dose
structur
volum
structur
receiv
gy
calcul
result
four
patient
hl
underw
rt
plan
patient
characterist
includ
median
age
rang
stage
iia
iva
ivb
hl
complet
respons
partial
respons
chemotherapi
averag
csrt
vs
crt
plan
respect
left
main
relaps
refractori
patient
receiv
six
cours
etoposid
prednisolon
ifosfamid
cisplatin
epic
involv
field
radiotherapi
ifrt
autolog
stem
cell
transplant
asct
treatment
choic
patient
poor
respons
first
four
cours
epic
result
median
age
diagnosi
male
two
patient
hiv
infect
cervic
region
commonest
site
primari
diseas
bulk
diseas
seven
bone
marrow
involv
stage
iv
diseas
record
patient
twenti
two
nodular
scleros
histolog
thirti
one
aliv
includ
two
lost
follow
remiss
includ
two
patient
stage
iii
diseas
relaps
treatment
salvag
one
stage
iv
patient
die
soon
admiss
four
stage
iv
patient
refractori
diseas
one
salvag
epic
asct
ifrt
os
ef
respect
whole
studi
group
os
stage
ii
iii
declin
stage
iv
ef
stage
ii
stage
iii
stage
iv
conclus
hybrid
chemotherapi
associ
good
outcom
stage
ii
iii
hodgkin
diseas
refractori
stage
iv
diseas
remain
problem
earlier
evalu
view
adopt
altern
strategi
warrant
patient
treat
combin
reduct
immunosuppress
chemotherapi
rituximab
four
patient
petct
diagnosi
lesion
seen
stage
ct
identifi
seven
patient
least
one
petct
followup
five
still
fdgavid
lesion
case
confirm
biopsi
one
case
petct
show
increas
uptak
area
unclear
ct
alon
howev
anoth
case
petct
identifi
addit
central
nervou
system
involv
demonstr
magnet
reson
imag
treatment
continu
five
petctposit
patient
five
patient
neg
petct
includ
two
case
ct
alon
show
persist
abnorm
uncertain
signific
five
patient
treatment
stop
remain
remiss
small
cohort
petct
found
valuabl
tool
stage
assess
treatment
respons
ptld
also
help
clarifi
equivoc
find
imag
modal
larger
cohort
studi
would
better
defin
potenti
role
petct
paediatr
ptld
result
children
age
year
diagnos
hodgkin
lymphoma
al
azhar
oncolog
center
new
case
pediatr
hematolog
malign
cancer
children
collect
studi
period
onehalf
case
boy
malefemal
ratio
averag
age
diagnosi
year
rang
year
twothird
case
diagnos
children
age
year
highest
rate
boy
note
year
girl
year
age
among
case
outcom
known
girl
die
studi
period
conclus
although
rare
cancer
children
substanti
impact
public
health
morocco
nation
cancer
registri
assist
better
plan
resourc
alloc
manag
includ
psychosoci
support
improv
qualiti
life
childhood
cancer
survivor
famili
pediatr
blood
cancer
doi
backgroundobject
current
treatment
paradigm
cure
children
hodgkin
lymphoma
even
develop
world
india
abvd
remain
prefer
chemotherapi
regimen
due
good
toler
despit
known
cardiac
pulmonari
late
effect
pet
scan
expens
becom
avail
recent
year
studi
plan
evalu
addit
cost
pet
scan
justifi
reduct
burden
therapi
designmethod
medic
record
children
yr
age
treat
review
pre
pet
scan
era
patient
receiv
six
cycl
abvd
involv
field
radiotherapi
reserv
bulki
residu
diseas
burden
treatment
assess
number
cycl
chemotherapi
use
radiotherapi
result
median
age
evalu
patient
year
rang
year
girl
mix
cellular
commonest
histolog
b
symptom
bulki
diseas
advanc
stage
observ
patient
respect
pet
scan
avail
patient
whose
demograph
diseas
characterist
similar
remain
cohort
fewer
patient
receiv
radiotherapi
pet
subgroup
versu
also
receiv
fewer
chemotherapi
cycl
versu
year
overal
event
free
surviv
subset
without
pet
scan
versu
respect
median
follow
month
trend
small
analysi
suggest
better
respons
assess
pet
scan
like
lead
reduct
burden
therapi
maintain
excel
surviv
pediatr
hodgkin
lymphoma
encourag
pediatr
oncologist
develop
countri
often
tend
treat
due
fear
abandon
relaps
backgroundobject
peripher
tcell
lymphoma
ptcl
rare
nonhodgkin
lymphoma
nhl
usual
associ
inferior
outcom
bcell
lymphoma
data
children
ptcl
particularli
rare
optim
therapi
defin
studi
analyz
clinic
characterist
treatment
outcom
children
ptcl
designmethod
studi
retrospect
investig
case
ptcl
diagnos
asan
medic
center
clinic
characterist
treatment
result
outcom
review
isol
cutan
tcell
lymphoma
anaplast
larg
cell
lymphoma
exclud
analysi
result
accord
world
health
organ
ptcl
classif
patient
ptcl
otherwis
specifi
ptclno
extranod
natur
killertcel
lymphoma
nasal
type
enkl
subcutan
panniculitislik
tcell
lymphoma
angioimmunoblast
tcell
lymphoma
patient
ptclno
treat
variou
multiag
chemotherapeut
regimen
design
tcell
acut
lymphoblast
leukemia
nhl
patient
enkl
receiv
upfront
radiotherapi
follow
multiag
chemotherapi
two
patient
relaps
ptclno
underw
allogen
hematopoiet
stem
cell
transplant
hsct
autolog
hsct
respect
patient
relaps
enkl
underw
autolog
hsct
patient
die
diseas
progress
treatmentrel
mortal
overal
eventfre
surviv
rate
case
ptclno
enkl
respect
conclus
although
children
ptcl
experienc
frequent
relaps
mani
could
rescu
salvag
treatment
result
compar
overal
surviv
outcom
nhl
multicent
trial
requir
refin
prognost
factor
ptcl
confirm
outcom
ptcl
children
subtyp
cmyc
coexpress
cmyc
gene
rearrang
childhood
dlbcl
unknown
designmethod
thirti
children
adolesc
dlbcl
includ
trial
bnhlbfm
r
malefemal
ratio
median
age
year
rang
till
stage
iii
reveal
patient
stage
iiiiv
group
group
gcbnongcb
dlbcl
subtyp
assess
han
talli
viscoyoung
immunohistochem
algorithm
cutoff
valu
myc
establish
myc
gene
rearrang
assess
fish
use
locusspecif
tricolor
dualfus
probe
locusspecif
myc
dualcolor
breakapart
probe
result
gcbnongcb
dlbcl
subtyp
reveal
case
han
viscoyoung
case
talli
ten
dlbcl
sampl
posit
myc
coexpress
myc
gene
rearrang
reveal
patient
gene
rearrang
reveal
fiveyear
overal
surviv
os
eventfre
surviv
ef
median
followup
month
rang
till
reveal
influenc
investig
marker
os
ef
conclus
number
patient
studi
enough
estim
authent
prognost
signific
marker
highintens
r
chemotherapi
show
good
therapeut
effect
patient
studi
continu
g
macey
j
hayden
backgroundobject
doublehit
leukaemia
dhl
complex
abnorm
myc
oncogen
rare
tumour
adult
patient
previous
report
paediatr
literatur
present
child
doublehit
leukaemia
literatur
review
rare
malign
designmethod
literatur
search
conduct
pubm
use
term
doublehit
leukaemia
dualhit
leukaemia
well
mesh
term
myc
yearold
girl
present
facial
gum
swell
difficulti
walk
bone
marrow
aspir
identifi
leukaem
infiltr
evid
central
nervou
system
cn
diseas
cerebrospin
fluid
csf
analysi
subsequ
genet
analysi
show
concurr
myc
transloc
confirm
dhl
patient
treat
standard
chemotherapi
burkitt
bcell
leukaemia
accord
group
c
unit
kingdom
children
cancer
leukaemia
group
cclg
guidelin
chemotherapi
result
complet
diseas
remiss
microscop
cytogenet
molecular
level
patient
present
day
complet
chemotherapi
left
hemiparesi
mri
scan
identifi
intracrani
mass
csf
analysi
bone
marrow
examin
confirm
combin
marrow
cn
relaps
patient
progress
die
month
initi
diagnosi
literatur
report
dhl
children
combin
myc
transloc
result
uncontrol
prolifer
malign
cell
aggress
clinic
phenotyp
bone
marrow
extranod
cn
involv
common
present
relapseprogress
consensu
manag
patient
prognosi
poor
primari
resist
chemotherapi
earli
relaps
median
surviv
month
conclus
doublehit
leukaemia
myc
transloc
childhood
rare
entiti
associ
similarli
dismal
prognosi
report
adult
research
develop
novel
treatment
strategi
rare
diseas
requir
result
first
symptom
diseas
involv
mild
abdomin
pain
icteru
stool
discolor
boy
also
suffer
lower
limb
pain
initi
interpret
reactiv
arthriti
upper
respiratori
tract
infect
laboratori
test
reveal
parenchym
liver
damag
alt
ast
sign
cholestasi
total
bilirubin
mgdl
conjug
mgdl
normal
liver
synthet
function
albumin
prothrombin
index
infecti
diseas
liver
exclud
hbv
hcv
ebv
hav
level
amylas
serum
increas
urin
initi
sonographi
reveal
abnorm
day
symptom
onset
sonographi
show
lesion
pancrea
initi
interpret
inflammatori
lesion
howev
day
later
imag
abdomen
reveal
significantli
enlarg
pancrea
expand
common
bile
duct
tumor
mass
pelvi
lesion
right
kidney
pelvic
mass
penetr
fill
spinal
canal
moreov
infiltr
femur
found
basi
histopatholog
examin
tumor
burkitt
lymphoma
iv
stage
cn
involv
diagnos
chemotherapi
accord
bnhl
introduc
conclus
localis
burkitt
lymphoma
pancrea
rare
might
mistaken
acut
pancreat
rapid
growth
rate
requir
prompt
diagnosi
initi
proper
treatment
therefor
essenti
consid
burkitt
lymphoma
confront
paediatr
present
pancreat
mass
j
menang
njimogu
backgroundobject
burkitt
lymphoma
bl
preval
children
cancer
cameroon
lethal
treat
curabl
lone
cyclophosphamid
cpd
therapi
combin
methrotrex
appli
june
june
crosssect
commun
studi
outcom
improv
treatment
support
care
designmethod
previou
survey
outcom
done
use
questionnair
base
aspect
palli
care
relat
cultur
view
tradit
belief
commun
special
attent
paediatr
oncolog
need
proven
vital
servic
improv
care
support
provid
ascertain
palli
care
need
possibl
practic
intervent
result
huge
gap
exist
western
palli
care
support
approach
commun
uniqu
super
attach
cultur
view
belief
compat
typic
modern
approach
death
rate
much
result
late
diagnosi
lack
health
unit
inaccess
treatment
product
conclus
poverti
unhealthi
cultur
note
main
hurdl
high
percentag
children
die
home
either
due
poverti
parent
assum
child
cancer
caus
superstit
child
taken
basic
health
care
clinic
expert
time
diagnos
similar
reason
studi
outcom
guid
new
treatment
support
advocaci
guidelin
difficult
copi
past
modern
approach
palli
care
support
though
evid
clear
modern
treatment
support
approach
remain
superb
even
commun
result
total
children
bl
diagnos
studi
period
mean
age
year
rang
year
male
predomin
male
femal
ratio
abdomen
commonest
site
tumor
present
jaw
nd
commonest
tumor
site
signific
associ
observ
girl
abdomin
tumor
p
well
boy
age
year
regim
outpati
basi
period
month
follow
data
analyz
age
sex
stage
diseas
histopatholog
subtyp
diagnosi
respons
therapi
relaps
earli
treatment
suspens
patient
result
mean
age
year
rang
male
femal
give
male
femal
ratio
mix
cellular
commonest
histolog
subtyp
observ
patient
forti
two
patient
achiev
complet
respons
partial
respons
one
patient
respond
three
patient
stage
iia
iia
ivb
lost
month
followup
fifteen
patient
known
dead
rest
aliv
tumor
free
conclus
abvd
combin
regard
present
moment
simplest
effect
drug
therapi
treat
childhood
hodgkin
diseas
backgroundobject
assess
efficaci
chemotherapi
alon
use
six
eight
cycl
abvd
stage
childhood
hodgkin
diseas
hd
designmethod
may
novemb
chart
hodgkin
diseas
patient
receiv
abvd
investig
analyz
retrospect
remiss
surviv
result
boy
girl
median
age
year
less
year
old
advanc
stage
diseas
iibiv
b
symptom
present
case
bulki
mediastin
mass
case
spleen
bone
marrow
involv
seven
case
respect
mix
cellular
mc
subtypewa
found
complet
remiss
achiev
patient
six
patient
relaps
three
patient
die
therapi
overal
surviv
os
diseas
free
surviv
df
conclus
although
group
patient
small
chemotherapi
alon
abvd
without
addit
radiotherapi
provid
high
rate
durabl
remiss
effect
childhood
hd
research
hospit
pediatr
endocrinolog
istanbul
turkey
istanbul
universityoncolog
institut
radiat
oncolog
istanbul
turkey
backgroundobject
aim
evalu
late
side
effect
chemotherapi
radiotherapi
thyroid
function
treat
hodgkin
lymhoma
childhood
designmethod
forti
patient
follow
treat
pediatr
hematologyoncolog
unit
evalu
demograph
featur
histopatholog
type
tumor
stage
age
time
radiotherapi
dose
radiat
time
period
radiotherapi
tsh
free
thyroglobulin
antithyroid
peroxydas
calcitonin
thyroid
ultrasonographi
occur
time
hypothyroid
nodul
record
whenev
nodul
detect
thyroid
ultrasonographi
scintigraphi
perform
follow
biopsi
indic
result
patient
radiotherapi
chemotherapi
thirti
four
male
six
femal
age
diagnosi
dose
radiotherapi
gy
patient
primari
local
head
neck
seven
patient
b
symptom
patient
stage
iiiiv
hypothyroid
detect
twelv
forti
patient
male
femal
thyroid
hormon
therapi
given
five
patient
due
clinic
hypothyroidismnon
patient
hyperthyroid
thyroid
antibodi
posit
nt
signific
relationship
accord
age
radiotherapi
time
radiotherapi
radiotherapi
dose
stage
hystopatholog
type
patient
hypothyroid
without
hypothyroid
respect
thyroid
nodul
detect
male
femal
patient
ultrasonographi
biopsi
perform
patient
accord
result
usg
thyroglobulin
scintigraphi
result
malign
nt
observ
none
nt
also
signific
relationship
accord
age
dose
radiotherapi
stage
hystopatholog
type
time
radiotherapi
longer
patient
nodul
time
develop
hypothyroid
year
nodul
format
year
nodul
format
time
significantli
longer
develop
hypothyroid
conclus
pediatr
patient
treat
due
hodgkin
lymphoma
increas
risk
thyroid
function
abnorm
long
term
followup
need
abdomen
frequent
onset
site
nonendem
burkitt
lymphoma
three
variant
describ
present
experi
case
burkitt
lymphoma
pediatr
age
group
refer
age
present
clinic
manifest
anatom
locat
manag
designmethod
studi
pediatr
case
burkitt
lymphoma
bl
gi
tract
feb
march
follow
featur
note
extent
diseas
determin
histori
physic
examin
baselin
complet
hemogram
liver
function
test
lactat
dehydrogenas
ldh
tumor
bulk
indic
uric
acid
serum
electrolyt
bone
marrow
biopsi
abdomin
ultrasound
andor
contrastenhanc
comput
tomographi
cect
scan
abdomen
qualiti
life
patient
receiv
chemotherapi
surgeri
compar
requir
surgeri
chemotherapi
result
two
case
present
intususcept
resolv
conserv
manag
one
case
present
subacut
intestin
obstruct
manag
initi
chemotherapi
requir
surgic
intervent
one
case
present
intususcept
suspect
leak
one
case
featuresof
subacut
intestin
obstruct
initi
treat
resect
follow
chemotherapi
group
patient
treat
surgic
initi
tolrat
chemotherapi
better
group
conclus
qualiti
life
chemotherapi
better
patient
receiv
chemotherapi
surgeri
initi
treat
chemotherapi
though
detail
studi
requir
definit
conclus
levashov
popa
g
mentkevich
backgroundobject
progress
treatment
advanc
stage
burkitt
lymphoma
bl
associ
intens
chemotherapi
support
care
rituximab
use
current
studi
investig
clinic
andor
biolog
featur
treatment
reduct
literatur
data
c
patt
possibl
reduc
treatment
earli
respond
intermedi
risk
patient
bnhl
studi
reduc
treatment
high
risk
bl
pt
designmethod
forti
one
newli
diagnos
bl
pt
murphi
stage
iiiiv
bfm
risk
group
treat
accord
rbnhlbfm
protocol
januari
februari
median
age
year
rang
malefemal
ratio
rituximab
administr
day
block
aa
bb
therapeut
effect
estim
result
eventfre
surviv
ef
rbnhlbfm
protocol
twenti
pt
achiev
earli
complet
respons
cr
block
chemotherapi
follow
treatment
consist
block
ccaabb
without
rituximab
al
pt
cr
remiss
follow
month
twenti
one
pt
get
cr
block
chemotherapi
continu
treatment
protocol
without
block
number
reduct
ccaabbcc
ef
two
pt
die
one
diseas
progress
anoth
pseudomona
aeruginosa
sepsi
conclus
result
suggest
earli
complet
respons
may
import
prognost
factor
treatment
reduct
near
advanc
stage
pediatr
burkitt
lymphoma
result
reveal
earli
respond
advanc
stage
bl
pt
excel
result
treatment
reduct
protocol
block
backgroundobject
evalu
clinic
characterist
treatment
regimen
outcom
patient
primari
central
nervou
system
lymphoma
cn
designmethod
five
patient
diagnos
primari
cn
lymphoma
retrospect
evalu
patient
treat
chemotherapi
radiotherapi
chemotherapeut
regimen
includ
lmb
high
dose
cytarabin
methotrex
result
patient
male
median
age
year
year
tumor
locat
frontal
lobe
pariet
tempor
lobe
thalamu
leptomening
b
cell
phenotyp
lmb
chemotherapi
protocol
use
patient
patient
protocol
patient
receiv
high
dose
cytarabin
methotrex
intratech
rituximab
use
two
patient
patient
receiv
radiotherapi
three
patient
treat
lmb
protocol
relaps
die
patient
diseasefre
followup
conclus
primari
cn
lymphoma
rare
childhood
although
high
dose
cytarabin
methotrex
seem
effici
one
patient
protocol
effect
anoth
seri
small
studi
need
result
snp
display
statist
signific
differ
hl
rh
control
p
test
haplotyp
acc
statist
overrepres
hl
versu
control
test
ebv
express
hl
rh
neither
genotyp
distribut
snp
haplotyp
show
differenti
associ
ebv
ebvhl
control
p
test
carrier
snp
ac
lower
event
free
surviv
global
surviv
specif
hl
group
ef
vs
gs
vs
conclus
acc
haplotyp
associ
increas
suscept
hl
even
though
g
allel
ata
haplotyp
protect
ebv
primari
infect
decreas
suscept
observ
ebvassoci
pediatr
hl
found
statist
signific
associ
carriag
snp
lower
surviv
studi
highlight
import
analyz
promot
polymorph
anoth
prognost
factor
glycolyt
rate
raji
investig
glucos
consumpt
assay
cell
cultur
hour
apoptosi
detect
flow
cytometri
cell
incub
hour
mrna
express
detect
rtpcr
techniqu
protein
express
nfkappa
b
detect
westernblot
method
result
indic
atorvastatin
could
inhibit
glycolyt
activ
raji
cell
treat
moll
atorvastatin
h
effect
inhibit
glycolyt
activ
raji
cell
strikingli
glycolyt
rate
reduc
p
addit
atorvastatin
could
induc
apoptosi
raji
cell
treat
moll
atorvastatin
apoptosi
raji
notabl
rate
p
basal
mrna
express
gene
control
group
treat
moll
atorvastatin
show
mrna
express
downregul
obvious
decreas
atorvastatin
inhibit
glycolyt
activ
induc
apoptosi
raji
cell
mechan
may
associ
nfkappa
b
signal
pathway
treatment
result
boy
girl
median
age
year
durat
symptom
median
day
patient
b
symptom
common
histolog
subtyp
mix
cellular
percentag
patient
local
diseas
stage
lll
advanc
diseas
stage
llllv
respect
firstlin
treatment
patient
copp
abvd
abvcopp
protocol
radiotherapi
administ
patient
eleven
patient
nt
receiv
radiotherapi
advanc
diseas
five
due
decis
differ
consult
doctor
median
followup
month
overal
os
eventfre
ef
surviv
rate
whole
group
found
statist
differ
group
receiv
radiotherapi
ef
vs
patient
stage
iiilv
diseas
significantli
lower
os
rate
compar
stage
lll
diseas
os
vs
patient
receiv
radiotherapi
firstlin
treatment
significantli
higher
os
rate
patient
nt
receiv
radiotherapi
os
vs
multivari
analysi
radiotherapi
found
posit
correl
os
conclus
treatment
approach
appli
depart
success
result
gener
surviv
rate
patient
advanc
diseas
treat
without
radiotherapi
shown
lower
compar
patient
local
diseas
treat
radiotherapi
emphas
necess
radiotherapi
patient
hl
backgroundobject
chronic
myeloid
leukemia
cml
childhood
rare
repres
pediatr
leukemia
philippin
gener
hospit
countri
nation
referr
center
surviv
rate
pediatr
cml
without
tyrosin
kinas
inhibitor
sinc
imatinib
made
local
avail
max
foundat
novarti
glivec
intern
patient
assist
program
gipap
report
outcom
patient
designmethod
medic
record
pediatr
cml
patient
diagnos
januari
review
demograph
data
collect
outcom
evalu
studi
endpoint
novemb
result
thirti
seven
patient
diagnos
studi
period
chart
avail
review
age
rang
year
mean
splenomegali
present
patient
philadelphia
chromosom
document
fish
karyotyp
patient
respect
diagnosi
chronic
phase
acceler
blastic
patient
receiv
imatinib
due
financi
constraint
chronic
acceler
phase
month
achiev
complet
hematolog
respons
chr
data
twenti
eight
percent
complet
cytogenet
respons
month
major
molecular
respons
month
studi
endpoint
achiev
complet
molecular
respons
loss
chr
due
treatment
abandon
die
diseas
eleven
patient
receiv
imatinib
die
diseas
abandon
hydroxyurea
treatment
remain
chr
hydroxyurea
year
overal
surviv
patient
imatinib
conclus
surviv
rate
among
pediatr
cml
patient
improv
imatinib
avail
better
complianc
financi
support
diseas
monitor
studi
need
defin
treatment
respons
backgroundobject
small
round
blue
cell
tumor
srbct
group
malign
occur
children
differenti
diagnosi
mainli
includ
rhabdomyosarcoma
rm
peripher
primit
neuroectoderm
tumor
ppnet
leukemia
lymphoma
neuroblastoma
among
other
immunohistochemistri
one
preval
conveni
method
patholog
diagnosi
howev
differenti
tumor
low
incom
countri
still
challeng
present
clinic
case
male
infant
small
round
blue
cell
tumor
designmethod
present
clinic
case
infant
srbctand
discuss
differenti
diagnosi
tumor
pediatr
popul
repres
challeng
low
incom
countri
result
old
month
male
admit
pediatr
oncolog
servic
centro
medico
nacion
de
noviembr
issst
mexico
citi
singl
small
bluish
color
skin
nodul
foot
plant
sinc
month
old
excision
biopsi
made
diagnosi
neuroblastoma
pathologist
review
biopsi
conclud
pnet
imag
studi
perform
primari
tumor
site
start
chemotherapi
accord
mexican
nation
protocolaft
cycl
chemotherapi
subcutan
soft
tissu
lesion
left
gluteou
appear
hystophatolog
diagnosi
pnet
bone
marrow
aspir
biopsi
made
final
diagnosi
acut
myeloid
leukemia
conclus
differenti
diagnosi
srbct
easi
low
incom
countri
lack
resourc
investig
oncologist
must
perform
complet
clinic
investig
clear
diagnosi
srbct
base
comprehens
analysi
involv
morpholog
immunoreact
panel
marker
also
investig
ocurr
major
chromosom
transloc
valid
diagnosi
perform
accur
diagnosi
treat
cancer
proper
way
sander
high
dose
etoposid
cyclophosphamid
hd
etopcyclo
achiev
complet
remiss
cr
rate
adult
refractoryrelaps
acut
leukaemia
brown
johni
trifilio
aim
evalu
efficacysafeti
hd
etopcyclo
children
adolesc
young
adult
refractori
acut
leukaemia
treat
institut
designmethod
retrospect
studi
patient
age
year
aml
acut
lymphoblast
leukaemia
andor
biphenotyp
leukaemia
bl
refractori
line
chemotherapi
either
initi
diagnosi
relaps
efficaci
assess
per
iwg
criteria
advers
event
accord
ctcae
studi
endpoint
overal
respons
cycl
eventfre
surviv
ef
os
result
nine
patient
includ
cycl
male
median
age
rang
year
aml
bl
refractori
diagnosi
follow
relaps
cr
cr
incomplet
platelet
recoveri
partial
respons
ci
patient
grade
g
neutropenia
thrombocytopenia
toxic
includ
febril
neutropenia
mucos
tumour
lysi
syndrom
lung
infect
one
nonrespond
respond
subsequ
underw
allogen
stem
cell
transplant
median
ci
ef
respond
month
median
ci
os
whole
cohort
month
one
nonrespond
one
respond
remain
diseasefre
year
hd
etopcyclo
respect
conclus
result
consist
report
adult
feasibl
administ
hd
etopcyclo
children
toxic
profil
similar
regim
use
relaps
set
henc
believ
hd
cycloetop
would
merit
evalu
prospect
studi
backgroundobject
nk
cell
function
fine
tune
inhibitori
irec
activ
arec
receptor
consist
miss
self
hypothesi
nk
cell
sens
loss
selfhlaclassi
hlai
inhibitori
killer
cell
immunoglobulinlik
receptor
kir
elimin
tumor
cell
nk
cell
function
also
depend
signal
deliv
interact
arec
ligand
arec
recogn
stressinduc
ulbp
protein
wherea
specif
recogn
polioviru
receptor
designmethod
express
ligand
ikir
hlai
hlac
arec
micab
evalu
acut
childhood
leukemia
diagnosi
ball
tall
aml
use
facscanto
flowcytomet
bone
marrow
tumor
cell
residu
lymphocyt
control
normalbas
express
hlai
hlac
express
normal
ratio
mean
fluoresc
intens
imf
tumor
cell
imf
control
cell
express
ligand
ikir
significantli
lost
tall
respect
hlai
hlac
maintain
hlai
slightli
decreas
hlac
ball
aml
compar
normal
lymphocyt
p
tall
vs
ball
aml
contrast
express
arec
ligand
significantli
result
nine
patient
diagnos
cml
male
predomin
f
patient
black
eight
patient
present
chronic
phase
diseas
one
patient
present
blastic
crisi
white
cell
count
rang
median
hydroxyurea
busulphan
mercaptopurin
use
patient
control
white
cell
count
outset
one
patient
treat
interferon
treat
imatinib
made
avail
via
donor
programm
four
patient
chronic
phase
diseas
progress
acceler
phase
one
resist
imatinib
dasatinib
avail
time
second
patient
salvag
nd
rd
line
tyrosin
kinas
inhibitor
tki
revert
chronic
phase
three
patient
acceler
phase
diseas
progress
blast
phase
cn
diseas
blastic
phase
patient
demis
poor
complianc
patient
progress
acceler
phase
difficult
social
circumst
fatigu
main
caus
noncompli
complianc
excel
subsequ
patient
patient
still
aliv
surviv
tki
three
imatininb
dasatininb
conclus
chronic
myeloid
leukaemia
rare
paediatr
malign
access
tki
via
donor
programm
improv
surviv
patient
critic
especi
countri
stem
cell
transplant
limit
good
complianc
pivot
prevent
progress
acceler
blast
phase
rtpcr
readili
avail
treatment
algorithim
well
defin
result
better
surviv
hussain
u
allen
islamabad
pakistan
tongji
medic
colleg
oncolog
depart
wuhan
china
backgroundobject
acut
myeloid
leukemia
aml
diagnos
among
pediatr
age
group
carri
great
risk
immunosuppress
superimpos
infect
patient
diseas
usual
die
relat
complic
rather
diseas
basic
aim
studi
rule
benefici
role
prophylact
gener
antibiot
regimen
patient
thu
enhanc
qualiti
life
decreas
morbid
designmethod
retrospect
studi
conduct
oncolog
depart
rawalpindi
medic
colleg
alli
teach
hospit
data
collect
period
year
pediatr
patient
age
year
consecut
diagnos
aml
treat
jan
dec
patient
treat
intern
treatment
guidelin
per
hospit
polici
protocol
data
extract
hard
copi
electron
chart
review
result
total
case
studi
detail
staphylococcu
major
bug
found
among
infect
case
total
chemotherapi
phase
among
patient
phase
report
prevent
antibiot
initi
daili
absolut
neutrophil
count
fall
cellsmcl
onset
fever
episod
bacteremia
document
predominantli
coagulaseneg
staphylococci
viridan
group
streptococci
confirm
infectionrel
death
occur
primarili
respiratori
tract
infect
lead
respiratori
failur
conclus
antibiot
coverag
organ
specif
commonest
organ
found
staph
group
respiratori
tract
infect
neutropenia
onset
fever
set
start
point
bug
specif
antibiot
report
experi
treat
pediatr
patient
high
risk
hematolog
malign
unmanipul
hfd
transplant
designmethod
thirtynin
patient
femal
receiv
unmanipul
hfd
transplant
august
juli
median
age
year
rang
patient
diagnos
follow
aml
jmml
mix
phenotyp
acut
leukemia
dendrit
cell
sarcoma
matern
donor
util
patient
patient
receiv
gcsf
mobil
peripher
blood
stem
cell
condit
regimen
follow
busulfanbas
tbibas
tbi
busulfanbas
rabbit
atg
given
day
prior
transplant
total
dose
mgkg
gvhd
prophylaxi
consist
cyclosporin
minidos
methotrex
result
median
cell
dose
infus
follow
tnc
kg
mnc
kg
kg
kg
cumul
incid
grade
iiiv
grade
iiiiv
acut
gvhd
respect
cumul
incid
overal
chronic
gvhd
extens
chronic
gvhd
respect
rate
relaps
transplantrel
mortal
trm
respect
eventfre
surviv
ef
cohort
none
factor
studi
includ
donor
gender
degre
hla
mismatch
signific
impact
ef
conclus
unmanipul
hfd
transplant
done
rabbit
atgbas
vivo
cell
deplet
feasibl
option
children
adolesc
high
risk
hematolog
malign
requir
allogen
hct
cure
although
trm
remain
low
measur
necessari
decreas
rate
acut
chronic
gvhd
standard
care
evid
respons
acut
lymphoblast
leukemia
type
therapi
report
three
case
tmyeloid
mix
lineag
leukemia
one
patient
achiev
complet
remiss
cr
type
therapi
two
earli
initi
clofarabin
failur
type
therapi
led
remiss
three
patient
underw
success
hematopoiet
stem
cell
transplant
hsct
conclud
tmyeloid
leukemia
may
common
previous
report
clofarabin
may
aid
achiev
earli
remiss
allow
hsct
designmethod
year
old
femal
year
old
male
year
old
male
diagnos
acut
tmyeloid
leukemia
immunophenotyp
bone
marrow
aspir
use
flow
cytometri
patient
mpo
partial
partial
tdt
dim
patient
partial
patient
mpo
partial
dim
partial
dim
patient
receiv
type
induct
chemotherapi
result
patient
achiev
cr
patient
requir
retriev
therapi
achiev
remiss
neg
minim
residu
diseas
mrd
addit
clofarabin
three
underw
hsct
without
relaps
third
patient
die
day
hsct
due
transplant
relat
complic
report
three
case
acut
tmyeloid
leukemia
achiev
mrd
neg
prior
hsct
associ
improv
prognosi
base
other
experi
type
induct
regimen
reason
instead
switch
acut
myeloid
leukemia
type
therapi
earli
initi
clofarabin
may
indic
improv
prognosi
hsct
neg
mrd
achiev
end
induct
first
allohsct
done
yo
boy
saa
fail
primarili
immunosuppress
therapi
condit
regimen
consist
fludarabin
cyclophosphamid
rabbit
atg
cyclosporin
csa
mycophenol
mofetil
gvhd
prophylaxi
due
poor
graft
function
underw
retransplant
donor
outsid
countri
two
hsct
perform
patient
aml
histori
hepat
c
condit
regimen
includ
treocymel
gvhd
prophylaxi
tacrolimu
methotrex
pcr
show
donor
chimer
sinc
year
continu
hematolog
remiss
first
patient
chimer
sinc
second
patient
aml
yo
girl
jmml
underw
hsct
treocymel
gvhd
prophylaxi
csa
engraft
detect
pcr
chimer
show
donor
cell
year
girl
underw
hsct
earli
bone
marrow
relaps
condit
regimen
treocymel
gvhd
prophylaxi
csa
engraft
detect
pcr
chimer
show
donor
cell
result
despit
limit
experi
hsct
none
patient
suffer
earli
transplant
mortal
one
suffer
acut
gvhd
grade
ii
day
treat
steroid
one
case
patient
day
allo
held
ascertain
diseas
relaps
aliv
earli
hsct
month
conclus
use
transplant
hsct
improv
outcom
children
differ
malign
nonmalign
disord
countri
backgroundobject
mutat
tet
oncogen
famili
member
gene
frequent
found
adult
acut
myeloid
leukemia
aml
patient
prognosi
effect
howev
report
mutat
children
limit
assess
preval
mutat
taiwanes
childhood
aml
attempt
analyz
prognosi
effect
designmethod
sixtynin
consecut
aml
children
enrol
analysi
perform
direct
sequenc
assum
mutat
accord
public
databas
literatur
document
bioinformat
tool
evalu
clinic
charact
overal
surviv
os
compar
patient
without
alter
result
intron
missens
mutat
identifi
nonsens
frameshift
mutat
two
put
diseasecaus
missens
mutat
identifi
patient
estim
preval
mutat
patient
common
polymorph
follow
patient
polymorph
tend
better
surviv
rate
patient
without
vs
p
thought
os
differ
kaplanmei
method
p
preval
mutat
childhood
aml
patient
lower
mutat
less
complex
adult
aml
prognosi
effect
mutat
need
investig
confirm
role
childhood
aml
backgroundobject
cml
compris
pediatr
leukemia
annual
incid
per
million
children
adolesc
year
age
designmethod
total
pediatr
adolesc
cml
case
year
prospect
diagnos
cytogenet
rtpcr
analysi
four
year
enrol
result
pediatr
yr
adolesc
yr
case
male
femal
ratio
present
massiv
splenomegali
chronic
phase
one
present
blast
crisi
high
tlc
diagnosi
wbc
count
l
normal
platelet
count
high
l
one
case
low
platelet
count
high
absolut
basophil
count
l
seen
case
case
low
lap
score
ph
posit
cytogenet
analysi
note
case
case
numer
structur
genet
chang
case
posit
bcrabl
transcript
type
rtpcr
analysi
type
transcript
transcript
case
receiv
imatinib
mgod
develop
relaps
die
respond
treatment
event
free
surviv
median
follow
month
overal
surviv
respond
month
conclus
pediatr
cml
though
rare
need
consid
case
high
tlc
high
absolut
basophil
count
bcrabl
studi
necessari
confirm
diagnosi
overal
outcom
imatinib
treatment
good
remiss
month
follow
backgroundobject
rare
form
childhood
leukemia
character
poor
respons
therapi
compar
patient
children
syndrom
ds
designmethod
compar
ds
non
ds
patient
treat
kfshrc
riyadh
saudi
arabia
data
analyz
clinic
characterist
patient
outcom
result
group
receiv
institut
aml
protocol
ds
group
patient
male
median
age
diagnosi
month
rang
two
patient
age
month
mean
wbc
count
rang
patient
cn
neg
patient
remiss
end
induct
relaps
one
patient
die
due
progress
diseas
six
patient
infecti
toxic
induct
bi
fi
fn
patient
post
induct
phase
bi
fi
fn
amongst
nond
aml
patient
male
median
age
diagnosi
month
rang
seven
patient
less
month
mean
wbc
cn
neg
ten
patient
achiev
remiss
end
induct
patient
relaps
median
relaps
free
time
month
patient
die
pd
infect
patient
develop
infecti
toxic
induct
bi
fi
fn
patient
post
induct
phase
bi
fi
fn
os
nond
group
compar
ds
group
ef
compar
ds
aml
group
conclus
result
support
favor
outcom
ds
aml
group
compar
non
ds
aml
group
effect
report
feasibl
outcom
ric
transplant
develop
world
set
designmethod
five
children
relaps
leukemia
comorbid
intracrani
invas
fungal
hepat
poor
gener
underw
ptci
ric
hsct
clinic
record
investig
sheet
analyz
retrospect
patient
followup
rang
result
mean
age
year
year
relaps
leukemia
acut
myeloid
chronic
myeloid
acut
lymphoblast
except
one
complet
remiss
cr
condit
fludarabin
mgm
cyclophosphamid
mgkg
atg
mgkg
thiotepa
mgkg
tbi
three
patient
match
sibl
peripher
blood
stem
cell
pbsc
graft
one
haploident
pbsc
one
doubl
cord
blood
dcb
graft
mean
cell
dose
kg
patient
pbsc
graft
kg
dcb
graft
ptci
given
dose
mgkgday
patient
engraft
mean
neutrophil
engraft
day
chimer
studi
show
fulli
donor
mix
chimer
child
mix
chimer
treat
success
donor
lymphocyt
infus
gvhd
seen
patient
two
death
patient
dcb
transplant
die
due
bk
viru
cytomegaloviru
infect
gvhd
second
patient
relaps
posttranspl
die
reinduct
mortal
overal
surviv
relaps
leukemia
patient
comorbid
ric
hsct
ptci
constitut
feasibl
effect
option
backgroundobject
lifraumeni
syndrom
cancer
predispos
syndrom
caus
germlin
mutat
associ
develop
variou
tumor
young
age
designmethod
investig
inactiv
second
allel
sequenc
topo
ta
clone
karyotyp
fish
three
differ
malign
develop
femal
child
lifraumeni
syndrom
choroid
plexu
carcinoma
age
month
secondari
acut
myeloid
leukemia
aml
age
year
wilm
tumor
age
year
result
de
novo
heterozyg
germlin
mutat
locat
within
dna
bind
domain
first
import
step
toward
tumorigenesi
investig
mutat
statu
three
tumor
tissu
show
choroid
plexu
carcinoma
known
germlin
mutat
detect
homozyg
state
result
loss
wildtyp
allel
duplic
mutant
allel
due
copynumb
neutral
lohuniparent
disomi
secondari
aml
complex
karyotyp
indic
increas
genom
instabl
led
loss
probabl
wildtyp
allel
due
delet
wilm
tumor
somat
acquir
mutat
identifi
lead
compound
heterozygos
find
show
complet
inactiv
either
loss
wildtyp
allel
compound
heterozyg
mutat
decis
step
toward
tumorigenesi
young
patient
lifraumeni
syndrom
resist
protein
measur
taqman
real
time
pcr
pretreat
sampl
children
aml
patient
treat
accord
multicent
studi
amlbfm
result
associ
lower
chanc
achiev
remiss
first
cours
chemotherapi
associ
lower
relaps
free
surviv
express
higher
level
subtyp
aml
favor
outcom
within
standard
high
risk
patient
associ
poor
outcom
strong
associ
observ
number
overexpress
abctransport
chanc
achiev
remiss
chanc
relaps
free
surviv
p
conclus
modern
intens
treatment
regimen
readili
overcom
drug
resist
caus
abctransport
inhibit
abctransport
could
particularli
use
patient
express
multipl
gene
backgroundobject
hematopoit
stem
cell
transplant
hsct
consid
one
cur
treatment
chronic
myeloid
leukemia
cml
rare
hematolog
malign
among
pediatr
popul
isol
extramedullari
relaps
central
nervou
system
cn
cml
pediatr
patient
hsct
never
report
designmethod
old
thai
boy
present
fever
mark
splenomagali
diagnos
chronic
phase
cml
institut
initi
blood
count
show
anemia
hyperleukocytosi
csf
cytolog
neg
bone
marrow
bm
karyotyp
show
xy
bm
patholog
compat
cml
chronic
phase
treat
hydroxyurea
follow
imatinib
repeat
bma
cytogenet
reveal
normal
studi
three
month
treatment
eleven
month
later
develop
episod
myeloid
blast
crisi
receiv
induct
remiss
chemotherapi
accord
thaipog
protocol
aml
consist
intraven
idarubicin
cytosin
arabinosid
concurr
intrathec
metrotrex
cytosin
arabinosid
hydrocotison
subsequ
achiev
remiss
underw
hsct
match
relat
donor
receiv
busulfan
plu
cyclophosphamid
condit
regimen
twelv
month
transplant
develop
ataxia
mri
brain
spine
reveal
infiltr
lesion
size
cm
involv
superior
cerebellar
vermi
leptomening
enhanc
along
conu
medullari
bm
examin
reveal
remiss
biopsi
cerebellar
tumor
show
infiltr
leukem
cell
mix
phenotyp
b
lymphoblast
myeloid
ihe
receiv
whole
brain
cgi
spinal
cgi
radiat
current
remiss
year
relaps
conclus
risk
factor
isol
cn
relaps
patient
includ
condit
regimen
without
total
bodi
irradi
poor
cn
penetr
imatinib
given
rariti
treatment
entiti
yet
well
defin
summari
report
treatment
experi
pediatr
patient
isol
cn
relaps
cml
follow
hsct
k
thoma
result
two
hundr
eleven
children
diagnos
pre
b
evalu
cytogenet
follow
data
includ
studi
patient
hhallthos
along
hhall
exclud
analysi
median
age
diagnosi
year
high
wbc
count
cellsml
observ
hhall
nonhhal
differ
median
age
sex
ratio
group
median
durat
follow
year
children
hhall
relaps
compar
group
chromosom
commonli
affect
follow
x
tripl
trisomi
observ
patientssix
patient
addit
structur
abnorm
three
children
hhall
relaps
compar
nonhhal
group
one
isol
cn
combin
relaps
signific
differ
note
regard
site
relaps
two
group
earli
relaps
month
common
nonhhal
case
six
hhall
patient
addit
cytogenet
abnorm
poor
outcom
compar
without
signific
differ
ef
hhdall
vs
non
hhall
os
vs
two
group
preval
hhall
chromosom
involv
similar
previous
publish
literatur
pattern
relaps
seem
differ
hhall
although
statist
significantaddit
structur
abnorm
reduc
prognost
benefit
hhall
backgroundobject
aim
studi
examin
effect
revaccin
pediatr
patient
solid
tumor
least
month
cessat
treatment
designmethod
studi
perform
prospect
patient
solid
tumor
diphtheria
tetanu
acellular
pertussi
hepat
b
hepat
measlesmumpsrubella
mmr
varicella
vaccin
appli
patient
patient
variou
solid
tumor
patient
complet
protect
diphtheria
tetanu
vaccin
hepat
seroneg
patient
achiev
protect
antibodi
level
one
dose
diphtheria
tetanu
hepat
vaccin
patient
protect
pertussi
hepat
b
pertussi
patient
achiev
protect
antibodi
level
one
dose
hepat
b
vaccin
patient
seroposit
measl
one
dose
seroneg
patient
achiev
protect
vaccin
patient
seroposit
rubella
mump
respect
seroneg
patient
achiev
full
protect
rubella
mump
one
dose
fiftynin
point
four
percent
patient
seroposit
varicella
vaccin
becam
seroposit
one
extra
dose
conclus
studi
patient
good
antibodi
respons
diphtheria
tetanu
hepat
rubella
mump
vaccin
least
month
cessat
therapi
perform
one
booster
dose
vaccin
appear
suffici
group
protect
pertusi
hepat
b
measles
varicella
zoster
vaccin
moder
level
patient
show
differ
antibodi
respons
vaccin
depend
age
time
pass
cessat
treatment
primari
vaccin
statu
antibodi
level
follow
evalu
respons
obtain
booster
consid
decreas
loss
antibodi
level
designmethod
use
silico
analysi
famili
member
mrna
level
protein
express
complex
level
neuroblastoma
line
select
biomark
sensit
venetoclax
immunoprecipit
bim
displac
vitro
vivo
serv
efficaci
biomark
sensit
venetoclax
vivo
experi
perform
nmri
nunu
mice
subcutan
kcnr
xenograft
result
show
venetoclax
induc
strong
apoptot
respons
cell
line
high
express
level
indic
dosedepend
cytochrom
c
releas
mitochondria
cytoplasm
parp
cleavag
vitro
efficaci
compound
ascertain
bim
displac
combin
venetoclax
cytostat
use
neuroblastoma
treatment
show
synergist
respons
venetoclax
significantli
inhibit
growth
high
express
neuroblastoma
xenograft
mice
despit
complet
displac
bim
increas
cleav
caspas
level
complet
tumour
regress
observ
conclus
taken
togeth
find
suggest
inhibit
venetoclax
strongli
induc
cell
death
neuroblastoma
cell
express
high
level
howev
resist
compound
occur
indic
necess
combin
treatment
target
inhibitor
cytostat
overcom
neuroblastoma
resist
venetoclax
c
bongulwar
backgroundobject
semiquantit
studi
use
mibg
score
devis
easi
use
short
train
time
reliabl
reproduc
facilit
comparison
result
obtain
differ
investig
centr
readili
adapt
multicent
use
valid
purpos
initi
evolv
score
system
includ
french
group
curi
score
curi
institut
franc
recent
evolv
siopen
score
aim
present
studi
comparison
modifi
curi
siopen
score
indian
patient
popul
term
interscor
interobserv
reliabl
correl
progress
free
surviv
designmethod
data
mibg
scan
patient
retrospect
analyz
patient
diagnos
suspect
stage
iv
high
risk
neuroblastoma
initi
stage
post
induct
follow
suspect
recurr
known
mibg
avid
diseas
score
assess
interscor
inter
observ
variabl
use
spearman
coeffici
variat
absolut
rel
score
post
therapi
score
divid
pre
therapi
score
obtain
correl
progress
free
surviv
use
kaplan
meier
surviv
analysi
done
result
score
result
highli
correl
method
inter
observ
reliabl
excel
initi
stage
post
induct
curi
score
siopen
score
best
cut
post
induct
correl
significantli
better
progress
free
survivalpati
lower
initi
score
like
reach
complet
remiss
end
induct
achiev
low
mibg
score
import
achiev
specifi
reduct
mibg
score
modifi
curi
score
siopen
score
excel
inter
observ
reliabl
excel
interscor
comparison
score
system
post
induct
correl
event
free
surviv
backgroundobject
bortezomib
proteasom
inhibitor
inhibit
cell
growth
angiogenesi
neuroblastoma
cell
aim
studi
evalu
safeti
efficaci
bortezomib
base
chemotherapi
relaps
neuroblastoma
bridg
mibg
therapi
autolog
stem
cell
transplant
sct
designmethod
children
relaps
neuroblastoma
treat
least
cours
chemotherapi
bortezomib
mgmt
cyclophosphamid
mg
mt
etoposid
mg
alltran
retino
acid
atra
mg
mt
take
inform
consent
parent
data
regard
side
effect
nci
grade
collect
prospect
respons
assess
cours
petct
scan
bone
marrow
bm
examin
result
three
children
relaps
autolog
sct
given
total
six
cours
median
age
year
site
relaps
mean
durat
hospit
stay
dayscycl
oral
mucos
thrombocytopenia
note
neutropenia
seen
cycl
sepsi
workup
neg
children
cycl
one
child
cycl
develop
invas
aspergillosi
one
grade
neurotox
form
selflimit
hallucin
normal
mri
brain
petct
post
cycl
could
done
third
child
move
anoth
centr
show
markedli
decreas
fgd
avid
lesion
bm
neg
tumor
cell
case
success
underw
mibg
therapi
combin
myeloabl
chemotherapi
follow
autolog
sct
one
haploident
sct
conclus
bortezomib
base
chemotherapi
safe
use
treat
relaps
neuroblastoma
accept
side
effect
efficaci
seem
good
bridg
mibg
sct
need
confirm
set
multicentr
clinic
trial
backgroundobject
neuroblastoma
repres
frequent
diagnos
solid
tumor
infant
chemoresist
major
obstacl
treat
high
risk
neuroblastoma
sever
studi
indic
deviant
express
certain
mirna
correl
poor
clinic
outcom
neuroblastoma
howev
role
mirna
neuroblastoma
cell
resist
chemotherapeut
drug
poorli
understood
understand
biolog
molecular
aspect
mirnamedi
drug
resist
neuroblastoma
may
provid
excit
opportun
therapi
aggress
neuroblastoma
aim
studi
determin
potenti
mirna
could
link
chemoresist
neuroblastoma
designmethod
investig
role
mirna
drug
resist
neuroblastoma
ten
neuroblastoma
cell
line
use
cell
line
consist
five
isogen
pair
isol
patient
treatment
relaps
result
mirna
cdna
librari
gener
neuroblastoma
cell
line
use
studi
identifi
differenti
express
mirna
cell
line
deriv
patient
chemotherapi
deep
sequenc
analysi
solid
sequenc
perform
use
mirna
cdna
librari
analyz
mirna
express
data
context
known
biolog
function
ingenu
pathway
analysi
ipa
use
conclus
differenti
express
mirna
upon
chemotherapi
neuroblastoma
cell
line
predict
alter
biolog
function
associ
drug
resist
manipul
one
mirna
could
potenti
new
therapeut
approach
overcom
neuroblastoma
chemoresist
backgroundobject
evalu
setup
error
pediatr
patient
neuroblastoma
use
cone
beam
ct
imag
cbct
discuss
margin
ctv
ptv
refer
treatment
plan
design
designmethod
ten
neuroblastoma
patient
select
octob
may
underw
daili
pretreat
local
cbct
posttreat
cbct
local
base
cbct
treatment
plan
ct
registr
setup
error
mediallater
ml
superiorinferior
si
anteriorposterior
ap
direct
obtain
interfract
intrafract
posit
error
calcul
base
weekli
daili
imag
result
later
longitudin
vertic
setup
error
mm
mm
mm
requir
weekli
cbct
daili
cbct
incorpor
setup
error
reduc
mm
mm
conclus
daili
local
base
cbct
reduc
requir
setup
error
neuroblastoma
patient
reduc
margin
ctv
ptv
therebi
reduc
normal
tissu
exposur
patient
particularli
import
pediatr
patient
intern
margin
need
investig
margin
ctv
ptv
backgroundobject
patient
lowrisk
neuroblastoma
repres
patient
surgeri
main
method
therapi
reduc
proport
patient
requir
chemotherapi
prioriti
purpos
studi
analyz
treatment
outcom
group
patient
lowrisk
neuroblastoma
treat
singl
oncolog
center
russia
designmethod
period
patient
neuroblastoma
observ
treat
intern
neuroblastoma
stage
system
criteria
use
stage
respons
evalu
patient
alloc
risk
group
base
criteria
german
neuroblastoma
studi
group
treat
accord
protocol
result
tumor
categor
group
accord
high
low
mir
express
level
base
cutoff
point
optim
criterion
determin
roc
analysi
found
downregul
associ
signific
reduct
overal
surviv
os
patient
overexpress
regardless
mna
notmna
neuroblastoma
low
express
os
lower
downregul
case
compar
high
express
neuroblastoma
exclud
impact
regul
found
high
level
express
correl
signific
decreas
os
os
rate
patient
high
express
compar
low
express
p
event
free
surviv
ef
rate
patient
high
express
compar
low
express
p
effect
express
os
rate
neuroblastoma
patient
reveal
conclus
result
suggest
possibl
use
level
express
neuroblastoma
prognost
risk
group
stratif
marker
kock
k
larsson
j
raouf
korotkova
ji
johnsen
pj
jakobsson
p
kogner
backgroundobject
highrisk
neuroblastoma
often
poor
prognosi
older
children
delet
tumor
show
resist
induct
chemotherapi
late
relaps
poor
outcom
despit
intensifi
treatment
although
adult
cancer
show
inflammatori
microenviron
knowledg
limit
potenti
signific
inflamm
childhood
malign
designmethod
human
tumor
analys
express
proinflammatori
lipid
mediat
xenograft
nude
mice
spontan
tumor
transgen
mice
treat
specif
inhibitor
inflammatori
pathway
result
highrisk
neuroblastoma
show
high
express
enzym
involv
product
proinflammatori
lipid
mediat
includ
microsom
prostaglandin
e
major
enzym
convert
prostaglandin
prostaglandin
lack
express
metabol
enzym
dehydrogenas
result
high
concentr
high
low
correspond
poor
surviv
delet
tumor
show
significantli
higher
subset
neuroblastoma
microenviron
show
abund
occurr
immunosuppress
macrophag
myeloidderiv
suppressor
cell
express
cell
indic
cancer
associ
fibroblast
caf
express
vimentin
fibroblast
activ
protein
fap
alpha
smooth
muscl
actin
plateletderiv
growth
factor
receptor
beta
specif
target
coxinhibit
celecoxib
novel
specif
inhibitor
significantli
delay
tumor
growth
vivo
tumor
weight
reduc
sacrific
transgen
thmycn
mice
nude
mice
delet
xenograft
compar
untreat
control
anim
treat
tumor
show
signific
decreas
macrophag
reduc
angiogenesi
found
high
prostaglandin
product
express
microsom
prostaglandin
e
coupl
highrisk
neuroblastoma
tumor
infiltr
cancerassoci
fibroblast
contribut
neuroblastoma
inflamm
microenviron
inflammatori
pathway
play
crucial
role
cancerrel
inflamm
provid
specif
therapeut
target
antiinflammatori
drug
combin
current
treatment
consid
novel
highrisk
neuroblastoma
therapi
backgroundobject
common
cytogenet
lesion
embryon
neural
tumor
medulloblastoma
mb
neuroblastoma
nb
affect
chromosom
isochromosom
approxim
onethird
mb
aberr
signific
indic
poor
clinic
outcom
similarli
nb
gain
power
genet
predictor
advers
clinic
outcom
correl
poor
surviv
populationbas
materi
found
aberr
chromosom
primari
neuroblastoma
specif
gain
serinethreonin
phosphatas
encod
gene
describ
gatekeep
regulatori
loop
involv
genet
stabil
inflamm
potenti
oncogen
contribut
carcinogenesi
designmethod
compar
genom
hybrid
cgh
use
examin
neuroblastoma
medulloblastoma
tumor
cell
line
knockdown
sknbe
cell
gener
shrna
transfect
test
vivo
tumor
xenograft
pharmacolog
inhibit
modul
inhibitor
rita
new
inhibitor
use
evalu
function
preclin
model
result
cgharray
analysi
detect
extra
copi
tumor
cell
line
contain
tumor
neuroblastoma
xenograft
develop
significantli
delay
show
median
tumor
develop
ml
doubl
median
day
vs
day
p
downregul
compar
scrambl
control
novel
inhibitor
highli
potent
cytotoxiccytostat
effect
varieti
neuroblastoma
medulloblastoma
cell
line
furthermor
inhibitor
significantli
inhibit
growth
establish
human
neuroblastomaand
medulloblastoma
tumor
nude
mice
treatment
p
result
show
oncogen
neuroblastoma
medulloblastoma
develop
provid
novel
therapeut
target
two
childhood
cancer
nervou
system
studi
investig
effect
inhibit
need
evalu
clinic
signific
evalu
quickli
without
gap
studi
evolut
beaconneuroblastoma
trial
relapsedrefractori
neuroblastoma
describ
result
beaconneuroblastoma
start
factori
trial
investig
role
two
agent
ad
backbon
temozolomid
chemotherapi
relapsedrefractori
neuroblastoma
bevacizumab
jung
design
irinotecan
likelihoodbas
bayesian
design
phase
ii
trial
obtain
initi
evid
activ
respons
becom
phase
iii
trial
evalu
efficaci
eventfre
surviv
agentsregimen
meet
phase
ii
success
criteria
result
recent
publish
promis
result
combin
topotecan
temozolomid
totem
beaconneuroblastoma
amend
factori
design
evalu
combin
addit
two
exist
question
recruit
target
initi
patient
comparison
amend
increas
sampl
size
patient
comparison
durat
studi
two
four
year
successor
beaconneuroblastoma
expand
approach
becom
ongo
mam
trial
adapt
design
beaconneuroblastoma
successor
allow
multipl
agent
evalu
quickli
effici
ineffect
one
drop
new
one
brought
becom
avail
roll
programm
research
backgroundobject
current
investig
feasibl
use
tandem
highdos
chemotherapi
treatment
mani
malign
solid
tumor
medulloblastoma
germ
cell
tumor
soft
tissu
sarcoma
highrisk
neuroblastoma
nevertheless
effect
convinc
result
nt
obtain
designmethod
year
depart
pediatr
oncolog
nation
cancer
institut
carri
tandem
transplant
tt
children
highrisk
neuroblastoma
patient
age
year
pt
primari
neuroblastoma
got
tt
chemotherapi
protocol
pt
consolid
relaps
secondlin
therapi
first
part
tandem
transplant
bumel
patient
twelv
patient
topotecanbas
regimen
second
part
tandem
transplant
three
patient
cem
regimen
time
interv
part
tandem
month
autolog
transplant
use
peripher
stem
cell
patient
receiv
retino
acid
convent
treatment
result
patient
success
complet
highdos
chemotherapi
neutropenia
thrombocytopenia
th
rate
oral
mucos
differ
degre
sever
patient
wbc
count
recov
first
cycl
day
plt
count
recov
day
patient
observ
neurotox
like
short
clonic
tonic
seizur
second
cycl
wbc
count
recov
second
cycl
day
plt
count
recov
day
current
patient
cr
patient
earli
relaps
continu
treatment
die
pd
followup
period
accomplish
tt
month
conclus
applic
tt
children
highrisk
neuroblastoma
result
threeyear
diseasefre
surviv
rate
overal
fouryear
surviv
rate
possibl
mibg
therapi
antibodi
therapi
use
tandem
transplant
provid
opportun
improv
outcom
case
chylou
fistula
patient
treat
conserv
approach
durat
drainag
significantli
associ
surgic
radic
furthermor
durat
drainag
significantli
associ
maximum
amount
fluid
drain
per
h
lymphat
fistula
significantli
associ
inss
stage
overal
surviv
os
demonstr
better
os
patient
without
aliv
pt
aliv
os
significantli
associ
maximum
amount
fluid
drain
per
hr
durat
drainag
conclus
frequent
complic
neuroblastoma
surgeri
case
substanti
loss
fluid
protein
treat
nearli
case
conserv
one
major
problem
delay
chemotherapi
radiat
howev
seem
great
impact
prognosi
backgroundobject
n
myc
amplif
one
factor
util
risk
stratif
neuroblastoma
molecular
profil
take
day
henc
possibl
predict
express
surrog
marker
could
help
earli
manag
decis
evalu
possibl
flurodeoxi
glucos
positron
emiss
tomographycomput
tomographi
fdg
petct
uptak
use
semiquantit
maximum
standard
uptak
valu
suv
max
surrog
marker
mycn
express
neuroblastoma
designmethod
method
retrospect
analysi
patient
neuroblastoma
male
femal
patient
month
age
part
hospit
protocol
done
correl
suv
max
primari
tumor
baselin
fdg
petct
studi
mycn
express
suv
max
primari
tumor
note
compar
mycn
amplif
done
use
pcr
fish
biopsi
sampl
paramet
analys
use
mann
whitney
u
test
cut
valu
suv
predict
express
mycn
dentifi
use
roc
curv
method
suv
max
rang
patient
mean
patient
show
fdg
uptak
mycn
express
patient
whose
suv
rang
median
mycn
express
rang
median
statist
analysi
use
mann
whitney
test
reveal
higher
suv
parament
correl
mycn
express
suv
cut
posit
mycn
calcul
specif
sensit
conclus
pilot
studi
show
correl
suv
mycn
patient
express
mycn
tend
show
higher
suv
level
small
sampl
size
deriv
suv
cut
predict
mycn
express
howev
need
valid
prospect
larg
popul
backgroundobject
program
death
protein
tcell
coinhibitori
receptor
one
ligand
play
pivot
role
abil
tumor
cell
evad
host
immun
system
investig
express
neuroblastoma
cell
immunohistochemistri
designmethod
fortyon
nb
patient
diagnos
treat
includ
studi
ten
patient
underw
primari
oper
po
remain
patient
patient
receiv
biopsi
alon
patient
underw
delay
primari
oper
chemotherapi
protein
express
detect
immunohistochemistri
formalinfix
paraffinembed
specimen
use
antihuman
monoclon
antibodi
tumor
posit
defin
tumor
cell
membran
stain
statist
analys
perform
use
fisher
exact
test
result
four
neuroblastoma
section
collect
po
posit
one
biopsi
specimen
posit
thu
demonstr
posit
specimen
obtain
chemotherapi
howev
specimen
obtain
posit
p
biopsi
specimen
vs
specimen
posit
specimen
obtain
relaps
occur
relaps
observ
patient
contrast
recurr
occur
patient
accord
find
neg
specimen
statist
correl
express
incid
relaps
thu
observ
ns
result
indic
primari
neuroblastoma
express
express
found
increas
chemotherapi
although
express
correl
recurr
may
nevertheless
backgroundobject
hepat
venoocclus
diseas
vod
sinusoid
obstruct
syndrom
unpredict
lifethreaten
complic
hematopoiet
stem
cell
transplant
hsct
sever
vod
svod
associ
mortal
character
clinic
multiorgan
failur
mof
european
union
defibrotid
approv
treatment
svod
hsct
unit
state
defibrotid
avail
ongo
expandedaccess
protocoldirect
treatment
ind
tind
studi
tind
surviv
post
hsctchemotherapi
analyz
pediatricadult
subgroup
designmethod
patient
receiv
defibrotid
mgkgday
day
recommend
elig
origin
svod
mof
renalpulmonari
baltimor
criteria
post
hsct
amend
includ
patient
post
hsctchemotherapi
nonsvod
without
mof
vod
per
modifi
seattl
criteria
biopsyproven
vod
result
patient
enrol
receiv
dose
median
treatment
durat
day
age
data
pediatr
age
adult
among
pediatr
adult
patient
post
hsct
surviv
respect
svod
occur
children
adult
among
svod
nonsvod
posthsct
subgroup
respect
pediatr
surviv
adult
surviv
pediatr
adult
patient
post
chemotherapi
surviv
respect
svod
subgroup
rate
advers
event
ae
occur
children
adult
treatmentrel
ae
respect
seriou
ae
occur
children
common
nonvodnonmof
pulmonari
hemorrhag
adult
common
nonvodnonmof
hypotens
conclus
defibrotid
gener
well
toler
manag
toxic
higher
surviv
rate
nonsvod
subset
indic
studi
warrant
determin
impact
treatment
earlier
cours
vod
tind
enrol
continu
support
jazz
pharmaceut
backgroundobject
plerixafor
select
revers
antagonist
capabl
interf
interact
stromal
cellderiv
factor
alpha
therefor
use
combin
granulocytecoloni
stimul
factor
gcsf
capabl
amplifi
effect
gcsf
mobil
haematopoiet
stem
cell
retrospect
review
singl
centr
experi
plerixafor
gcsf
mobil
stem
cell
five
extrem
heavi
pretreat
oncolog
patient
primari
method
mobil
designmethod
patient
start
gcsf
day
prior
first
administr
plerixafor
plerixafor
administ
mgkg
first
day
apheresi
administ
subsequ
day
stem
cell
harvest
requir
result
patient
mobil
day
alon
achiev
kg
patient
continu
rise
level
demonstr
day
apheresi
increment
number
achiev
day
although
measur
level
preharvest
show
drop
patient
patient
mobil
extrem
well
day
alon
yield
posit
stem
cell
dose
requir
apheresi
patient
develop
sign
symptom
hypocalcaemia
correct
oral
calcium
correct
whilst
patient
harvest
requir
phosphat
potassium
correct
conclus
plexiaflor
combin
gcsf
shown
encourag
result
small
select
patient
heavili
pretreat
prior
undertak
stem
cell
mobilis
regimen
although
small
cohort
patient
data
obtain
provid
foundat
futur
research
within
larger
patient
group
review
medic
error
depart
show
medic
error
primarili
relat
error
prescript
discov
dispens
step
nurs
administr
parent
order
optim
patient
safeti
depart
pharmaci
initi
project
pharmacist
review
medic
designmethod
purpos
project
ensur
prescript
error
discov
correct
dispens
administr
correct
eventu
error
dialogu
prescrib
physician
b
ensur
best
practic
drug
prescrib
c
ensur
effect
appropri
use
medicinestwo
pharmacist
review
medicin
prescrib
admit
children
everi
weekday
review
medic
priorit
follow
children
complex
treatment
unstabl
diseas
recent
admit
children
children
transfer
depart
within
day
case
inappropri
prescript
pharmacist
contact
respons
physician
order
chang
prescript
relev
review
record
central
databas
date
age
child
devianc
best
practic
intervent
accept
physician
result
within
period
februari
prescript
review
deviat
best
practic
error
prescrib
dose
incorrect
durat
treatment
found
accept
physician
remain
find
concern
side
effect
dispens
interv
formul
drug
interact
drug
conclus
review
prescrib
medic
paediatr
oncolog
depart
collabor
pharmacist
prescrib
doctor
improv
qualiti
medic
reduc
advers
event
patient
ask
perform
standard
oral
care
soc
upon
first
day
chemotherapi
day
oral
mucosa
assess
daili
upon
complet
chemotherapi
base
world
health
organ
scale
oral
mucos
patient
receiv
chemotherapeut
agent
second
cours
chemotherapi
ask
gurgl
use
ab
four
time
daili
addit
soc
mucosa
rate
perform
second
chemotherapi
cours
period
mucos
becam
intens
blood
sampl
drawn
measur
citrullin
level
result
stage
oral
mucos
found
lower
second
chemotherapi
cours
given
soc
plu
ab
compar
first
chemotherapi
cours
given
soc
alon
mean
plasma
citrullin
level
obtain
chemotherapi
decreas
nmolml
chemotherapi
cours
given
soc
alon
p
decreas
nmolml
extent
decreas
plasma
citrullin
level
assess
greater
cours
given
soc
alon
compar
given
soc
plu
ab
conclus
base
result
ab
exhibit
benefici
effect
prophylaxi
treatment
oral
mucos
howev
multicent
experi
studi
larger
sampl
size
need
introduct
ab
primari
oral
care
treatment
protocol
oral
mucos
improv
qualiti
treatment
care
team
clinic
pharmacist
involv
pho
unit
univers
hospit
leuven
guarante
optim
continu
standard
interview
essenti
designmethod
differ
type
interview
defin
first
discharg
interview
basic
discharg
interview
startup
corticosteroid
startup
oral
chemotherapeut
mainten
therapi
taper
corticosteroid
interview
pharmacist
regist
patient
type
interview
result
februari
januari
patient
year
follow
new
diagnos
patient
alreadi
treatment
total
interview
perform
greatest
attent
paid
basic
discharg
interview
follow
startup
corticosteroid
first
discharg
interview
interview
done
hospit
interview
perform
dayclin
conclus
given
great
amount
interview
fulltim
presenc
clinic
pharmacist
pho
unit
need
interview
discharg
interview
perform
team
pharmacist
structur
approach
interview
need
guarante
content
qualiti
near
futur
qualit
survey
carri
physician
nurs
patient
famili
evalu
content
interviewsthi
project
fund
nationalcancerplan
kinderkankerfond
leuven
aston
backgroundobject
everi
member
paediatr
oncolog
nurs
team
play
vital
role
deliv
best
care
patient
within
paediatr
oncolog
role
clinic
support
worker
staff
nurs
senior
sister
everi
level
compet
nurs
staff
impact
influenc
shape
practic
deliv
patient
famili
model
servic
deliv
paramount
designmethod
role
clinic
support
worker
undergon
mani
chang
throughout
time
clinic
role
nonclin
role
back
current
challeng
climat
less
qualifi
nurs
avail
employ
role
clinic
support
worker
need
develop
adapt
underpin
support
role
qualifi
paediatr
oncolog
nurs
person
experi
career
start
clinic
support
worker
progress
ward
manag
author
great
insight
understand
role
clinic
support
worker
within
paediatr
oncolog
entail
result
increas
number
clinic
support
worker
employ
undertak
trust
wide
educ
develop
programm
aim
support
recruit
retent
clinic
support
worker
nurs
staff
shape
tailor
train
educ
programm
within
paediatr
oncolog
clinic
support
worker
endeavour
compliment
clinic
support
worker
role
play
essenti
part
deliveri
care
assist
nurs
staff
clinic
duti
also
support
patient
parent
journey
ever
chang
cultur
fewer
nurs
come
nurs
train
programm
role
clinic
support
worker
paediatr
oncolog
pivot
ever
deliv
influenc
shape
best
care
within
paediatr
oncolog
first
howev
avail
reliabl
valid
instrument
accur
assess
fatigu
crucial
intervent
plan
evalu
studi
aim
examin
psychometr
properti
chines
version
fatigu
scale
adolesc
fsa
assess
factori
structur
confirmatori
factor
analysi
cfa
designmethod
crosssect
studi
design
employ
outpati
clinic
conveni
sampl
two
hundr
adolesc
surviv
cancer
invit
particip
intern
consist
testretest
reliabl
content
valid
construct
valid
chines
version
fsa
assess
result
cronbach
alpha
coeffici
intraclass
correl
coeffici
respect
content
valid
index
strong
posit
correl
r
score
adolesc
fatigu
depress
strong
neg
correl
r
score
adolesc
fatigu
qol
mean
score
fatigu
survivor
found
significantli
lower
children
receiv
cancer
treatment
significantli
higher
healthi
counterpart
result
cfa
show
fourfactor
model
adequ
fit
data
obtain
chines
version
fsa
indic
factori
structur
origin
version
result
provid
evid
support
chines
version
fsa
reliabl
valid
instrument
assess
fatigu
among
adolesc
surviv
cancer
backgroundobject
child
cancer
feel
need
know
go
even
famili
tri
hide
diagnosi
inform
child
diseas
increas
cooper
reduc
passiv
also
increas
control
situat
major
avail
inform
nt
adequ
necessari
establish
pattern
abl
homogen
mean
word
phrase
symbol
contribut
minim
barrier
understand
provid
effici
reliabl
mean
inform
exchang
purpos
base
inform
architectur
consist
design
share
inform
environ
seek
ensur
comfort
first
secondli
technolog
inform
design
equat
syntact
semant
pragmat
aspect
audienc
designmethod
compil
necessari
relev
inform
patient
famili
beabook
born
educ
booklet
consist
oncolog
word
term
method
use
develop
materi
includ
categor
label
taxonomi
perspect
knowledg
manag
lexivisu
interfac
stage
product
process
creation
product
valid
approvalth
target
audienc
effect
particip
beabook
implement
process
collect
data
theoret
approach
qualit
analysi
product
expect
open
way
patient
famili
contribut
provid
good
qualiti
inform
nt
enough
necessari
avail
appropri
target
audienc
reflect
think
knowledg
skill
relat
subject
investig
consequ
contrari
propos
object
crisi
contemporari
societi
reflect
difficulti
transform
data
inform
knowledg
necessari
consid
architectur
design
inform
disciplin
addit
effect
consum
particip
creativ
product
process
nordoff
backgroundobject
number
children
young
peopl
cyp
oncolog
diagnosi
receiv
anaesthesia
lumbar
punctur
lp
intrathec
agent
bone
marrow
aspir
bma
increas
due
implement
ukal
protocol
howev
number
nurs
within
daycar
dc
set
compet
recov
cyp
post
anaesthesia
repres
increas
patient
number
standardis
develop
pathway
compet
document
support
train
paediatr
recoveri
nurs
within
dc
set
ptc
requir
designmethod
data
collat
ptc
organisationsassoci
compet
document
pathway
avail
recoveri
nurs
develop
within
oncolog
dc
set
includ
explor
extern
coursessimul
day
avail
recoveri
nurs
result
establish
nation
local
compet
role
develop
pathway
specif
paediatr
oncolog
recoveri
nurs
within
dc
set
avail
extern
coursessimul
day
found
costli
meet
requir
role
within
dc
conclus
support
anaesthet
team
compet
document
produc
ratifi
trust
document
confirm
key
skill
knowledg
requir
recoveri
cyp
within
oncolog
dc
set
complet
alongsid
annual
complianc
complet
paediatr
intermedi
life
support
studi
day
stabilis
deterior
child
achiev
local
level
save
time
financ
meet
oper
demand
continu
role
develop
oncolog
dc
nurs
shown
aid
job
satisfact
increas
opportun
vari
role
result
greater
nurs
retent
develop
innov
document
also
ensur
patient
famili
receiv
personalis
holist
oncolog
journey
care
provid
within
one
clinic
unit
multiskil
nurs
know
specif
need
care
requir
cyp
month
month
everi
month
ccss
visit
clinic
late
effect
cancer
treatmentcurr
state
full
time
worker
part
time
worker
student
selfemploy
unemploy
backgroundobject
research
suggest
parent
children
cancer
prone
feel
anxieti
depress
uncertain
children
live
treatment
work
due
vulner
may
perceiv
child
experienc
poor
hrqol
turn
could
affect
child
treatment
outcom
roy
adapt
model
mishel
uncertainti
ill
theori
guid
theoret
framework
studi
designmethod
studi
util
longitudin
exploratori
design
onehundr
newli
diagnos
children
cancer
age
year
receiv
care
boston
children
hospit
recruit
aim
describ
child
hrqol
time
diagnosi
month
month
diagnosi
describ
relationship
parent
uncertainti
hrqol
children
cancer
relationship
chang
time
determin
degre
concord
child
selfreport
parent
proxi
report
hrqol
determin
perceiv
social
support
trait
anxieti
depress
function
moder
parent
uncertainti
hrqol
children
cancer
parent
complet
beck
depress
inventori
multidimension
scale
perceiv
social
support
statetrait
anxieti
inventori
adult
baselin
children
parent
complet
pediatr
qualiti
life
inventori
cancer
modul
scale
parent
complet
parent
percept
uncertainti
ill
scale
within
first
two
week
diagnosi
month
month
diagnosi
studi
ongo
howev
baselin
assess
data
present
relationship
parent
uncertainti
children
hrqol
understood
intervent
develop
help
famili
longterm
goal
improv
children
hrqol
h
pearson
backgroundobject
palli
care
children
cancer
rare
hospit
centr
predomin
care
provid
commun
hospic
set
vast
research
look
experi
children
nurs
provid
palli
care
within
child
home
environ
hospic
research
suggest
nurs
need
adequ
support
avoid
stress
burnout
parent
view
focu
nurs
attribut
oppos
clinic
skill
requir
research
studi
want
ascertain
whether
specif
educ
prepar
support
need
prepar
children
cancer
nurs
provid
palli
care
acut
hospit
set
designmethod
research
studi
use
qualit
approach
semistructur
depth
interview
across
three
primari
treatment
centr
within
unit
kingdom
provid
cancer
care
childrendata
collect
analys
use
phenomenolog
approach
data
collect
octob
februari
interview
took
place
particip
prefer
locat
last
forti
five
sixti
minut
data
analys
use
strauss
corbin
method
result
five
theme
emerg
lack
plan
manag
symptom
famili
experi
categori
within
theme
devis
particip
narr
find
research
studi
suggest
nurs
need
specif
palli
care
educ
preregistr
level
also
continu
profession
develop
particip
suppos
examin
assign
prefer
base
clinic
experi
need
particular
assign
focus
sibl
notic
entir
famili
affect
child
suffer
lifethreaten
ill
aim
exam
therefor
explor
sibl
experi
brother
sister
life
threaten
diseas
designmethod
literatur
review
conduct
eight
articl
focus
sibl
age
year
brother
sister
life
threaten
diseas
sibl
express
anxieti
regard
ill
brother
sister
die
felt
anxieti
parent
wellb
also
regard
would
becom
ill
well
describ
famili
life
routin
chang
parent
absent
sibl
took
much
greater
respons
home
time
describ
famili
got
better
cohes
sibl
difficulti
school
concentr
homework
want
particip
care
brothersist
need
better
medic
inform
diagnosi
onward
sibl
also
express
need
support
extend
famili
member
friend
well
adult
result
research
integr
care
environ
nurs
main
concern
famili
opportun
particip
studi
nurs
believ
would
benefici
child
famili
obtain
inform
consent
nurs
balanc
advocaci
patern
nurs
use
number
strategi
order
make
sure
inform
consent
obtain
includ
adapt
inform
gentli
introduc
research
sell
research
conclus
languag
barrier
psycholog
barrier
impact
famili
abil
give
inform
consent
immedi
risk
nurs
give
weight
patern
balanc
advocaci
furthermor
problem
meet
child
right
abl
give
consent
particip
research
studi
near
futur
care
pediatr
oncolog
patient
netherland
central
pmc
becom
largest
center
europein
central
process
nurs
staff
academ
hospit
merg
new
motiv
team
team
challeng
larg
varieti
care
withdraw
blood
central
line
flush
afterward
varieti
caus
differ
experi
approach
academ
hospit
aim
harmon
protocol
work
uniformtherefor
purpos
project
defin
import
differ
care
reinforc
conform
develop
evidencebas
protocol
highli
variabl
practic
designmethod
weekli
evidencebas
practic
ebp
meet
held
two
nurs
ebp
experi
train
chair
meet
support
experienc
clinic
research
base
structur
discuss
nurs
team
defin
import
differ
care
thereaft
uncertainti
priorit
patientinterventioncomparisonoutcom
pico
made
pico
one
nurs
subsequ
review
avail
evid
prepar
critic
apprais
topic
cat
depend
result
cat
lead
new
evidencebas
care
protocol
result
sinc
januari
defin
larg
varieti
care
ebp
meet
result
present
confer
exampl
remark
differ
care
academ
hospitalsth
prioriti
pico
ebp
meetingsexampl
chang
care
conclus
project
show
way
solv
differ
care
protocol
new
larg
pediatr
oncolog
center
improv
conform
ensur
high
qualiti
uptod
protocol
score
meet
occasion
meet
meet
regular
basi
appli
standard
result
pow
pmh
meet
six
standard
regular
basi
score
neither
orient
pow
nurs
nurs
polici
procedur
locat
pow
score
pow
occasion
met
nurs
patient
ratio
although
nurs
alway
oncolog
train
score
continu
educ
avail
hour
annual
prescrib
standard
score
nurs
includ
part
multidisciplinari
team
howev
dedic
paediatr
oncolog
nurs
score
although
improv
made
includ
hand
sanit
environment
ward
defici
remain
includ
limit
person
protect
equip
isol
facil
score
conclus
base
sioppodc
criteria
pmh
current
meet
standard
paediatr
oncolog
nurs
avail
oncolog
train
curricula
dedic
paediatr
oncolog
unit
mentorship
twin
partnership
paediatrictrain
nurs
make
reach
standard
realiti
hospit
auckland
new
zealand
starship
children
hospit
starship
simul
depart
auckland
new
zealand
backgroundobject
much
publish
posit
effect
teamtrain
simul
healthcar
set
healthcar
team
commun
effici
expect
improv
team
process
lead
better
patient
outcom
decreas
advers
event
siop
confer
held
auckland
deleg
given
opportun
take
part
trial
human
factor
teamtrain
simul
session
design
specif
paediatr
oncolog
environ
interest
amongst
deleg
high
major
state
increasingli
want
activ
learn
opportun
bedsid
designmethod
find
trial
session
run
siop
confer
lead
us
develop
perman
paediatr
oncolog
programm
build
foundat
alreadi
laid
starship
simul
team
abl
take
work
area
hospit
tailor
specif
need
take
insitu
human
factor
teamtrain
bedsid
allow
us
meld
togeth
combin
differ
learn
style
enabl
us
demonstr
improv
patient
manag
bedsid
result
appli
principl
crisi
resourc
manag
note
respons
manag
deterior
child
improv
greatli
standardis
teach
model
abl
creat
standard
approach
care
also
evid
improv
commun
within
team
lead
quicker
identif
manag
deterior
child
within
one
year
built
insitu
human
factor
simul
programm
paediatr
oncolog
environ
previous
uncertainti
fear
around
simul
willing
embrac
insitu
simul
varieti
differ
educ
techniqu
backgroundobject
issu
transit
central
theme
repeat
experi
survivorship
follow
childhood
cancer
treatment
mani
case
involv
transit
activ
treatment
surveil
long
term
follow
upsupport
self
manag
well
transit
across
paediatr
teenag
adult
servic
final
transit
differ
childhood
diseas
cancer
longer
problem
howev
potenti
complex
outcom
creat
depend
paediatr
oncolog
set
may
delay
transit
process
late
adolesc
earli
adulthood
staff
work
singl
paediatr
oncolog
centr
uk
reflect
multipl
transit
depend
meet
ongo
need
adulthood
progress
could
smoother
proactiv
user
focus
clinic
nurs
insert
cannula
administ
vincristin
check
second
nurs
step
incur
long
period
wait
patient
famili
busi
treatment
clinic
nursel
clinic
set
improv
patient
pathway
eas
congest
consultantl
clinic
designmethod
follow
initi
written
consult
referr
children
book
minut
appoint
everi
week
child
review
anp
vcr
given
immedi
consult
anp
act
second
checker
cannul
nurs
children
elig
clinic
receiv
dose
vcr
dexamethason
patient
signific
toxic
receiv
dose
remain
consultantl
clinic
clinic
first
week
famili
offer
opportun
complet
hospit
friend
famili
survey
data
collect
ascertain
length
time
patient
spent
clinic
also
collect
patient
attend
consultantl
clinic
enabl
data
comparison
result
clinic
attend
averag
time
spent
nursel
clinic
minut
compar
hour
minut
consultantl
clinic
patient
seen
averag
within
minut
appoint
time
compar
minut
consult
parent
complet
hospit
friend
famili
survey
said
extrem
like
recommend
servic
other
data
collect
demonstr
nursel
clinic
provid
time
effici
servic
without
compromis
patient
famili
satisfact
center
provid
cultur
sensit
languag
appropri
train
ongo
mentor
pediatr
oncolog
nurs
educ
role
pioneer
latin
america
program
designmethod
effort
assess
nurs
educ
role
program
intern
outreach
program
partner
site
includ
outsid
latin
america
intern
outreach
nurs
program
conduct
audit
webbas
survey
survey
assess
orient
program
continu
educ
content
nurs
educ
role
respons
satisfact
nurs
patient
ratio
thirtytwo
nurs
educ
andor
administr
twentyf
hospit
nineteen
countri
invit
particip
survey
result
respons
receiv
twenti
nurs
repres
sixteen
countri
six
lowermiddl
incom
countri
thirteen
uppermiddl
incom
countri
one
high
incom
countri
fourteen
report
pediatr
oncolog
nurs
orient
program
addit
hospitalbas
orient
program
survey
orient
defin
two
week
pediatr
oncolog
educ
addit
hospit
orient
fourteen
two
met
criteria
howev
support
document
provid
eleven
twenti
report
fulltim
pediatr
oncolog
nurs
educ
parttim
educ
posit
involv
staf
supervisori
respons
limit
amount
time
nurs
educ
averag
nursetopati
ratio
rang
nine
hospit
nurs
patient
ration
conclus
pediatr
oncolog
nurs
low
middl
uppermiddl
incom
countri
continu
less
optim
support
educ
major
impedi
contribut
dispar
surviv
rate
high
low
incom
countri
acknowledg
thank
american
lebanes
syrian
associ
chariti
alsac
backgroundobject
despit
advanc
paediatr
oncolog
undernutrit
still
major
concern
among
patient
around
world
howev
nutrit
therapi
often
neglect
regardless
studi
demonstr
undernutrit
strongli
associ
poorer
outcom
remedi
poor
nutrit
statu
result
surviv
compar
children
optim
nutrit
statu
use
nutrit
protocol
essenti
standardis
nutrit
care
follow
aim
studi
investig
whether
implement
nutrit
therapi
protocol
tertiari
paediatr
oncolog
hospit
sao
paulo
brazil
impact
undernutrit
designmethod
databas
contain
nutrit
assess
children
adolesc
cancer
analys
data
divid
implement
nutrit
therapi
protocol
percentag
patient
classifi
undernourish
mid
upper
arm
circumfer
th
percentil
accord
frisancho
compar
chisquar
test
use
verifi
statist
signific
differ
frequenc
result
total
nutrit
assess
oncolog
patient
year
analys
femal
mean
age
year
femal
mean
age
year
implement
protocol
frequenc
undernourish
patient
drop
p
implement
nutrit
therapi
protocol
decreas
frequenc
undernutrit
group
paediatr
oncolog
patient
measur
muac
backgroundobject
nursel
clinic
patient
solid
tumor
introduc
ward
initi
focus
children
diagnos
brain
tumor
often
receiv
combin
surgeri
chemotherapi
andor
radiotherapi
inevit
contact
wide
rang
profession
goal
improv
patient
care
introduc
nurs
case
manag
complex
pathwayin
nursel
clinic
consult
take
place
well
describ
time
point
well
demand
patient
parent
consult
free
charg
designmethod
analyz
month
record
newli
establish
solid
tumor
clinic
compar
expect
number
visit
base
time
point
realiti
look
reason
consult
result
thirti
patient
diagnos
andor
treat
brain
tumor
includ
studi
consult
took
place
averag
number
visit
patient
visit
differ
topic
discuss
inform
treatment
follow
often
combin
emot
support
patient
parent
common
discuss
item
consid
keytim
point
diagnosi
surgeri
start
chemotherapi
end
treatment
expect
visit
patient
parent
ask
extra
visit
hospit
email
telephon
despit
short
period
implement
experienc
patient
parent
find
way
nursel
clinic
keytim
point
nurs
consult
access
need
provid
inform
main
goal
futur
inform
health
care
provid
involv
care
children
nursel
clinic
anchor
clinic
pathway
children
brain
tumor
infect
control
practic
commun
well
time
reinforc
given
lowest
score
given
explan
orient
phase
diagnosi
physiolog
diseas
treatment
prognosi
child
trend
seen
patient
admit
first
time
satisfi
admit
nurs
score
mean
score
refer
given
social
help
given
hospit
variou
ngo
memori
hospit
present
siop
auckland
show
holist
care
provid
children
favor
impact
morbid
mortal
purpos
studi
understand
impact
st
jude
qualiti
life
patientfamili
commun
return
home
treatment
use
find
support
famili
well
improv
model
designmethod
pilot
studi
conduct
famili
centr
establish
paramet
studi
random
select
famili
return
home
agre
particip
studi
home
visit
interview
home
photograph
checklist
item
observ
maintain
return
home
famili
counsel
handl
readjust
three
older
children
also
particip
voluntarili
contact
follow
feedback
record
result
observ
chang
better
entir
famili
daili
routin
cleanli
home
eat
habit
improv
famili
manag
keep
home
clean
children
learn
good
habit
pass
other
thirteen
famili
reloc
better
home
school
famili
counsel
prior
return
home
found
session
valuabl
appreci
ongo
support
found
inform
regard
water
purif
maintain
harmoni
relat
famili
member
respond
medic
emerg
particularli
use
studi
show
impact
holist
care
long
last
rippl
effect
extend
famili
commun
mari
hospit
paediatr
oncolog
london
unit
kingdom
univers
colleg
london
ucl
health
creativ
london
unit
kingdom
london
south
bank
univers
faculti
health
social
care
london
unit
kingdom
great
ormond
street
hospit
psychosoci
famili
servic
london
unit
kingdom
great
ormond
street
hospit
london
south
bank
univers
children
young
peopl
cancer
care
london
unit
kingdom
backgroundobject
littl
known
young
children
view
hospit
care
whether
servic
meet
need
measur
aim
children
older
seven
year
reli
parent
proxi
younger
age
group
lack
valid
measur
children
cancer
multiprofession
work
group
undertook
develop
measur
children
cancer
age
four
twelv
report
experi
hospit
designmethod
group
employ
rigor
develop
process
draw
principl
servic
evalu
literatur
review
first
undertaken
identifi
domain
question
around
measur
would
structur
creativ
process
group
artist
follow
identifi
format
imag
measur
input
profession
stakehold
parent
develop
measur
obtain
mean
expert
advisori
forum
measur
share
children
cancer
famili
oneday
interact
workshop
includ
design
test
activ
feedback
utilis
revis
measur
inform
develop
digit
version
key
domain
identifi
review
overal
experi
physic
environ
social
environ
interact
treatment
procedur
feel
measur
consist
seri
card
positiveneg
imag
opposit
side
explor
domain
list
question
accompani
imag
act
addit
prompt
collabor
approach
involv
children
famili
profession
stakehold
artist
enabl
work
group
develop
measur
design
specif
children
cancer
measur
build
exist
knowledg
highlight
import
consult
children
creation
earli
test
prototyp
develop
process
present
follow
demonstr
digit
version
k
braveri
r
sweet
z
berger
great
ormond
street
hospit
haematolog
oncolog
london
unit
kingdom
backgroundobject
cancer
childhood
social
practic
emot
consequ
addit
effect
child
physic
health
uk
nation
guidelin
state
keywork
usual
specialist
nurs
need
assess
document
need
address
multidisciplinari
work
signpost
patient
key
concern
assess
holist
need
assess
hna
date
hna
tool
cancer
literatur
adultfocus
tailor
individu
need
design
childfocus
tool
recognis
wellb
child
cancer
depend
whole
famili
support
pilot
project
undertaken
great
ormond
street
hospit
address
gap
designmethod
holist
need
assess
tool
suitabl
children
famili
develop
specialist
cancer
nurs
given
tailormad
train
cours
introduc
tool
enhanc
commun
skill
practic
use
tool
semistructur
interview
actor
pilot
use
tool
recent
diagnos
children
famili
result
effect
hna
tool
assess
evalu
famili
nurs
feedback
holist
need
assess
well
analysi
time
take
nurs
specif
case
exampl
share
question
work
complement
work
wider
multidisciplinari
team
includ
social
worker
psychologist
also
address
conclus
train
specialist
nurs
carri
holist
need
assess
equip
servic
better
identifi
meet
emot
social
need
children
cancer
famili
challeng
process
develop
introduc
new
tool
use
specialist
nurs
discuss
backgroundobject
cn
prophylact
treatment
reduc
risk
cn
relaps
therebi
result
remark
increas
surviv
rate
howev
improv
surviv
rate
achiev
without
neuropsycholog
sequela
therefor
studi
aim
examin
impact
protocol
behavior
problem
children
diagnos
designmethod
children
diagnos
receiv
crt
hdmtx
part
treatment
protocol
includ
child
behaviour
check
list
age
use
assess
behaviour
problem
anxiousdepress
withdrawndepress
social
somat
complaint
attent
thought
rule
break
five
assess
done
induct
end
reinduct
end
reinduct
ii
commenc
mainten
end
mainten
children
compar
group
healthi
children
baselin
post
assess
complet
healthi
children
baselin
post
assess
done
children
parent
complet
behaviour
check
list
questionnair
across
five
phase
result
behavior
problem
somat
complaint
rule
break
aggress
behavior
differ
significantli
among
five
assess
compar
first
second
third
fourth
assess
mean
score
children
score
decreas
somat
complaint
aggress
behaviour
fifth
assess
complet
cn
prophylact
treatmentther
signific
differ
treat
healthi
children
respect
behavior
problem
anxietydepress
withdrawn
depress
aggress
behavior
baselin
assess
although
signific
differ
observ
treat
children
healthi
children
anxiousdepress
withdrawndepress
social
problem
thought
problem
attent
problem
aggress
behavior
post
assess
conclus
behaviour
problem
somat
complaint
aggress
behaviour
rulebreak
behaviour
concern
diagnosi
intens
phase
treatment
found
gradual
reduc
baselin
score
normal
behaviour
evid
complet
treatment
backgroundobject
diagnosi
cancer
child
alway
stress
famili
speak
nativ
languag
countri
receiv
care
object
studi
explor
perspect
hispan
famili
limit
english
profici
receiv
care
child
cancer
aim
studi
program
develop
would
best
meet
need
famili
designmethod
parent
recruit
tertiari
care
pediatr
care
institut
midwest
particip
qualit
focu
group
conduct
spanish
total
parent
famili
particip
focu
group
digit
record
transcrib
verbatim
spanish
translat
english
doubl
check
accuraci
certifi
bilingu
translat
analyz
theme
pertin
experi
famili
result
three
main
theme
emerg
focu
group
interpret
error
miscommun
burden
sibl
patient
interpret
famili
languag
key
build
relationship
trust
cancer
experi
share
sociocultur
experi
cornerston
providerpati
trust
conclus
studi
demonstr
import
access
bilingu
provid
speak
directli
patient
languag
avoid
challeng
interpret
form
direct
meaning
relationship
provid
sociocultur
compet
care
spanishspeak
clinic
dedic
bilingu
provid
oncolog
care
import
identifi
bilingu
provid
provid
equal
care
famili
limit
english
profici
regardless
primari
languag
particularli
deal
longterm
lifethreaten
ill
ghiasuddin
j
wong
siu
consist
children
lymphoprolif
cancer
acut
lymphoblast
leukemia
n
lymphoma
diagnosi
solid
tumor
oncolog
treatment
complet
patient
cancer
survivor
treatment
continu
patient
healthi
children
match
age
sex
econom
statu
parent
educ
famili
structur
constitut
control
group
sleep
evalu
use
valid
turkish
version
children
sleep
habit
questionnair
cshq
clinic
characterist
treatment
detail
patient
record
medic
record
signific
differ
found
parent
patient
control
respect
age
gender
educ
level
result
sleep
problem
detect
half
patient
cancer
statist
signific
differ
total
sleep
score
subscal
score
patient
healthi
control
signific
differ
averag
bedtim
length
wake
total
sleep
durat
exist
group
sole
waketim
found
significantli
differ
patient
control
could
nt
demonstr
signific
differ
sleep
score
sleep
characterist
patient
receiv
intratech
chemotheraphi
hd
methotrex
hd
cytarabin
craniospin
radiotherapi
conclus
although
result
indic
neither
childhood
cancer
survivor
patient
cancer
treatment
period
sleep
problem
healthi
peer
sleep
problem
uncommon
whole
studi
group
sleep
problem
identifi
half
children
cancer
also
healthi
control
studi
underlin
need
screen
assess
manag
sleep
problem
children
diagnosi
cancer
median
age
patient
year
mf
ratio
mean
age
mother
year
total
qol
score
chronic
diseas
qol
score
patient
respect
total
qol
score
chronic
diseas
qol
score
patient
mother
perspect
respect
qol
score
patient
patient
parent
perspect
found
correl
maximum
minmum
score
patient
famili
wellb
subscal
physic
wellb
subscal
respect
gender
differ
total
score
qol
qol
score
mother
physic
field
physicolog
field
social
field
environment
field
self
esteem
score
patient
environment
field
score
mother
found
correl
backgroundobject
remain
great
challeng
inform
sever
ill
child
bad
news
eg
treatment
avail
diseas
lead
death
studi
focus
child
perspect
wish
receiv
bad
news
present
studi
interview
children
malign
regard
prefer
wish
receiv
bad
news
designmethod
conduct
individu
interview
ten
children
age
year
treatment
malign
singl
pediatr
oncolog
unit
central
sweden
interview
audiotap
analyz
qualit
methodolog
use
systemat
text
condens
result
children
express
want
truth
inform
want
exclud
bad
news
regard
ill
howev
even
though
express
wish
truth
inform
also
want
bad
news
given
posit
word
possibl
allow
keep
hope
addit
children
want
receiv
bad
news
time
parent
word
could
understand
conclus
children
studi
express
strong
wish
receiv
truth
inform
even
case
bad
news
importantli
wish
bad
news
deliv
sensit
way
allow
glimps
hope
remain
find
may
assist
physician
struggl
inform
sever
ill
children
poor
prognosi
caregiv
complet
demograph
inform
famili
symptom
inventori
measur
child
caregiv
depressionanxieti
symptom
state
record
provid
local
number
pediatrician
median
commun
incom
distanc
singl
specialti
pediatr
oncolog
center
calcul
use
googlemap
analys
conduct
spss
result
child
demograph
variabl
age
diagnosi
gender
ethnic
independ
relat
child
caregiv
depressionanxieti
p
number
local
pediatrician
median
commun
incom
distanc
specialti
oncolog
care
also
relat
child
caregiv
depressionanxieti
p
howev
caregiv
financi
difficulti
associ
child
p
caregiv
p
depressionanxieti
symptom
african
american
caregiv
report
financi
difficulti
white
caregiv
p
conclus
access
local
medic
care
specialti
oncolog
care
associ
psycholog
outcom
pediatr
oncolog
sampl
howev
psycholog
health
dispar
appear
exist
african
american
famili
due
frequent
financi
difficulti
patten
gagnon
patten
patten
due
invas
procedur
suffer
betathalassemia
caus
great
psycholog
distress
children
caregiv
klein
studi
show
preval
psychiatr
problem
thalassem
patient
hoseini
sh
et
al
current
studi
aim
determin
risk
factor
frequenc
depress
trend
children
adolesc
suffer
betathalassemia
designmethod
sampl
consist
regist
patient
amtf
base
age
rang
sampl
divid
two
group
group
children
year
group
b
adolesc
year
detail
interview
selfmad
screen
measur
administ
parent
find
level
depress
patient
result
chisquar
ttest
appli
order
analyz
data
result
show
high
preval
depress
depress
n
depress
analys
reflect
age
influenc
level
depress
adolesc
children
analysi
also
show
differ
level
depress
gender
p
conclus
high
possibl
develop
depress
trend
children
affect
beta
thalassemia
especi
femal
therefor
dire
need
psycholog
screen
appropri
treatment
order
improv
physic
well
mental
health
concept
reliabl
measur
problem
discrep
health
relat
qol
person
satisfact
life
tend
look
new
approach
late
effect
childhood
brain
tumor
new
way
seem
assess
adapt
behavior
defin
perform
abil
daili
activ
requir
person
social
suffici
measur
vinelandii
designmethod
psycholog
repeat
test
longterm
observ
perform
childhood
brain
tumor
survivor
variou
type
local
tumor
determin
psychosoci
late
effect
qol
age
psycholog
diagnosi
rang
year
patient
examin
use
batteri
neuropsycholog
method
psycholog
interview
analysi
medic
histori
also
perform
group
randomli
select
patient
assess
vineland
adapt
behavior
scale
expand
form
vinelandii
result
sampl
patient
present
low
score
domain
commun
daili
live
skill
social
motor
skill
significantli
low
level
social
contact
typic
problem
area
difficulti
appropri
express
emot
inadequ
mimic
bodi
languag
problem
establish
maintain
peer
relationship
low
toler
frustrat
troubl
postpon
gratif
interest
problem
emerg
research
requir
deeper
explor
differ
declar
patient
parent
express
psycholog
interview
real
level
adapt
behavior
result
studi
suggest
adapt
behavior
concept
well
describ
explain
problem
group
patient
vinelandii
use
reliabl
tool
assess
psychosoci
late
effect
survivor
cancer
group
well
method
individu
assess
also
allow
prepar
individu
psycholog
intervent
rehabilit
program
particular
patient
lymphomaleukemia
brain
tumor
receiv
irb
permit
rmc
subject
contact
one
investig
conduct
individu
telephon
interview
accord
prearrang
list
question
predetermin
respons
option
refer
four
theme
behavior
indic
bodili
sensat
organ
sensit
nightmar
result
question
consid
togeth
signific
differ
found
chisquar
two
group
behavior
indic
question
differ
significantli
two
group
bodili
sensat
organ
sensit
nightmar
demonstr
signific
differ
term
chisquar
two
group
wherebi
first
group
score
higher
second
result
demonstr
group
earlier
diseas
onset
yr
bodili
memori
group
later
diseas
onset
explan
could
either
earlier
diseas
onset
relat
stronger
emot
impact
cognit
elabor
languag
develop
promot
cope
accept
less
develop
earli
age
backgroundobject
cognit
dysfunct
common
concern
children
brain
tumor
receiv
neurotox
treatment
childand
parentperceiv
cognit
function
pcf
could
use
repeat
assess
given
eas
administr
low
cost
relev
patient
daili
live
purpos
analysi
evalu
whether
agreement
parentand
childreport
pcf
associ
rate
scale
type
frequenc
vs
intens
whether
level
agreement
differ
children
versu
without
cancer
designmethod
data
children
mean
yr
drawn
us
gener
popul
parent
children
cancer
brain
tumor
mean
yr
analyz
cancer
sampl
receiv
radiat
therapi
chemotherapi
surgeri
mean
year
sinc
last
treatment
complet
two
version
newli
develop
pediatr
perceiv
cognit
function
shortform
pedspcfsf
item
stem
differ
rate
scale
frequenc
none
time
time
intens
much
weight
kappa
use
evalu
agreement
individu
item
level
parentand
childreport
pedspcfsf
intraclass
correl
icc
use
evalu
agreement
scale
level
result
cancer
sampl
weight
kappa
children
parent
intens
frequenc
gener
popul
weight
kappa
intens
frequenc
respect
scale
level
higher
agreement
found
gener
popul
sampl
intens
frequenc
respect
cancer
sampl
respect
conclus
studi
show
higher
agreement
children
parent
without
cancer
compar
cancer
result
studi
appli
improv
assess
futur
cancer
studi
backgroundobject
due
improv
surviv
rate
pediatr
oncolog
attent
given
psychosoci
factor
grow
evid
resili
one
import
factor
resili
impli
abil
withstand
stress
literatur
confound
lack
consensu
definit
sever
differ
conceptu
preexist
trait
allow
person
thrive
face
advers
dynam
process
posit
adapt
final
outcom
aim
present
studi
investig
resili
time
parent
child
cancer
designmethod
june
decemb
parent
child
new
diagnosi
cancer
invit
particip
eventu
parent
coupl
gave
consent
particip
resiliencescalenl
assess
four
time
diagnosi
month
year
year
diagnosi
total
score
mother
father
compar
time
point
age
gender
norm
result
signific
differ
found
time
point
resili
score
coupl
compar
averag
norm
score
howev
signific
differ
found
diagnosi
total
group
particip
score
still
within
normal
limit
tscore
parent
obtain
clinic
deviant
score
tscore
time
point
longitudin
studi
demonstr
major
parent
resili
neg
affect
diagnosi
cancer
treatment
child
howev
parent
obtain
clinic
deviant
score
addit
studi
provid
preliminari
evid
stabil
resili
research
need
investig
group
parent
low
resili
score
order
find
strategi
support
better
potenti
vulner
group
result
sibl
advic
relat
support
wish
includ
either
get
support
want
involv
brotherssist
care
want
better
medic
inform
practic
involv
suggest
hcp
give
parent
guidanc
involv
sibl
advic
relat
ill
child
care
eg
listen
ill
child
want
care
sibl
wish
hcp
mediat
hope
also
realism
sibl
advic
focus
inclus
diagnosi
bereav
order
facilit
sibl
psychosoci
need
health
care
set
also
within
famili
openend
question
help
grief
death
brother
sister
analyz
content
analysi
result
mani
sibl
strategi
either
relat
differ
way
distract
distress
thoughtsfeel
relat
griev
think
feel
express
grief
differ
way
strategi
distract
relat
keep
busi
work
hobbi
return
everyday
routin
think
feel
express
relat
griev
includ
eg
talk
other
cri
write
also
talk
dead
brothersist
sibl
also
evok
posit
memori
good
time
togeth
neg
memori
eg
brotherssist
suffer
thinkfeel
express
thought
feel
relat
griev
versu
distract
distress
feelingsthought
alway
compet
individu
report
strategi
relat
aspect
famili
friend
pet
often
assist
sibl
express
feelingsthought
also
distract
strategi
associ
religi
belief
eg
sibl
meet
wait
time
pass
also
mention
strategi
sinc
sibl
convinc
time
would
heal
grief
conclus
sibl
report
wide
rang
differ
strategi
cope
grief
copingstrategi
found
access
may
valuabl
health
care
profession
order
support
futur
bereav
sibl
h
ani
backgroundobject
cancer
diagnosi
immedi
crisi
famili
psycholog
support
vital
compon
treatment
child
life
field
dedic
provid
psychosoci
support
children
famili
face
difficult
circumst
healthcar
set
although
child
life
new
concept
within
indian
healthcar
set
pediatr
psychooncolog
program
use
child
life
princip
philosophi
valu
right
child
play
stimul
enrich
safe
clean
healthcar
environ
promot
optim
develop
cankid
child
life
project
object
improv
qualiti
life
children
cancer
india
designmethod
cankid
initi
child
life
project
serv
low
cost
model
cancer
institut
organ
initi
outlin
advoc
implement
child
friendli
ward
project
child
life
intervent
make
hospit
environ
best
possibl
place
children
start
educ
sensit
hospit
import
psychosoci
care
partner
result
implement
child
life
project
across
india
provid
optimum
healthcar
experi
children
famili
face
cancer
project
bring
breakfast
game
tabl
art
display
board
shoe
rack
toy
book
librari
addit
implement
child
life
intervent
resourc
promot
health
psycholog
wellb
encourag
continu
proper
develop
throughout
healthcar
process
conclus
goal
spread
awar
child
right
safe
stimul
environ
partner
hospit
effectu
child
friendli
ward
individu
counsel
group
counsel
play
therapi
implement
project
amount
stress
experienc
children
famili
face
cancer
reduc
healthcar
provid
empow
effect
work
child
famili
backgroundobject
thalassemia
continu
common
form
hemolyt
anemia
dubey
parakh
dublish
preval
pakistani
popul
ahm
result
poor
physic
mental
health
among
patient
azarkeivan
et
al
moreov
caus
substanti
disturb
everi
aspect
life
wellbeingsinc
depress
anxieti
continu
major
ailment
associ
thalassemia
mednick
et
al
kiskek
krim
turhan
turan
much
attent
given
behavior
deficit
comorbid
thalassemia
berati
found
high
frequenc
opposit
defianc
disord
thalassem
children
along
high
ferritin
rate
studi
bring
light
preval
behavior
abnorm
thalassem
children
associ
medic
factor
constitut
diagnosi
odd
designmethod
studi
popul
compris
regist
betathalasem
patient
amtf
gender
ratio
compos
femal
male
sampl
classifi
age
base
group
group
preadolesc
year
group
adolesc
year
sampl
screen
selfstructur
questionnair
measur
level
odd
along
detail
clinic
interview
backgroundobject
diagnosi
cancer
seldom
disclos
children
discuss
develop
countri
complet
chemotherapi
present
data
extent
pattern
social
stigma
associ
diagnosi
childhood
cancer
middl
incom
famili
india
complet
therapi
designmethod
retrospect
oral
questionnair
done
parent
children
treat
india
ten
year
period
children
less
year
old
therapi
remiss
year
chosen
studi
popul
parent
question
paramet
discuss
treatment
cancer
child
attitud
toward
follow
care
fear
regard
long
term
side
effect
treatment
result
total
parent
interview
studi
diagnosi
leukaemia
children
hodgkin
lymphoma
nhl
children
two
parent
discuss
diagnosi
cancer
child
follow
offer
fear
sensit
question
children
children
children
come
regular
annual
follow
sinc
discharg
parent
express
fear
delay
side
effect
chemotherapi
especi
pubert
growth
fertil
wish
discuss
issu
child
separ
appoint
made
perform
chart
review
patient
parent
address
issu
late
side
effect
social
stigma
cancer
chemotherapi
societi
result
huge
loss
data
psychosoci
aspect
cancer
impact
famili
cope
program
creat
opportun
parent
empower
requir
overcom
barrier
help
support
famili
long
term
backgroundobject
thalassemia
lifelong
conditionrequir
adher
cumbersom
medic
procedur
cours
disord
affect
physic
condit
child
also
imped
hisher
mental
health
mednick
anxieti
disord
consid
common
type
psychopatholog
affect
child
adolesc
ratio
bersntein
ga
et
al
moreno
et
al
mani
research
conduct
western
societi
investig
preval
anxieti
betathalassemia
patient
howev
dearth
research
data
pakistan
calcul
risk
factor
research
paper
bring
light
preval
incid
symptomat
anxieti
preadolesc
adolesc
suffer
transfus
depend
betathalassemia
designmethod
sampl
popul
compris
betathalassemia
patient
regist
afzaal
memori
thalassemia
foundat
inclus
criteria
encompass
age
rang
year
wherebi
categori
preadolesc
age
rang
year
ii
adolesc
age
rang
year
made
selfmad
screen
questionnair
administ
caregiv
along
depth
histori
clinic
observ
child
psychotherapi
session
result
result
find
indic
high
incid
anxieti
children
suffer
betathalassemia
chisquar
valu
show
anxieti
found
anxieti
significantli
higher
preadolesc
compar
adolesc
signific
differ
level
anxieti
among
gender
p
studi
indic
children
suffer
betathalassemia
higher
risk
develop
anxieti
disord
strong
need
adjunct
psychotherapeut
session
medic
treatment
allevi
qualiti
life
mental
health
regard
question
feel
burnt
scale
burnt
nurs
team
answer
averag
oppos
medic
team
singl
question
correl
statist
analysi
subquestionnair
demonstr
differ
group
emot
fatigu
deperson
emot
focus
cope
nurs
report
higher
burn
feel
signific
correl
found
nurs
staff
age
group
emot
fatigueth
higher
averag
age
higher
feel
emot
fatigu
studi
found
differ
nurs
team
medic
team
level
burnout
well
level
cope
find
consid
basic
differ
nurs
physician
explain
especi
support
receiv
outsid
workplac
backgroundobject
import
hospit
school
rise
last
decad
gain
lot
influenc
live
children
teenag
treatment
differ
diseas
paediatr
hematologyoncolog
unit
except
though
hospit
school
nowaday
capabl
synchron
work
patient
regular
school
purpos
project
present
describ
case
report
underlin
de
role
hospit
school
teach
tool
use
goal
educ
student
global
comprehens
way
designmethod
present
case
year
old
boy
mere
patient
local
osteosarcoma
requir
preoper
postop
chemotherapi
high
complex
surgeri
inmunotherapi
without
kind
learn
activ
approach
necessarili
crossdisciplinari
present
report
educ
perspect
stress
function
possibl
advantag
disadvantag
hospit
school
within
paediatr
oncolog
unit
coordin
rest
staff
put
patient
middl
scope
trough
humanist
vision
emphas
real
mean
educ
methodolog
qualit
patient
finish
obligatori
educ
stage
nt
enrol
school
apathet
neg
experi
former
hospit
schoo
hospit
school
paediatr
hematologyoncolog
unit
hm
hospit
becam
curiou
motiv
student
conclus
though
singl
conclus
project
conclud
hospit
school
way
link
patient
regular
school
power
tool
help
heal
process
sinc
cancer
physic
psychic
effect
consequ
result
total
patient
studi
indic
petmri
radiat
therapi
plan
relaps
st
anaplast
ependimoma
dissemin
pinealoblastoma
end
treatment
evalu
hodgkin
diseas
restag
relaps
medulloblastoma
relaps
neuroblastoma
petmri
techniqu
integr
imag
high
sensit
specif
diagnosi
pediatr
tumor
signific
decreas
rate
exposur
ioniz
radiat
children
compar
diagnost
techniqu
oncolog
austria
c
sibinov
k
dieckmann
backgroundobject
austria
year
small
amount
children
receiv
radiat
five
differ
centr
due
limit
amount
case
inhomogen
group
tumour
expert
level
difficult
achiev
collabor
among
centr
base
commun
via
telephon
email
postal
servic
object
develop
central
webbas
platform
evalu
standard
nationwid
pediatr
radiotherapi
subsequ
build
nationwid
regist
designmethod
children
receiv
radiotherapi
regist
start
treatment
webbas
qualiti
assur
platform
relev
diagnost
report
radiolog
imag
upload
pseudonym
thereaft
patient
case
discuss
among
pediatr
radiat
oncologist
group
defin
target
volum
treatment
plan
evalu
respect
dose
distribut
tumour
organ
riskth
implement
roll
four
stage
simplifi
unifi
actual
process
data
aggreg
data
represent
grante
easi
data
access
collabor
centresstag
first
use
digit
dicomarch
stage
enabl
secur
digit
data
transfer
data
access
archiv
via
standalon
client
softwarestag
standalon
client
softwar
replac
webbas
onlin
viewerstag
complet
fulli
access
web
applic
ad
upload
featur
automat
process
apart
web
front
end
allow
user
interact
exchang
data
anoth
crucial
part
platform
back
end
respons
data
manag
data
archiv
medic
multimedia
data
first
result
present
congress
conclus
nation
qualiti
assur
platform
regist
pediatr
radiat
oncolog
built
research
advanc
train
treatment
room
equip
gantri
allow
beam
line
degre
freedom
robot
treatment
tabl
two
orthogon
xray
devic
ct
onrail
one
room
conebeam
ct
two
horizont
beam
line
place
third
room
center
equip
also
dedic
ct
mri
anesthesia
area
octob
facil
start
clinic
activ
adult
patient
plan
accept
pediatr
patient
around
six
month
later
result
evalu
pediatr
case
nation
intern
refer
physician
parent
famili
member
mean
age
year
rang
histolog
rhabdomyosarcoma
highrisk
medulloblastoma
diffus
intrins
pon
glioma
meningioma
primit
neuroectoderm
tumor
choroid
plexu
carcinoma
ewe
sarcoma
lowgrad
glioma
chordoma
atyp
teratoid
rhabdoid
tumor
pituitari
germinoma
osteosarcoma
malign
schwannoma
nineteen
patient
evalu
elig
receiv
proton
radiat
although
radiat
time
alway
correctli
set
six
patient
declin
due
metastat
progress
diseas
alreadi
treat
high
dose
radiat
conclus
trento
proton
center
expect
treat
near
futur
pediatr
patient
contribut
limit
grow
bodi
literatur
demonstr
effect
safeti
proton
pediatr
tumor
agarw
backgroundobject
report
case
spt
pancrea
highlight
chemotherapi
may
use
adjunct
surgeri
manag
tumor
avoid
morbid
surgic
resect
designmethod
report
case
spt
manag
success
use
low
dose
chemotherapi
follow
limit
surgeri
result
yr
old
femal
present
sever
abdomin
pain
biliou
projectil
vomit
sign
shock
firm
abdomin
mass
palpabl
epigastr
region
usg
abdomen
reveal
larg
heterogen
mass
lesser
sac
cect
show
larg
ruptur
necrot
hemorrhag
mass
relat
bodi
tail
pancrea
exploratori
laparotomi
plan
major
debulk
ruptur
pancreat
tumor
done
biopsi
solid
pseudopapillari
neoplasm
pancrea
tumor
cell
stain
posit
synaptophysin
cd
beta
catenin
neg
chromogranin
howev
develop
recurr
symptom
month
cect
abdomen
show
evid
larg
mass
relat
tail
pancrea
residu
tumor
opin
surgic
resect
point
time
would
mean
complet
pancreatectomi
splenectomi
bowel
resect
temporari
colostomi
consult
gastrosurg
team
decid
give
cycl
vac
chemotherapi
reassess
surgeri
later
show
decreas
size
mass
plan
take
surgeri
distal
pancreatectomi
splenectomi
done
resect
margin
free
tumor
region
lymph
node
tumor
free
three
month
surgeri
asymptomat
evid
recurr
conclus
spt
pancrea
rare
tumor
littl
literatur
manag
guidelin
success
combin
chemotherapi
surgeri
young
girl
avoid
morbid
surgic
outcom
underw
thyreoidectomi
neck
dissect
eight
cours
radioact
iodin
final
three
cours
retinoid
pulmonari
metastas
progress
thyreoglobulin
increas
sign
pulmonari
insuffici
develop
offlabel
use
sorafenib
initi
mg
daili
stepwis
increas
twice
mg
month
hematolog
sideeffect
minim
also
cutan
sideeffect
mild
grade
hand
foot
syndrom
due
cramp
diarrhea
weight
loss
therapi
decreas
daili
mg
year
increas
full
dose
month
thereaft
minor
reduct
dose
necessari
month
two
year
patient
toler
full
dose
mg
hardli
sideeffect
thyrotropinsuppress
therapi
calcium
calcitriol
therapi
continu
result
one
month
initi
sorafenib
extens
pulmonari
metastas
show
mild
reduct
thereaft
observ
stabl
diseas
mri
ct
thyreoglobulin
level
thyreoglobulin
antibodi
remain
elev
without
signific
decreas
due
fluctuat
valu
thyreoglobulin
ngml
ngml
conclus
case
pediatr
ptc
progress
pulmonari
metastas
rai
option
sorafenib
con
help
stabil
diseas
adult
dosag
mg
without
sever
sideeffect
backgroundobject
primari
chest
wall
tumour
origin
differ
construct
thorac
wall
soft
tissu
boni
thorax
extrapleur
region
tumour
rare
manag
lesion
challeng
often
controversi
report
multidisciplinari
experi
manag
primari
chest
wall
tumour
designmethod
patient
year
receiv
treatment
chest
wall
lesion
evalu
studi
period
extend
year
data
obtain
demographi
present
manag
surgic
techniqu
outcom
result
primari
chest
wall
tumour
note
ten
patient
seven
femal
three
male
patient
common
present
mass
patholog
includ
rhabdomyosarcoma
osteochondroma
lipoblastoma
ewe
tumour
three
patient
lesion
benign
common
site
distant
metastasi
lung
treatment
includ
surgeri
alon
surgeri
neoadjuvantadjuv
treatment
reconstruct
surgeri
undertaken
two
patient
postop
recoveri
mostli
unev
one
patient
small
pneumothorax
two
patient
muscl
paresi
success
treat
conserv
median
hospit
stay
day
rang
diseas
free
surviv
note
eight
patient
date
two
patient
amen
cur
surgeri
present
late
stage
local
advanc
diseas
given
palli
treatment
lead
mortal
conclus
chest
wall
tumour
rare
major
amen
surgic
resect
morbid
associ
surgic
resect
low
delay
present
signific
impact
outcom
although
predominantli
occur
children
young
adult
age
distribut
wide
slight
femal
predilect
tumor
usual
present
slowli
grow
mass
within
deep
dermi
subcuti
although
deepseat
lesion
describ
often
aris
within
extrem
also
occur
trunk
neck
surgeri
remain
mainstay
manag
effect
control
local
recurr
metastas
herein
describ
case
report
girl
whose
present
concern
lypoma
subsequ
review
relev
literatur
designmethod
yearold
girl
present
painless
mass
right
arm
month
without
constitut
symptom
physic
exam
demonstr
mobil
nontend
palpabl
mass
along
later
aspect
right
arm
without
erythema
soft
tissu
swell
patient
underw
en
bloc
surgic
excis
whose
biopsi
report
afh
patient
local
recurr
month
oper
tumor
excis
biopsi
wide
resect
perform
report
afh
diseasefre
margin
two
month
oper
present
new
local
relaps
decid
meet
radiotherapi
current
serv
treatment
result
afh
rare
soft
tissu
tumor
commonli
occur
children
adolesc
young
adult
surgeri
alon
wide
local
excis
util
establish
local
control
howev
case
margin
excis
plan
radiat
therapi
util
maxim
control
conclus
afh
rare
diseas
often
misdiagnos
initi
lympadenopathi
fever
chest
pain
palpit
hematuria
pericardi
pleural
effus
ascit
headach
convuls
vomit
dic
back
pain
patholog
fractur
result
sixtyfour
children
met
inclus
criteria
median
age
present
year
present
mean
gfr
patient
gfr
less
hypertens
last
visit
mean
gfr
children
gfr
less
hypertens
albuminuria
found
correl
chemotherapi
type
decreas
gfr
increas
blood
pressur
radiotherapi
signific
risk
factor
protein
secret
renal
length
increas
significantli
present
last
visit
r
maxim
growth
rate
observ
first
postnephrectomi
year
conclus
although
overal
prognosi
children
nephrectomi
wt
guard
present
cohort
rate
impair
renal
function
long
term
radiotherapi
increas
risk
proteinuria
close
followup
patient
popul
necessari
monitor
effect
hyperfiltr
remnant
kidney
determin
need
treatment
backgroundobject
paediatr
renal
tumour
rare
childhood
account
less
paediatr
malign
present
case
seri
recent
experi
tumour
demonstr
atyp
behaviour
designmethod
patient
present
atyp
featur
renal
malign
last
five
year
identifi
hospit
patient
record
multidisciplinari
document
patient
demograph
clinic
symptom
radiolog
find
outcom
record
analys
result
ten
patient
identifi
median
age
present
year
year
two
patient
present
extens
hepat
involv
one
patient
histori
multipl
system
haemangiomata
pose
diagnost
challeng
requir
addit
liver
biopsi
localis
liver
resect
one
patient
present
atyp
featur
trilobul
wilm
tumour
appear
separ
vessel
crosssect
imag
two
younger
patient
present
bilater
patholog
first
patient
found
stage
v
diseas
requir
nephronspar
surgeri
screen
suspect
beckwithwiedemann
syndrom
second
patient
present
sepsi
abdomin
pain
follow
blunt
trauma
crosssect
imag
reveal
renal
ruptur
contralater
pyonephrosi
associ
pelviureter
junction
obstruct
followup
imag
show
mass
traumat
side
confirm
wilm
tumour
unilater
nephrectomi
contralater
pyeloplasti
perform
three
patient
present
extens
local
diseas
first
involv
collect
system
bladder
present
haematuria
difficulti
void
two
older
patient
present
inferior
vena
cava
involv
presum
diagnosi
wilm
tumour
howev
biopsi
result
confirm
primit
neuroectoderm
tumour
case
conclus
paediatr
renal
tumour
present
sever
distinct
clinic
morpholog
reemphasis
import
individualis
multidisciplinari
team
approach
manag
unusu
case
clinic
laboratori
patient
improv
rapidli
defibrotid
hepat
portal
venou
flow
also
record
normal
one
week
defibrotid
treatment
defibrotid
treatment
maintain
day
patient
patient
complet
chemotherapi
protocol
without
problem
conclus
defibrotid
antithrombot
antiischem
antiinflammatori
thrombolyt
singlestrand
polydeoxyribonucleotid
fibrinolyt
properti
safe
well
toler
efficaci
therapi
vod
trend
also
note
optic
nerv
resect
margin
involv
vs
howev
overal
surviv
progress
free
surviv
affect
express
entir
group
well
subgroup
patient
extraocular
metastat
retinoblastoma
conclus
cytoplasm
express
frequent
found
retinoblastoma
specimen
despit
associ
cytoplasm
express
high
risk
histopatholog
featur
effect
surviv
note
activ
reloc
nucleu
may
activ
nonmut
retinoblastoma
potenti
target
treatment
patient
retinoblastoma
proband
patient
least
one
eye
enucl
affect
eye
enucl
affect
eye
radiat
hand
affect
famili
member
one
eye
enucl
affect
eye
enucl
singl
patient
receiv
radiat
eye
salvag
rate
significantli
higher
affect
famili
member
proband
seri
patient
diagnos
screen
sign
symptom
eye
salvag
excel
visual
outcom
without
need
radiat
even
chemotherapyat
last
day
follow
proband
dead
due
metastasi
second
malign
osteosacrcoma
field
radiat
singl
case
famili
member
metastasi
dead
conclus
awar
famili
possibl
retinoblastoma
one
person
famili
affect
diseas
adequ
screen
even
absenc
genet
test
show
significantli
higher
rate
eye
salvag
patient
famili
retinoblastoma
suggest
author
earli
refer
ophthalmologist
pediatr
oncologist
educ
program
around
sign
symptom
leukocoria
strabismu
inflammatori
abnorm
nation
media
conclus
earli
diagnosi
retinoblastoma
critic
landmark
risk
factor
manag
patient
delay
diagnosi
account
highli
advanc
clinic
poor
prognosi
therapi
lack
differenti
led
difficulti
understand
tumor
histogenesi
shown
ew
ppnet
could
express
cytokeratin
suggest
partial
epitheli
differenti
indic
intercellular
junction
includ
tight
cellcel
junction
designmethod
analyz
specimen
primari
tumor
tissu
patient
ew
ppnet
specimen
obtain
diagnost
biopsi
fix
buffer
formalin
embed
paraffin
ecadherin
express
analysi
use
rtpcr
immunohistochemistri
ihc
method
specif
antibodi
ihc
includ
analysi
pancytokeratin
epitheli
marker
specimen
previous
analyz
standard
histopatholog
method
includ
ihc
posit
express
membran
glycoprotein
rtpcr
analysi
specif
transloc
provid
definit
diagnosi
result
ihc
specimen
low
posit
pancytokeratin
individu
cell
small
cluster
specimen
posit
membran
posit
membran
ecadherin
one
specimen
show
nuclear
stain
marker
individu
cell
rtpcr
specimen
posit
ecadherin
conclus
ihc
rtpcr
method
use
determin
compar
result
ecadherin
express
ew
tumor
specimen
strong
correl
two
method
express
rtpcr
mainli
nonexpress
ecadherin
accord
exist
cellcel
adhes
receptor
partial
epitheli
differenti
determin
posit
express
pancytokeratin
obtain
ihc
primari
tumor
specimen
studi
could
clarifi
possibl
signific
find
registri
document
incid
ks
among
children
ssa
use
key
word
pediatr
kaposi
sarcoma
respect
countri
name
studi
report
pediatricspecif
data
exclud
sixtyfour
studi
two
registri
evalu
countri
ssa
six
casecontrol
studi
one
registri
includ
incid
data
extract
visual
map
includ
studi
came
eastern
southeastern
africa
notabl
absenc
data
swaziland
world
highest
hiv
preval
indirect
adjust
pediatr
popul
incid
ks
among
children
rang
per
personyear
equatori
nation
kenya
per
personyear
neighbor
equatori
countri
uganda
conclus
dearth
epidemiolog
inform
ks
among
children
ssa
contrari
adult
studi
report
incid
ks
highest
equatori
ssa
review
suggest
live
equatori
ssa
may
increas
risk
ks
among
children
larger
nation
region
studi
need
determin
overal
burden
diseas
ks
among
children
ssa
elucid
associ
geograph
locat
ks
year
life
case
median
age
month
rang
month
f
ratio
elev
alphafetoprotein
level
diagnosi
patient
local
diseas
patient
distant
metastas
local
metastas
includ
lung
lung
opposit
lobe
liver
lung
left
adren
gland
periton
metastas
two
patient
initi
tumor
ruptur
patient
ir
iv
patient
local
diseas
due
tumor
ruptur
surgeri
done
patient
delay
resect
initi
resect
secondari
resect
patient
unresect
tumor
median
number
chemotherapi
cycl
rang
cycl
outcom
patient
aliv
evid
diseas
month
die
due
earli
progress
conclus
data
confirm
unfavor
prognosi
due
advanc
stage
diseas
poor
respons
therapi
howev
intensifi
dosecompress
chemotherapi
aggress
surgic
resect
could
potenti
cur
subset
patient
differ
use
chemotherapi
p
util
chemotherapi
pnet
malign
small
cell
sarcoma
acin
soft
tissu
sarcoma
embryon
sarcoma
util
chemotherapi
four
sarcoma
surviv
rate
loss
followup
rate
mortal
rate
twoyear
surviv
rate
fiveyear
surviv
rate
conclus
sever
type
soft
tissu
sarcoma
need
diagnos
patholog
examin
nonrhabdomyosarcoma
soft
tissu
sarcoma
perform
radic
oper
radic
oper
plu
chemotherapi
backgroundobject
qualit
studi
conduct
investig
impact
soft
touch
therapi
palli
end
life
care
among
children
cancer
observ
children
palli
end
life
care
report
persist
pain
increas
heart
rate
anxieti
aggress
irrit
distress
designmethod
review
literatur
soft
touch
therapi
provid
randomli
children
irrit
aggress
anxiou
distress
behavior
purpos
sampl
select
children
cancer
unit
indu
hospit
karachi
qualit
chang
behavior
observ
term
reduc
pain
anxieti
irrit
aggress
heart
rate
return
normal
slightli
studi
last
two
year
necessari
precaut
kept
mind
backgroundobject
noncommunic
diseas
cancer
emerg
increasingli
signific
caus
childhood
mortal
highincom
countri
hic
childhood
cancer
surviv
compar
low
middl
incom
countri
lmic
establish
paediatr
cancer
centr
hic
like
hospit
sick
children
sickkid
toronto
canada
well
posit
share
clinic
expertis
counterpart
resourceconstrain
countri
launch
march
sickkidscaribbean
initi
sci
aim
enhanc
care
children
cancer
blood
disord
caribbean
countri
bahama
barbado
jamaica
st
lucia
st
vincent
grenadin
trinidad
tobago
order
prevent
death
due
complic
treatment
intervent
intens
protocol
regimen
must
match
appropri
support
care
designmethod
consult
caribbean
clinician
prioriti
area
support
care
identifi
febril
neutropenia
chemotherapyinduc
nausea
vomit
hyperleukocytosi
tumour
lysi
syndrom
transfus
medicin
specialist
develop
survey
respect
area
circul
caribbean
clinician
exist
intern
sickkid
clinic
practic
guidelin
use
refer
draft
document
integr
survey
feedback
current
practic
avail
resourc
result
upcom
workshop
sci
repres
review
document
consider
paid
local
institut
implement
adher
adapt
institut
use
countri
clinic
deleg
institut
respons
develop
implement
plan
clinic
set
final
document
local
use
questionnair
openend
question
administ
sampl
parent
whose
children
receiv
palli
care
die
cancer
inform
consent
obtain
result
ten
famili
approach
six
agre
interview
parent
opinion
cancer
could
cure
understood
palli
care
make
child
reliev
symptom
peac
death
note
although
almost
children
receiv
morphin
pain
relief
half
state
inadequ
input
child
care
although
parent
felt
relationship
profession
good
two
dissatisfi
profession
hardli
understand
us
three
famili
encount
clinic
psychologist
two
impress
quot
forgot
everi
patient
uniqu
improv
suggest
includ
individu
care
privaci
spiritu
input
conclus
palli
care
form
import
compon
paediatr
oncolog
train
health
worker
develop
countri
effect
symptom
control
respons
individu
need
children
famili
backgroundobject
children
treat
cancer
risk
signific
complic
even
death
neutropen
fever
fn
episod
knowledgegap
factor
predict
risk
sever
infect
lead
great
variat
clinic
practic
manag
fn
nationwid
studi
investig
incid
antimicrobi
treatment
among
children
age
year
first
six
month
start
cancer
treatment
designmethod
januari
may
children
newli
diagnos
cancer
start
therapi
invit
particip
accept
diseas
treatment
relat
data
collect
particip
medic
record
includ
inform
fn
laboratori
data
well
demograph
data
episod
infect
defin
individu
period
time
use
oral
intraven
antimicrobi
treatment
associ
symptom
infect
result
episod
antimicrobi
treatment
identifi
children
first
six
month
cancer
treatment
child
median
prescrib
two
rang
antimicrobi
treatment
microbi
cultur
obtain
episod
children
diagnos
sarcoma
often
receiv
antimicrobi
treatment
wherea
children
diagnos
central
nervou
system
cn
tumour
hodgkin
lymphoma
seldom
receiv
antimicrobi
treatment
children
diagnos
acut
lymphoblast
leukaemia
cn
tumour
larger
extent
undergo
episod
wherea
children
sarcoma
acut
myeloid
leukaemia
larger
extent
undergo
episod
also
provid
data
posit
blood
cultur
presenc
antimicrobi
resist
major
children
receiv
antimicrobi
treatment
first
six
month
treatment
cancer
children
sarcoma
identifi
highrisk
group
fn
togeth
aml
patient
alnassan
awadi
hmood
sultan
king
hussien
cancer
center
pediatr
amman
jordan
king
hussien
cancer
center
depart
amman
jordan
backgroundobject
resuscit
order
dnr
crucial
plan
endoflif
care
success
discuss
order
depend
famili
background
care
giver
percept
patient
condit
designmethod
retrospect
analyz
chart
patient
dnr
order
place
januari
decemb
analyz
demograph
dnr
order
document
time
dnr
order
relat
diagnosi
death
result
evalu
chart
patient
male
median
age
diagnosi
year
rang
dnr
order
obtain
first
attempt
patient
major
order
obtain
primari
oncologist
rest
place
palli
care
team
intens
care
consult
order
place
outpati
clinic
inpati
unit
intens
care
unit
median
durat
dnr
order
placement
death
month
rang
significantli
longer
patient
solid
tumor
month
comparison
cn
tumor
month
leukemialymphoma
patient
month
studi
show
clear
obstacl
place
dnr
order
among
patient
believ
better
analysi
requir
better
document
process
includ
unsuccess
attempt
place
order
patient
leukemialymphoma
center
endoflif
plan
done
earlier
stage
result
pediatr
patient
admit
bmt
mean
age
year
male
femal
major
patient
hematolog
malign
aml
lymphoma
follow
betathalassemia
sickel
cell
anemia
aplast
anemia
fanconi
anemia
solid
tumor
includ
neuroblastoma
medulloblastoma
hlh
other
miscellan
disord
allogen
transplant
remain
autolog
transplant
cmv
reactiv
observ
patient
within
day
post
bmt
major
asymptomat
remain
clinic
manifestationorgan
involv
liver
skin
git
cn
result
total
parent
interview
median
age
parent
year
post
primari
educ
interview
parent
said
use
form
cam
either
past
current
treatment
child
herb
use
dietari
supplement
combin
among
herbal
remedi
common
type
use
oliv
oil
follow
black
seed
nigella
sativa
seed
garlic
kurkum
dietari
supplement
util
includ
honey
camel
milk
royal
jelli
queen
bee
honey
regard
altern
treatment
recit
vers
alquran
use
holi
water
zamzam
spring
makkah
almukaramah
follow
report
use
perfum
oil
sampl
parent
use
cam
occasion
child
around
use
daili
basi
overal
parent
satisfi
use
cam
howev
nearli
use
without
knowledg
treat
oncologist
high
incid
use
cam
among
pediatr
cancer
patient
warrant
establish
region
modul
integr
cam
cancer
therapi
underlin
import
health
care
profession
ask
routin
use
cam
popul
backgroundobject
death
inevit
peopl
handl
death
differ
studi
aim
evalu
intens
grief
experienc
health
care
provid
hp
death
pediatr
cancer
patient
designmethod
prospect
crosssect
descript
studi
done
measur
intens
grief
among
hp
experienc
bereav
death
pediatr
patient
cancer
use
texa
revis
inventori
grief
trig
result
total
respond
particip
studi
respons
rate
includ
medic
intern
nurs
pediatr
resid
fellow
consult
other
pediatr
resid
show
intens
level
past
grief
present
grief
compar
rest
respond
consult
score
lowest
percentil
trig
score
pertain
absenc
grief
follow
nurs
belong
age
group
year
old
show
signific
intens
grief
past
present
grief
respect
small
number
studi
particip
palli
train
half
respond
sought
emot
support
experienc
bereav
statist
differ
level
grief
among
male
femal
respond
conclus
children
cancer
endear
special
group
patient
child
cancer
die
indel
mark
left
behind
especi
among
took
care
everyday
encount
patient
endear
hp
reason
alon
grief
experienc
hp
especi
patient
die
experienc
grief
long
process
endur
henc
emot
psycholog
support
import
grief
ignor
suppress
may
becom
sourc
stress
even
dysfunct
result
pain
studi
fatigu
gastrointestin
respiratori
symptom
preval
symptom
cite
symptom
gener
report
context
particip
consid
context
differ
age
group
development
stage
studi
consid
symptom
preval
intract
regard
subcategori
diagnosi
eg
brain
tumour
time
sinc
enter
palliat
term
statist
analysi
mark
inconsist
report
paramet
age
group
diseas
classif
sex
treatment
receiv
length
palliat
concern
low
percentag
tya
data
report
extract
identifi
literatur
studi
adolesc
conclus
despit
effect
analgesia
clinic
experi
manag
pain
remain
preval
symptom
endoflif
children
cancer
given
small
patient
number
acknowledg
problem
treat
manag
teenag
young
adult
tya
tya
data
extract
major
publish
result
find
need
consist
present
statist
treatment
publish
research
find
avail
subcategori
data
c
barton
result
parent
recruit
around
elig
parent
father
mother
reason
cite
increas
matern
involv
studi
mother
primari
caregiv
father
primari
provid
financi
father
found
difficult
particip
retrospect
prospect
studi
patern
mental
health
reason
involv
studi
includ
desir
contribut
care
other
hope
lengthen
time
child
particip
research
improv
frequenc
qualiti
commun
whilst
receiv
palli
care
conclus
parent
recruit
palli
research
children
cancer
motiv
affect
multipl
factor
factor
prospect
retrospect
studi
potenti
sourc
bia
consid
health
qualiti
life
need
children
die
cancer
need
dissemin
improv
qualiti
futur
research
backgroundobject
hospit
healthcar
provid
strive
deliv
safest
care
possibl
howev
drugrel
problem
commonli
report
hospit
incidentreport
system
implement
part
qualiti
assur
system
improv
patient
safeti
qualiti
care
incid
discuss
multidisciplinari
team
expert
prevent
correct
action
defin
elabor
designmethod
retrospect
analysi
drugrel
incid
collect
incidentreport
system
perform
pediatr
hematooncolog
ward
incid
subclassifi
drug
involv
categor
accord
anatom
therapeut
chemic
atc
classif
system
enabl
identifi
class
drug
frequent
involv
result
total
nearli
report
incid
involv
drug
atc
level
could
retriev
defin
class
l
antineoplast
immunomodul
agent
commonli
involv
repres
n
drugrel
incid
follow
class
b
blood
blood
form
organ
especi
perfus
solut
j
antiinfect
system
use
n
n
nervou
system
n
alimentari
tract
metabol
h
system
hormon
prepar
v
variou
drug
conclus
drug
frequent
involv
incid
report
system
mainli
includ
antineoplast
immunomodul
agent
might
reflect
profil
complex
pediatr
oncolog
ward
prevent
action
includ
optim
electron
medicationchemotherapi
prescriptionadministr
program
especi
antineoplasticimmunomodul
agent
perfus
solut
well
introduct
new
revis
exist
guidelin
support
care
agent
antiinfect
pain
medic
chemotherapi
induc
nausea
vomit
final
must
mention
underreport
incid
suspect
backgroundobject
report
err
human
institut
medicin
conclud
mani
death
occur
hospit
unit
state
result
error
one
initi
promot
institut
healthcar
improv
recommend
strategi
decreas
number
prevent
inpati
death
one
recommend
strategi
implement
rapid
respons
team
rrt
also
known
medic
respons
team
avail
hour
per
day
evalu
patient
icu
develop
sign
symptom
clinic
deterior
pediatr
inpati
manifest
deterior
sever
hour
cardiopulmonari
arrest
rrt
potenti
effect
intervent
pediatr
inpati
object
analyz
reason
rtt
call
attend
pediatr
oncohematolog
patient
designmethod
retrospect
analysi
pediatr
oncohematolog
inpati
attend
rtt
result
call
pediatr
rtt
institut
oncohematolog
patient
base
diagnost
febril
neutropenia
neuroblastoma
bone
marrow
transplant
caus
rtt
call
fall
convuls
sepsi
respiratori
failur
other
patient
evalu
icu
pediatrician
took
conduct
revalu
sent
patient
icu
one
patient
sent
icu
other
remain
unit
staff
care
conclus
rtt
may
caus
signific
reduct
number
cardiorespiratori
arrest
oncohematolog
pediatr
patient
present
symptom
deterior
evalu
taken
care
team
independ
caus
call
none
evalu
patient
develop
cardiac
arrest
howev
classic
manifest
well
known
neuroblastoma
continu
present
atyp
except
symptom
make
real
enigmat
diseas
seri
one
hundr
sixti
seven
patient
neuroblastoma
review
report
atyp
clinic
characterist
initi
diagnosi
within
evolut
analyz
treatment
featur
designmethod
perform
retrospect
studi
pediatr
oncolog
unit
chu
de
beni
messou
one
hundr
sixti
seven
patient
neuroblastoma
regist
evalu
biochem
imag
investig
classifi
treat
accord
convent
protocol
regimen
result
four
patient
present
paraneoplast
neurolog
symptom
includ
opsoclonusmyoclonu
ataxia
syndrom
oma
bulbar
syndrom
polyradiculoneur
two
patient
cardiomyopathi
three
patient
develop
central
nervou
metastasi
observ
two
case
multifoc
neuroblastoma
two
children
exhibit
secondari
acut
leukemia
end
treatmentsurviv
rate
poor
patient
central
nervou
system
involv
secondari
acut
leukemia
except
oma
cardiomyopathi
conclus
patient
paraneoplast
symptom
exhibit
delay
diagnosi
metastasi
central
nervou
system
secondari
leukemia
associ
poor
prognosi
backgroundobject
hypnosi
effici
method
reduc
pain
anxieti
induc
invas
medic
procedur
diseas
cancer
easier
hypnot
adult
children
behav
differ
hypnosi
less
limit
cognit
stereotyp
permeabl
boundari
imagin
realiti
howev
procedur
children
often
fidget
appear
restless
requir
sustain
anim
hypnot
suggest
perform
observ
studi
determin
feasibl
benefit
hypnosi
pediatr
cancer
center
designmethod
two
psychologist
one
pediatr
oncologist
center
train
hypnosi
particular
focu
pediatr
hypnot
techniqu
propos
children
famili
altern
complementari
approach
pain
andor
anxieti
manag
relat
diseas
treatment
invas
medic
procedur
patient
younger
year
vulner
psycholog
profil
autism
psychosi
exclud
result
februari
februari
session
hypnosi
achiev
pediatr
patient
age
year
treat
cancer
hematolog
diseas
common
indic
lumbar
punctur
patient
pain
manag
patient
anxieti
manag
patient
placement
venou
cathet
patient
placement
nasogastr
tube
patient
invas
procedur
hypnosi
associ
analges
mixtur
nitrogen
monoxid
oxygen
meopa
hypnosi
increas
durat
cost
procedur
patient
report
posit
experi
prefer
meopa
alon
sedat
propofol
follow
procedur
conclus
hypnosi
inexpens
timeconsum
method
easili
implement
pediatr
cancer
center
improv
well
patient
famili
da
trehan
bansal
backgroundobject
bacteri
fungal
infect
contribut
morbid
mortal
children
cancer
studi
analys
spectrum
microbiologicallydocu
infect
mdi
attempt
identifi
riskfactor
designmethod
children
febril
neutropenia
fn
prospect
evalu
cultureposit
bacteri
infect
includ
invas
fungal
infect
ifi
classifi
proven
probabl
possibl
use
eortcmsg
aspergillu
candida
pseudallescheria
twentysixperc
develop
complic
metabol
fluidrefractori
shock
respiratori
failur
icu
admiss
neutropen
enterocol
acut
kidney
injuri
encephalopathi
neuroblastoma
one
hundr
forti
one
patient
expir
lost
follow
still
follow
morphin
use
pain
manag
syrup
inject
form
psycholog
support
provid
current
palli
care
program
hospit
base
futur
plan
extend
palli
care
home
provid
oral
morphin
extend
period
conclus
palli
care
essenti
right
child
cur
treatment
option
good
supportivepalli
care
avail
throughout
journeyaim
treatment
make
patient
pain
free
throughout
treatment
respiratori
distress
anxieti
end
life
manag
appropri
psycholog
support
anxiolyticssed
pakistan
access
use
morphin
limit
algorithm
proper
end
life
carepalli
care
recogn
essenti
compon
health
care
health
care
profession
gener
public
need
educ
palli
care
backgroundobject
decis
admit
child
statefund
picu
base
probabl
immedi
long
term
surviv
context
sever
resourc
constraint
aim
studi
determin
whether
referr
paediatr
oncologist
picu
appropri
challeng
percept
oncolog
patient
poor
prognos
thu
refus
admiss
picu
designmethod
retrospect
descript
audit
picu
admiss
period
perform
indic
admiss
underli
oncolog
diagnos
surviv
rate
caus
death
analys
result
one
hundr
seven
patient
admit
time
averag
durat
stay
icu
day
rang
day
underli
diagnos
central
nervou
system
tumour
solid
tumour
haematolymphoid
malign
tumour
indic
admiss
includ
postop
care
neutropaen
sepsi
mortal
rate
oncolog
patient
compar
overal
mortal
rate
picu
patient
six
patient
admit
neutropaen
sepsi
die
admiss
postop
care
patient
die
treatment
complic
five
year
surviv
rate
oncolog
patient
discharg
picu
death
occur
result
surgic
complic
neutropaen
sepsi
conclus
set
oncolog
patient
admit
picu
rel
low
mortal
rate
impli
select
criteria
picu
admiss
suffici
stringent
valid
score
system
admiss
oncolog
patient
decis
admit
patient
picu
base
overal
project
prognosi
oncolog
condit
paediatr
oncologist
refer
patient
expect
good
prognosi
refer
patient
neutropaen
sepsi
multiorgan
failur
backgroundobject
due
lack
exercis
recommend
pediatr
oncolog
exercis
adher
supervis
help
paramet
describ
subject
exert
therefor
essenti
children
adolesc
capabl
reflect
pattern
physic
activ
respect
amount
intens
present
studi
investig
reliabl
children
cancer
abl
selfestim
physic
activ
acut
treatment
designmethod
cours
previou
studi
physic
activ
et
al
subgroup
evalu
object
assess
tool
stepwatch
tm
activ
monitor
sam
addit
selfreport
questionnair
result
two
instrument
compar
regard
daili
minut
walk
amount
moderatetovigor
physic
activ
mvpa
sam
measur
walk
defin
intens
moder
activ
gait
cycl
per
minut
result
patient
year
age
month
initi
diagnosi
variou
tumor
entiti
leukemia
bone
tumor
other
blandaltman
plot
indic
averag
underestim
questionnair
min
limit
agreement
rang
min
ie
fairli
symmetr
underand
overestim
mvpa
deviat
minut
limit
agreement
min
comparison
day
least
min
mvpa
show
mark
differ
selfreport
day
versu
measur
day
result
pilot
work
indic
patient
may
reliabl
selfestim
physic
activ
therefor
exercis
therapi
also
incorpor
counsel
selfcompet
respect
percept
physic
activ
possibl
solut
would
selfsupervis
activ
commerci
activ
tracker
eg
fitbit
approach
evalu
institut
backgroundobject
feasibl
physic
activ
exercis
pediatr
oncolog
treatment
proven
evid
posit
effect
increas
baumann
et
al
braam
et
al
howev
exercis
promot
program
yet
gener
establish
current
offer
select
hospit
therefor
nationwid
network
call
activeoncokid
found
link
extend
exist
program
offer
exercis
pediatr
patient
cancer
well
establish
sustain
fund
possibl
designmethod
network
establish
compris
sport
scientist
physiotherapist
medic
doctor
psychologist
network
meet
organ
everi
two
year
network
member
twice
year
within
smaller
steer
group
discuss
current
progress
problem
potenti
scientif
collabor
result
sinc
establish
abl
success
support
addit
hospit
sport
club
implement
exercis
program
pediatr
patient
cancer
compos
multicentr
research
applic
cooper
health
insur
compani
gain
confid
medic
profession
although
progress
well
clinic
pediatr
oncolog
offer
exercis
program
children
adolesc
cancer
start
sustain
could
achiev
yet
project
financi
secur
conclus
next
step
plan
evalu
train
program
adjust
method
assess
scientif
evalu
effici
exercis
larg
multicentr
studi
draft
risk
contraind
well
entityspecif
aspect
train
control
furthermor
transnat
collabor
requir
exchang
local
experi
carri
joint
scientif
studi
work
group
backgroundobject
emerg
medicin
simul
train
program
well
establish
specif
program
skill
train
simul
pediatr
oncolog
lack
therefor
develop
threestep
train
simul
program
staff
member
pediatr
oncolog
designmethod
first
analysi
need
perform
via
questionnairebas
survey
empathi
commun
skill
well
practic
skill
perform
lumbar
punctur
bone
marrow
aspir
knowledgebas
topic
sideeffect
chemotherapi
complic
manag
transfus
medicin
identifi
hot
topic
accord
need
concept
compos
three
modul
set
result
first
modul
staff
member
learn
basic
principl
pediatr
oncolog
use
commerci
avail
model
lumbar
punctur
central
venou
line
manag
could
train
model
simul
bone
marrow
punctur
yet
avail
therefor
newli
develop
besid
commun
train
challeng
handson
exercis
one
focu
set
divers
pedagog
method
enhanc
learn
success
second
modul
contain
problemorient
task
particip
receiv
challeng
resolv
small
team
manag
given
complic
eg
tumorlysi
syndrom
third
modul
focuss
basic
teambas
task
quest
complex
feedback
spotlight
complet
cours
particip
felt
selfconfid
job
effect
sustain
backgroundobject
background
pediatrician
pediatr
oncologist
lack
space
relat
disciplin
theater
often
chanc
perform
art
activ
promot
help
staff
profession
perspectivesobject
spread
project
perform
pediatr
hospit
play
written
indian
nobel
prize
winner
rtagor
post
offic
adapt
perform
exclus
health
personnelshow
video
trailer
work
doneserv
exampl
continu
dissemin
initi
within
pediatr
oncolog
commun
designmethod
materialadapt
made
origin
work
r
tagor
post
officeperform
use
cast
pediatrician
attend
doctor
resid
assist
nurs
pediatrician
four
daughtersdirect
pediatrician
train
theaterther
perform
local
theater
ticket
sold
produc
benefit
associ
pediatr
palli
care
childrenmethodprepar
play
drive
element
teamworkthey
work
sceneri
stage
aspect
stage
present
speech
memori
emot
aspect
death
lost
aspect
work
help
acquir
skill
help
us
improv
aspect
need
profession
work
patient
famili
difficult
situat
child
palli
carether
also
social
profit
result
signific
econom
contribut
associ
dedic
children
palli
care
gener
uniqu
effort
multidisciplinari
collabor
among
peopl
creativ
project
reciproc
enrich
person
skill
teamwork
pneumonia
hospit
broad
spectrum
antibiot
administ
nonneutropen
mild
respiratori
tract
infect
treat
support
approach
outpati
patient
influenza
treat
oseltamivir
death
due
respiratori
tract
infecton
seri
conclus
virus
major
caus
respiratori
tract
infect
children
cancer
oseltamivir
effect
treatment
influenza
children
cancer
sinc
effect
antivir
agent
respiratori
virus
infect
control
earli
diagnosi
import
prevent
spread
infect
case
hospit
support
care
need
reduc
morbid
avoid
mortal
backgroundobject
physic
educ
pe
school
aim
promot
children
physic
psychosoci
abil
contribut
develop
longterm
activ
lifestyl
germani
pediatr
patient
cancer
often
attend
school
therefor
particip
pe
acut
treatment
undergo
cancer
therapi
children
physic
activ
level
reduc
dramat
winter
et
al
physic
limit
persist
throughout
adulthood
ness
et
al
primari
object
analyz
statu
particip
pe
yet
suffici
examin
whether
pediatr
patient
return
pe
follow
cancer
treatment
secondli
barrier
handicap
reintegr
identifi
designmethod
data
collect
use
standard
questionnair
kiggsstudi
german
health
interview
examin
survey
children
adolesc
supplement
question
relat
pe
reason
particip
use
instrument
enabl
comparison
ageand
genderrel
refer
valu
healthi
children
result
patient
cancer
year
age
month
posttreat
attend
school
sinc
least
two
month
includ
leukemialymphoma
bone
tumor
brain
tumor
solid
tumor
although
patient
desir
particip
pe
particip
full
extent
whereof
report
particip
mention
partli
particip
problem
becam
obviou
patient
treat
bone
tumor
partlynonparticip
identifi
barrier
includ
person
physicalpsychosoci
social
parentsclassm
structur
reason
teachercurriculum
conclus
contrari
patient
motiv
high
percentag
particip
pe
school
within
two
year
posttreat
initi
attempt
reintegr
program
depart
detail
examin
barrier
show
success
conquer
commun
profession
advic
support
patient
teacher
parent
winter
et
al
children
cancer
addit
increas
cancerrel
burden
presum
lead
persist
problem
like
reduc
motor
perform
et
al
treatment
kest
et
al
furthermor
patient
ask
supervis
train
session
individu
support
motiv
et
al
object
implement
train
program
pediatr
patient
cancer
treatment
designmethod
last
six
year
supervis
individuallytailor
train
program
offer
children
age
year
treatment
variou
entiti
differ
physic
limit
local
depart
content
adapt
sport
histori
person
goal
medic
condit
agerel
physic
educ
topic
intens
vari
low
moder
high
load
depend
ondit
result
train
program
could
feasibl
implement
local
stationari
ambul
pediatr
cancer
ward
patient
show
high
accept
frequent
presenc
physic
complaint
also
underlin
need
broad
rang
exercis
method
allow
minimum
program
even
poor
gener
condit
futhermor
exercis
promot
offer
home
stay
program
provid
individu
safe
enhanc
physic
activ
cancer
ward
expand
exercis
promot
includ
home
stay
treatment
well
current
evalu
twopart
model
consist
supervis
exercis
intervent
inpati
stay
person
train
schedul
compris
individu
goal
exercis
home
stay
activ
tracker
fitbit
provid
feedback
daili
step
home
stay
regular
commun
mail
phone
facetofac
ensur
support
safeti
special
offer
could
feasibl
altern
cancer
sport
group
difficlut
realiz
pediatr
patient
cancer
due
limit
incid
larg
catchment
area
ensur
child
receiv
qualiti
care
deserv
struggl
health
profession
face
accuraci
object
essenti
compon
patient
care
specif
pediatr
patient
concern
may
abl
verbal
physic
psycholog
discomfort
distress
well
adult
henc
becom
imper
nurs
technician
abl
identifi
sourc
distress
discomfort
pediatr
patient
cancer
designmethod
pilot
studi
carri
student
enrol
nurs
technician
program
children
cancer
unit
ccu
indu
hospit
nurs
technician
test
observ
skill
ward
children
cancer
unit
taught
mind
skill
train
test
observ
skill
pediatr
patient
cancer
qualit
analysi
data
reveal
observ
skill
improv
remark
post
intervent
student
abl
accur
gaug
sign
physic
psycholog
distress
discomfort
pediatr
patient
conclus
inaccur
bias
report
major
hurdl
pediatr
care
make
health
profession
overlook
symptom
may
life
threaten
effect
observ
skill
miss
qualiti
care
pediatr
patient
alreadi
compromis
time
abl
voic
accur
concern
symptom
may
caus
distressth
data
yield
result
mind
skill
use
effect
gather
object
accur
inform
regard
patient
thu
improv
qualiti
care
backgroundobject
children
suffer
cancer
excruci
pain
especi
end
life
care
phase
order
improv
qualiti
life
end
life
stage
becom
prioriti
reduc
physic
psycholog
distress
reiki
complementari
altern
energi
therapi
use
allevi
stress
anxieti
increas
relax
improv
overal
qualiti
life
children
cancer
reduc
physic
psycholog
distress
designmethod
hundr
session
reiki
carri
period
two
year
children
cancer
end
life
care
children
cancer
unit
indu
hospit
result
session
session
result
reduct
physic
psycholog
distress
patient
sometim
children
would
call
lay
hand
affect
area
magic
reiki
help
allevi
suffer
gave
respit
constant
excruci
pain
suffer
conclus
reiki
need
part
end
life
care
children
suffer
cancer
provid
relief
physic
distress
also
reduc
psycholog
distress
associ
impend
death
progress
diseas
hospit
hear
appal
mani
thought
issu
complex
ask
physician
role
incorrect
help
involv
hospit
administr
thought
inappropri
conclud
hod
total
incorrect
sinc
hospit
need
receiv
payment
continu
function
surfac
case
hospit
hod
may
obviou
hospit
may
sign
contract
patient
ensur
patient
legal
bound
pay
hospit
fee
therapi
fail
hospit
may
use
pressur
tactic
partial
waiv
fee
overal
hod
may
grossli
underrecogn
underreport
base
analys
area
futur
focu
research
includ
percept
survey
standard
hod
definit
acknowledg
complex
hod
within
health
system
account
transpar
may
promot
without
blame
work
fieldbas
team
member
engag
human
right
health
law
polici
govern
ethic
conclus
present
report
highlight
need
explor
perspect
role
physician
hod
practic
across
set
differ
polici
may
place
integr
part
health
care
deliveri
system
physician
could
play
pivot
role
stop
hospit
detent
kumar
backgroundobject
one
rapidli
grow
aspect
palli
care
servic
need
day
care
enough
research
avail
prove
itthu
studi
conduct
aim
assess
impact
day
care
center
improv
qualiti
life
qol
pediatr
cancer
patient
provid
palli
care
servic
multidisciplinari
team
approach
near
tertiari
care
hospit
new
delhi
designmethod
prospect
compar
studi
conduct
evalu
effect
palli
care
servic
inpati
depart
day
care
transit
home
cankid
nongovernment
organ
day
care
patient
compar
comparison
group
provid
type
palli
care
servic
order
examin
effect
day
care
time
semistructur
interview
carri
entri
studi
day
care
week
week
week
respect
interview
schedul
includ
palli
care
outcom
scale
po
measur
health
relat
qol
form
questionnair
result
fifti
patient
randomli
select
male
median
year
resid
new
delhi
week
period
admit
day
care
center
palli
care
servic
recruit
studi
comparison
group
also
consist
patient
male
median
year
resid
new
delhi
requir
palli
care
support
receiv
receiv
standard
treatment
cancer
tertiari
center
differ
statist
signific
qol
studi
group
receiv
palli
care
servic
day
care
center
compar
comparison
group
conclus
studi
demonstr
patient
offer
palli
care
servic
day
care
better
qol
backgroundobject
rehabilit
young
cancer
patient
whose
psycholog
locomotor
function
affect
due
treatment
provid
therapi
session
collabor
srccccd
rehabilit
centr
designmethod
tmh
along
ugam
collabor
srccccd
multi
specialti
rehabilitationtherapi
centr
mumbai
offer
therapi
young
cancer
patient
disturb
psycholog
locomotor
function
execut
administr
ugam
member
charg
facilit
collabor
centr
conduct
physiotherapi
occup
therapi
speech
therapi
educ
therapi
session
evalu
patient
patient
given
rate
good
fair
poor
base
aforesaid
evalu
monthli
report
sent
hospit
give
detail
assess
recommend
follow
patient
may
may
advis
follow
give
due
consider
hisher
sensori
adl
psycholog
psychosoci
locomotor
function
evalu
evalu
done
free
cost
srccccd
conclus
srccccd
taken
except
step
rehabilit
activ
cancer
patient
session
boon
patient
parent
also
doctor
abl
rehabilit
patient
success
implement
rehabilit
session
imper
long
term
physic
mental
develop
patient
expect
sever
cancer
patient
get
benefit
activ
backgroundobject
fever
common
complaint
children
cancer
outpati
oncolog
clinic
emerg
depart
ed
potenti
lifethreaten
complic
requir
immedi
identif
manag
broadspectrum
antibiot
conduct
qualiti
improv
project
decreas
time
antibiot
triag
administr
minut
less
febril
oncolog
patient
central
venou
cathet
cvc
undergo
treatment
designmethod
util
model
improv
methodolog
collect
baselin
data
month
discuss
occur
relev
stakehold
includ
ed
oncolog
provid
md
np
rn
identifi
barrier
achiev
goal
minut
antibiot
administr
subsequ
develop
intervent
conduct
pdsa
plan
studi
act
cycl
target
barrier
month
statist
process
control
chart
use
prospect
analyz
data
result
identifi
barrier
includ
lack
staff
parent
educ
import
time
administr
antibiot
ed
clinic
staff
discomfort
administ
antibiot
prior
know
child
neutrophil
count
difficulti
ed
nurs
access
troubleshoot
cvc
particularli
mediport
follow
intervent
bundl
develop
staff
educ
guidelin
manag
febril
oncolog
patient
b
provid
educ
estim
patient
neutrophil
count
c
distribut
parentalpati
cvc
card
ed
nurs
educ
enhanc
cvc
access
skill
median
time
antibiot
decreas
minut
overal
percent
patient
receiv
antibiot
minut
increas
conclus
discuss
provid
care
febril
pediatr
oncolog
patient
identifi
barrier
target
decreas
time
antibiot
month
barrier
may
institut
specif
other
may
global
barrier
may
help
creat
febril
pediatr
oncolog
patient
manag
guidelin
backgroundobject
intens
treatment
strategi
children
cancer
support
care
play
increasingli
import
role
unfortun
evidencebas
guidelin
avail
area
might
contribut
suboptim
conflict
support
care
children
cancer
studi
object
explor
current
practic
variat
support
care
children
cancer
netherland
designmethod
conduct
indepth
review
local
guidelin
protocol
among
dutch
pediatr
cancer
center
compil
list
compris
import
support
care
topic
verifi
pediatr
oncologist
center
assess
correspond
daili
support
care
practic
hospit
subsequ
evalu
clinic
practic
pediatr
oncolog
center
concord
center
partli
concord
almost
center
discord
center
questionnair
compris
question
regard
support
care
topic
found
concord
item
partial
concord
item
discord
item
explor
conform
three
current
evidencebas
guidelin
vari
gener
low
conclus
netherland
major
variat
exist
daili
practic
support
care
childhood
cancer
patient
develop
integr
clinic
practic
guidelin
daili
practic
potenti
greatli
contribut
uniform
evidencebas
practic
therebi
contribut
better
outcom
childhood
cancer
patient
develop
implement
guidelin
next
step
project
backgroundobject
neuropath
pain
pain
relat
bone
vasoocclus
crise
children
often
treat
pain
killer
respons
mani
side
effect
lidocain
patch
recommend
treatment
neuropath
pain
adult
evalu
childrenth
purpos
studi
evalu
safeti
efficaci
lidocain
pediatr
popul
designmethod
trial
design
phase
ii
prospect
open
nonrandom
multicent
studi
patient
yearsold
suffer
neuropath
pain
superfici
bone
vasoocclus
crise
propos
particip
rate
success
defin
rate
patient
least
consecut
day
show
decreas
point
visual
analogu
pain
scale
va
lidocain
patch
applic
measur
made
hour
use
onestag
fleme
design
patient
enrol
minimum
success
necessari
conclud
treatment
effect
toler
determin
rate
patient
advers
reaction
accord
criteria
nation
cancer
institut
common
terminolog
criteria
advers
event
result
forti
patient
enrol
studi
analys
day
va
score
significantli
reduc
least
two
point
patient
patient
decreas
least
two
point
va
consecut
day
patient
experienc
grade
toxic
conclus
use
patch
allow
reduc
intens
pain
half
popul
studi
howev
ca
nt
conclud
efficaci
use
statist
design
beforehand
establish
nevertheless
consid
good
toler
state
safe
could
integr
therapeut
arsen
avail
pediatr
pain
manag
consequ
diseas
progress
central
sensit
painkil
side
effect
like
opioid
induc
hyperalgesia
lead
intract
pain
despit
well
conduct
treatment
ketamin
n
methyl
aspart
receptor
antagonist
shown
effici
reliev
cancer
pain
adult
popul
literatur
regard
children
scarc
designmethod
prospect
multicentr
observ
studi
approv
french
regulatori
cctri
cnil
aim
assess
efficaci
safeti
opioidspar
effect
low
dose
ketamin
ad
opioid
analges
improv
refractori
cancer
pain
children
result
thirtyeight
patient
median
age
french
pediatr
oncolog
center
regist
month
period
receiv
ketamin
either
intraven
oral
adjuv
treatment
refractori
pain
mean
pain
score
overal
popul
significantli
decreas
day
mean
va
day
mean
va
p
va
score
reduc
least
two
point
patient
initi
ketamin
nine
patient
experienc
poor
toler
least
side
effect
infus
rate
lower
mgkgh
none
limit
toxic
concomit
prescript
benzodiazepin
shown
effici
control
side
effect
opioidspar
effect
highlight
four
patient
prescrib
patient
found
ketamin
addit
help
even
experienc
improv
pain
score
conclus
adjunct
low
dose
ketamin
opioid
analges
children
suffer
refractori
cancer
pain
allow
reduc
intens
pain
half
popul
studi
howev
ca
nt
conclud
efficaci
use
statist
design
beforehand
establish
nevertheless
ketamin
may
interest
safe
option
improv
treatment
refractori
pain
children
cancer
inclus
criteria
compris
children
year
old
repres
least
particip
activ
treatment
cancer
cm
use
exclus
criteria
includ
failur
includ
least
one
core
outcom
rate
type
reason
use
primari
studi
type
includ
without
languag
exclus
articl
screen
data
extract
independ
conduct
two
review
discrep
resolv
consensu
result
abstract
retriev
abstract
screen
duplic
remov
qualifi
fulltext
review
articl
countri
report
relev
data
lowincom
countri
lic
lowermiddleincom
countri
lmic
uppermiddleincom
countri
umic
highincom
countri
hic
report
rate
cm
use
among
pediatr
oncolog
patient
vari
median
liclmic
compar
median
hic
public
span
report
rate
cm
use
appear
increas
time
provis
care
tradit
healer
report
frequent
lic
lmic
hic
abandon
convent
cancer
care
delay
diagnosi
associ
cm
use
set
conclus
cm
strategi
use
commonli
paediatr
oncolog
patient
worldwid
integr
cm
practic
paediatr
oncolog
program
may
offer
opportun
improv
treatment
adher
outcom
median
time
diagnosi
death
iqr
nineteen
patient
met
criteria
septic
shock
neutropen
leukemia
lymphoma
solid
tumor
medulloblastoma
common
primari
site
infect
respiratori
tract
follow
gastrointestin
skin
patient
primari
site
infect
evid
pathogen
identifi
children
bacteri
agent
gram
fungal
agent
virus
three
patient
coinfect
two
gram
fungu
one
gram
gram
bacteria
fifteen
patient
die
intens
care
unit
pou
ward
local
hospit
ward
conclus
infect
major
caus
toxic
death
children
cancer
improv
overal
surviv
especi
submit
agress
treatment
new
strategi
infect
prevent
treatment
develop
well
educ
tool
profession
famili
backgroundobject
mucos
term
describ
inflammatori
respons
mucos
surfac
bodi
respons
cytotox
effect
oncolog
treatment
oral
mucos
one
receiv
attent
due
high
incid
impact
patient
qualiti
life
uniform
standard
manag
aim
small
studi
describ
aspect
relat
dental
health
oral
care
aleatori
sampl
pediatr
oncohematolog
patient
designmethod
sampl
aleator
patient
gregorio
hospitaloncohematolog
paediatr
depart
analyz
three
odontoestomatologist
order
describ
differ
paramet
oral
health
statu
dental
care
prevent
oral
mucos
small
studi
observ
patient
never
receiv
prior
dental
board
sweet
cold
food
prefer
follow
cold
salti
one
enhanc
fact
cryotherapi
effect
pain
treatment
mucos
accept
oral
hygien
time
evalu
among
patient
evalu
inpati
outpati
mucos
patient
brush
teeth
treatment
accord
result
studi
patient
receiv
hygien
tip
present
higher
degre
mucos
valu
probabl
relat
highest
risk
mucos
longer
neutropeniadrug
radiotherapytyp
cancer
patient
receiv
treatment
mucos
report
chlorhexidin
best
option
heal
conclus
need
unifi
criteria
develop
prevent
therapeut
protocol
clinic
applic
includ
pharmacolog
nonpharmacolog
treatment
teeth
brush
cryotherapi
aim
new
biggest
studi
begun
backgroundobject
despit
signific
increas
surviv
childhood
cancer
remain
signific
caus
death
children
young
peopl
paediatr
palli
care
evolv
subspecialti
whose
primari
aim
work
young
peopl
famili
improv
qualiti
life
ultim
death
intern
increas
emphasi
involv
patient
carer
decis
make
palliationinclud
decis
regard
locat
death
die
aim
literatur
review
determin
prefer
place
death
identifi
factor
influenc
decis
designmethod
embas
medlin
cumul
index
nurs
alli
health
literatur
cinahl
search
use
term
child
cancer
place
death
independ
review
assess
articl
relev
inclus
result
studi
includ
countri
major
studi
retrospect
review
death
certif
medic
record
four
studi
use
semistructur
questionnair
given
bereav
parent
three
prospect
studi
locat
death
vari
significantli
home
death
rang
hospit
death
minor
patient
die
hospic
rang
intern
signific
differ
locat
death
children
young
peopl
die
cancer
review
identifi
mani
factor
contribut
place
death
patient
demograph
diseas
diagnosi
stage
time
diagnosi
geographi
cultur
belief
socioeconom
statu
signific
avail
paediatr
palli
care
servic
abil
provid
end
life
care
prefer
place
death
key
role
palli
care
facilit
parent
patient
choic
health
profession
ensur
develop
flexibl
servic
provid
care
requir
locat
choic
power
advoc
uniqu
vulner
group
posit
respons
obtain
follow
questionnair
complet
respons
rate
age
rang
individu
involv
year
increas
use
form
extrem
rang
form
use
neonat
transit
set
uptak
reflect
popul
distribut
across
nation
form
fill
peopl
live
central
belt
clinician
rate
form
use
easi
easi
similar
proport
rate
polici
good
excel
backgroundobject
scottish
manag
servic
network
msn
children
young
peopl
cancer
establish
scottish
govern
ensur
equiti
access
provis
care
popul
scotland
irrespect
locat
manageri
secretari
support
provid
network
independ
health
board
despit
recent
work
suggest
number
children
life
limit
threaten
diagnosi
much
greater
thought
remain
rare
provid
often
isol
physic
intellectu
weekli
telephon
monthli
video
multi
disciplinari
meet
began
may
link
profession
across
disciplin
site
designmethod
retrospect
review
mdt
attend
log
review
servic
result
median
profession
attend
phone
confer
iqr
median
attend
video
confer
iqr
hospic
commun
secondari
tertiari
care
paediatr
nurs
staff
alway
attend
alli
health
profession
attend
meet
becam
establish
paediatr
haematologist
attend
profession
clear
meet
enhanc
work
practic
welcom
formal
structur
provid
msn
meet
univers
rate
import
mdt
attend
conclus
use
proforma
frame
case
discuss
welcom
meet
would
happen
without
manageri
support
msn
need
done
engag
haematolog
colleagu
impact
practic
improv
integr
care
develop
qualiti
indic
rapidli
improv
practic
deliveri
uniqu
vulner
patient
group
backgroundobject
pediatr
oncolog
patient
current
practic
includ
administ
varicellazost
immunoglobulin
vzig
postexposur
prophylaxi
pep
varicellazost
viru
vzv
isol
patient
day
pediatr
oncolog
patient
immun
vzv
prior
cancer
diagnosi
repres
popul
like
preserv
immun
diseas
popul
need
vzig
isol
poorli
valid
may
undu
health
care
cost
inconveni
patient
therefor
assess
vzv
serolog
postchemotherapi
marker
persist
immun
chemotherapi
designmethod
approv
research
ethic
board
children
hospit
eastern
ontario
cheo
obtain
prior
studi
varicella
antibodi
titer
collect
pediatr
oncolog
patient
treat
cheo
patient
includ
studi
posit
titer
time
malign
diagnosi
antibodi
test
postchemotherapi
treatment
result
one
hundr
eighti
two
patient
posit
vzv
antibodi
titer
diagnosi
repeat
test
perform
posttreat
posit
neg
equivoc
vzv
antibodi
titer
respect
moreov
chickenpox
develop
shingl
chemotherapi
posttreat
retest
vzv
antibodi
titer
correl
age
tumour
type
preserv
vzv
antibodi
titer
major
pediatr
oncolog
patient
prior
vzv
antibodi
titer
preserv
vzv
immun
post
chemotherapi
consequ
popul
vzig
pep
isol
hospit
may
necessari
japan
unit
kingdom
acyclovir
use
costeffect
altern
patient
vzv
seroposit
prior
malign
studi
determin
risk
factor
predispos
patient
breakthrough
diseas
may
identifi
subgroup
patient
vzig
pep
isol
hospit
necessari
backgroundobject
one
program
associ
care
pediatr
oncolog
patient
palli
care
program
mani
latin
american
countri
start
form
lack
place
program
relat
field
medicin
polici
sometim
drive
exist
programslatin
america
compos
countri
share
languag
cultur
trait
defici
health
system
make
us
differ
region
nation
test
countri
palli
care
program
may
partial
success
requir
take
account
multiethn
cultur
variou
characterist
place
spiritu
express
designmethod
program
train
pediatr
palli
care
nurs
start
one
local
nurs
train
nurs
central
america
caribbean
start
two
month
rotat
guatemala
object
program
achiev
qualiti
earli
immers
palli
care
oncolog
diseas
although
patient
curabl
symptom
manag
emot
support
patient
trajectori
diseas
cultur
approach
patient
palli
care
understand
spiritu
variabl
character
profession
trainer
direct
observ
train
nurs
two
consecut
month
plu
draft
countri
methodolog
train
trainer
project
multipli
effect
countri
train
train
backgroundobject
incid
malnutrit
children
cancer
vari
depend
diagnosi
extent
diseas
well
type
antineoplast
therapi
malnutrit
associ
lower
toler
delay
chemotherapi
frequent
sever
side
effect
compromis
immun
function
aim
studi
show
experi
total
parenter
nutrit
tpn
children
cancer
point
import
nutrit
support
pediatr
oncolog
designmethod
twenti
four
children
receiv
tpn
treatment
cancer
children
hospit
rijeka
includ
studi
indic
start
nutrit
support
follow
bodi
weight
percentil
age
andor
bodi
mass
index
percentil
age
diagnosi
bodi
weight
loss
greater
prior
diagnosi
treatment
children
refus
unabl
mucos
diarrhea
take
food
result
averag
length
tpn
day
rang
day
seventi
six
percent
children
weight
gain
median
rang
patient
mild
hepatotox
observ
requir
discontinu
chemotherapi
three
adolesc
concomit
steroid
therapi
glucos
intoler
need
insulin
therapi
observ
side
effect
occur
conclus
result
confirm
tpn
effect
method
establish
proteinenergi
balanc
pediatr
patient
cancer
weight
gain
satisfactori
complic
rare
transitori
result
thrombos
port
system
observ
patient
cathet
associ
bloodstream
infect
pneumothorax
migrat
cathet
wire
intern
jugular
bloodstream
observ
subclavian
vein
intern
jugular
vena
opposit
side
first
attempt
manag
punctur
ijv
catheter
conclus
use
ultrason
mark
permit
avoid
injuri
adjac
anatom
structur
reduct
durat
surgeri
use
xray
scanner
posit
port
cathet
prevent
migrat
cervic
vein
enabl
place
tip
cathet
v
cava
superior
directli
right
atrium
entri
site
backgroundobject
treatment
tumor
imposs
without
venou
access
kind
properti
possess
safe
easi
use
implant
treatment
cours
minim
risk
associ
implant
use
aim
prevent
complic
intraven
chemotherapeut
agent
administr
designmethod
monitor
treatment
children
age
month
year
differ
tumor
patient
underw
subclavian
vein
catheter
patient
venou
port
implant
result
complic
technic
difficulti
cathet
insert
observ
case
venou
port
implant
case
complic
subclavian
cathet
venou
port
use
observ
case
respect
subclavian
cathet
compromis
cancer
treatment
patient
implant
venou
port
patient
patient
subclavian
cathet
underw
central
venou
catheter
time
mean
time
treatment
cathet
dwell
time
exceed
recommend
limit
patient
except
case
cathet
remov
patient
multipl
occas
patient
discharg
subclavian
cathet
place
conclus
venou
port
obvious
match
criteria
mention
introduct
subclavian
cathet
use
result
cancer
treatment
protocol
deviat
almost
case
thu
lead
poorer
prognosi
significantli
increas
number
invas
procedur
instanc
gener
anesthesia
need
backgroundobject
stenotrophomona
maltophilia
emerg
multidrug
resist
gramneg
bacillu
ubiquit
natur
concern
immunocompromis
host
potenti
life
threaten
analyz
clinic
characterist
risk
factor
outcom
pediatr
oncolog
patient
maltophilia
infect
center
designmethod
microbiolog
data
pediatr
oncolog
bmt
patient
retrospect
analyz
hospit
record
analyz
treatment
receiv
outcom
result
smaltophilia
isol
blood
cultur
patient
studi
period
around
febril
neutropenia
episod
patient
posit
blood
cultur
age
patient
rang
year
underli
diagnosi
acut
promyelocyt
leukemia
burkitt
lymphoma
aplast
anemia
thalassemia
major
post
cord
blood
transplant
respiratori
symptom
grade
mucos
one
chest
wall
abscess
pu
cultur
endotrach
secret
posit
case
indwel
central
venou
access
devic
time
infect
subsequ
remov
three
patient
neutropen
onset
infect
durat
neutropenia
last
week
patient
patient
receiv
broadspectrum
antibiot
receiv
steroid
prior
ill
fall
wbc
count
notic
patient
onset
infect
organ
sensit
levofloxacin
cotrimoxazol
ceftazidim
treat
cotrimoxazol
receiv
levofloxacin
two
patient
succumb
ill
patient
recoveri
neutrophil
count
till
death
rest
neutropenia
recov
improv
sepsi
conclus
although
ubiquit
less
virul
smaltophilia
caus
sever
sepsi
death
immunocompromis
host
remov
indwel
cathet
prompt
initi
appropri
antibiot
recoveri
neutropenia
help
surviv
pediatr
cancer
patient
famili
assess
current
practic
effect
perspect
pediatr
acp
pacp
regard
cancer
designmethod
search
pubm
empir
literatur
pacp
concern
cancer
publish
januari
decemb
key
word
pediatr
cancer
advanc
care
plan
advanc
direct
result
examin
studi
identifi
pacp
relat
cancer
studi
focus
exclus
teen
adolesc
studi
includ
famili
includ
end
life
care
refer
way
provid
pacp
refer
effect
preliminari
data
suggest
pacp
cancer
patient
famili
success
implement
perceiv
help
may
emot
reliev
facilit
commun
help
improv
decisionmak
conclus
think
acp
process
helpful
children
cancer
well
teen
adolesc
research
children
year
age
difficult
find
case
children
basic
convers
done
cours
differ
comprehens
children
differ
age
adjust
support
accordingli
order
adopt
acp
children
build
trust
relationship
start
earli
stage
need
therefor
would
like
conduct
research
within
younger
age
bracket
find
way
appli
pacp
effect
backgroundobject
high
risk
infertil
success
childhood
cancer
treatment
prepubert
boy
fertil
preserv
might
possibl
freez
testicular
biopsi
chemotherapi
thank
still
ongo
research
spermatogoni
stem
cell
ssc
isol
cryopreserv
tissu
propag
autotranspl
adult
patient
facilit
natur
conceptionalthough
basic
research
still
need
interv
biopsi
autotransplant
legitim
start
cryopreserv
research
set
approv
dutch
central
ethic
commiss
designmethod
everi
prepubert
boy
present
children
oncolog
depart
malign
requir
chemotherapi
increas
risk
infertil
consid
fertil
preserv
gener
anesthesia
unilater
testicular
biopsi
taken
use
microsurg
techniqu
link
central
line
placement
chemotherapi
separ
anaesthesia
necessari
follow
patient
includ
postop
examin
surgeri
relat
complic
ultrasonographi
testi
predetermin
time
interv
month
postsurgeri
test
evalu
abnorm
testi
parenchyma
testicular
perfus
result
parent
boy
ask
particip
declin
sign
inform
consent
testicular
biopsi
perform
without
complic
spermatogonia
preserv
patient
one
spermatogonia
found
patient
evalu
year
surgeri
patient
minor
disturb
testi
parenchyma
patient
normal
testi
parenchyma
normal
perfus
fertil
preserv
perform
testicular
biopsi
prior
chemotherapi
prepubert
boy
cancer
safe
procedur
therefor
routin
offer
backgroundobject
test
valu
novel
promis
anticanc
medic
clinic
trial
children
essenti
parent
perspect
regard
clinic
trial
particip
child
incur
cancer
specif
child
burden
import
topic
warrant
attent
aim
studi
explor
parent
perspect
particip
child
incur
cancer
clinic
trial
designmethod
retrospect
questionnair
send
parent
lost
child
cancer
parent
request
whether
child
incur
cancer
particip
clinic
trial
palli
phase
motiv
particip
child
perceiv
burden
whether
would
enrol
median
followup
time
year
year
result
parent
deceas
children
indic
child
particip
clinic
trial
palli
phase
parent
reason
child
particip
one
answer
possibl
treatment
futur
patient
follow
hope
cure
prolong
child
life
reason
question
child
burden
particip
parent
mark
burdensom
parent
burdensom
remain
parent
score
none
parent
would
declin
particip
would
situat
conclus
perform
clinic
trial
even
vulner
popul
children
cancer
end
life
may
alway
lead
increas
burden
none
parent
would
futur
given
circumst
declin
particip
clinic
trial
backgroundobject
number
studi
explor
longterm
adjust
bereav
sibl
limit
lack
conclus
evid
psychosoci
adjust
sibl
death
brother
sister
cancer
gain
knowledg
longterm
adjust
sibl
import
abl
adequ
meet
need
sibl
designmethod
parent
lost
child
cancer
ask
retrospect
complet
two
statement
wellb
sibl
embed
larger
studi
explor
parent
perspect
paediatr
palli
care
parent
ask
rate
statement
fivepoint
likert
scale
rang
disagre
agre
result
sixtyeight
parent
complet
question
sibl
wellb
total
parent
somewhat
agre
statement
children
experienc
lot
problem
period
death
brothersist
interestingli
parent
mention
sibl
still
experienc
neg
consequ
result
death
brothersist
median
followup
time
year
parent
conclus
neg
consequ
child
loss
still
occur
bereav
sibl
even
mani
year
later
though
report
find
small
evalu
use
valid
instrument
measur
sibl
wellb
find
valuabl
stress
need
support
sibl
could
improv
futur
paediatr
palli
care
consid
impact
sibl
loss
upcom
studi
focu
develop
support
intervent
strategi
sibl
explor
whether
potenti
effect
intervent
strategi
sustain
time
pediatr
blood
cancer
doi
multipl
pattern
present
differ
biolog
behavior
sever
lesion
vari
wide
rang
asymptomat
lifethreaten
complic
designmethod
record
infant
children
day
year
old
respect
giant
hepat
hemangioma
decemb
februari
collect
clinic
data
includ
sex
age
symptom
size
number
locat
tumor
preoper
liver
function
test
complic
retroact
review
follow
inform
avail
patient
result
three
patient
underw
therapi
propranolol
mgkgdie
newborn
repeat
ultrasonographi
month
show
almost
complet
clearanc
hepat
focal
lesion
advers
event
therapi
entir
durat
treatment
child
treatment
past
two
year
evid
diseas
recurr
patient
year
old
indic
surgic
intervent
left
hepat
lobectomi
abdomin
pain
increas
hemangioma
size
two
month
third
patient
wait
result
one
month
therapi
conclus
mani
treatment
option
avail
hepat
hemangioma
close
observ
reserv
symptomat
tumor
surgic
resect
offer
symptom
relief
complic
hemangioma
lesion
diagnosi
uncertain
experi
hepat
hemangioma
associ
prenat
cardiac
disord
larg
volum
one
enlarg
hepat
vessel
poorer
outcom
requir
specif
perinat
multidisciplinari
manag
backgroundobject
pediatr
surgic
practic
diagnosi
either
hors
shoe
kidney
bilater
wt
uncommon
combin
extrem
rare
share
rare
associ
bilater
wt
hors
shoe
kidney
associ
wagr
syndrom
delet
syndrom
challeng
cours
manag
designmethod
child
present
month
age
hypospadia
right
nonpalp
undescend
testi
udt
also
aniridia
nystagmu
diagnos
wagr
syndrom
complex
regular
monthli
follow
one
half
year
age
underw
laparoscop
fowler
stephen
orchidopexi
elsewher
year
present
abdomin
full
pain
defec
evalu
found
bilater
wt
hors
shoe
kidney
result
child
receiv
week
neoadjuv
chemotherpay
vincristindactinomycindoxorubicin
subject
surgeri
left
nephroureterectomi
tumor
involv
entir
left
moieti
partial
nephrectomi
right
side
perform
postop
child
develop
hypertens
renal
insuffici
put
hemodialysi
hemodialysi
continu
chemotherapi
plan
continu
ambulatori
periton
dialysi
capd
chemotherapi
child
later
admit
emerg
loos
stool
shock
succumb
sever
unrespons
shock
conclus
patient
wagr
syndrom
carri
higher
risk
develop
wt
also
risk
end
stage
renal
diseas
risk
increas
tumor
bilater
recommend
frequent
follow
first
year
earli
diagnosi
evalu
surveil
patient
wagr
syndrom
backgroundobject
pulmonari
metastas
may
identifi
either
primari
diagnosi
relaps
aim
determin
feasibl
safeti
effect
treatment
decis
long
term
outcom
pulmonari
metastasectomi
designmethod
patient
underw
pulmonari
metastasectomi
identifi
institut
patholog
databas
case
note
retrospect
review
result
nineteen
patient
male
median
age
year
month
iqr
year
solid
tumour
underw
metastasectomi
ten
patient
underw
surgeri
end
first
line
therapi
treatment
relaps
eleven
metastas
identifi
cxr
ct
ct
least
metastat
nodul
remov
hemithorac
patient
unilater
bilater
thoracoscop
major
postop
complic
observ
patient
excis
complet
patholog
radiolog
one
patient
underw
initi
thoracoscopi
requir
subsequ
open
resect
achiev
viabl
tumour
resect
patient
remain
nonviablenecrot
tumour
excis
determin
need
lung
radiotherapi
chang
chemotherapi
patient
nine
patient
complet
resect
aliv
median
followup
month
iqr
patient
die
achiev
complet
resect
nodul
radiolog
conclus
experi
support
evid
pulmonari
metastasectomi
paediatr
solid
tumour
feasibl
safe
complet
excis
achiev
radiolog
patholog
aid
ongo
manag
decis
may
contribut
improv
long
term
outcom
therefor
recommend
care
consider
given
surgic
resect
pulmonari
metastat
diseas
optim
surgic
rout
depend
number
locat
metastat
nodul
thoracoscop
excis
reserv
pleural
metastas
whilst
thoracotomi
employ
within
lung
parenchyma
backgroundobject
achiev
resect
ewe
sarcoma
es
chest
wall
often
challeng
children
reconstruct
even
exig
present
child
local
es
aris
bodi
sternum
manag
neoadjuv
chemotherapi
nact
follow
surgic
resect
chest
wall
reconstruct
designmethod
retrospect
case
studi
result
boy
present
cough
chest
pain
month
respiratori
distress
day
chest
xray
show
right
side
opac
ct
chest
reveal
cm
heterogen
anteriormediastin
mass
necrot
area
displac
compress
mediastin
structur
imag
guid
biopsi
confirm
es
posit
ihc
metastat
workup
neg
bone
scan
reveal
focal
abnorm
uptak
sternum
suggest
origin
es
given
nact
vincristin
doxorubicin
cyclophosphamid
altern
etoposid
ifosphamid
everi
week
vdcie
reevalu
week
show
reduct
tumor
size
good
pr
tumor
measur
cm
abut
great
vessel
resect
tumor
cm
sternal
bodi
adjoin
costal
cartilag
either
side
done
sternal
defect
reconstruct
prosthet
materi
biopor
confirm
neg
margin
frozen
section
histopatholog
confirm
residu
es
necrosi
wide
free
margin
excel
cosmesi
paradox
movement
chest
wall
current
consolid
chemotherapi
week
radiotherapi
defer
sinc
local
control
achiev
surgeri
alon
conclus
multimod
treatment
local
es
chest
wall
facilit
resect
cytoreduct
newer
prosthet
materi
promis
sternal
reconstruct
howev
long
term
followup
essenti
look
futur
chest
wall
deform
tang
w
tanigawa
k
tanino
k
tanni
e
tany
tanyildiz
g
tanyildiz
hg
tanyildiz
taormina
c
tarai
b
tarasevich
r
tarasik
tari
tarso
p
tascedda
